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 CONTEXT AND RESEARCH FOCUS    
Glaucoma is a leading cause of blindness worldwide and an increasingly important public 
health concern in the aging population. Its pathogenesis is characterized by progressive 
degeneration of retinal ganglion cells (RGCs), the neurons that form the connection between 
the eye and the visual centers in the brain1,2. As progression of this neurodegenerative 
disease results in permanent blindness, early detection and treatment are critical. While age 
and genetic background are important in glaucoma etiology, the only controllable risk factor 
and the focus of clinical intervention today is elevated intraocular pressure (IOP) or ocular 
hypertension (OHT)1,2. IOP control generally slows disease progression but it does not stop 
RGCs from dying3,4. Therefore, novel therapeutic strategies for preservation of visual 
function in glaucoma focus on neuroprotection5. In order to develop such neuroprotective 
approaches, it is of utmost importance to enhance comprehension of the pathological 
processes underlying glaucomatous RGC death.  
Although glaucoma has long been considered a retinal disease, involvement of the visual 
brain centers is increasingly becoming recognized6-8. It is nowadays generally accepted that 
an early event in the initiation of glaucoma is disrupted transport along the RGC axons, 
thereby also inhibiting the retrograde delivery of neurotrophins from the RGC projection 
areas in the brain to the RGC soma in the retina9,10. According to the neurotrophin 
deprivation hypothesis, diminished axonal transport causes RGCs to suffer from 
neurotrophic deprivation, which is believed to trigger apoptotic signaling pathways10. Within 
this context, this PhD project aims to contribute new knowledge about the relationship 
between glaucomatous RGC degeneration and the brain, and to develop novel 
RGC-protective strategies, based on molecular and activity-related modulation of the central 
direct retinal target regions. 
Chapter 1 provides a general overview of the visual system of humans and mice. Also the 
current understanding on glaucoma pathogenesis is described, and how mouse models have 
significantly contributed to this knowledge. Furthermore, basic biochemical features of 
neurotrophins and their possible role in glaucoma are explained. The first chapter also 
provides an introduction to optogenetics, a recently established technique that allows timely 
control over neuronal activity with high spatial resolution.  
Because animal disease models are crucial to unravel underlying pathogenic mechanisms in 
the search for novel therapeutic strategies, Chapter 2 focuses on the introduction and 
characterization of two mouse models of glaucoma. First, a comparison is made between 
the baseline characteristics of the visual system of three mouse strains, C57Bl/6, 
XX   __________________________________________________   CONTEXT AND RESEARCH FOCUS 
C57BL/6-Tyrc, and CD-1. Subsequently, their susceptibility to RGC degeneration, evoked by 
two commonly used methods, is verified. In the first model, OHT is induced by impairing 
aqueous humor outflow11, which results in experimental elevation of the IOP. In the second 
model, RGCs are damaged by crushing their axons in the optic nerve (optic nerve crush, 
ONC), mimicking the situation of human glaucoma, in which the primary site of RGC injury is 
also located in the axon12.  Finally, the RGC degeneration patterns are mapped in both 
models to provide a guideline for the design of further experiments.  
Chapter 3 focuses on the link between glaucoma and the brain. Using the hypertension 
based mouse model characterized in Chapter 2, the effect of OHT on the main visual target 
areas in the adult brain is addressed. In the mouse, approximately all RGCs project their axon 
towards the superficial layers of the superior colliculus (sSC)13-15. Therefore, this brain 
structure is chosen to study subcortical morphological alterations, like degeneration of RGC 
axon terminals and glial responses. Furthermore, functional changes in cortical activity are 
investigated in the primary visual cortex and the higher order visual areas. Both an early and 
late time point after OHT induction are included, allowing to distinguish between acute and 
chronic effects.  
Based on the neurotrophin deprivation hypothesis10, and because retrograde signaling from 
the SC was shown necessary for proper RGC function16, it is hypothesized that delaying or 
preventing glaucomatous RGC death can be achieved by interference at their main target 
area, either molecularly, e.g. via enhanced expression of neurotrophins, or by modulation of 
the functionality, e.g. by influencing the electrical circuits (cfr. deep brain stimulation) 
through optogenetic stimulation. In light of this hypothesis, Chapter 4 aims for the 
optimization of viral vector technology for application in the mouse SC, which may then be 
used to deliver neurotrophin genes or optogenes to specific SC cell types. In search for a viral 
vector capable of targeting many cells throughout the entire SC without retrograde 
transduction of the retina, various viral vector types are evaluated for tropism, efficiency, 
and retrograde transduction capacity. Subsequently, the effect of different promoters on the 
cell-specificity of viral vector-based reporter gene expression is studied. After defining the 
viral vector type and the promoter of choice, a vector to induce overexpression of brain-
derived neurotrophic factor (BDNF), a neurotrophin of which the neuroprotective power has 
repeatedly been illustrated10, is developed and validated. Besides neurotrophin 
upregulation, a second way of collicular modulation that is hypothesized to have RGC 
supporting features, is optogenetic stimulation. Optogenetics is a method that allows for 
very precise regulation of neuronal activity, based on the expression of opsins, ion-
conducting channels of which the activity can be controlled by illumination with a specific 
wavelength17. Viral vector-induced expression and membrane incorporation of the stabilized 
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step-function opsin (SSFO), the opsin that has been selected for this project because of its 
slow kinetics18, is evaluated.  
Chapter 5 covers the role of neurotrophin signaling in glaucoma. Temporal expression 
patterns of BDNF and its main receptor, tropomyosin receptor kinase B (TrkB)19, are 
determined in the retina and SC after experimental glaucoma induction, using both the OHT 
and ONC mouse models. Furthermore, the previously reported anti-degenerative effect of 
intravitreally-delivered recombinant BDNF20-22 is re-examined. Moreover, based on the 
neurotrophin deprivation hypothesis, RGC neuroprotection is attempted through 
upregulation of BDNF in the SC, the main extraretinal source of trophic support for RGCs in 
mice, by means of the viral vector developed and validated in Chapter 4.  
Besides neurotrophin administration, also electrical stimulation has successfully been 
applied to increase survival in retina-degenerative models, presumably because such activity 
stimulates survival promoting signaling pathways23-25. As electrical stimulation has been 
associated with increased production of neurotrophic factors23-25, increasing neuronal 
activity in the SC might serve as a broader strategy to elevate the release of a whole 
spectrum of neurotrophic factors. Taking this into account, the objective put forward is to 
investigate whether modulation of neuronal activity in the SC can protect against RGC loss, 
experimentally induced by the two established mouse models of glaucoma. For activity 
modulation, the novel revolutionary technology of optogenetics permits a more accurate 
methodology compared to electrical stimulation, based on its unprecedented time 
resolution and cell specificity26. As a start to this larger research project, in Chapter 6, 
several steps in the optimization of a setup for chronic optogenetic SC stimulation in awake 
and freely moving mice are described.  
Finally, in Chapter 7, the results obtained throughout the series of experiments are 
thoroughly discussed against the backdrop of the existing literature on glaucoma 
pathogenesis and future perspectives are outlined.  
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1 THE VISUAL SYSTEM OF HUMAN AND MICE 
The capacity to see and visually interpret the world may appear a simple and natural part of 
life. However, taking a closer look at the visual system of mammals reveals how millions of 
cells cooperate to create an image of the environment in the brain.  
1.1 THE EYE: TRANSLATION OF LIGHT INTO NEURONAL SIGNALS 
Vision starts with the eye capturing light emitted by or reflected off objects in the 
environment. Light enters the eye through the cornea, passing through the anterior 
chamber, the pupil surrounded by the iris, the lens and the vitreous body, and finally reaches 
the retina (Figure 1.1). The amount of incoming light is determined by pupil size, as 
regulated by contraction and relaxation of the iris. The combined refractive power of the 
cornea and the lens focuses light rays onto the retina to form sharp images. The shape of the 
lens, and therefore its refractive effect, can be modulated by the ciliary muscles in order to 
focus on objects nearby or far away, in a process called accommodation27,28.  
 
 
Figure 1.1: Anatomical organization of the eye and the retina. Light entering the eye is focused onto the retina 
due to the combined refractive power of the cornea and the lens. Light passes through the upper layers of the 
retina before light energy is captured by the photoreceptor outer segments, transferring this energy into 
neuronal signals. Next, visual information flows from the photoreceptors, cones (1) and rods (2), via the bipolar 
cells (3) to the retinal ganglion cells (4), which project their very long axons out of the eye in the optic nerve 
towards the brain. Horizontal cells (5) and amacrine cells (6) can modify this direct circuitry via lateral 
connections. Adapted from Bear et al.
27
.  
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The retina is considered part of the central nervous system (CNS), organized in a laminar 
way, from the sclera, connective tissue surrounding the back of the eye, to the vitreous: the 
layer of photoreceptor outer segments, the outer nuclear layer, the outer plexiform layer, 
the inner nuclear layer, the inner plexiform layer, the ganglion cell layer (GCL), and the nerve 
fiber layer (NFL) (Figure 1.1). Counterintuitively, it is the outermost layer of the 
neurosensory retina that contains the cells directly sensitive to light. Light energy passes the 
inner, relatively transparent layers and is captured by photopigment in the outer segments 
of the photoreceptor cells and converted into electrochemical neural signals. These signals 
then travel to the innermost layer of the retina, first passing through the bipolar cells before 
arriving at the retinal ganglion cells (RGCs). Along the way, horizontal and amacrine cells can 
support an extra indirect signaling pathway via lateral connections between bipolar cells and 
RGCs, respectively. The visual information leaves the retina via RGCs, firing action potentials 
along their very long axons towards the visual centers in the brain. Remarkably, at a central 
spot in the human retina, called the fovea centralis, the upper retinal layers are displaced 
laterally to allow direct illumination of photoreceptors without any scattering of light, 
making this region specialized for high-resolution vision. Furthermore, in the fovea, 
photoreceptor cells and RGCs are communicating in a one-to-one fashion. Of note is that 
mice, a widely employed model for studies of vision, lack a fovea in contrast to humans27-29.  
In both humans and mice, two morphological types of photoreceptor cells can be 
distinguished, namely rods and cones, which are differentially distributed throughout the 
retina. In the fovea centralis, only cones are present, with the cone to rod ratio decreasing 
from the central to the peripheral retina. In the murine eye, the cone to rod ratio is uniform 
throughout the retina, resembling the periphery of a human retina. A strongly rod-
dominated retina is characteristic for nocturnal animals because rods contain higher 
concentrations of photopigment, rendering them much more sensitive to light and making 
them the photoreceptors responsible for vision under scotopic, or dim light, conditions. 
Conversely, cones mainly contribute to vision under photopic, or bright, conditions. Human 
cones can be divided into three categories, based on the type of photopigment they possess, 
with each type of photopigment being activated by light in a specific range of the 
wavelength spectrum; as such, cones are responsible for perceiving color. Unlike humans 
that possess trichromatic color vision, mice only have two types of cones and are 
dichromatic28-31.  
RGCs also exist in different forms - about 20 types have been described in mammals - and 
vary with respect to morphology, electrophysiological properties, responses to certain 
stimuli, projection sites in the brain, receptive fields, etc.31-34. As is the case for 
photoreceptors, RGCs are also non-equally distributed throughout the human retina. RGC 
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density is the highest in the central retina and lowers towards the peripheral retina. This is 
also the case in mice. Furthermore, mice exhibit a nasal-temporal strip with increased RGC 
density in the dorsal retina, called the “visual streak”35. 
Apart from neurons, the retina also contains three types of glial cells. The macroglia, 
comprised of both Müller cells and astrocytes, are essential for homeostasis of the 
extracellular environment and metabolic support for the neurons. Müller cells span the 
entire retina radially, while astrocytes are star-shaped and mainly located in the GCL. 
Furthermore, both types of macroglia also contribute to signal transmission, via modulation 
of neuronal activity36. Microglial cells, small cells found in every layer of the retina, belong to 
the immune system and are resident macrophages that will become reactive upon trauma or 
stress. They are responsible for phagocytosis of degenerating retinal neurons37,38.  
1.2 THE CENTRAL VISUAL PATHWAY 
1.2.1 The retinofugal projection: to cross or not to cross  
RGCs transmit visual information from the eye to the brain via the optic nerve and optic 
tract. In mammals, the RGC axons exit the eye via the optic nerve head (ONH), the transition 
zone between unmyelinated RGC axons in the retina and the point at which they become 
myelinated by oligodendrocyte glia39, and bundle together in the optic nerves. In the optic 
chiasm, the optic nerves from both eyes converge and partial decussation, or midline 
crossing, occurs. More specifically, RGC axons originating in the nasal part of the retina cross 
over and proceed into the contralateral optic pathway, while RGCs located in the temporal 
part of the retina do not decussate and project ipsilaterally (Figure 1.2). As such, visual 
information originating in the left visual hemifield will be processed by the right hemisphere 
and vice versa27,28. The amount of decussation is related to the position of the eyes and the 
degree of binocular overlay in the visual field. In primates, such as humans, having frontally 
positioned eyes and a binocular field overlay of 130 to 140°, 53 % of RGCs cross the midline 
in the optic chiasm, while 47 % project ipsilaterally28. Mice, however, have laterally 
positioned eyes, leading to a smaller binocular field of 30 to 40° and only 2-3 % of their RGCs 
project ipsilaterally, all located in the ventrotemporal crescent (VTC) of the retina29,40-42. 
Beyond the optic chiasm, the RGC axons continue their way through the optic tract towards 
various retinorecipient nuclei. The most important projection areas in the context of vision 
are the lateral geniculate nucleus (LGN), located in the lateral thalamus, and the superior 
colliculus (SC), located in the midbrain just below the thalamus27, both discussed in more 
detail below. Other examples of retinorecipient areas are the suprachiasmatic nucleus at the 
base of the anterior hypothalamus, mainly involved in circadian responses to light, and the 
olivary and posterior pretectal nuclei in the midbrain, responsible for the pupillary light 
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reflex27,28. Input to these nuclei is chiefly provided by a special type of light-sensitive RGC, 
expressing melanopsin pigment43. 
 
Figure 1.2: Retinofugal projections and the main visual brain centers in humans (left) and mice (right). RGC 
axons leave the eye to form the optic nerve. In the optic chiasm, a fraction of the RGC axons decussate to 
segregate information from the left and right visual hemifields. As such, the left visual hemifield is projected 
onto the right hemisphere and vice versa. The main retinofugal pathway in humans is responsible for conscious 
vision and goes from the retina via the LGN towards the primary visual cortex. In mice, the main retinal 
projection site is the SC. Key: RGC, retinal ganglion cell; LGN, lateral geniculate nucleus; SC, superior colliculus. 
1.2.2 The geniculocortical pathway: visual perception  
In humans, the majority of RGC axons project towards the LGN, a critical relay station 
between the retina and the primary visual cortex (V1), where relevant visual information is 
filtered before it reaches the cortex44. This geniculocortical pathway is responsible for 
conscious visual perception. The LGN is retinotopically organized, meaning that neighbouring 
RGCs in the retina send information to neighboring cells in the LGN, creating a topographic 
map of the visual field on this subcortical brain center28,44. The human LGN is comprised of 
six main neuronal layers, each with monocular input, with layers 1, 4, and 6 receiving RGC 
projections from the contralateral eye, and layers 2, 3, and 5 receiving RGC projections from 
the ipsilateral eye (Figure 1.3 A)27,28,44. Besides driving retinal input to V1, the LGN also 
receives modulatory feedback signals from V1, from the thalamic reticular nucleus, and from 
the brainstem44. The mouse LGN consists of the dorsal LGN (dLGN), the ventral LGN (vLGN) 
and the intergeniculate leaflet (IGL)40. Both vLGN and IGL receive binocular retinal input and 
are thought to be important for regulation of circadian behavior and pupillary light 
reflexes40. The dLGN is functionally related to the human LGN, serving as a filtering relay 
station between the RGCs and V1. Although the mouse dLGN lacks a clear cytoarchitectural 
laminar organization, as is seen in the human LGN, information of the ipsilateral and 
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contralateral eyes still remain segregated. Ipsilateral projections terminate in a patch located 
in the dorsomedial dLGN, while contralateral projections fill the rest of the dLGN, 
surrounding this patch (Figure 1.3 B)29,40,42. When taking a closer look at the binocular zone 
of the dLGN, a laminar pattern can be distinguished following a contra-ipsi-contralateral 
design, evocative of the pattern in species with a clear laminar morphology42. 
 
Figure 1.3: Structures of the geniculocortical pathway: the lateral geniculate nucleus and the primary visual 
cortex. A. The human LGN contains six layers, with layers 2, 3, and 5 receiving ipsilateral input (green) and 
layers 1, 4, and 6 receiving contralateral input (blue). B. The mouse dLGN does not contain layers; however, 
input from the ipsilateral eye remains segregated in a patch located in the dorsomedial dLGN, surrounded by 
contralateral input. C. The mammalian primary visual cortex consists of six layers. LGN projection neurons 
mainly synapse on layer IV neurons, but also to a minor extent on layer II/III. Specific layers project output 
towards particular brain regions as depicted. Adapted from Bear et al.
27
. Key: LGN, lateral geniculate nucleus; 
dLGN, dorsal lateral geniculate nucleus; IGL, intergeniculate leaflet; vLGN, ventral lateral geniculate nucleus; SC, 
superior colliculus; LPN, lateral posterior nucleus.   
From the LGN, the visual signal is subsequently transferred along the optic radiation to V1, 
preserving the retinotopic map. In the mammalian cortex, V1 neurons are organized in six 
layers, with each layer having a specific function (Figure 1.3 C). LGN axons mainly form 
synapses on layer IV neurons, but also to a minor extent on neurons of layers II and III. In 
layer IV, the segregation of information from the ipsilateral and contralateral eyes is 
conserved in so-called ocular dominance columns27,28. Notably, to date, the existence of 
ocular dominance columns has not been shown in mice41; however, different eye-specific 
subdivisions can be made45. The murine V1 exists of a monocular and a binocular part, yet 
there is a strong dominance of the contralateral eye throughout both regions41,45. Layer IV 
neurons further transfer the information to upper layers II and III, where information of both 
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eyes combine. From there, the signal is further spread horizontally within layers II/III and 
towards the lower layers V and VI27. After partial processing of the visual information, V1 
sends out cues towards higher-order visual areas, for further processing, and receives 
reciprocal connections from these areas, important for fine-tuning of the processing of 
incoming stimuli28. In addition, projection neurons of layers V and VI also send feedback 
information to the SC and LGN respectively27.  
1.2.3 The superior colliculus: integration and orientation  
Although the SC is an important retinal target structure in mammals, the amount of RGC 
innervation differs between species. In humans, less than 10 % of RGCs synapse in the SC, 
while in mice, almost all RGC axons project to the SC14,27. In both humans and mice, the SC is 
a laminar structure consisting of seven alternating fibrous and cellular layers: the stratum 
zonale (SZ), the stratum griseum superficiale (SGS), the stratum opticum (SO), the stratum 
griseum intermediale (SGI), the stratum album intermediale (SAI), the stratum griseum 
profundum (SGP), and the stratum album profundum (SAP) (Figure 1.4 A)46,47. RGC axons 
enter the SC through the SO, arborize, and terminate almost exclusively in the three 
superficial layers of the SC (sSC). As was the case for the LGN, and as is also the situation in 
the sSC, RGC terminals synapse retinotopically, projecting a topographic environmental map 
on the sSC48. Although the number of ipsilateral projecting RGCs differ between primates 
and mice28,29,49, in the sSC of both species, contralateral projecting RGCs form synapses in all 
three layers of the sSC, while ipsilateral projecting RGC terminals are restricted to patches in 
the lower SGS and the SO in the rostromedial parts of the sSC (Figure 1.4 A)46,49-52. The role 
of this patchy structure remains poorly understood53. Besides retinal input, the sSC also 
receives input from the LGN and from V1 layer V46. Corticocollicular back-projections are 
organized such that they match the retinocollicular topographic map48,54.  
There are several ways that signal processing in the sSC can influence visually-guided 
behavior (Figure 1.4 B). First, sSC neurons project back to the LGN46; thus, sSC activity might 
modulate the geniculocortical pathway55. Second, the lateral posterior nucleus (LPN) of the 
thalamus is also a target structure of sSC projection neurons and the LPN, in turn, 
communicates with several higher-order visual cortical areas46,56,57. However, the functional 
role of this colliculocortical pathway remains unclear at present56. Third, the sSC neurons 
transfer visual information to the deeper layers of the SC (dSC), where visual, auditory, and 
somatosensory information is integrated55,58. The dSC has an important sensory motor 
function in controlling eye, head, and body orientation towards sensory cues27,43,57. In 
addition, the control of spatial attention and stimulus selection is also guided by dSC 
neurons32,59,60.  
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Within the sSC, five main neuronal cell types exist, differing based on morphological and 
electrophysiological properties (Figure 1.5)55. Wide-field cells are the main projection 
neurons of the sSC. They have somas in the SGS and SO and extend widely branched 
dendrites to the dorsal surface of the sSC. Wide-field cells project to the dSC and also project 
to the LPN, contributing to the collicular thalamocortical pathway described above55,61. 
Narrow-field cells have somas in the SGS and extend neurites ventrally in the SO and dorsally 
to the sSC surface. These cells also form a connection between the sSC and the dSC55,61. 
Marginal cells are the third type of cell forming connections between the sSC and the 
dSC55,61. Marginal cells have somas located in the SZ, with their neurites extending ventrally 
towards the SO28,33. Horizontal cells are located in the SGS and extend long, horizontally 
oriented dendrites. Stellate cells are small neurons with a limited field of neurites in all 
directions, located throughout the sSC55,61. Horizontal and stellate cells have long been 
considered local inhibitory interneurons61, however, it has recently been shown that these 
cells also project to the LGN and thus might influence the geniculocortical pathway55. In 
addition, all sSC cell types, except for the wide-field cells, project to the parabigeminal 
nucleus in the midbrain, a “satellite” nucleus that projects back to the sSC and is thought to 
be involved in stimulus competition for attention55,61.  
 
 
Figure 1.4: The mammalian superior colliculus. A. Contralateral (blue in left SC) and ipsilateral (green in left SC) 
RGC input to the sSC on a frontal section through the anterior part of the mouse SC. Left and right SC come 
together to form a mirrored structure. B. Basic scheme of input and output of the mammalian sSC. Key: SZ, 
stratum zonale; SGS, stratum griseum superficiale; SO, stratum opticum; SGI, stratum griseum intermediale; 
SAI, stratum album intermediale; SGP, stratum griseum profundum; SAP, stratum album profundum; sSC, 
superficial superior colliculus; dSC, deep layers of the superior colliculus; LGN, lateral geniculate nucleus; V1, 
primary visual cortex; LPN, lateral posterior nucleus.  
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Figure 1.5: Five neuronal cell types in the superficial superior colliculus of mammals. All five cell types of the 
sSC respond to visual stimuli. Wide-field cells (1), narrow-field cells (2), and marginal cells (3) project the visual 
information towards the dSC. Wide-field cells also project towards the LPN in the thalamus. Horizontal (4) and 
stellate (5) cells form local connections, but also project towards the LGN. Key: sSC, superficial layers of the 
superior colliculus; dSC, deep layers of the superior colliculus; RGC, retinal ganglion cell; SZ, stratum zonale; 
SGS, stratum griseum superficiale; SO, stratum opticum; LPN, lateral posterior nucleus. 
 
2 GLAUCOMA  
2.1 PATHOLOGY 
Glaucoma is a leading cause of blindness worldwide and an increasingly important public 
health concern because of the aging world population62. It is a complex, multifactorial 
disease, characterized by optic neuropathy that involves structural damage to the optic 
nerve, RGC death, and visual field defects2. While age and genetic background, amongst 
other factors, are important in terms of risk, the only controllable risk factor and sole target 
for clinical intervention is elevated intraocular pressure (IOP), more commonly known as 
ocular hypertension (OHT). IOP is determined by the balance in production and drainage of 
aqueous humor, a clear fluid containing nutrients needed by the avascular lens and the 
cornea, that fills the anterior chamber63. Aqueous humor is produced by the ciliary body and 
leaves the eye via the anterior chamber angle, the structure formed by the joining of the iris 
and the cornea (Figure 1.6). For the outflow, there are two pathways. In the conventional 
pathway, the aqueous humor leaves the eye through the trabecular meshwork, a porous 
structure consisting of connective tissue surrounded by endothelium, flowing into 
Schlemm’s canal; from there, it is drained via the episcleral venes (Figure 1.6 A). In the 
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uveoscleral pathway, aqueous humor flows through the ciliary body and ciliary muscles 
towards the suprachoroidal space between the sclera and the choroid - a vascular layer 
between the sclera and the retina that is responsible for providing oxygen and nutrients to 
the outermost layers of the retina - from where it is absorbed by the venous system of the 
sclera, choroid, and the ciliary body (Figure 1.6 B)11,63. Imbalance between production and 
outflow of aqueous humor can disrupt IOP, enhancing the risk of developing glaucoma. 
However, people with elevated IOP do not necessarily develop glaucoma and a number of 
glaucoma patients do not seem to suffer from OHT. Thus, glaucoma is typically, but not 
exclusively, associated with OHT4,39.  
 
Figure 1.6: Schematic diagram illustrating the two pathways of aqueous humor outflow
11
. Aqueous humor is 
produced by the ciliary body and flows through the pupil towards the anterior chamber, eventually leaving the 
eye via the chamber angle. A. In the conventional pathway, the fluid flows out through the trabecular 
meshwork in Schlemm’s canal and is subsequently absorbed into the episcleral veins. B. In the uveoscleral 
pathway, the aqueous humor flows through the ciliary body and muscles towards the suprachoroidal space, 
from where it is absorbed by the venous system via collector channels of the ciliary body, choroid, and sclera.  
In order to develop novel therapeutic strategies to halt glaucoma disease progression, it is 
very important to know why and how the RGCs die. Glaucomatous pathogenesis starts with 
local damage to the RGC axons in the ONH (Figure 1.7)64,65. Several suggestions have been 
made to explain the link between OHT and initial axonal damage. One direct effect might be 
that IOP-generated mechanical stress is passed on the lamina cribrosa, sheets of scleral 
connective tissue surrounding the ONH, and physically compresses the optic nerve 
axons65,66. However, other hypotheses also exist. For instance, glial cells located in the ONH 
and in the lamina cribrosa change their gene expression and behavior upon OHT or other 
stressors64,67, modulating the ONH environment and possibly leading to the loss of energy 
supply for RGCs. This in turn results in RGC axons being unable to perform normal energy 
demanding functions and this functional deficit is followed by degeneration39,65. Whatever 
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the initial trigger is, it is generally accepted that one of the early events in glaucoma is the 
blocking of RGC axonal transport67,68. Failure of anterograde intra-axonal transport leads to 
malfunction of RGC pre-synaptic active zones and subsequent loss of axon terminals in the 
central projection sites39. Diminished retrograde transport results in reduced delivery of 
neurotrophic peptides from the brain to the retina (section 3.2), believed to be essential for 
survival of the RGC soma. Trophic impairment is supposed to activate the apoptotic pathway 
in the RGC soma64,65,69. Subsequently, the dying RGCs release their intracellular glutamate 
into the extracellular space, where it might excessively activate glutamate receptors on 
neighboring RGCs, precipitating disproportionate calcium influx and apoptosis in those cells. 
Thus, primary RGC death might lead to a second wave of RGC degeneration via mechanisms 
of excitotoxicity64,65. However, the mechanism underlying excitotoxicity is not fully 
understood. Besides a direct influence of primary RGC degeneration on neighboring RGCs via 
glutamate release, yet another possibility is an indirect effect via retinal glial cells. Müller 
cells are responsible for the very tight regulation of glutamate concentrations in the 
extracellular retinal space by the uptake of excess glutamate. Disturbance of glutamate 
turnover by glia might lead to extracellular glutamate levels being toxic for the 
glutamate-sensitive RGCs65. Müller cells and microglia can have both a beneficial and a 
detrimental role in glaucomatous disease progression. In response to insult, Müller glial cells 
undergo a first step of reactive gliosis characterized by release of neuroprotective factors,  
 
 
Figure 1.7: Retinal ganglion cell degeneration in glaucoma. Disease-relevant stress factors impact the RGC 
axons in the ONH, leading to failure of anterograde and retrograde axonal transport and subsequent loss of 
synapses in the retinal target areas in the brain and apoptosis of the cell soma in the retina. Dying RGCs induce 
changes in the extracellular environment, leading to an excitotoxic second wave of RGC degeneration. Key: 
RGC, retinal ganglion cell; ONH, optic nerve head.  
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during which gliosis is mainly neuroprotective64. Microglia can clear toxic debris, release 
neurotrophic factors and signal towards the immune system in order to contribute to RGC 
survival69. However, in a further stage, both Müller and microglial cells can become over-
activated and secrete cytokines, some of which are neurotoxic to RGCs, potentially initiating 
the observed second wave of cytotoxic RGC degeneration65,69. In a later phase of glaucoma, 
when a severely detrimental amount of RGCs have already died, glia change their behavior 
again, forming connective tissue, called the glial scar64,69. Noteworthy, these theories of 
toxicity-based secondary degeneration are based on studies of animal models of glaucoma. 
Whether the described events actually occur in human glaucoma patients, or are instead 
artifacts of the used models, remains controversial so far65.  
2.2 RODENT GLAUCOMA MODELS  
In order to study the underlying mechanisms of glaucoma pathogenesis, animal models of 
glaucoma have been developed. Experimental induction of OHT in non-human primates via 
laser ablation of the trabecular meshwork has long been the standard model in glaucoma 
studies, yielding important knowledge on glaucoma pathology64. However, more recently 
the focus has shifted towards murine models of experimentally-induced or inherited 
glaucoma, either OHT-based or independent of IOP70.  
Elevation of IOP can be induced in rats and mice by several methods. As IOP is regulated by 
the strict balance between production and outflow of aqueous humor (section 2.1), 
experimentally disturbing this equilibrium can induce OHT12,71-73. As such, laser 
photocoagulation (LP) of the trabecular meshwork74-76 and/or the episcleral and perilimbal 
veins13,77-79 impairs the drainage of aqueous humor and results in an elevated IOP. A variant 
of these laser models is episcleral vein cauterization, in which only two or three veins are 
targeted and locally burned, also leading to OHT80,81. Yet an alternative approach is the 
injection of hypertonic saline into the episcleral veins, resulting in sclerosis of the trabecular 
meshwork82. The so called microbead occlusion model, on the other hand, is based on the 
obstruction of the aqueous humor outflow pathways by injection of polysterene microbeads 
into the anterior chamber, either alone or accompanied by viscous fluids such as hyaluronic 
acid12,71,83. These beads flow into the trabecular meshwork, occluding the aqueous humor 
passage. Alternatively, the use of magnetic beads allows directing them specifically towards 
the trabecular meshwork using a magnet84. These various approaches to elevate the IOP 
result in divergent durations of OHT, ranging from five days in the LP mouse models13,77 to 
two and a half months upon episcleral vein cauterization in rats80. Recently, LP of the 
trabecular meshwork was combined with intracameral microbead injection to achieve more  
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prolonged OHT, lasting for more than ten weeks in mice85. Besides experimentally inducing 
an increase in IOP, also inherited OHT-based glaucoma models exist12,64,70,72. DBA/2 mice 
spontaneously develop OHT-based glaucoma upon aging. Specifically, DBA/2 mice contain a 
mutation in the tyrosinase-related protein 1 gene (Tyrp1b) and a stop codon in the 
glycoprotein nmb gene (Gpnmb), leading to iris atrophy, pigmentation dispersion, and 
consequential blockade of aqueous humor outflow and OHT, the latter resulting in a 
glaucomatous pattern of RGC degeneration86-88. In addition to this spontaneous 
glaucomatous mouse strain, genetic mouse lines have been developed carrying mutations in 
genes implicated in human glaucoma. For example, mice carrying a targeted mutation in the 
type I collagen gene (Colla1r/r) show gradual development of OHT because of inefficient 
humor drainage due to collagen deposition in the outflow pathways72,89,90. Although very 
relevant, there are some disadvantages to genetic models compared to experimentally-
induced models, mainly based on the high variability and the rather slow disease progression 
that makes studies using these animals very expensive and time consuming. 
Besides OHT-based models, RGC loss can be experimentally induced without any changes in 
IOP12,72. Optic nerve crush (ONC) and optic nerve transection (ONT) are relatively acute 
models that are commonly used to mechanically injur the intraorbital optic nerve20,91,92. 
These models are believed to share certain similar characteristics to human glaucoma, as the 
primary injury to RGCs is axonal and possibly occurs through mechanical forces in the ONH. 
Furthermore, after crushing or transecting the optic nerve, axonal transport is blocked, also 
supposed to be an early feature of human glaucoma. In the N-methyl-D-aspartate (NMDA) 
model, the non-hydrolysable analogue of glutamate, NMDA, is injected intravitreally (ivt) to 
induce excitotoxic RGC degeneration through over-activation of ionotropic glutamate 
receptors. This model is therefore very relevant to study possible excitotoxic aspects of 
glaucoma pathology12,72. Besides NMDA, ivt administration of kainic acid has been applied to 
evoke similar excitotoxic effects93. Likewise, induction of acute retina ischemia, followed by 
reperfusion, has been used to study RGC degeneration related to glaucoma, as a result of 
the speculation that reduced blood supply to the retina might play a role in glaucoma12. 
Ischemia-reperfusion can be induced by temporary ligation of the central retinal artery or by 
inducing local thrombosis in this vessel by injection of Rose Bengal12,94,95.  
Overall, as glaucoma is a multifactorial and very complex disease, combining data from 
studies using several different glaucoma models is important in order to assess and try to 
understand the complete picture of glaucoma pathology.  
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2.3 GLAUCOMA AND THE BRAIN  
Glaucoma has long been considered a disease confined to the eyes, but recent anatomical 
and functional examinations in patients and animal models have revealed degenerative 
changes in several retinal target structures in the brain7,96-101, manifesting glaucoma as a 
disease beyond the eye. Postmortem histological analyses as well as magnetic resonance 
imaging disclosed atrophy of the LGN, reduced cortical thickness, and activity changes in V1 
of glaucoma patients6,7,100,102-105. Volumetric gains in several structural components of the 
higher-order visual cortex, e.g. the occipital and frontal gyrus, have been detected in 
patients at an early stage of glaucoma; however, these volumes decreased tremendously as 
the disease progressed106. A number of studies using primate OHT models revealed altered 
metabolic activity in the LGN and V1, as well as neuronal loss, neuronal shrinkage, structural 
dendritic plasticity, microglial activation, and gliosis in the LGN8,96,98,99,107-115. Furthermore, 
cell loss in the sSC has been described in the murine ONC model116 and in the NMDA model, 
glial reactivity, upregulation of neurotrophic factors, and neuron loss was observed in the 
LGN and the sSC117,118. The glial response and neurotrophic factor increase in these areas 
were confirmed in a rat OHT model and in DBA/2 mice119. Furthermore, OHT induction in 
rats resulted in dendritic changes of both LGN and sSC neurons120; and sSC neurons of OHT 
mice exhibited weakened responses to visual stimulation85. Changes in cortical visual evoked 
potentials (VEP), a sign of reduced transmission of visual information, were measured in the 
visual cortex of rats with severe RGC damage upon ONC121. Also in aged DBA/2 mice, VEPs 
have been shown to be impaired122. All of these examples stress the importance of 
considering the entire visual system in retinodegenerative disease research.  
One of the main questions remains what exactly the pathogenic mechanisms are that 
underlie glaucomatous involvement of the brain. One hypothesis states that the 
glaucomatous effects on the central visual areas are secondary to RGC damage, and that 
neuronal damage in glaucoma spreads anterogradely from the RGCs to the central visual 
pathway7,8,109. There are several means by which transsynaptic degeneration might be 
induced. First, if RGCs die, their target structures lose their input, possibly leading to 
degeneration. Secondly, retinal terminals of dying RGCs might transmit death signals that 
could induce apoptosis in their target cells. Third, early in glaucoma, axonal transport in 
RGCs is diminished in both directions (Figure 1.7), which might lead to a decline in delivery of 
trophic factors from the eye to the brain123. Thus, possibly, brain involvement in glaucoma is 
triggered by the retina. However, on the other hand, it is also conceivable that, in some 
cases, the brain is the primary site of damage, leading to retrograde effects on the retina. A 
reduction of retrograde neurotrophic support as a consequence of brain insults possibly 
renders the RGCs more susceptible to local stress factors, like IOP (section 3.2). In support of 
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this hypothesis, indirect evidence indicates a link between glaucoma and Alzheimer’s disease 
(AD), as the prevalence of glaucoma is significantly higher in AD patients as opposed to the 
general population. However, these AD patients do not show elevated IOP. Unfortunately, 
the mechanism bridging glaucoma and AD is currently unknown123. As such, further 
investigation of the visual brain areas in glaucoma is definitely crucial to obtain a cohesive 
portrait of disease pathogenesis.  
 
3 NEUROTROPHINS  
3.1 STRUCTURE AND FUNCTION 
Neurotrophins are a family of growth factors that support the development and 
maintenance of neurons9,19,124. In the CNS, both glial cells and neurons produce 
neurotrophins, which either act in an autocrine way, in a paracrine way on neighboring cells 
or are anterogradely/retrogradely transported along the axons towards their site of action. 
In mammals, the family of neurotrophins counts four members: nerve growth factor (NGF), 
brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and neurotrophin-4 (NT-
4)19,125. These diffusible peptides typically bind to two types of receptors, tropomyosin-
related kinase receptors (Trk) and the p75 neurotrophin receptor (p75NTR), to activate 
various signaling pathways with different biological functions126,127. Neurotrophins are 
synthesized as pro-forms (30-35kDa) and subsequently processed by protease cleavage, 
mainly by the serine protease, plasmin128, to generate their mature forms (12-14kDa). 
Intracellular pro-neurotrophins have three possible fates: intracellular cleavage followed by 
secretion, secretion followed by extracellular cleavage or secretion without subsequent 
cleavage19,126,128. Each mature neurotrophin binds with the highest affinity to a subtype of 
Trk receptors: NGF to TrkA, BDNF and NT-4 to TrkB and NT-3 to TrkC (Figure 1.8). However, 
NT-3 can also interact with TrkA and TrkB, albeit with less efficiency19,126,127. Pro-
neurotrophins similarly bind to the Trk receptors, although with very low affinity129,130. As 
Trk receptors are single-pass transmembrane receptor tyrosine kinases, upon ligand binding, 
they dimerize and transphosphorylate one another, leading to recruitment of adaptor 
proteins and enzymes to the submembrane area, and subsequent pathway activation. The 
three main signaling pathways activated by Trk receptors in response to neurotrophins are 
all known to play a role in neuronal survival. First, the mitogen-activated protein 
kinase/extracellular signal-regulated protein kinase (MAPK/ERK) pathway activates a 
signaling cascade leading to stimulation of activity and expression of anti-apoptotic proteins, 
such as B-cell lymphoma 2 (Bcl-2) and the transcription factor cyclic AMP-responsive 
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element-binding protein (CREB)128. Second, the phosphatidylinositol 3-kinase/protein kinase 
B (PI3K/PKB) pathway suppresses cell death by inhibiting the apoptotic activities of Bcl-2-
associated death protein (BAD)128. Third, the phospholipase C/inositol 1,4,5-triphosphate 
(PLC/IP3) pathway induces cytoplasmic release of calcium from intracellular sources, 
believed to modulate synaptic functioning both pre- and postsynaptically126. In contrast to 
the specific mature neurotrophin-Trk signaling, all uncleaved neurotrophins activate p75NTR, 
a member of the tumor necrosis factor receptor superfamily, with high affinity. In addition, 
all mature neurotrophins can bind p75NTR, albeit with lower affinity. The high affinity pro-
neurotrophin binding site is created by a complex of p75NTR and the cell surface protein 
sortilin, with p75NTR binding to the mature portion of the neurotrophin and sortilin 
interacting with the pro-domain. Unlike the Trk receptors, p75NTR does not contain a 
catalytic motif, but interacts with several intracellular proteins that relay the signal upon 
ligand binding19. A simplified yin and yang model of neurotrophin action has been proposed, 
based on the fact that the binary actions of neurotrophins depend on both the form of the 
neurotrophin (pro versus mature), and the class of receptor that is activated (Figure 1.8)128. 
This model is supported by the fact that p75NTR signaling generally includes the downstream 
activation of c-Jun N-terminal kinases (JNK) and is coupled to the mitochondrial apoptotic 
pathway131. However, functions attributed to p75NTR are complex and far from completely 
understood for the time being, since p75NTR signaling has been implicated in both survival 
and apoptotic pathways9,127,132. Possible neurotrophin-related functions attributed to p75NTR 
are facilitating ligand binding to Trks and enhancing Trk ligand specificity by acting as a co-
receptor, reducing Trk ubiquitination-regulated internalization for degradation, promoting 
Trk endocytosis to form signaling endosomes upon ligand binding, functioning on its own as 
a receptor for mature and immature neurotrophins inducing a pro-apoptotic response, and 
functioning in the anterograde and retrograde transport of neurotrophins19,126,133. Thus, 
although very attractive, the simplistic theory of life-death decisions made by activation of 
one receptor or the other, does not tell the complete story, since diverse receptors and 
intracellular signaling pathways interact with one another in a complex way. Remarkably, 
even the cellular response to a specific receptor-ligand interaction can be different 
depending on the site of signal initiation: in the cell body, in the axon terminals or on the 
dendrites. Moreover, it has been shown that molecular pathways activated by internalized 
receptor complexes, embedded in vesicles, are distinct from signaling with the receptors 
that remain in the plasma membrane at the cell surface9,126,134,135. For example, in vitro 
studies demonstrated that when the NGF-TrkA complex is internalized at the level of the 
axonterminus and subsequently transported towards the cell body, the MAPK/ERK pathway 
is activated more pronouncedly than the PI3K/PKB pathway, while the opposite is observed 
when the internalization is inhibited136,137.  
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Neurotrophins are highly involved in neuron-target dependence, whereby they are produced 
and secreted by cells located in a target area, in order to support the innervating neurons. 
Upon release and binding to their membrane receptors at presynaptic terminals, the 
activated receptor-neurotrophin complexes are internalized in the so-called signaling 
endosome, and retrogradely transported via the dynein-microtubule transport system 
towards the cell body, where they regulate nuclear and cytosolic events known to be 
important for the survival of these neurons9,135,138-140. Failure of this target-derived 
neurotrophic support, also called neurotrophin deprivation, and taking place after CNS 
trauma or in neurodegenerative diseases such as Alzheimer’s disease and glaucoma, is 
thought to be detrimental for neuronal functioning and survival.  
 
 
 
Figure 1.8: The neurotrophins and their receptors. Mature neurotrophins bind preferentially to specific Trk 
receptors to enhance cell survival, whereas unprocessed pro-neurotrophins bind to p75
NTR
 to induce cell death. 
Key: NGF, nerve growth factor; BDNF, brain-derived neurotrophic factor; NT4, neurotrophin-4; NT3, 
neurotrophin-3; Trk, tropomyosin-related kinase; p75
NTR
, p75 neurotrophin receptor. 
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3.2 THE ROLE OF NEUROTROPHINS IN GLAUCOMA 
3.2.1 Retinal ganglion cells talk the neurotrophin language 
Proper development and subsequent survival of RGCs strongly depends on tight regulation 
of neurotrophic signaling through the different receptors. In the healthy retina, TrkA is 
expressed by developing RGCs, but TrkA levels in adult RGCs are low, while developing and 
adult RGCs both express high levels of TrkB. TrkC is expressed by RGCs during development, 
however only a small population of adult RGCs express TrkC. Interestingly, although 
developing RGCs express p75NTR, it is controversial whether this receptor is expressed by 
RGCs in the adult stage69,141. A number of studies have noted that only a subpopulation of 
adult RGCs express p75NTR 142-144. Very recently, a structurally-related receptor, TROY, 
expressed by almost all adult RGCs, has been suggested to mediate some of the functions 
originally attributed to p75NTR 145,146. Besides the receptors, all four neurotrophins, NGF, 
BDNF, NT-3 and NT-4, are produced and secreted by RGCs144,147. Furthermore, other retinal 
cells, e.g. Müller glia125,143,148-150 and amacrine cells143,147,151, produce neurotrophins which 
can be internalized by RGCs upon secretion. In humans as well as in rodents, RGCs transport 
these neurotrophins along their axons anterogradely towards the retinal target areas in the 
brain in order to support long-term potentiation (LTP) or survival of postsynaptic 
neurons128,141. However, they may also serve as local surviving signals in the retina and form 
trophic support for RGCs as well as other retinal cells. Neurotrophins are also produced by 
neurons and glial cells situated in the RGC target regions in the brain, e.g. the LGN and 
SC118,119,152, and subsequently, as a neurotrophin-receptor complex, transported 
retrogradely via the RGC axons towards their soma69. Target-derived neurotrophic support 
plays a very important role in RGC development, with only those RGCs that receive enough 
neurotrophic support survive, while the others undergo developmental apoptosis. This 
process can be influenced by exogenous delivery of neurotrophins, as has been shown in 
hamsters, where intracollicular BDNF injections reduced the developmental RGC 
apoptosis153.  
3.2.2 The neurotrophin deprivation hypothesis  
As mentioned before, it is generally accepted that one of the early events during the 
initiation of glaucoma is axonal dystrophy within the optic nerve, perturbing the axonal 
transport of neurotrophins10,69. As a consequence of diminished retrograde transport, RGCs 
suffer from neurotrophin scarcity, believed to trigger apoptotic signaling pathways (Figure 
1.9). This theory is referred to as the neurotrophin deprivation hypothesis5,10,69. Indirect 
support for this hypothesis is provided by observations of both anterograde and retrograde  
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Figure 1.9: The neurotrophin deprivation hypothesis
69
. Diminished retrograde delivery of target-derived 
neurotrophins, due to axonal transport obstruction, leads to neurotrophin deprivation and apoptotic RGC soma 
death in glaucoma. Key: ONH, optic nerve head; RGC, retinal ganglion cell. 
axonal transport of tracers being blocked in rat and mouse OHT glaucoma 
models13,77,119,154,155 and in DBA/2 mice49,156, as well as in experimental glaucoma models in 
primates134. Furthermore, accumulation of the dynein motor complex, which mediates 
retrograde axonal transport in RGCs, in the ONH has been described in a rat OHT model140. 
Retrograde transport of collicular-injected tagged BDNF was diminished and accompanied by 
accumulation of TrkB receptor in the ONH of both rats and monkeys upon OHT 
induction157,158, and in dogs with glaucoma159. Furthermore, in human patients, changes in 
the ONH at the level of the lamina cribrosa, compatible with blockage of retrograde 
axoplasmic transport, have been described68. Importantly, according to different glaucoma 
models, this RGC axonal transport failure precedes the structural degeneration of axons and 
cell somata73,156. RGC malfunctioning, anteceding glaucomatous cell death, is detectable as 
alterations in the pattern electroretinogram (PERG). Remarkably, blocking retrograde 
transport along RGC axons, through lidocaine application at the level of the ONH or in the 
SC, reversibly influenced PERG signals in a similar way16. These results suggest that indeed, 
intact retrograde signaling is necessary for normal RGC responsiveness, and that disturbed 
transport is very likely one of the factors preceding and possibly inducing and/or amplifying 
RGC death in glaucoma.  
Based on all neurotrophins being produced in the retina143,144,147,151, endogenous retinal 
neurotrophic support might compensate for the deprived delivery of target derived 
neurotrophin-receptor complexes. Evidence that retina-derived neurotrophins may 
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temporarily support the survival of RGCs that have been disconnected from their target was 
derived from studies where LGN or SC tissue was ablated in adult animals, but subsequent 
RGC soma degeneration only became significant at several weeks post-lesion160-162. 
However, RGCs eventually died, possibly because the physiological roles of locally produced 
neurotrophins differ from target-derived signaling126. 
3.2.3 Glaucomatous effects on neurotrophin levels 
Supportive of the neurotrophin deprivation hypothesis, strong evidence for reduced 
neurotrophin signaling associated with glaucoma, was provided by Gupta et al.163, 
demonstrating a reduction in BDNF levels and its downstream survival signaling factors in 
the ONH, both in a mouse OHT model as well as in human glaucoma patients. BDNF levels 
decreased and phosphorylated (p) TrkB/TrkB, pErk/Erk, pAkt/Akt ratios declined while the 
total amount of TrkB, Erk, and Akt remained stable. In line with this observation, in the rat 
hypertonic saline model, BDNF, NT-4, NGF, and TrkA levels have been described to decrease 
in the ONH164-167, and TrkB mRNA levels were reduced in RGCs soon after ONT and before 
RGC death168. Furthermore, elevated IOP gave rise to augmented 2-macroglobulin 
production in the retina of rats, and enhanced 2-macroglobulin levels were also measured 
in the aqueous humor of these rats, as well as in glaucoma patients169,170. 2-macroglobulin 
is believed to form complexes with NGF, preventing the neurotrophin from performing its 
neuroprotective taskin the retina and ONH. Links between reduced neurotrophin levels and 
glaucoma have not only been described for the retina and ONH. In a rat glaucoma model, 
NGF concentrations were shown to be lowered in the LGN and visual cortex171. In addition, 
reduced BDNF detection in the tears and serum of glaucoma patients has been proposed to 
be of use as a biomarker for glaucoma diagnostics172,173.  
In contrast to the aforementioned decrease in neurotrophin levels, several other studies 
using divergent glaucoma models report no alteration, stable enhancement, or fluctuating 
mRNA and protein levels of neurotrophins in the retina and ONH in different glaucoma 
models10,174-177. At first, this might seem contradictory to the theory of neurotrophin 
deprivation inducing RGC apoptosis. However, local upregulation of neurotrophin expression 
in the eye may be a mechanism trying to overcome the loss of retrograde delivery of trophic 
support from the target areas in the brain. Additionally, upregulation of downstream actors 
of the neurotrophin-induced survival pathways, such as Nrn1, have recently been detected 
in the ONC model, and were proposed to occur in an attempt to overcome obstructed 
retrograde delivery of neurotrophin signaling178. Unfortunately, changes in receptor 
expression, availability, and location can modify the protective effect of neurotrophins on 
RGC survival126. As such, while the retinal NGF protein level raised with hypertonic saline 
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OHT induction in rats, the TrkA/p75NTR ratio shifted towards p75NTR, diminishing a potential 
RGC survival effect of NGF174. Similarly, although no alteration in retinal BDNF mRNA was 
detected, TrkB mRNA expression significantly decreased and p75NTR mRNA expression 
increased after IOP elevation via vein cauterization in the rat10. Other studies, using the 
same model, showed an increase of retinal BDNF175,176, but no change in TrkB mRNA 
levels175. Also in the ONC model, enhanced BDNF mRNA levels were measured in the GCL179. 
Although NT-3 levels remained unchanged upon ONC and total TrkC expression was 
increased, the expected neuroprotective role of NT-3/TrkC signaling was insufficient to 
prevent RGC degeneration175. One explanation might be that these elevated TrkC levels were 
mainly caused by upregulation of inactive truncated isoforms, overwhelming the active 
form, of which the expression level remained unchanged175. In another study using the vein 
cauterization model for OHT, no alterations in retinal neurotrophin levels were detected; 
however, complex changes in receptor mRNA and protein levels were observed and linked 
to RGC apoptosis180. Additionally, in the brain, neurotrophin upregulation has been 
described to occur prior to RGC axon terminal degradation, possibly as a means to rescue 
from initial damage. In the NMDA-induced excitotoxicity model, upregulation of BDNF has 
been reported in dLGN neurons and astrocytes, and in SC neurons, preceding neuronal 
death in these brain areas118,152. In comparison, in DBA/2 mice as well as in mice subjected 
to the microbead-based OHT model, pre-degenerative anterograde transport deficits were 
accompanied by an increase in BDNF in the SC119.  
In summary, the above findings indicate that defining a specific role for all of the different 
players involved in neurotrophin signaling within glaucoma pathology is extremely difficult, 
because of the complex interplay between those factors.  
3.2.4 Neurotrophin administration as a therapy for glaucoma 
Despite the fact that the exact role of neurotrophins in glaucoma is far from completely 
elucidated, interfering with neurotrophin signaling is a very attractive tool to try to achieve 
neuroprotection. Indeed, based on the neurotrophin deprivation hypothesis, several 
research groups have aimed to supply exogenous neurotrophic factors, neurotrophins or 
other factors such as ciliary neurotrophic factor (CNTF) and glial cell line-derived 
neurotrophic factor (GDNF), to curb neurodegeneration in experimental glaucoma models. 
In several experimental approaches, growth factors have been supplied via ivt injections, via 
ivt implantation of slow-releasing devices, via viral vector-based overexpression in RGCs 
and/or Müller glia and via ivt stem cell transplantation22,181-184. Any neuroprotective effect 
might be attributed to direct communication with Trk receptors located on RGCs, or 
indirectly via stimulation of Müller cells to express other survival factors167. Local 
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administration of neurotrophic factors already successfully reduced loss of RGCs in various 
glaucoma models, although the neuroprotective effect was mostly transient and insufficient 
to support sustained RGC survival5,168. For example, one single ivt injection of CNTF, BDNF, or 
NT-4 has been shown to significantly delay, but not stop, RGC degeneration in the rat ONC 
model185. Single or multiple ivt administrations of BDNF and/or GDNF also delayed death of 
axotomized rat or mice RGCs186-188, as well as in a rat OHT model21,22,189. Repetitive injections 
of NGF had a positive effect on RGC survival in rats with ONT190 and topical administration of 
NGF exerted a temporary protective effect on OHT-induced RGC degeneration in rats165,191. 
In DBA/2 mice, both ivt and topical BDNF treatments were shown to enhance RGC survival 
and to rescue visual responses in the retina and in the cortex122. Moreover, topical 
applications of recombinant growth factors, e.g. nerve growth factor (NGF), have 
sporadically been reported to result in visual improvement in glaucoma patients191-193. 
However, these studies provided limited evidence because of the restricted numbers of 
subjects, requiring the promising results to be confirmed in larger clinical trials. The 
temporary effect of ivt injection or topical drops of recombinant factors could possibly be 
attributed to a restricted supply and short half-life194. Unfortunately, repeated 
administrations could not fully overcome this problem. Therefore, in order to provide a 
slower and more prolonged delivery of neurotrophic support, slow-release devices, e.g. 
neurotrophic factor containing microspheres, have been developed, and were shown to 
have a longer protective effect on RGCs in animal glaucoma models as compared to ivt 
injection of recombinant proteins. Ivt transplantation of GDNF-infused microspheres 
significantly reduced RGC death in DBA/2 mice as well as in a rat model of OHT195-197. While 
slow release microspheres prolong the interval between treatments, it is unlikely that they 
can really surmount the need for retreatment, as they can only be loaded with a limited 
amount of factor5. In order to avoid retreatment and obtain a sustained delivery of 
neurotrophic support, gene therapy might be the way forward183. Regrettably, although RGC 
survival could be extended using this as compared to the previously discussed methods, the 
effect of retinal transduction with viral vectors containing BDNF, CNTF or GDNF genes 
remained transient both in a rat OHT model181,182 and after ONT198,199. Another approach to 
provide sustained delivery of neurotrophic factors is ivt transplantation of stem cells, which 
naturally secrete different neurotrophic factors, or can be genetically engineered to 
overexpress specific factors. Ivt transplantation of non-manipulated bone marrow-derived 
mesenchymal stem cells (MSCs) in rats with induced OHT significantly delayed RGC 
death200,201. Also, BDNF overexpressing MSCs showed preserving effects on RGCs in a rat 
OHT model202. Furthermore, ivt grafted neural stem cells, genetically modified to excessively 
secrete CNTF, significantly attenuated RGC death in the ONC mouse model203. All of these 
methods focus on the delivery of neurotrophic molecules to the RGC soma. However, since 
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the place of signaling cascade onset is very important in neurotrophin-receptor signaling, it 
might be important to deliver these factors more naturally on both sides, i.e. at the cell 
soma in the retina and at the axon termini in the target regions in the brain. Indeed, a very 
novel treatment paradigm that combined ivt injection with chronic delivery of brain-derived 
neurotrophic factor (BDNF) in the visual target areas of the brain resulted in prolonged and 
enhanced RGC survival in cats subjected to optic nerve trauma as compared to merely 
treatment in the eye194,204. These recent findings largely confirm the neurotrophin 
deprivation hypothesis. 
When thinking of neurotrophin administration as a glaucoma therapy, one should take into 
account several possible drawbacks, such as the risk of activating the wrong signaling 
cascades, leading to incorrect live-death decisions of the cell, as well as the risk of 
desensitization of the cells over time due to a change in receptor reactivity. As already 
mentioned above, in addition to promoting cell survival via Trk communication, 
neurotrophins can also trigger apoptotic pathways, mainly through p75NTR signaling. 
Therefore, it has been suggested that the limitation of neurotrophin neuroprotective effects 
could be the result of simultaneous activation of the p75NTR pathways. In favor of this 
hypothesis, delivery of a selective TrkA agonist, instead of exogenous NGF, showed a more 
robust neuroprotective effect in rat OHT eyes205 and in optic nerve transected mice or 
rats206, compared to NGF treatment. Besides, the combination of NGF, or the selective TrkA 
agonist, with a p75NTR inhibitor, further potentiated RGC survival206. The detrimental side 
effect of NGF administration was proven to work indirectly via stimulation of p75NTR on 
Müller glia, activating these cells to secrete tumor necrosis factor  (TNF), which is 
neurotoxic to RGCs207. Similarly, p75NTR activation weakens the beneficial effect of BDNF 
administration5, and specific activation of TrkB, but not p75NTR, by a TrkB agonist, enhanced 
RGC survival after axotomy208. Next to activation of the incorrect pathway, prolonged 
delivery of neurotrophins might also have limited neuroprotective capacities because of 
desensitization by either injury- or drug-induced decrease in Trk receptor expression, 
reducing the effectiveness of the treatment over time184,209,210. To circumvent this problem, 
a combination of neurotrophin administration and treatment to enhance receptor 
availability has been proposed. Indeed, in the ONT model, vector-mediated overexpression 
of TrkB in RGCs, in combination with a single ivt BDNF injection, showed better preservation 
of RGC survival than either of the treatments alone168. In addition to overexpression, 
increasing the recruitment of Trk receptors to the surface may also restore the 
responsiveness of RGCs to neurotrophins209. Enhancement of intracellular cAMP levels by 
pharmacologic treatment or stimulatory electrical activity was indeed shown to result in 
enhanced neurotrophin sensitivity in RGCs, via Trk recruitment to the cell membrane209.  
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The data acquired thus far concerning the use of neurotrophins in neuroprotective glaucoma 
therapy are very promising. However, a comprehensive understanding of the molecular 
mechanisms underlying the merely temporary neuroprotective effects is critical to develop 
novel treatment paradigms that can serve as RGC protectors in the long-term. 
 
4 OPTOGENETICS  
4.1 THE BASIC PRINCIPLE 
Optogenetics, a term introduced by Karl Deisseroth in 2006211, is a revolutionary method 
that enables the modulation of neuronal activity in freely moving animals with 
unprecedented precision and cell specificity by combining optical and genetic 
techniques26,212. The basic principle underlying optogenetics, chosen as “Method of the Year 
2010” by Nature Methods26,213, is the introduction of genes encoding light-sensitive proteins, 
named opsins, into cells using gene transfer technology. After gene introduction, e.g. via 
viral vectors, those cells that express the opsins can be manipulated using light of an opsin 
specific wavelength17,26. The advantages of optogenetics when compared to traditional 
methods used to influence neuronal communication, e.g. electrical, pharmacological, and 
genetic methods, is that it combines a non-invasive character with the choice of stimulating, 
inhibiting or modulating the activity of cells, it has outstanding spatial specificity, it allows for 
reversibility, and has a very high temporal resolution at the scale of single action potentials 
(Figure 1.10 A)26,214.  
Two major superfamilies of opsins exist: microbial, or type I, opsins, present in prokaryotes, 
algae, and fungi; and animal, or type II, opsins, only existing in higher eukaryotes and mainly 
involved in vision. Every opsin requires retinal, a vitamin A-related cofactor naturally present 
in neuronal tissue, to fulfill its light-sensitive function. Upon illumination and photon 
absorption, retinal isomerizes, leading to a conformation change of the opsin. Retinal-bound 
opsins are called rhodopsins215,216. Type I opsins are very typically unitary in nature, meaning 
that the photoreceptor and ion flux unit are intimately linked in a single protein17. Type II 
opsins are G protein-coupled receptors, indirectly inducing their effect via a second 
messenger cascade. The first described type I opsins were classified as bacteriorhodopsins, 
blue light-driven outward proton pumps, first discovered in Halobacterium halobium in 1971 
(Figure 1.10 B)217. A second class of opsins, called the halorhodopsins, are yellow-light driven 
chloride pumps, that were originally discovered in the same species a couple of years 
later218,219. Third, channelrhodopsins are blue light-activated nonspecific cation channels, 
initially isolated from the green algae, Chlamydomonas reinhardtii220,221.  
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At first, these single-component microbial systems were thought to be unlikely to work in 
neurons and scientists rather focused on multicomponent strategies to control activity of 
specific cell types by light26. In 2002, a pioneering paper reported that upon co-expression of 
three components of the Drosophila phototransduction system (rhodopsin, arrestin-2, and 
the -subunit of a heterotrimeric G-protein) in mammalian neurons, electrical depolarizing 
currents and action potentials in these neurons could be driven by light222,223. Unfortunately, 
this system lacked the ability to elicit high frequency firing rates, probably due to its 
multiprotein nature221,222. Heterologous ligand-gated ion channels, combined with ligands 
that were rendered inert by photoremovable blocking groups, came up as an optogenetic 
system with a higher temporal resolution224,225. However, this approach still relied on 
diffusible ligands, whose time course of removal limited quick reversibility. Chemical gates 
that confer direct light-sensitivity to ion channels were shown to be able to switch action 
potential firing on and off very fast226. 
 
Figure 1.10: Basic principles of optogenetics. A. Optogenetics can be used for stimulation, using blue light-
sensitive channelrhodopsins, or inhibition, using yellow light-activated halorhodopsins, with a cell type-specific 
resolution, without losing the high time resolution of electrical stimulation. Electrodes cannot distinguish 
between different cell types, while the genetic factor of optogenetics makes this possible
26
. B. The main classes 
of microbial opsins used in optogenetics are bacteriorhodopsins, halorhodopsins and channelrhodopsins. 
Bacteriorhodopsins and halorhodopsins are ion pumps respectively pumping protons out of and chloride ions 
(Cl
-
) in the cell. Channelrhodopsins are cation channels, conducting less selectively cations, such as calcium 
(Ca
2+
), sodium (Na
+
), potassium (K
+
), and protons (H
+
), along their electrochemical gradient.  
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In 2005, for the very first time a type I opsin, more precisely channelrhodopsin-2 (ChR2), was 
successfully introduced into mammalian neurons, rendering these cells reliably responsive to 
light on a millisecond time scale227. Upon 473 nm light induced photoisomerization of 
retinal, the seven-pass transmembrane protein, ChR2, changes its conformation and allows 
the influx of protons (H+), sodium (Na+) and calcium (Ca2+) ions, as well as the efflux of 
potassium ions (K+), down their electrochemical gradient, leading to depolarization of the 
membrane, opening of voltage-gated Na+ and Ca2+ channels, and triggering action potential 
firing. Thus, the neurons are activated by light. On the contrary, bacteriorhodopsins and 
halorhodopsins hyperpolarize the targeted neurons upon illumination, leading to neuronal 
silencing (Figure 1.10)214,216.  
During a few hundred milliseconds of bright illumination of ChR2, the initially induced cation 
current decreases from an early peak to a stationary level (Figure 1.11 A). Remarkably, this 
initial peak is smaller upon a second light pulse following a short dark period, as compared to 
the first pulse upon a long period of dark-adaptation. These observations can be explained 
by the photocycle of ChR2, which is the transition cycle between closed and open 
conformations (Figure 1.11 B)26,215,228. The most recent and currently accepted photocycle 
model of ChR2 contains four main states: two closed non-conducting states and two open 
conducting states. Upon illumination, the dark-adapted closed ground state (Cstart) 
transforms into a conducting open state 1 (O1), resulting in an early strong but transient ion  
 
 
Figure 1.11: The ion current and branched photocycle of channelrhodopsin-2. A. Illumination of ChR2 evokes 
an initial ion current peak, equilibrating toward a lower stationary current. B. The branched photocycle model 
explains kinetics of ChR2 function with the existence of two open states and two closed states. The blue arrow 
represents illumination with a pulse of blue light. Adapted from Hegemann and Möglich
213
. Key: ChR2, 
channelrhodopsin-2; O1, conducting open state 1; O2, conducting open state 2; Cstart, closed ground state; Cdes, 
desensitized closed state. 
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current. Subsequently, O1 converts into open state 2 (O2), having lower conductance 
capacity and modified ion selectivity properties228, explaining the fast decrease in current 
amplitude upon illumination. Under continuous light conditions, O1 and O2 will be in 
equilibrium, O2 being the most important contributor, resulting in reduced stationary 
current reflecting a mixture of currents through O1 and O2. Upon light off, O1 mainly converts 
to the ground state, Cstart, while O2 changes into a desensitized closed state (Cdes)
213,229,230. 
Next, the transition of Cdes towards the original Cstart takes place, though is quite slow
230, 
justifying the slow reactivation of ChR2. Alternative light-induced transition of the Cdes into 
O2 is possible; however, this transition is of lower efficiency than the normal Cstart to O2 
transition229.  
4.2 EXPANDING THE OPTOGENETIC TOOLBOX  
Despite the success of wild type ChR2 in the first optogenetic reports, its rather small ion 
current and propensity towards desensitization are not ideal for all biological applications. 
Furthermore, blue light is not the best to use in high light-scattering media, such as 
mammalian brain tissue214. Thanks to both the discovery of new types of naturally occurring 
opsins and mutational engineering of known ones, the optogenetic toolbox has been 
expanding rapidly, resulting in dozens of light-sensitive proteins activated by various 
wavelengths of light, with numerous ion selectivity and kinetic properties, varying from 
millisecond to minute timescales17,26,213,216.  
4.2.1 Improving kinetic and conductance properties 
The deactivation time, the time between light cessation and channel closure, of wild type 
ChR2 is about 10-12 ms in neurons215,230. This means that when light pulses are offered at 
frequencies above 40 Hz, the next light flash will occur before all channels have closed and 
transformed back to the Cstart state (Figure 1.11 B)
215. Thus, cells that express more channels 
will have a larger pool of activatable channels left, and hence, remain more sensitive to the 
next light flash. With this, higher expression levels lead to faster kinetics. Codon 
optimization, formation of hybrid opsins, and the addition of membrane-trafficking 
stimulating modifications have improved the expression of microbial genes and 
incorporation of the proteins in the membrane of mammalian cells213,215.  
Besides better expression, mutational engineering affecting the transition between different 
states of the photocycle can also ameliorate the kinetic properties of an opsin, making it 
either faster or slower. By rapidly destabilizing the active conformation of retinal, channels 
that close very fast upon switching off the light have been generated, allowing for improved 
high-frequency action potential firing induced by series of light pulses. For example, the 
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E123T mutation of wild type ChR2 resulted in a new opsin called ChETA, an ultrafast cycling 
channel designed for high frequency stimulation of up to 200 Hz17,213,215,231. On the contrary, 
mutations that stabilize the active retinal isomer lead to prolonging the open state of the 
channel even after switching off light. These variants are called step-function opsins (SFOs). 
Deactivation time of SFOs vary from seconds to minutes as compared to the 12 ms of wild 
type ChR2. Strikingly, activated SFOs can be closed by amber light of 590 nm, pushing retinal 
isomerization towards the inactive state, allowing very tight control of their activation 
time17,232. By adding only two point mutations to the wild type ChR2 (ChR2-C128S-D156A), 
the stabilized SFO (SSFO) was generated, with an incredibly long deactivation time, 
approaching 30 min18. Furthermore, this SSFO is extremely light-sensitive, allowing non-
invasive stimulation of larger and/or deeper located brain regions. As for SFOs, SSFO can be 
closed with amber light. Therefore, SSFO can be turned on and off with very low power and 
very short-lasting light pulses of varying wavelengths. In contrast to fast-spiking opsins, 
which directly trigger action potential firing in illuminated neurons, SSFO activation increases 
the responsiveness to endogenous stimuli, by lifting the membrane resting potential closer 
to the threshold level17. Thus, the behavior of an SSFO-stimulated cell remains fairly natural, 
reducing the risk of adverse effects during prolonged and repeated stimulation regimes. 
Last year, as an alternative strategy to changing the opsin itself, synthetic retinal analogues 
were combined with microbial opsins to modify kinetic and spectral (section 4.2.2) 
properties. For example, compared to naturally all-trans retinal, dimethylamino-retinal slows 
down the photocycle of several ChR2 variants and also red-shifts their maximum wavelength 
sensitivity233. The big advantage here is that these new retinal analogues can be used to 
modify optogenetic characteristics in already existing cell or animal lines expressing certain 
opsins, simply by supplementing the medium or animal diet with the actual retinal 
analogues233.  
4.2.2 Changing spectral properties  
Besides modifying kinetic properties, defined by the photocycle, major efforts have been 
made to discover or generate variants of opsins with different properties of spectral peak 
activation17. As mentioned before, wild type ChR2 is maximally activated by 473 nm blue 
light. Unfortunately, due to its short wavelength, blue light is widely scattered when 
traveling through dense brain tissue234. Therefore, opsins with a red-shifted absorption 
spectrum are of great interest, as red light, with its longer wavelength, allows deeper 
penetration into brain tissue and thus larger volume illumination. For example, VChR1, 
discovered in Volvox carteri, is maximally activated by illumination with 589 nm yellow 
light235. Further molecular engineering improved the applicability of these newly discovered 
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red-shifted channels. As such, the creation of a chimeric opsin, named C1V1, containing 
parts of ChR1 and parts of VChR1, succeeded in combining the best properties of both 
channels - the large current and rapid kinetics of ChR1, combined with the red-shifted 
activation spectrum of VChR1215. Furthermore, by introducing mutations near the retinal 
binding pocket of existing opsins, color-shifts in spectral properties have been achieved17,213. 
As mentioned previously, the absorption spectrum might also be adapted by using 
chemically produced retinal analogues233. Characteristically, retinal derivatives with reduced 
numbers of double bonds have absorption maxima in the UV-light range, while retinal-based 
structures containing azulene rings absorb beyond 750 nm213. The downside of this approach 
is that the chemically produced chromophores need to be implemented into the biological 
system under study, which might lead to currently unknown side effects213.  
The discovery and design of opsins with different spectral properties has brought about the 
possibility to independently modulate distinct neural populations in the same region. The 
fundamental limitation in creating an independent two-color channelrhodopsin pair is that 
all non-chemical retinal-based opsins can be activated to some extent by blue light. 
Therefore, simply combining blue and red-shifted channelrhodopsins has its restrictions in 
terms of cross-activation. However, in 2014, Chronos and Chrimson, two newly discovered 
respectively blue/green and red drivable channelrhodopsins, have successfully been 
combined in two-color activation of neural spiking in separate cell populations in mouse 
cortical slices236. The success of this combination is based on the Chrimson spectrum being 
far more red-shifted than all previously described red-shifted opsins, and Chronos being 
extremely light-sensitive, allowing very faint blue light illumination to activate Chronos, 
without any cross-activation of Chrimson236.  
4.2.3 Inhibitory opsins  
Activating channelrhodopsins have been used extensively to study the function of specific 
classes of neurons within large intact networks. However, inhibiting specific neuronal 
populations might be of interest in order to study their role and necessity in certain 
biological processes by means of loss-of-function experiments. Typically, for this purpose, 
originally discovered halorhodopsins and bacteriorhodopsins, and engineered variants with 
improved kinetic and spectral properties, have been used to hyperpolarize neurons17,237. 
Natronomonas pharaonis halorhodopsin (NpHR) is one of the first halorhodopsins that was 
used in optogenetic setups and has its spectral absorption peak at 570 nm. More recently, a 
chloride pump, engineered from an opsin naturally expressed by Halobacterium salinarum, 
was named Jaws. Its novelty lies in the fact that it has the most red-shifted spectrum of any 
hyperpolarizing opsins to date238. Besides inward chloride pumps, also outward proton 
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pumps, such as Archaerhodopsin 3 (Arch) from Halorubrum sodomense and its more light-
sensitive version, ArchT, have been shown to effectively suppress neuronal signaling239,240. In 
contrast to channelrhodopsins, that are ion-conducting channels, halorhodopsins and 
bacteriorhodopsins are light-activated ion pumps, only capable of transporting one single ion 
per photocycle. As a consequence, these pumps require constant illumination of rather high 
intensity in order to induce hyperpolarisation of the host cell, making them less valuable for 
in vivo applications241. Effective inhibition with ion pumps has only been demonstrated in 
small tissue volumes close to the light source. However, substitution of one single amino 
acid, E90R, in the normally depolarizing cation channel, ChR2-T159C, in which the T159C 
mutation is responsible for better membrane targeting and retinal binding, resulted in a 
change in ion selectivity of the channel. Activation of ChR2-E90R-T159C, also known as 
chloride-conducting ChR (ChloC), leads to the rapid inward hyperpolarizing currents of 
chloride ions. Analogous to the activating SFOs, one extra mutation converted ChloC into 
slow ChloC (ChloC-D156N), showing a prolonged open state lifetime of about 10 s upon a 
short light flash and a much higher sensitivity to low light intensities as compared to ChloC. 
These new inhibiting optochannels have been shown to be efficient in preventing action 
potential triggering by shunting excitatory currents in hippocampal neurons237.  
4.2.4 Stimulation of non-neuronal cell types: biochemical optogenetics 
The optogenetic story started with modulating the excitability of neurons by the use of type I 
opsins. However, by now, optogenetics is reaching beyond neuroscience and is also being 
applied to non-excitable cells. As covered above, upon light dependent opening, 
channelrhodopsins allow H+, Na+, and Ca2+ to enter the cell. Besides the widely studied effect 
of depolarizing the membrane potential, these ion currents also have two other effects on 
the stimulated cell: reduction of the intracellular pH and elevation of the intracellular Ca2+ 
concentration. All three of these phenomena might modulate the activity level of neurons, 
but also of glial cells242. Indeed, the ChR2-mediated Ca2+ influx and/or pH decrease has been 
shown to induce adenosinetriphosphate (ATP) release from astrocytes242-244. Newly created 
knockin mouse lines, expressing ChR2(C28S)-YFP specifically in astrocytes or microglia, due 
to regulation by the Mlc1 or Iba1 promoter respectively, are making it possible to further 
engage optogenetics in glia research245. Furthermore, this ‘side effect’ of type I opsin 
stimulation might also be implemented in driving Ca2+-mediated signaling in a broad 
spectrum of other non-neural cells besides glia26.  
Even more promising for the use of optogenetics as a biochemical tool is the implementation 
of type II opsins. As mentioned before, type II opsins, like type I opsins, are light-sensing 
proteins that covalently bind retinal. However, these proteins are not transferring ions over 
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the membrane; it are seven-transmembrane G-protein coupled receptors (GPCR), 
communicating via the intracellular coupled G-protein. Since almost all cells exhibit G-
protein-based signaling pathways, all these signaling cascades can be modulated by means 
of type II opsins26. However, the interaction of type II opsins with these G-proteins is 
different from the native opsin coupled G-protein, transducin, as it is less efficient, 
sometimes resulting in rather aspecific signaling17. Development of chimeras between type II 
opsins and conventional ligand-activated GPCRs, called optoXR246, enables to combine the 
opsins’ light-sensitivity with the biochemical signaling functionality of specific GPCRs26,214. 
These tools allow non-invasive interference with intracellular biochemical signaling in freely 
moving animals, with very precise cell specificity and temporal resolution26.  
Recently, besides type II opsin GPCRs, other light-driven proteins and enzymes have been 
implemented into the optogenetic field. To assure usefulness as a tool for cell biological 
research, light-gated proteins should use light-sensitive cofactors that are ubiquitously 
present in the system of study, e.g. mammalian tissue, as was the case for the opsin 
cofactor, retinal. The first described examples are photoactivated adenylyl cyclases (PAC), 
derived from various microbial sources247-249. For example, PAC from the soil bacterium 
Beggiatoa uses the flavin chromophore for light-sensing and activation with blue light has 
been shown to induce reproducible cAMP increase in different cell types, from neurons248 to 
sperm250, with no need to add cofactors. Almost all signal-driven enzymes contain a signal-
sensitive sensor module and an effector module. By combining microbial photosensor 
modules, responsible for light-sensitivity, with effector modules of choice, new 
light-dependent protein complexes can be designed. One example is the red light-activated 
human cAMP/cGMP phosphodiesterase, which is a combination of the bacterial photosensor 
module of the Deinococcus radiodurans phytochrome, using bilin as a chromophore, and the 
effector module of Homo sapiens’ phosphodiesterase 2A. Since bilin is widely available in 
mammalian tissue, there is no need for addition of this cofactor251. Such experiments largely 
contributed to extend the optogenetic field from excitable neurons to essentially every 
biological cell type246. 
Yet another application of optogenetics, reaching far beyond conventional neuronal 
investigation, is its use to control gene transcription and epigenetic features252. One of the 
most exciting recent developments has been the light-inducible transcriptional effector 
(LITE) system, developed by Konermann et al.253 (Figure 1.12 A). It is comprised of two 
important components:  1) a customizable DNA-binding part fused to the light-sensitive 
cryptochrome 2 (CRY2) protein from Arabidopsis thaliana; 2) the interacting partner of CRY2, 
cryptochrome-interacting basic-helix-loop-helix 1 (CIB1), fused to an effector domain of 
choice. In the absence of light, component 1 binds to the promoter region of the target 
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gene, while component 2 is found in the nuclear compartment of the cell. Blue light 
illumination triggers a conformational change in CRY2 and subsequently recruits component 
2 to the DNA to mediate transcription modulation. Depending on the effector, this technique 
can be used to activate or repress gene expression253. In addition to gene expression, specific 
epigenetic chromatin modifications can also be obtained with the LITE system (Figure 1.12 
B). In this case, CIB1 is fused to a histone effector domain, which can be histone 
deacetylases, methyltransferases, or acetyltransferase inhibitors, as well as histone 
deacetylase or methyltransferase recruiting proteins, to change epigenetic characteristics of 
a specifically targeted DNA region253.  
 
 
 
 
Figure 1.12: The light-inducible transcriptional effector system. A. By combining optogenetics and 
transcriptional regulatory techniques, transcription can be modulated by illumination on a cell specific and 
narrow time resolution. B. The LITE system can also be applied to induce light-driven epigenetic modifications. 
Adapted from Konermann et al.
253
. Key: LITE, light-inducible transcriptional effector; Ac, acetyl group; CRY2, 
cryptochrome 2; CIB1, cryptochrome-interacting basic-helix-loop-helix 1.  
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4.2.5 In vivo delivery of light  
While light-driven proteins used in optogenetics have evolved during the past decade, as 
discussed in the previous paragraphs, so have light delivery methods. In vivo light delivery is 
challenging, since the mammalian brain tissue scatters light excessively, demanding the light 
source to be very close to the cells of interest. Furthermore, light delivery systems must not 
disturb the animals in their behavior214. Illumination of superficial cortical neurons can be 
achieved via small commercially available light-emitting diodes (LED), mounted over a 
thinned skull area or on top of a cranial glass window (Figure 1.13 A)214,254,255. In the first 
attempts to target deep brain regions, guide cannulas were permanently implanted and 
optical fibers, connected to a laser or LEDs, were temporarily inserted via the cannula at the 
time of the experiment (Figure 1.13 B)214,254,255. In order to avoid the risk of fiber breaking 
because of repeated insertion, to minimize brain damage, and to reduce the risk of infection 
because of environmental exposure of brain tissue through the cannula, the new approach is 
to permanently implant a short fiber segment reaching the target region that, during 
experiments, can be coupled to a long fiber connected to the light source (Figure 1.13 
C)214,254. An important breakthrough has been made through the design of novel wirelessly 
controlled systems, avoiding any free movement obstructions that come with conventional 
fibers and cables, and allowing for experiments with multiple mice being stimulated 
simultaneously, though independently, without the risk of becoming tangled in each other’s 
cables256-258.  
 
Figure 1.13: In vivo light delivery systems. A. Superficial areas can be illuminated by use of LEDs, placed above 
a cranial window. The LEDs are connected to a computer for programming the stimulation protocols. B. To 
reach deeper brain regions, a guide cannula is implanted permanently and an optic fiber, coupled to a light 
source, is guided through the cannula to reach the region of interest during illumination. The light source might 
be computer coupled to drive the stimulation protocol. C. A short fiber segment is permanently implanted to 
reach the targeted brain area, while a long optic fiber, connected to a light source and computer, can be 
transiently attached at the moment of stimulation. Adapted from Carter and Lecea
214
. Key: LED, light emitting 
diode. 
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4.3 OPTOGENETICS IN THE VISUAL SYSTEM   
As has been described in the preceding sections, optogenetics is a fast evolving field, and is 
currently being used by many research groups to address unique questions. This tool has 
also been successfully applied in the visual system to map neuronal networks, to study cell 
specific functionalities, and even to counteract neurodegeneration.  
In the retina, electrical activity induced by electrodes has been shown to enhance RGC 
survival in retinal dystrophies of photoreceptor degeneration. Retinal prostheses, based on 
electrodes transforming light into electrical signals, the normal function of photoreceptors, 
have shown very promising results, even in clinical trials25. However, until now, the main 
negatives have been the large dimensions of the electrodes, inflammation reactions upon 
implantation, and limited cell specificity. Here, optogenetics might offer a solution, since it 
overcomes the technical issues of implantation and offers very specific spatial resolution25. 
To this end, promising results have been obtained in multiple mouse models of retinal 
degeneration. Incorporation of ChR2 in ON-bipolar cells, which are depolarized in light and 
hyperpolarized in the dark, has been shown to protect RGCs from degenerating259, to 
improve visual task performance259, and to restore electrical responses at both retinal and 
cortical levels260,261. In contrast, similar approaches non-selectively targeting ON- and OFF-
RGCs did not elicit improved visual performance, possibly because of lower expression levels 
of the optochannels in this study and the simultaneous stimulation of light and dark 
pathways indistinctly262. Both in patients and animal models exhibiting photoreceptor 
degeneration, rod photoreceptors have been described to die quickly, whereas a 
subpopulation of cones turns inactive instead of dying263. Expressing the halorhodopsin 
NpHR in surviving but desensitized cones, can restore retinal circuit functionality, by 
mimicking the normal activity of cones, which is to become hyperpolarized upon light 
stimulation263. Since viral vector-mediated retinal gene therapy has been proven to be 
applicable in human patients264, including optogenetic genes in this therapeutic field seems 
quite reasonable and thus optogenetics might become clinically relevant in the future.  
Optogenetics has also been applied to further unravel the connections between and within 
the central visual areas. For example, ChR2 stimulation of spatially defined sets of mouse 
dLGN neurons resulted in different activation maps recorded from V1, confirming previously 
described retinotopic maps265. Furthermore, local optogenetic stimulation in the frontal eye 
field cortical area in primates, known to be involved in saccadic eye movements, yields 
activity in several other visual areas as detected by functional MRI measurements. This 
proves the applicability of optogenetics to non-invasively study neuronal network 
connections in awake animals266.  
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Besides network connections, the contribution of certain brain regions to a specific function 
can be elucidated with the help of optogenetics. For example, in mice that have learned to 
orient themselves towards a specific cue, unilateral ChR2-mediated stimulation of the SC 
evoked a bias to contralateral orienting movement, while unilateral NpHR mediated SC 
inhibition biased the mice to ipsilateral turning267. In line with this finding, optogenetic 
inactivation of SC neurons by use of the outward proton pump ArchT, resulted in clear 
deficits in saccadic eye movements towards visual targets in primates268. In addition, ChR2 
stimulation in the frontal eye field cortical area of primates shortened the latency time in a 
visually-guided saccade task266. Additionally, V1 function has recently been studied by 
optogenetics. As an example, ChR2-based activation of inhibitory interneurons has been 
used to transiently suppress overall neuronal V1 activity in mice. Suppressing V1 activity 
substantially impaired performance in perceptually demanding visual behavior tasks, such as 
detection of orientation and contrast changes, shedding light on the important contributions 
of V1 to visual perception269.  
Not only can the function of whole brain nuclei be addressed by optogenetics, but the 
specificity of this unique methodology also allows functional dissections, so that the relative 
contributions of individual cell types and their synaptic connections to specific brain 
functions can be discerned. This is evidenced by a study investigating the connections and 
interplay between different types of inhibitory interneurons in V1, by independently 
stimulating one or multiple cell types optogenetically, in combination with single cell 
electrical recordings270. Furthermore, to be able to specifically study characteristics of one 
source of input onto neurons that receive input from different sources, it is necessary to 
specifically silence all other inputs. By subsequently eliminating the reversible silencing 
effect, the effect of the other inputs can be taken into account as well. As such, through 
optogenetic activation of inhibitory interneurons, it has been established that local circuits 
arriving in V1 layer IV were silenced, leaving only thalamic input to this layer unchanged. 
Characteristics of this specific input could then be studied in greater detail, thanks to 
optogenetics271.  
In conclusion, optogenetics is finding its way to multiple physiological research fields, and 
has become an integral part of visual neuroscience research. 
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1 INTRODUCTION 
The retina is an extension of the central nervous system (CNS), specialized to capture light 
and transmit it into neuronal signals, which are then relayed to the brain through the optic 
nerve73. The optic nerve is comprised of axons that arise from retinal ganglion cells (RGCs), a 
population of neurons located within the innermost layer of the retina73. Glaucomatous 
optic neuropathies (GONs) are a complex, multifactorial group of diseases, characterized by 
degeneration of RGCs and their axons, resulting in visual field defects1,2,73. For the moment, 
the pathophysiological mechanisms underlying glaucomatous RGC degeneration are not 
completely understood. Although age, corneal thickness, and genetic background have been 
identified as important risk factors to develop the disease1, the only modifiable factor 
associated with glaucoma and the sole target for clinical intervention at present is increased 
intraocular pressure (IOP) or ocular hypertension (OHT)1,2,73. To better understand the 
contribution of different factors to disease progression, studies using animal models of 
experimental glaucoma have been indispensable. Mouse models are especially attractive 
based on their potential for genetic manipulation, short lifespan, and low cost12. 
Furthermore, the structure and physiology of the murine visual system is relatively similar to 
humans, making rodents valuable models to study healthy and diseased visual systems29.  
As OHT is strongly associated with the onset and progression of glaucoma, mouse models in 
which RGC degeneration is mediated through OHT induction are commonly used to study 
glaucoma12,73. OHT may be induced in rodents by obstructing the aqueous humor outflow 
through laser photocoagulation (LP) of the trabecular meshwork74-76 and/or the episcleral 
and perilimbal veins13,77-79, by cauterization of the episcleral veins80,81, by injection of 
hypertonic saline into the episcleral veins82, or by intracameral injection of microbeads 
occluding the trabecular meshwork12,71,83,272. Besides these various OHT models, IOP-
independent or normotensive RGC degenerative mouse models have also been 
developed12,73. The optic nerve crush (ONC) and optic nerve transection (ONT) models are 
defined by mechanical trauma to the optic nerve20,91,92. Although rather acute, these nerve 
injury models share important features with human glaucoma, where the primary injury to 
RGCs is also axonal and possibly occurs through OHT-related mechanical forces stressing 
axons in the optic nerve head (ONH)12. Moreover, impairment in the axonal transport, 
involved in the bidirectional communication between the retina and the brain, is an early 
event69, both in human glaucoma68 and in OHT-based glaucoma models10,73. In the ONC and 
ONT models, this transport is pronouncedly blocked by crushing or transecting the optic 
nerve12. As reduced retinal blood supply has been linked to glaucoma pathogenesis as well, 
induction of retinal ischemia has also been applied to study glaucomatous RGC death12. 
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Ischemia can be evoked by temporary ligation of the central retinal artery or by inducing 
local thrombosis by injection of Rose Bengal12,94,95. Additionally, intravitreal (ivt) delivery of 
excitotoxic compounds, such as the glutamate analogue, N-methyl-D-aspartate (NMDA), 
results in overstimulation of ionotropic glutamate receptors and subsequent excitotoxic RGC 
death. This model has mainly been applied in order to study a possible role for excitotoxicity 
in glaucoma64,65. However, the mechanism underlying excitotoxicity is not fully understood 
and some controversy exists concerning its role in human patients65. Although no 
experimental mouse model can fully encompass the complexity of human GON, each of 
them contributes to the step-by-step progression towards a real comprehension of this 
multifactorial disease. Within this PhD project, we chose two experimental mouse models to 
work with, each focusing on different aspects of glaucoma: the OHT model in which elevated 
IOP is induced by LP of the episcleral and perilimbal veins, and the normotensive ONC 
model.  
Several vision-related characteristics, such as aqueous humor dynamics273, IOP levels274-276, 
IOP diurnal rhythm276, sclera biomechanics275,277, photoreceptor density278, total number of 
RGCs35,279, RGC density279, central projection patterns279,280, and performance in visual acuity 
tasks281,282, have been reported to differ between mouse strains. Therefore, choosing the 
strain best-suited to address various research questions is essential. Of particular 
importance for glaucoma research is the difference in susceptibility to experimentally-
evoked RGC death83,275, the basis of experimental glaucoma models. In this context, the 
current study focused on three mouse strains, more precisely C57Bl/6, C57Bl/6-Tyrc, and CD-
1. The C57Bl/6 and CD-1 mouse strains are commonly used in glaucoma research13,74,77-
79,81,83,156,188,283. One major advantage of using CD-1 mice for the LP-induced OHT model, is 
the clearly visible ocular vasculature, allowing very precise laser targeting and minimal 
secondary damage to the eye284. However, because of the interest of the research group in 
studying the role of specific proteins in glaucoma by using transgenic mouse lines with a 
C57Bl/6 genetic background, together with the fact that CD-1 mice are visually 
impaired285,286 and might therefore be less suitable to use in vision-related research, effort 
was made to adapt the LP-induced OHT model for application in C57Bl/6 mice. 
Unfortunately, laser parameters cannot simply be transferred from CD-1 to C57Bl/6 animals 
as a consequence of absorption of the laser-energy by the ocular pigment. The tyrosinase 
deficient C57Bl/6 mice were put forward by Fu and Stretavan284 as a solution to work in a 
C57Bl/6 background, while also avoiding problems related to ocular pigmentation. This was 
the reason for including C57Bl/6, C57Bl/6-Tyrc, and CD-1 mice in this study. C57Bl/6-Tyrc 
mice share their genetic background with C57Bl/6, except for one homozygous null mutation 
in the tyrosinase (Tyr) gene. As a consequence of the mutated tyrosinase protein not being 
40   ________________________________________________________________   CHAPTER 2 
 
active, these mice show an oculocutaneous albinism phenotype287,288. CD-1 mice have a 
distinct genetic background but share the Tyr null mutation and the albino characteristics 
with the C57Bl/6-Tyrc animals. While both C57Bl/6 and C57Bl/6-Tyrc are inbred strains, 
thereby implying genetic homogeneity289, the CD-1 strain is an outbred strain possessing 
genetic heterogeneity290. 
The purpose of the experiments described here was to introduce, optimize, and characterize 
two experimental mouse glaucoma models. First, a comparison was made between a 
number of basic characteristics of the visual system of the three mouse strains, namely 
C57Bl/6, C57Bl/6-Tyrc, and CD-1 mice, focusing on IOP, RGC density, and retinofugal 
projections. Next, susceptibility of these three mouse strains to the LP-induced OHT and the 
ONC model was determined. Finally, following optimization, the unique RGC degeneration 
patterns in both models were outlined in detail.  
 
2 MATERIALS AND METHODS  
2.1 ANIMALS AND ANESTHETICS  
All experiments were approved by the KU Leuven Animal Ethics Committee and were 
conducted in accordance with the guidelines of the ARVO statement for the use of animals 
in ophthalmic and vision research. Adult C57Bl/6, C57Bl/6-Tyrc, and CD-1 mice at two to four 
months of age during the experimental period were housed under a 12/12h light/dark cycle 
with food and water available ad libitum.  
Surgical procedures to induce experimental glaucoma or intravitreal (ivt) tracer injection 
were performed under general anaesthesia, brought on by intraperitoneal (i.p.) 
administration of ketamine (75 mg/kg body weight, Anesketin, Eurovet, Belgium) and 
medetomidine (1 mg/kg body weight, Domitor, Janssen Pharmaceutics, Belgium). 
Additionally, a droplet of local analgesic, oxybuprocaine hydrochloride (0.4 %, Unicaïne, 
Théa, Belgium) was applied to the eye. After the procedure, atipamezole (1 mg/kg body 
weight, Antisedan, Pfizer, Belgium) was administered i.p. to reverse anaesthesia. During 
recovery, antibiotic tobramycin eye ointment (Tobrex, Alcon, TX, USA) was applied to the 
cornea of both eyes to prevent infection and desiccation and mice were placed on a heat 
pad to avoid hypothermia. 
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2.2 EXPERIMENTAL GLAUCOMA INDUCTION  
Experimental glaucoma was always induced in the left eye (oculus sinister, OS), while 
untreated eyes of naive animals served as external controls. For the detailed 
characterization of RGC degeneration patterns, the right untreated eye (oculus dexter, OD) 
of mice subjected to glaucoma induction was included in the study as well.  
2.2.1 Ocular hypertension  
Ocular hypertension (OHT) was induced through laser photocoagulation (LP) of the 
perilimbal and episcleral veins as described previously13,291,292. This technique was 
introduced into the research group via collaboration with Prof. M. Vidal-Sanz (Department of 
Ophthalmology, University of Murcia). After dilating the pupil by a droplet of tropicamide 
(1 %, Mydriacyl, Alcon, TX, USA) a 532 nm diode laser (Vitra, Quantel Medical, France) was 
employed to deliver laser burns to the vessels. The number of laser spots applied per eye, 
the laser power intensity, and the laser exposure time were optimized for each strain 
independently. For C57Bl/6 mice, 140 spots were delivered with a 0.1 W power and 0.05 s 
exposure time. For C57Bl/6-Tyrc mice, 100 spots were targeted to the veins with a laser 
power of 0.2 W and 0.5 s exposure time. For CD-1 mice, the vessels were coagulated with 70 
spots with a laser power and exposure time of 0.3 W and 0.5 s, respectively. Before and 
immediately after LP, funduscopy was performed to examine ischemic effects. Animals 
showing ischemia were excluded from the study. Depending on the experiment, mice were 
sacrificed at different time points post-LP (days post-injury, dpi), as clearly indicated in the 
Results.  
2.2.2 Optic nerve crush 
2.2.2.1 Traditional optic nerve crush  
Traditional optic nerve crush (ONC)293 was introduced into the research group via 
collaboration with Prof. M. Vidal-Sanz (Department of Ophthalmology, University of Murcia). 
The procedure was identically applied to all mice, regardless of the strain. A skin incision was 
made on the midline of the head running from the nose to between the ears. Next, the optic 
nerve was accessed by tightening the skin, making an incision in the superior orbital rim, 
dissecting the superoexternal orbital contents, cutting the superior and external rectus 
muscles, and tilting the globe. The connective tissue surrounding the optic nerve was gently 
removed and the optic nerve was crushed for 10 s with watchmaker’s forceps (SS/45, Fine 
Science Tools, Germany) at 1 mm behind the globe. Before and after surgery, funduscopy 
was performed to assess the perfusion of the retinal vasculature. Depending on the 
experiment, mice were sacrificed at 4, 7, and/or 14 dpi.  
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2.2.2.2 Mild optic nerve crush: optimization  
Based on the invasiveness and robustness of the traditional ONC model, several adaptations 
were made to the surgical procedure to obtain a less invasive and less severe ONC model 
(Table 2.1). Optimization of what became the “mild” ONC model was performed in C57Bl/6 
mice. In the first variation of the traditional ONC model, self-closing cross-action forceps 
(11262-30, Fine Science Tools, Germany) were placed behind the globe without any prior 
optic nerve exposure. The optic nerve together with the surrounding tissue was pressed for 
10 s. As tissue surrounding the optic nerve was not removed before the crush, this 
procedure was called the tissue-including ONC. For the second, third, and fourth forms of 
modified  ONC models, the optic nerve was neatly exposed as described previously294. A 
small incision was made in the conjunctiva near the temporal corner of the eye, the 
temporal canthus. By gently retracting the conjunctiva, the globe was then rotated nasally. 
Subsequently, blunt dissection was used to create a space between the temporal lateral 
rectus muscle and the inferior oblique muscle to expose the optic nerve. Connective tissue 
surrounding the optic nerve was gently removed. At this point, for the second and third 
variants of the more classical ONC model, the optic nerve was crushed 1 mm behind the 
globe for 5 s or 10 s using cross-action forceps (11262-30, Fine Science Tools, Germany) in 
order to provide constant and consistent pressure. These models were named the cross-
action ONC 5 s and cross-action ONC 10 s, respectively. In the fourth variation on the 
traditional ONC model, called the clamp ONC, after exposure, the optic nerve was 
mechanically pressed using micro aneurysm clamps (00396, S&T AG, Switzerland). These 
clamps were placed 0.5 mm behind the globe and remained positioned for 10 s. Before and 
after all ONC procedures, funduscopy was performed to ensure that the retinal blood vessels 
were in suitable condition. Animals were sacrificed at 4 and 7 dpi.  
Table 2.1: Various ONC models with their main characteristics. Key: ONC, optic nerve crush. 
Model Optic nerve exposure Crushing tool 
Distance to 
the globe 
Crush 
duration 
Traditional ONC Via superior orbital rim Watchmaker’s forceps 1 mm 10 s 
Tissue-including ONC Not exposed, blind crush Cross-action forceps Not determined 10 s 
Cross-action ONC 5 s Via temporal canthus Cross-action forceps 1 mm 5 s 
Cross-action ONC 10 s Via temporal canthus Cross-action forceps 1 mm 10 s 
Clamp ONC Via temporal canthus Aneurysm clamps  0.5 mm 10 s 
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2.3 ANTEROGRADE LABELING OF THE RETINOFUGAL PROJECTIONS  
To visualize retinofugal projections to the dorsal lateral geniculate nucleus (dLGN) and the 
SC, 2 µl of 0.5 % cholera toxin B subunit (CTB)-conjugated to Alexa Fluor-488 (C22841, 
Invitrogen, CA, USA), dissolved in 0.01 M phosphate-buffered saline (PBS) containing 0.5 % 
DMSO (Sigma-Aldrich, MO, USA), was injected ivt into the left eye. Injections were 
performed using a Hamilton syringe connected to a micromanipulator and a microinjector 
(Micro4 Microsyringe pump controller, World Precision Instruments, Sarasota, USA). After 
injection, the capillary was left in the eye for another 2 min to minimize reflux. Seven days 
after ivt tracer delivery, mice were anesthetized through i.p. administration of sodium 
pentobarbital (200 mg/kg body weight, Nembutal, Ceva Sante Animale, France) and 
transcardially perfused with 0.9 % NaCl, followed by 4 % paraformaldehyde (PFA, Acros 
Organics, NJ, USA) in PBS. Brains were dissected and post-fixed overnight in 4 % PFA. The 
dLGN and SC brain regions, between Bregma -1.70 mm and -4.84 mm, were sectioned in 50 
µm coronal sections, using the Micron H650 vibratome (Thermo Scientific, MA, USA) and 
stored in PBS with 0.004 % sodium azide (Schuchardt, Germany) at 4°C until 
immunohistochemistry (IHC). 
2.4 INTRAOCULAR PRESSURE MEASUREMENT 
As reported in literature273,275,276,295 and based on personal experience, anesthetics are 
known to highly influence IOP. Furthermore, IOP has been described to follow a diurnal 
rhythm which peaks during the dark period276. Therefore, using a calibrated rebound 
tonometer (Tono-Lab, Icare, Finland), the IOP was measured in awake animals and at a 
defined daily time point, specifically between 8:00 and 10:00 A.M.. To compare 
normotensive IOPs between the three strains, IOP was repeatedly measured, five times a 
week during three weeks. In addition, in relation to the OHT model, IOP was followed up 
before and every 24 h up to 7 dpi. To obtain consistent and reproducible results, with 
exclusion of accidental incorrect measurements due to blinking of the eye or an imperfect 
angle or distance between the tonometer and the cornea, ten measurements were made 
consecutively in each eye. The two lowest and two highest values were excluded and the 
remaining values were averaged.  
2.5 IMMUNOHISTOCHEMISTRY  
Eyes were enucleated with curved forceps and fixed for 1 h in 4 % PFA. After rinsing in PBS, 
retinas were dissected and flat-mounted on filter paper. The flat-mounted retina was fixed 
in 4 % PFA for 1 h and transferred to PBS until further processing. On these whole-mount 
retinas, IHC for Brn3a, a POU-domain transcription factor and a reliable marker for 
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RGCs20,91,188, was performed. Therefore, the retinas were placed in PBS containing 0.5 % 
Triton X-100 (Fisher Scientific, NY, USA) (PBST0.5). Next, the tissue was permeabilized in 
PBST0.5 by freezing for 15 min at −80°C. After rinsing, the whole-mounts were incubated 
overnight at room temperature with primary antibody, goat anti-Brn3a (1:500, sc-31984, 
Santa Cruz Biotechnology, TX, USA), diluted in PBS containing 2 % rabbit pre-immune serum 
(Invitrogen, CA, USA) and 2 % Triton X-100. Next, the samples were washed in PBST0.5 and 
incubated with a secondary antibody, Alexa Fluor-conjugated rabbit anti-goat IgG (1:500, 
Invitrogen, CA, USA), diluted in PBS containing 2 % Triton X-100. Finally, they were rinsed 
three times in PBST0.5 and once in PBS, mounted with the vitreous side up on a microscope 
slide and covered with Mowiol (Sigma-Aldrich, MO, USA) and a cover slip. The stained retinal 
whole-mounts were imaged with the FV1000-M multiphoton microscope (Olympus 
Corporation, Japan), controlled by Fluoview 4.0 software.  
The brain sections were stained for vesicular glutamate transporter 2 (VGluT2), a discrete 
marker for presynaptic glutamatergic terminals that can be used to delineate dLGN 
boundaries296 and different layers of the SC297. The vibratome sections were placed on 
gelatin-coated microscope slides and dried overnight at 37°C. After rehydration, the sections 
were permeabilized in PaxD buffer, PBS containing 5 % bovine serum albumin (BSA, PanReac 
Applichem, Germany), 0.3 % Triton X-100 (Fisher Scientific, NY, USA), and 0.3 % sodium 
deoxycholate (Sigma-Aldrich, MO, USA). After blocking for 1 h in 0.01 M Tris-buffered saline 
(TBS) containing 0.5 % blocking reagent (Perking Elmer, MA, USA) (TNB) and 20 % normal 
donkey serum (Invitrogen, CA, USA), sections were incubated overnight with rabbit anti-
VGluT2 (1:300, Invitrogen, CA, USA) diluted in PBS containing 0.3% Triton X-100 and 10 % 
normal donkey serum, and rinsed with PaxD. Subsequently, the secondary antibody, donkey 
anti-rabbit Alexa Fluor-647 (1:200, Invitrogen, CA, USA), was applied for 2 h, followed by 
rinsing with PaxD and 30 min incubation with 4’,6-diamidino-2-phenylindole (DAPI, 1 µg/ml 
in PBS, Dako, Denmark). Finally, the sections were cover slipped with Mowiol (Sigma-Aldrich, 
MO, USA). Immunofluorescence was imaged utilizing the FV1000-D laser confocal scanning 
microscope (Olympus Corporation, Japan), controlled by Fluoview 4.0 software. 
2.6 IMMUNOHISTOCHEMICAL ANALYSES  
The RGC density (number of RGCs/mm²) was calculated on images of Brn3a stained 
whole-mount retinas using an in-house script developed for freely available ImageJ software 
(National Institute of Health, MD, USA) (Geeraerts et al., manuscript in preparation). Briefly, 
in the first stage, RGC-like objects were automatically identified in the complete image based 
on local thresholding and selection criteria for size and shape. Next, the retinal surface was 
manually outlined and small areas determined to be excluded from further analysis, such as 
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artifacts, were marked. Finally, the selected retinal surface and the number of RGCs located 
herein were quantified. At this point, retinal images were transformed into pseudocolor 
isodensity maps to have a better view on the spatial differences in RGC density13,35,298, with 
the pseudocolor scale representing low (dark blue) to high (red) RGC densities. 
The RGC axon terminals, labeled via CTB tracing, were quantified using a script for freely 
available ImageJ software (National Institute of Health, MD, USA) developed by Drs. E. 
Geeraerts. Quantitative analyses were performed with the operator blind to the procedure 
in order to avoid biased results. Within the dLGNs, outlined based on VGluT2 IHC, four zones 
of interest were established, of which three were located in the dLGN contralateral towards 
the CTB-injected eye (Figure 2.1, left). The contralateral zone was defined as the main zone  
 
 
Figure 2.1: Zones of interest for quantitative analysis of CTB tracing towards the dLGN. LGNs contralateral 
and ipsilateral towards the tracer-injected eye are depicted left and right, respectively. Blue color illustrates 
theoretical projections to the dLGN from the CTB-injected eye. Key: CTB, cholera toxin B subunit; LGN, lateral 
geniculate nucleus; dLGN, dorsal lateral geniculate nucleus, IGL, intergeniculate leaflet, vLGN, ventral lateral 
geniculate nucleus.  
 
Figure 2.2: Zones of interest for qualitative analysis of CTB tracing towards the SC. Left: Top view on both SCi, 
contralateral and ipsilateral towards the tracer-injected eye. Right: Coronal sections related to the position of 
the dotted lines in the top view on the left. Blue color illustrates theoretical projections from the CTB-injected 
eye. Key: CTB, cholera toxin B subunit; SC, superior colliculus; SZ, stratum zonale; SGS, stratum griseum 
superficiale; SO, stratum opticum.  
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in which contralateral projecting RGC axons terminate. Within this contralateral zone and 
adjacent to the optic tract, a dense CTB-labeled small patch was occasionally visible and 
named the contra patch. Axon terminals originating from the contralateral eye, synapsing 
within the core of the zone that, in theory, was determined by ipsilateral projections, were 
defined as contra in ipsi region. The fourth zone of interest was the ipsilateral zone located 
within the dLGN ipsilateral towards the CTB-injected eye (Figure 2.1, right). On each coronal 
brain section, a defined number of circles (diameter 50 µm) were randomly placed within  
each zone: 10 for the contralateral zone, 1 for the contra patch (if visible), 1 for the contra in 
ipsi region, and 4 for the ipsilateral zone. In addition, on each image, two Ø 50 µm circles 
were placed in a non-CTB containing region of the section to allow for background 
correction. Within all circles, the intensity of the CTB signal per µm² was detected and, after  
background subtraction, a mean value was calculated per zone and per 
section.Contralateral, contra in ipsi region, and ipsilateral zones were analyzed on three 100 
µm spaced coronal sections per animal within the rostrocaudal region between Bregma -
2.10 mm and -2.60 mm. The contralateral patch was analyzed on every section between 
Bregma -2.40 mm and -2.80 mm showing this feature, and averaged per mouse.  
CTB-tracing towards the SC was qualitatively analyzed on sections between Bregma -3.16 
mm and -4.84 mm. The boundary between the visually driven superficial layers of the SC, 
including the stratum zonale (SZ), stratum griseum superficiale (SGS), and stratum opticum 
(SO), and the underlying deep SC, was outlined based on VGluT2 IHC. A scheme of the 
theoretical contralateral and ipsilateral RGC projection zones is depicted in Figure 2.2. 
2.7 STATISTICS 
Statistical analyses were performed using GraphPad Prism S5 (GraphPad Software, CA, USA). 
Outliers were determined via Grubbs’ test for outliers and excluded from further analyses. 
Using the Kolmogorov-Smirnov test, a normal distribution was verified and parallel equal 
variance between groups was tested. If the test requirements were fulfilled, a parametrical 
ANOVA was used to compare three or more groups and Bonferroni post hoc tests were used 
for pairwise comparisons between groups. To compare two independent groups, a Student’s 
t-test was performed. For all tests, a probability level (α-level was set to 0.05) of <0.05 was 
accepted as statistically significant.  
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3 RESULTS  
3.1 BASELINE CHARACTERISTICS OF C57BL/6, C57BL/6-TYRC, AND CD-1 MICE 
To evaluate whether baseline characteristics of the visual system differed between the three 
mouse strains under study, the IOP, RGC density, and retinofugal projections were 
investigated. 
3.1.1 IOP and RGC density 
In considering the baseline IOP, a significant variation between strains was detected. Strains 
can be arranged from the highest to the lowest IOP as follows: C57Bl/6-Tyrc > C57Bl/6 > CD-1 
(p<0.001, N=12, Figure 2.3 A). Baseline IOP of C57Bl/6-Tyrc mice was elevated by 17.6 ± 
1.3 % compared to C57Bl/6 mice and 26.3 ± 1.4 % compared to CD-1 mice. C57Bl/6 mice 
baseline IOP was measured 7.5 ± 0.7 % higher than IOP of CD-1 mice. Despite the 
significantly raised IOP in C57Bl/6-Tyrc mice, no effect on RGC density (3,104 ± 92.5 
RGCs/mm², N=10) was detected when compared to C57Bl/6 animals (2,954 ± 54.5 
RGCs/mm², N=10, Figure 2.3 B). Conversely, the CD-1 strain exhibited significantly higher 
RGC densities (3,798 ± 86.6 RGCs/mm², N=10) than both C57Bl/6 and C57Bl/6-Tyrc strains, 
with differences of 28.5 ± 2.9 % and 22.3 ± 2.8 %, respectively (p<0.001).  
 
 
Figure 2.3: Baseline IOP and RGC density in C57Bl/6, C57Bl/6-Tyr
c
, and CD-1 mice. A. As compared to C57Bl/6 
wild type mice, C57Bl/6-Tyr
c
 mice have a higher, while CD-1 mice have a lower, baseline IOP (N=12). B. RGC 
density does not differ between C57Bl/6 and C57Bl/6-Tyr
c
 strains, but CD-1 mice have a higher RGC density as 
compared to both Bl6 strains (N=10). Data are mean ± SEM. Significant differences are based on one-way 
ANOVA with Bonferroni post hoc test, *** p<0.001.  
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3.1.2 Retinofugal projections  
One week after monocular ivt delivery of the anterograde tracer, CTB, retinal projections 
towards the dLGN and sSC were studied on coronal brain sections of the three mouse 
strains. Prominent differences in patterns of retinal termination in the dLGN and SC were 
observed between C57Bl/6, C57Bl/6-Tyrc, and CD-1 mice.  
In the ipsilateral dLGN of C57Bl/6-Tyrc and CD-1 mice, the uncrossed projection appeared 
more diffuse as compared to the C57Bl/6 mice (Figure 2.4 A). In addition, the core of the 
ipsilateral zone within the contralateral dLGN was not delineated by a clear lack of CTB signal 
in albino mice. These observations were confirmed by quantification of the CTB signal 
(Figure 2.4 B). Indeed, ipsilateral projections showed a lower CTB intensity/µm² value, which 
is to be interpreted as a lower density of RGC axon termini, for both albino strains (N=3) as 
compared to the C57Bl/6 strain (N=4) (p<0.01). Moreover, for the pigmented mice, lower 
densities were measured for contralateral RGC axons terminating within the core of the 
ipsilateral zone (p<0.001 versus C57Bl/6-Tyrc, p<0.01 versus CD-1). This is in line with the fact 
that the ipsilateral core within the contralateral dLGN was observed as a black hole in the 
CTB signal in pigmented C57Bl/6 mice, but not in the albinos, C57Bl/6-Tyrc and CD-1. In 
addition, in C57Bl/6 animals, the CTB signal intensity/µm² did not differ between the 
contralateral zone within the contralateral dLGN and the ipsilateral zone within the 
ipsilateral dLGN. However, in C57Bl/6-Tyrc and CD-1 mice, ipsilateral projections showed  
 
 
Figure 2.4: CTB-labeled RGC axon terminals in the dLGN contralateral and ipsilateral to the tracer-injected 
eye in C57Bl/6, C57Bl/6-Tyr
c
, and CD-1 mice. Patterns of retinal termination in the dLGN differ between mouse 
strains. A. In C57Bl/6-Tyr
c
 and CD-1 mice, the ipsilateral projection is more diffuse as compared to the C57Bl/6 
mice and no clear hole is delineating the core of the ipsilateral zone within the contralateral dLGN. The dLGN is 
outlined based on VGluT2 IHC. B. In C57Bl/6 mice (N=4), there is no difference in the density of ipsilateral or 
contralateral projecting RGC axon termini. In contrast, in C57Bl/6-Tyr
c
 (N=3) and CD-1 mice (N=3), ipsilateral 
termini are less dense compared to contralateral projections. When comparing ipsilateral projections between 
strains, both albino strains show lower values as compared to the pigmented C57Bl/6 strain. In addition, 
C57Bl/6-Tyr
c
 and CD-1 mice have more contralateral projecting RGCs terminating within the ipsilateral core. C. 
In C57Bl/6-Tyr
c
 mice (N=3), the density of RGC axon terminals within the contralateral patch (depicted in D) is 
higher compared to the density within the normal contralateral zone. For CD-1 mice (N=2), this difference is 
less clear. D. Separated from the main zone of contralateral axon terminals, a patch of contralateral axon 
terminals (arrowheads) is detected in all four C57Bl/6-Tyr
c
 (upper panel) and in two out of four CD-1 mice 
(lower panel). This phenotype is never observed in C57Bl/6 wild types. To facilitate interpretation, compare 
these data to Figure 2.1 in the Materials and methods section. Data in B and D are mean ± SEM and significant 
differences are based on two-way ANOVA with Bonferroni post hoc test in B and Student’s t-test in D, *p<0.05, 
**p<0.01, ***p<0.001. Scale bars: 100 µm. Key: CTB, cholera toxin B subunit; dLGN, dorsal lateral geniculate 
nucleus; contra, contralateral; ipsi, ipsilateral; VGluT2, vesicular glutamate transporter 2; IHC, 
immunohistochemistry.  
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lower CTB intensity/µm² values versus contralateral projections (p<0.01 for C57Bl/6-Tyrc, 
p<0.001 for CD-1). These results suggested a less clear segregation of eye-specific zones and 
reduced, or at least more diffuse, ipsilateral projections in C57Bl/6-Tyrc and CD-1 strains 
compared to C57Bl/6 animals. An even more striking observation was made upon more 
detailed investigation of the contralateral dLGN. A cluster of contralateral axon terminals 
appeared separated from the other contralateral projections in two out of four CD-1 mice 
(Figure 2.4 D, lower panel) and in all four C57Bl/6-Tyrc mice (Figure 2.4 D, upper panel), 
while such a patch was never observed in C57Bl/6 wild types. This patch was located in the 
caudal dLGN, adjacent to the optic tract. In CD-1 animals, the patch was only visible on 1 
section of a 100 µm separated series of 50 µm sections, while in the C57Bl/6-Tyrc mice, the 
patch was noticed in 5 to 6 serial sections, thus spreading over a distance of about 500 µm 
over the anteroposterior axis. Quantifying the density of this CTB signal revealed that in the 
C57Bl/6-Tyrc strain, RGC axon termini within this patch were more dense versus the main 
contralateral zone measured within the same sections (p<0.05, Figure 2.4 C). This difference 
was less pronounced in CD-1 mice. Of note, for the CD-1 mice, no statistics could be 
performed because only two mice exhibited this phenotype.  
As for the retinogeniculate projection, differences between strains were also observed for 
the retinal input of the SC. For all three strains, contralateral projecting RGCs terminated in 
superficial layers of the SC (sSC), including the SZ, SGS, and SO (Figure 2.2). Ipsilateral 
projecting RGC axon terminals only appeared in the lower part of the SO and to a slight 
extent in the upper part of the underlying stratum griseum intermediale (SGI). Rostral in the 
SC, ipsilateral projections formed distinct patches along the lateromedial axis (Figure 2.5, 
upper panels, arrows). Along the anteroposterior axis, the ipsilateral zone extended as a 
tube running parallel to the brain midline (Figure 2.5, middle and lower panels, unfilled 
arrowheads). Similar to what was seen in the dLGN, ipsilateral RGC derived SC input was less 
dense and less delineated in C57Bl/6-Tyrc and CD-1 compared to C57Bl/6 animals. The 
disparities were most pronounced when comparing C57Bl/6 with CD-1. Although ipsilateral 
patches were visible in the rostral SC of CD-1 mice, the patches appeared more 
interconnected. Furthermore, the anteroposterior tube was less round and more stretched 
along the lateromedial axis. C57Bl/6-Tyrc ipsilateral projection features could be described as 
being in-between the C57Bl/6 and CD-1 phenotype. Rostral patches were more delineated 
compared to CD-1; however, less densely CTB labeled compared to C57Bl/6. Furthermore, 
the anteroposterior tube appeared less delineated and slightly larger than what was 
observed in C57Bl/6, but not as stretched as seen in the CD-1 strain.  
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Surprisingly, all C57Bl/6 and C57Bl/6-Tyrc mice exhibited a densely labeled small patch of 
ipsilaterally projecting RGC axons terminating in the medial SZ (Figure 2.5, upper panels, 
filled arrowheads), which was only visible on 1 section of a 100 µm separated series of 50 
µm sections in both strains. This was never observed in CD-1 animals and might therefore be 
linked to the C57Bl/6 genetic background. 
3.2 SUSCEPTIBILITY OF C57BL/6, C57BL/6-TYRC, AND CD-1 MICE TO 
EXPERIMENTAL GLAUCOMA INDUCTION  
To assess the applicability of the three selected mouse strains in glaucoma research, the 
susceptibility of each strain to each of the two selected models of experimental glaucoma 
was investigated. To reduce the number of animals, the naive controls represented in 
section 3.1 were used for comparison to the experimental eyes of both the OHT and 
traditional ONC model.  
First, the effect of LP-induced OHT on RGC survival was studied. Following LP, successful and 
comparable OHT was obtained in C57Bl/6, C57Bl/6-Tyrc, and CD-1 mice (N=10, Figure 2.6 A). 
From 24 h post-LP onwards, a significant increase in IOP was measured, resulting in an 
average IOP of 41.9 ± 1.6 mmHg. This OHT was sustained for at least 3 d, after which the IOP 
gradually declined to baseline levels by 7 d post-LP. Although the IOP-profiles after LP were 
very similar, OHT-induction did have a different effect on the RGCs depending on the mouse 
strain (Figure 2.6 B). At 14 dpi, RGC densities in the LP eyes were 2,348 ± 131.3 RGCs/mm², 
2,297 ± 287.4 RGCs/mm², and 526 ± 84.6 RGCs/mm² for C57Bl/6 (N=11), C57Bl/6-Tyrc 
(N=10), and CD-1 (N=10) mice respectively. RGC survival was lower in CD-1 mice (13.1 ± 
6.7 %) as compared to C57Bl/6 (74.03 ± 3.83 %, p<0.001) and C57Bl/6-Tyrc (71.64 ± 9.0 %, 
p<0.001) mice. Isodensity maps of the retinas showed a sectorial pattern of RGC death on 
top of diffuse RGC loss in all experimental eyes (Figure 2.7). Furthermore, comparison of the 
median and interquartile range (IQR) indicated differences in interindividual variation within 
the strains (Figure 2.6 C). Interindividual variability was low for the C57Bl/6 (median 73.4 %, 
IQR 16.9 %) and CD-1 (median 12.2 %, IQR 8.1 %) strains; however, substantial variability was 
noticed for the C57Bl/6-Tyrc strain (median 81.3 %, IQR 42.9 %). Based on the low variability 
between CD-1 animals and the fact that LP was experienced easier to apply in albino 
compared to pigmented animals, CD-1 was the strain of choice for the LP-induced OHT 
model.  
 
MOUSE GLAUCOMA MODELS   ____________________________________________________   53 
 
 
 
Figure 2.6: RGC degeneration in OHT and ONC models of glaucoma in C57Bl/6, C57Bl/6-Tyr
c
, and CD-1 mice. 
A. LP treatment of one eye results in temporary monocular hypertension. IOP patterns are similar for C57Bl/6, 
C57Bl/6-Tyr
c
, and CD-1 mice (N=10). IOP measured before LP is presented as 0 dpi. B. RGC survival at 14 d post-
LP is lower in CD-1 mice (N=11) compared to both Bl6 strains (NC57Bl/6=10, NC57Bl/6-Tyrc=11). C. Interindividual 
variation in RGC survival rates is highest within the C57Bl/6-Tyr
c
 strain (N=11). Mice of the C57Bl/6 (N=10) and 
especially of the CD-1 (N=11) strain show less variability in the amount of OHT-induced RGC degeneration. D. 
ONC results in similar survival rates of RGCs at 7 dpi in the three strains under study (N=11). E. ONC-induced 
RGC degeneration is very reproducible based on very low interindividual variation between RGC survival rates 
(N=11). Data in A, B, and D are mean ± SEM, data in C and E represent individual animals with median and IQR 
per strain. Significant differences are based on ANOVA with Bonferroni post hoc test with ***p<0.001.  Key: 
OHT, ocular hypertension; ONC, optic nerve crush; LP, laser photocoagulation; IOP, intraocular pressure; RGC, 
retinal ganglion cell. 
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Figure 2.7: Isodensity maps of representative naive and glaucomatous retinas of C57Bl/6, C57Bl/6-Tyr
c
, and 
CD-1 mice. OHT induces both sectorial and diffuse RGC death, while in the ONC model, only diffuse RGC 
degeneration is detected. Numbers indicate percentages of surviving RGCs compared to naive. The 
pseudocolor scale represents low (dark blue) to high (white) RGC densities. Key: OHT, ocular hypertension; 
ONC, optic nerve crush; RGC, retinal ganglion cell; dpi, days post-injury.  
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In contrast to the OHT model, the effect of traditional ONC on RGC survival in the three 
mouse strains was largely comparable (N=11). At 7 dpi, RGC density of crushed eyes was 
1,150 ± 22.4 RGCs/mm² for C57Bl/6 mice, 1,162 ± 32.1 RGCs/mm² for C57Bl/6-Tyrc mice, and 
3,172 ± 56.6 RGCs/mm² for CD-1 mice; representing 38.4 ± 0.7 %, 37.4 ± 1.0 %, and 31.0 ± 
0.8 % RGC survival, respectively (Figure 2.6 D). CD-1 mice tended to be slightly more 
susceptible to ONC-induced RGC death, although this trend was not statistically significant. 
Isodensity maps of the ONC retinas showed diffuse RGC loss throughout the retina (Figure 
2.7). Based on median and IQR, there was a low interindividual variability for all three strains 
(Figure 2.6 E). Median and IQR values were 38.9 % and 2.2 % for the C57Bl/6 strain, 37.8 % 
and 4.7 % for the C57Bl/6-Tyrc strain, and 30.8 % and 3.6 % for the CD-1 strain. 
3.3 FURTHER OPTIMIZATION OF THE ONC MODEL: LESS INVASIVE AND LESS ACUTE 
With the invasiveness and robustness of the traditional ONC model in mind, several 
adaptations were made to the surgical procedure in order to obtain a less invasive and less 
acute ONC model. This optimization was performed in C57Bl/6 animals. RGC counts 
measured in differentially crushed eyes were all compared to one group of naive animals 
(N=12). In the traditional ONC model at 4 and 7 dpi, 34.9 ± 2.2 % and 86.8 ± 3.6 % of the 
RGCs died (N=6, Figure 2.8 A). The tissue-including ONC group appeared to have less drastic 
RGC morbidity, with only 38.06 ± 11.45 % RGC death at 7 dpi, while no degeneration was 
detected at 4 dpi (N=6, Figure 2.8 B). Similarly, the cross-action ONC 5 s and 10 s animals 
showed no significant RGC degeneration at 4 dpi, though a noticeable trend was seen with 
7.4 ± 5.4 % and 10.7 ± 7.1 % RGC death induced by 5 s and 10 s of crush, respectively (N=5, 
Figure 2.8 C). At 7 dpi, however, RGC counts were diminished with 59.6 ± 2.2 % and 61.7 ± 
2.2 % for 5 and 10 s, respectively. Thus, duration of the cross-action crush did not have any 
impact on the RGC death at the time points included in this study, and therefore, data from 
the cross-action ONC 5 s and 10 s models were grouped together for analysis of 
interindividual variation. Clamp ONC showed degeneration rates of 21.4 ± 2.9 % RGC death 
at 4 dpi and 29.7 ± 6.3 % at 7 dpi (N=5, Figure 2.8 D). According to median and IQR 
determination, the tissue-including ONC exhibited the most variation between animals, 
while the other models elicited reproducible results (Figure 2.9). 
Overall, the results indicated that cross-action ONC was the model of choice. The procedure 
was less invasive, less acute, and evenly reproducible when compared to traditional ONC; it 
was also easier to apply than the clamp ONC. 
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Figure 2.8:  RGC degeneration patterns in the different versions of the ONC model. A. Traditional ONC induces 
progressive RGC degeneration at 4 and 7 dpi (N=6). B. First signs of RGC death induced by tissue-including ONC 
are visible at 7 dpi (N=6). C. Cross-action ONC results in RGC survival rates progressively decreasing from 4 to 7 
dpi (N=5). Although at 4 dpi, a slight reduction in the amount of RGCs is visible, this is not yet significant. 
Duration of the crush does not influence the degeneration pattern. D. Clamp ONC-induced RGC degeneration is 
detectable from 4 dpi onwards with no significant progression towards 7 dpi (N=5). Data are mean ± SEM and 
significant differences are compared to naive (N=12) based on ANOVA with Bonferroni post hoc test, **p<0.01, 
***p<0.001. Key: RGC, retinal ganglion cell; ONC, optic nerve crush; dpi, days post-injury. 
 
 
Figure 2.9: Interindividual variation in the different ONC models. Tissue-including ONC (N=6) exhibits large 
interindividual variation, while all other approaches, traditional (N=6), cross-action (N=10), and clamp (N=5) 
ONC, show low variability. Data are represented as individual values with mean and IQR. Key: RGC, retinal 
ganglion cell; dpi, days post-injury.  
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3.4 RGC DEGENERATION PATTERNS IN THE OHT AND ONC MODELS 
Based on the results described above, the two models of choice for further research were 
the OHT model applied to CD-1 mice and the optimized cross-action ONC model in C57Bl/6 
mice. From this point forward, cross-action ONC will be referred to as ONC. For both models, 
RGC degeneration patterns were characterized by Brn3a IHC performed at several time 
points post-injury (Figure 2.10).  
After OHT induction (Figure 2.10 A), RGC densities in the LP eyes were significantly reduced 
(p<0.001) at 5 dpi (3,010 ± 128.0 RGC/mm², N=8), 7 dpi (2,086 ± 140.9 RGC/mm², N=12), 14 
dpi (470 ± 42.9 RGC/mm², N=14), 21 dpi (337 ± 48.9 RGC/mm², N=9), and 28 dpi (477 ± 144.4 
RGC/mm², N=7) compared to naive animals (4,065 ± 107.0 RGC/mm², N=10) (Figure 2.10 B). 
RGCs died progressively between 5 dpi and 14 dpi, while the RGC density remained stable 
thereafter. A portion of the RGCs seemed to be insusceptible to OHT-induced damage, as 
even at 28 dpi, the latest time point included in the present work, 12 ± 3.6 % of the RGCs 
survived. On top of diffusely distributed RGC death all over the retina, a pie-shaped sectorial 
degeneration pattern was observed (Figure 2.11). Remarkably, while only the left eye was 
lasered, the right eye also showed a reduction in RGC density at 14 dpi (3,610 ± 120.5 
RGC/mm², N=5, p<0.05), 21 dpi (3,593 ± 55.8 RGC/mm², N=9, p<0.01), and 28 dpi (3,358 ± 
105.2 RGC/mm², N=7, p<0.001) with a decrease of 17 ± 2.8 % at 28 dpi versus naive.  
The onset of ONC-induced RGC death was situated between 4 dpi (3,102 ± 197.1 RGC/mm², 
N=5) and 5 dpi (2,550 ± 36.5 RGC/mm², N=3, p<0.001) (Figure 2.10 C), while at 3 dpi, RGC 
densities (3,429 ± 20.8 RGC/mm², N=4) were similar to naive condition (3,294 ± 29.4 
RGC/mm², N=9). Between 5 and 21 dpi, RGC degeneration progressed, with RGC density 
measured at 7, 14, and 21 dpi being 1,392 ± 59.3 RGC/mm² (N=10), 756 ± 99.2 RGC/mm² 
(N=6), and 376 ± 12.7 RGC/mm² (N=3), respectively. In the ONC model, the contralateral 
eyes showed RGC densities of 3,457 ± 67.8 RGC/mm² (N=22), comparable to naive retinas. 
ONC-induced RGC degeneration was diffuse throughout the retina (Figure 2.12). 
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Figure 2.10: RGC degeneration patterns induced by OHT and ONC. A. LP of the perilimbal and episcleral veins 
results in a steep IOP elevation at 1 and 2 dpi (N=52), returning to baseline levels by 7 dpi (N=42).  B. OHT 
induces progressive RGC degeneration in the LP eye (OS), reaching final levels at 14 dpi (Nnaive=10, N5dpi=8, 
N7dpi=12, N14dpi=14, N21dpi=9, N28dpi=7). In the contralateral eye (OD), degenerative effects are observed at from 
14 dpi onwards. C. ONC-induced RGC death is progressive between 4 and 21 dpi (Nnaive=9, N3dpi=4, N4dpi=5, 
N5dpi=3, N7dpi=10, N14dpi=6, N21dpi=3). No contralateral effects are seen in the ONC model. Data are mean ± SEM 
and significance is based on two-way ANOVA with Bonferroni post hoc test in comparison to OD (A) or naive (B 
and C) with * p<0.05, ** p<0.01, and *** p<0.001. Key: RGC, retinal ganglion cell; OHT, ocular hypertension; 
ONC, optic nerve crush; dpi, days post-injury; LP, laser photocoagulation; OS, oculus sinister; OD, oculus dexter.  
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Figure 2.11: LP-induced OHT yields progressive diffuse and sectorial RGC degeneration. RGCs are visualized 
through Brn3a IHC (left and middle panels). Middle panels are a magnification of the indicated area on the left 
panel. Right panels show isodensity map and the numbers indicate percentages of surviving RGCs compared to 
naive. The pseudocolor scale represents low (dark blue) to high (white) RGC densities. Scale bars left: 500 µm, 
middle: 50 µm. Key: OHT, ocular hypertension; RGC, retinal ganglion cell; dpi, days post-injury; IHC, 
immunohistochemistry.  
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Figure 2.12: ONC yields progressive RGC degeneration diffusely distributed throughout the retina. RGCs are 
visualized through Brn3a IHC (left and middle panels). Middle panels are a magnification of the indicated area 
on the left panel. Right panels show isodensity map and the numbers indicate percentages of surviving RGCs 
compared to naive. The pseudocolor scale represents low (dark blue) to high (white) RGC densities. Scale bars 
left: 500 µm, middle: 50 µm. Key: ONC, optic nerve crush; RGC, retinal ganglion cell; dpi, days post-injury; IHC, 
immunohistochemistry. 
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4 DISCUSSION  
Glaucoma is a heterogeneous group of disorders in which progressive degeneration of RGC 
axons in the optic nerve and apoptosis of RGC soma in the retina result in progressive visual 
field deficits and blindness1,2,12,73. Animal models of glaucoma are essential to elucidate the 
underlying pathophysiological mechanisms and to develop therapeutic strategies to halt or 
even reverse disease progression12. Therefore, the first goal of this PhD project was to 
introduce a mouse model of glaucoma into the research group. A wide variety of studies use 
different mouse models for glaucoma, applied in various mouse 
strains13,20,35,79,83,156,283,284,291,292. Here, several vision-related basic characteristics were 
compared between three strains, C57Bl/6, C57Bl/6-Tyrc, and CD-1. Next, the susceptibility of 
these mice to experimentally-induced RGC degeneration through LP-induced OHT or ONC 
was investigated to determine the best strain-model combination for further research. 
Temporal RGC degeneration patterns were characterized in the models of choice. 
4.1 BASIC VISUAL SYSTEM CHARACTERISTICS DIFFER BETWEEN C57BL/6, 
C57BL/6-TYRC, AND CD-1 MICE 
As a first visual system-related feature, baseline IOP was determined. The IOP is of particular 
importance in relation to glaucoma research because elevated IOP, also called OHT, is 
strongly associated with the initiation and progression of RGC degeneration12,73. Moreover, 
the only clinically approved treatments for glaucoma at present, involve pharmacological or 
surgical therapy to reduce the IOP12,73. Small but significant differences were observed in IOP 
when comparing the three mouse strains under study. Compared to the C57Bl/6 mice, the 
IOP of C57Bl/6-Tyrc mice was higher and in CD-1 mice, it was lower. Variations in IOP 
amongst genetically distinct strains of mice have been reported before, with average IOPs 
ranging from 10 to 20 mmHg273-276. These dissimilarities are attributed largely to differences 
in resistance of the aqueous humor outflow pathway through the trabecular meshwork273. 
Interestingly, IOP values also vary between studies77,95,274,275,278,283,291-293, which might be 
attributed to different modes of IOP measurement and whether or what kind of anesthetics 
are used273,275,276. However, IOP values reported for CD-1 mice95,278,291,292 are generally lower 
compared to C57Bl/6 mice77,274,283,293, which is in line with the current results. Studies that 
were not able to distinguish between baseline IOP in CD-1 and C57Bl/6 mice275 might have 
missed the small difference because they measured in anesthetized animals. Furthermore, in 
accordance with the results presented here, elevated IOP in albino C57Bl/6 mice lacking 
tyrosinase activity compared to pigmented congenic animals has been documented 
previously276. Tyrosinase is the first enzyme of the melanin pigment production pathway and 
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converts tyrosine to L-3,4-dihydroxyphenylalanine (L-Dopa) and L-Dopa to dopaquinone276. 
Tyrosinase deficiency thus amounts to disregulated L-Dopa levels, possibly leading to various 
developmental consequences as L-Dopa is an important developmental regulator299. Indeed, 
a Tyrc null mutation in C57Bl/6 mice results in disturbance of anterior chamber angle 
development and this phenotype can be rescued by L-Dopa administration299. Incorrect 
development of the anterior chamber affects the aqueous humor outflow and may 
therefore account for the elevated IOP of C57Bl/6-Tyrc.  
Besides IOP, RGC densities were also compared between C57Bl/6, C57Bl/6-Tyrc, and CD-1 
mice. CD-1 mice were shown to have a higher RGC density versus both C57Bl/6 strains, 
which did not differ from each other. This is in agreement with previous reports, describing 
higher absolute RGC numbers12,20 and densities54 in CD-1 animals compared to the Bl6 
genetic background. Based on a heredity genetic study, genetic factors have been 
determined as the main contributor to variation in RGC numbers observed between 
different types of mice300.  
Not only eye features, such as IOP and RGC density, but also retinofugal projections were 
seen to be strain dependent. Under normal circumstances, partial decussation of RGC axons 
in the optic chiasm results in each brain hemisphere processing information of the opposite 
visual hemifield - that is, the right hemisphere “sees” the left visual field and vice versa301. 
Inappropriate retinofugal projections disturb these retinotopic visual field representations 
and may affect visual functioning. In both dLGN and SC, the ipsilateral projections appeared 
to be reduced in density, more diffuse, and less delineated in C57Bl/6-Tyrc and CD-1 mice 
when reviewed against the C57Bl/6 strain. Indeed, quantification of the ipsilateral RGC 
terminals in the dLGN revealed lower density in both albino strains. These results are in line 
with previous reports describing enhanced decussation of RGC axons at the optic chiasm 
associated with albinism or hypopigmentation in mice279,280,302-307, rats53,308, guinea pigs309, 
rabbits305,310, cats311-313, tigers314, and monkeys315. Also in humans, the crossing of RGC axons 
is enhanced in albinism301,316-318, typically associated with reduced visual acuity and 
diminished binocular vision301.  
The link between failure of melanin production as a consequence of tyrosinase deficiency 
and mistargeting of RGC axons was supported by rescue experiments, where the 
introduction of functional tyrosinase led to correction of visual projections in tyrosinase 
deficient mice305,319,320. As mentioned earlier, tyrosinase deficiency, a feature of both the 
C57Bl/6-Tyrc and CD-1 mice included in our study, results in decreased production of L-Dopa, 
a developmental regulator299. The timing of melanin, and thus L-Dopa, formation in 
pigmented mice coincides with the onset of RGC development and might possibly be 
involved in differentiation of RGCs321. In mice, development of contralateral projecting RGCs 
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starts at embryonic day 11.5 (E11.5) in the central retina, subsequently expanding to the 
peripheral retina until postnatal day 0 (P0)307. All ipsilateral projecting RGCs develop during a 
shorter time window, from E11.5 to E16.5307, in a defined part of the retina, the 
ventrotemporal crescent (VTC)40,280. However, during late embryogenesis, from E16.5 to P0, 
RGCs that develop in the VTC are directed to the contralateral hemisphere307,322. The 
expression of guidance receptors on growth cones determine whether RGC axons cross or 
do not cross at the optic chiasm. Indeed, growth cones of retinal axons expressing ephrin 
receptor B1 (EphB1) are repelled by ephrin-B2 expressing glia at the optic chiasm midline, 
and therefore, EphB1 expressing RGCs are directed to the ipsilateral optic tract323. Remains 
the question of how the regulation of guidance receptor expression is related to albinism. 
Zic2, inducing EphB1 expression68,69, and Islet2 are transcription factors spatiotemporally 
correlated with the development of RGCs that project ipsilaterally and contralaterally, 
respectively307. Early-born VTC-originating RGCs express Zic2 and project ipsilaterally, while 
late-born VTC-originating RGCs express Islet2 and project contralaterally307. Hence, external 
and/or internal, yet to be identified factors, potentially linked to L-Dopa signaling, that 
induce Zic2 or Islet2 specification might be time dependent. In accordance with this, 
Bhansali et al.307 demonstrated a delay in the production of VTC RGCs in the retina of albino 
mice. According to their findings, an altered cell cycle length and/or the failure of cells to exit 
the cell cycle at the proper time, culminates in fewer postmitotic RGCs at early stages. This 
disruption of the timing of neurogenesis was shown to be associated to altered Zic2 and Islet 
2 expression and thus perturbed regulation of ipsilateral and contralateral fate of VTC 
originating RGCs307.  
Besides reduced ipsilateral projection, eye-specific segregation, which is crucial for proper 
binocular vision324, was incomplete in C57Bl/6-Tyrc and CD-1 mice. In the dLGN contralateral 
to the tracer-injected eye of these mice, CTB labeling was visible across the entire dLGN, 
with thinning in regions corresponding to uncrossed projections observed on the opponent 
hemisphere. This is contrary to C57Bl/6 mice, where a black hole in CTB-signal delineated 
the core of the ipsilateral recipient zone in the contralateral dLGN. Quantification of 
contralateral terminals in the ipsilateral region confirmed this observation. Similar 
phenotypes have been described in a study comparing C57Bl/6 mice with the NMRI albino 
strain306. Notably, the RGC projection towards the dLGN was rescued in these NMRI mice by 
introduction of a yeast artificial chromosome carrying the mouse tyrosinase gene. These 
studies again revealed a crucial role for this single gene306.  
Furthermore, in the dLGN, a cluster of separated contralateral RGC axon terminals was 
observed adjacent to the zone where late-born contralateral RGCs, originating in the VTC, 
normally terminate304 in 50 % of the CD-1 mice and in all C57Bl/6-Tyrc mice included in this 
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study. Possibly the genetic diversity of the CD-1 outbred strain290 can explain why this was 
only visible in a fraction of the animals. Rebsam et al.304 described a similar contralateral 
patch in tyrosinase deficient C57Bl/6 animals, and using 1,1'-Dioctadecyl-3,3,3',3'-
Tetramethylindocarbocyanine Perchlorate (DiI) tracing, they showed that these axon 
terminals originate from VTC RGCs in the contralateral eye. As the patch is located close to 
the region innervated by normal late-born contralaterally projecting VTC RGCs, these may be 
the extra late-born VTC RGCs resulting from the disturbed timing of neurogenesis307. 
However, it remains to be established whether the VTC RGCs forming the contralateral patch 
in the dLGN are RGCs that would normally project ipsilaterally but changed their crossing 
behavior, or whether these RGCs were designed to project contralaterally but were 
misguided in the end304. 
The reduced density and rather diffuse appearance of the ipsilateral zones described for the 
dLGN was similarly observed in the SC of C57Bl/6-Tyrc and CD-1 mice when compared to 
C57Bl/6 animals, possibly indicating less eye-specific segregation in this subcortical area as 
well. In line with our SC observations, a study comparing retinal input towards the SC in 
pigmented versus congenic tyrosinase deficient rats detailed a patch-like arrangement of 
ipsilateral retinal input in the rostral SC in normal rats, whereas albino rats had a more 
evenly distributed and less dense ipsilateral projection53. As mentioned before, a disturbed 
timing during development could explain the imbalance of ipsilaterally and contralaterally 
projecting RGCs in tyrosinase deficient mice307. 
Even more striking, the results presented here show a densely labeled delineated patch of 
ipsilaterally projecting RGCs located medial in the SZ in C57Bl/6 and C57Bl/6-Tyrc mice, but 
not in CD-1 animals. In consequence, this feature seems to be connected to the C57Bl/6 
genetic background, in contrast to all previous differing characteristics that were related to 
the albino phenotype. No other studies describing ipsilateral and contralateral input towards 
the SC in mice280,325,326, rats53, or other rodents327-330 mentioned this patch. Only one study 
has accounted for generally sparse ipsilateral innervations of the SZ in C57Bl/6 mice325. 
In general, the three investigated visual system-related characteristics - IOP, RGC density, 
and RGC projection - all varied between the three mouse strains under study. Part of the 
dissimilarity can be attributed to the tyrosinase deficiency exhibited by C57Bl/6-Tyrc and CD-
1 mice, however other yet-to-be-defined genetic factors also appear to be at play.   
4.2 DIFFERENTIAL SUSCEPTIBILITY OF C57BL/6, C57BL/6-TYRC, AND CD-1 MICE 
TO EXPERIMENTAL GLAUCOMA INDUCTION 
Although divergent features, such as age, genetic background, reduced central corneal 
thickness, axial length, and diabetes have been associated to glaucoma, OHT is still 
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considered the main and only modifiable risk factor to develop this multifactorial 
disease277,331. Therefore, OHT-based glaucoma models are very relevant to study 
mechanisms underlying glaucomatous RGC degeneration73. Initially, our intention was to 
induce persistent OHT through obstruction of the trabecular meshwork by injections of 
microbeads into the anterior chamber of mice46,47,60. During the first year of this PhD 
mandate, much effort has been gone into optimizing this technically challenging procedure. 
Unfortunately, no consistent and reproducible IOP elevations and RGC death could be 
obtained. Therefore, another model for experimental OHT induction in mice was introduced 
into the research group, in close collaboration with an expert in the method, Prof. M. Vidal-
Sanz (Department of Ophthalmology, University of Murcia)13. LP of the episcleral and 
perilimbal veins reduces aqueous humor outflow, resulting in an IOP elevation that lasts for 
about four to six days13. Although this method has been described to be successful both in 
albino13,79,291 and pigmented76,77,332,333 mice, based on personal communications, CD-1 
animals were the most optimal to perform the initial experiments. The most important 
advantage of using CD-1 mice is the clear visibility of the episcleral and perilimbal vessels284. 
Unfortunately, as CD-1 mice suffer from visual impairment285,286, they are considered less 
suitable to use in vision-related research. Besides, our research group is particularly 
interested in investigating the role of specific proteins in glaucoma by using transgenic 
mouse lines with a C57Bl/6 genetic background. Therefore, we intended to adapt the LP-
induced OHT model for application in C57Bl/6 mice. Unfortunately, due to absorption of the 
laser-energy by the ocular pigment in these mice it was hard to find the optimal laser 
parameters. In this context, tyrosinase deficient C57Bl/6 mice might offer a solution to work 
in a C57Bl/6 background, whithout ocular pigmentation-related problems284. This was the 
rationale for including C57Bl/6, C57Bl/6-Tyrc, and CD-1 mice in our comparative study. 
However, as shown by the comparison of the basic characteristics between the three strains 
covered above, the tyrosinase mutation induces a more dramatic effect on the visual system 
than solely changing the pigmentation of the eye. Therefore, caution must be taken when 
choosing a specific strain to address a specific research question.  
After optimization of the laser parameters, independently for each strain, IOP profiles 
followed overlaying patterns. Despite similar OHT induction, CD-1 mice showed significantly 
more RGC death at 14 dpi compared to both pigmented and albino C57Bl/6 strains. This is 
supported by other investigations comparing susceptibility of CD-1 and C57Bl/6 mice to 
similar levels of OHT, induced through intracameral microbead injection, where higher 
degrees of RGC degeneration were observed in CD-1 mice35,83. Furthermore, matching up 
independent reports applying the LP-induced OHT model in CD-113,291 or in C57Bl/677,332,333 
mice also reveals more severe loss of RGCs in the CD-1 strain. Strain-specific differences in 
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sclera biomechanics have been proposed to promote or prevent the transmission of 
IOP-related mechanical pressure from the sclera to the RGC axons in the ONH and therefore 
be - at least in part - responsible for strain-specific variation in the extent of OHT-induced 
RGC death35,277. The less severe phenotype observed in C57Bl/6 and C57Bl/6-Tyrc mice might 
be considered an advantage with respect to mimicking the chronic slow degeneration 
observed in glaucoma patients. However, within the CD-1 strain, the interindividual 
variability was demonstrated to be smaller, increasing the statistical relevance of performing 
experiments with limited numbers of animals. Therefore, to study morphological and 
functional effects of OHT on the central visual pathway (Chapter 3) and to test a novel 
approach to protect RGCs from OHT-induced dying (Chapter 5), the CD-1 strain was chosen.  
Although IOP independent, the ONC model is considered to be a valid glaucoma model as 
well, since also in human glaucoma, the primary injury to RGCs is axonal12. This model can be 
used to study RGC degeneration induced by axonal injury at the ONH. Furthermore, ONC 
elicits molecular changes, similar to glaucoma models in which induced or intrinsic IOP 
elevation is involved294. Compared to the LP-induced OHT model, ONC was easier to perform 
and intersubject variability was shown to be very small. No optimization was needed to 
successfully apply the model in the three strains. As was the case for the OHT model, in the 
ONC model, CD-1 mice also tended to be slightly more susceptible to RGC degeneration, 
although this effect was not significant. Discrepancies in the responses of several mouse 
strains to ONC-induced RGC degeneration have been reported before334,335. The underlying 
reasons for this discriminative susceptibility remain to be clarified in more detail; however a 
complex interplay between different genes is thought to be involved334-336. In contrast to 
OHT induction, which quite indirectly influences RGCs, ONC acts on the RGCs directly334. 
Therefore, non-RGC intrinsic differences between strains that might be involved in the 
diversity of susceptibility to OHT-based RGC degeneration, such as sclera biomechanics35,277 
and glial responses334, are less probable to play a role in ONC-induced RGC degeneration334. 
This might explain why the genetic background-dependent difference in RGC vulnerability 
was more pronounced in the OHT model than in the ONC model. Based on the results 
presented here, the ONC model was decided to be equally utilizable in the C57Bl/6, 
C57Bl/6-Tyrc, and CD-1 mice. The same reasons that stimulated the optimization of the OHT 
model in C57Bl/6 mice, as discussed above, formed the basis to proceed using the C57Bl/6 
strain for optimization of the ONC model.  
4.3 OPTIMIZATION OF A MILDER ONC MODEL 
As the traditional ONC model, used to compare the susceptibility of different mouse strains 
to ONC, was rather invasive and induced fast RGC degeneration, leaving only about 65 % and 
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35 % survival at 4 and 7 dpi, respectively, alternative methods to crush the optic nerve were 
tested. The severity of ONC-induced RGC loss is believed to depend on several variables, like 
the distance from the crush site to the ocular globe293 as an example. Furthermore, the 
duration of the crush and the exact pressure applied to the axons might govern the 
difference between a partial and a complete crush293. In different research groups, ONC in 
mice has been induced at different distances from the posterior pole of the globe, ranging 
from 0.5 to 2 mm337-339, with crush applications varying from 5 s crushing with normal 
whatchmaker’s forceps337, to 1 s339, 3-5 s92, and 15 s340 using self-closing cross-action forceps, 
and even for 40 s by use of micro artery clips338. In the traditional ONC model, a normal 
watchmaker’s forceps was used and the crush site was located 1 mm behind the globe. In an 
attempt to better control the applied pressure, the use of self-closing cross-action forceps or 
pressure-balanced micro aneurysm clamps to crush the RGC axons was tested. The tissue-
including approach, in which the cross-action forceps were simply placed behind the eye 
without exposing the optic nerve before, showed large interanimal variation considering 
RGC degeneration, which may be ascribed to differences in buffering capacity of the tissue 
between the forceps and the optic nerve in different animals. As a result, although less 
invasive and less acute, the tissue-including ONC was no longer considered for further use. 
Exposing the optic nerve through a small incision in the conjunctiva was found to be less 
invasive and faster to perform compared to the traditional way of opening the skin 
overlaying the superior orbital rim. After exposure of the optic nerve to circumvent the 
surrounding tissue being included in the crush, traditional, cross-action, and clamp crushes 
showed equally low interanimal variability, suggesting that a consistent and reproducible 
crushing force was applied by either the watchmakers’ forceps, cross-action forceps, or the 
aneurysm clamps. Of note, in the present study, all experiments were performed by one 
investigator. As another person might press the watchmakers’ forceps slightly softer or 
harder, intersurgeon variation might reduce the comparability between experiments. 
Therefore, we still preferred a pressure-balanced method, using cross-action forceps or 
aneurysm clamps, over the use of normal watchmaker’s forceps, in order to obtain 
reproducible and consistent results, even when surgery is being performed by distinct 
investigators. Furthermore, the onset of significant RGC death occurred later when the crush 
was induced by cross-action forceps compared to the traditional forceps, and by 7 dpi, less 
RGCs had died in both the cross-action ONC and clamp ONC compared to the traditional 
model. Consequently, both new approaches were considered less acute, offering a larger 
window for neuroprotection of RGCs. When comparing degeneration patterns induced by 
cross-action versus clamp ONC, the latter showed significance in RGC death at 4 dpi already, 
but degeneration did not progress towards 7 dpi, leaving about 70 % of the RGCs alive; cross-
action ONC resulted in no significant RGC death at 4 dpi, progressing towards 60 % death at 
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7 dpi. The aneurysm clamps were designed for clamping veins with a diameter of 400 µm to 
1 mm, the smallest commercially available variants. As the mouse optic nerve is about 300 
µm in diameter, the applied pressure is probably lower than the theoretical value of 15 
g/mm. Moreover, the clamping surface is 1 mm wide, and thus, a rather large longitudinal 
part of the optic nerve is crushed, which is markedly different from the very localized crush 
site afforded by the fine tips of cross-action forceps. In our opinion, it might be interesting 
for future experiments to order custom-made clamps that better fit the anatomical 
dimensions of the mouse optic nerve. As such, it might be possible to induce slow but 
progressive and well-controlled RGC degeneration. Based on all these arguments, together 
with the fact that placing the clamps on the optic nerve is technically more demanding 
compared to a forceps based crush, the cross-action ONC was considered the best model for 
further experiments. In addition, as crushing for 5 s or 10 s did not affect RGC degeneration 
patterns, a crush of 5 s was applied in subsequent research, including characterization of a 
temporal pattern of RGC death, discussed below, and to study the role of neurotrophins in 
glaucoma (Chapter 5).  
4.4 DEGENERATION PATTERNS UPON OHT AND ONC  
Based on the results discussed so far, it is clear that the two glaucoma models of choice to 
perform in further experiments were the LP-induced OHT model applied in CD-1 mice and 
the cross-action 5 s ONC, from now on briefly called ONC, in C57Bl/6 mice. Before 
proceeding towards new investigations using those experimental glaucoma models, the time 
line of RGC degeneration was characterized.  
Worth mentioning are the remarkable variations in the number20,35,292,300,334,341,342 and 
density20,188,335,339,342,343 of RGCs in healthy mouse retinas discerned through appraising the 
literature. This inconsistency may be understood not only through genetic differences 
between the mouse strains, as discussed before, but also by the way RGCs are visualized, 
e.g. using Nissl staining334,336, IHC for a diversity of RGC markers91,344-347, reporter lines348-350, 
or retrograde tracing35, along with different imaging and quantification methods. This should 
also be taken into account when comparing degrees of RGC death described in experimental 
glaucoma models.  
In the present study, Brn3a IHC was used to label surviving RGCs. Brn3a+ RGCs were 
quantified across the entire retinal surface and expressed as number of RGCs/mm², as 
described in detail by Geeraerts et al. (manuscript in preparation). Brn3a is a transcription 
factor that is involved in RGC differentiation and dendritic modeling351, and has been 
documented to be an appropriate marker for specific labeling of approximately 85 % of the 
RGCs in C57Bl/6 mice20 and 94 % in CD-1 mice188. Brn3a is expressed in particular by RGCs 
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that project mainly contralaterally to the retinothalamic and retinocollicular pathway, the 
LGN and SC, but not the accessory optic, pretecal, or hypothalamic pathways352. Because 
Brn3a IHC yields nuclear staining91 with RGCs appearing as clearly distinguishable roundly-
shaped structures, counting is facilitated as compared to cytoplasmic markers such as 
Bex1/2346, also labeling axons overlaying the RGC cell bodies, which can complicate 
counting91. An advantage of using IHC to label surviving RGCs after injury over pre-injury RGC 
labeling through retrograde tracing from the target areas in the brain35 is that it leaves the 
possibility of studying post-injury axonal transport functionality (by use of tracers) and cell 
soma death (by use of IHC) in parallel. The loss of Brn3a expression is thought to be a sign of 
the cell entering the apoptotic pathway91 because Brn3a has been described to counteract 
the p53-mediated activation of Noxa and Bax, two pro-apoptotic proteins353, and to activate 
Bcl-2 and Hsp27, which promote cell survival354,355.  Therefore, although there is a slight 
disparity in time of Brn3a signal loss and actual cell soma disappearance, counting Brn3a-
labeled RGCs is considered a relevant estimation of ultimately surviving RGCs91.  
Upon OHT, RGC loss occurred diffusely throughout the retina with pie-shaped sectors of 
severe RGC death superposing the diffuse degeneration pattern, as clearly demonstrated by 
the isodensity maps. This pattern reflects a typical glaucomatous retinal degeneration 
pattern described in human patients356 and several animal models13,73,77,79,357. Although IOP 
elevation was acute and transient, which may be considered a disadvantage when keeping in 
mind the chronic feature of human glaucoma, OHT-induced degeneration continued after 
IOP had normalized. Indeed, a decrease in RGC density was apparent with increasing time 
post-LP until 14 dpi without further diminution thereafter, leaving 12 % of the RGCs. Using 
the same model in CD-1 mice, Salinas-Navarro et al.13 reported Brn3a-based survival rates of 
about 50 % at 7 dpi, which is in accordance with the present results, progressing towards 
20 % at 35 dpi. As no in-between time points were included in this study, we cannot exclude 
that the final degree of degeneration was already reached by 14 dpi, without further 
progression afterwards, similarly to what was shown by our results. Fu and Stretavan79, on 
the other hand, reported significant progression in RGC degeneration from 40 % loss at 14 
dpi to 80 % at 35 dpi. However, comparison is difficult, as in their experiments, Brn3b 
instead of Brn3a was used as a marker to label RGCs79. Furthermore, it is possible that the 
higher end point Brn3a+ RGC survival observed by Salinas-Navarro et al.13 is related to 
slightly lower levels of OHT achieved in their study, which reached two to three times the 
baseline levels, compared to IOPs in the current study rising three to four times above the 
baseline IOP. However, as exactly the same laser parameters were applied in a similar mouse 
strain, the difference in measured IOP values may instead be related to the effect of 
anesthetics on eye pressure273,275,276,295. Finally, variations in survival rates based Brn3a-
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labeled RGC counts might also be attributed to distinctive imaging and quantification 
methods, as mentioned earlier. In contrast to the stabilized RGC densities after 14 dpi 
observed here, a very recent report applying the LP-induced OHT model in C57Bl/6 mice 
shows progressive Brn3a-visualized RGC degeneration between 14 dpi and 28 dpi77. 
However, as already mentioned, LP-induced OHT is less acute when applied to C57Bl/6 
animals compared to CD-177, which might explain this discrepancy.  
Remarkably, and in direct contrast to the literature13,77,358, LP of the perilimbal and episcleral 
veins of one eye also resulted in a significant decrease in RGC densities in the contralateral 
eye from 14 dpi onwards. Other changes in the untreated fellow eye, such as micro-358-360 
and macroglial358 activation, have been reported before in this glaucoma model, and have 
been related to the presence of retino-retinal projecting RGCs, projecting from one retina to 
the other, representing between 0.006 and 0.03 % of the RGC population341. On the other 
hand, systemic immune responses might become activated after unilateral LP and spread 
towards the contralateral eye. Further research combining Brn3a IHC with micro- and 
macroglial investigation is needed to elucidate the possible relationship between 
contralateral glial responses described in the literature358-360 and the contralateral 
degenerative effects demonstrated by our data.  
Although not reinvestigated in this project, it is important for the convenience of the reader 
to recapitulate the different phases of RGC damage induced by the LP-induced OHT model in 
CD-1 animals, reported in depth before13. Firstly, within one week after LP, RGCs lose their 
ability to actively transport factors from the target areas in the brain towards the cell soma 
in the retina along their long axons. However, at this point, plenty of RGCs lacking retrograde 
transport capacity still label for Brn3a and are therefore considered alive but functionally 
impaired. Subsequently, passive diffusion from the optic nerve towards the cell bodies is 
blocked at the level of the ONH. Between one and five weeks post-LP, RGCs that were 
functionally impaired early after OHT induction, as shown by missing retrograde transport of 
tracers, also lost Brn3a immunoreactivity. A small portion of the original RGC population 
maintained the capacity of active retrograde transport, as well as passive diffusion over the 
ONH, and normal Brn3a expression levels. These RGCs seem not to be affected by OHT13.  
The second mouse model of experimental glaucoma in which the temporal degenerative 
pattern was characterized, was the ONC model. ONC-triggered retinal neurodegeneration 
had an onset between 4 and 5 dpi, progressively evolving towards a survival ratio of 12 % at 
21 dpi. Including later time points would be of interest to verify further degeneration as the 
RGC density had not stabilized yet. Notably, during the experimental period, no RGC 
degenerative effects were measured in the contralateral eye after unilateral ONC. RGC loss 
after ONC appeared diffuse and affected the whole retina, without any evidence of a 
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sectorial pattern, as was the case with the OHT model. Different RGC degeneration rates 
upon ONC have been reported by others337-339, reasoned to be caused by variations in 
experimental procedures, such as distance between the crush site and the globe293, and the 
duration and force of the crush12, as already discussed above. In general, complete 
transection of the optic nerve is considered more acute compared to ONC91. Indeed, 
research using C57Bl/6 mice and Brn3a-based visualization of surviving RGCs followed by 
automatic quantification in the whole retina, reported ONT-induced RGC death to start soon 
after axotomy, reaching significance by 5 dpi, when approximately 50 % of the RGCs had 
died20, compared to 23 % in the present ONC experiments. In the same ONT study, 
degeneration progressed rapidly between 5 and 9 d post-transection, after which no further 
significant decrease in RGC counts was measurable, with 11 % survival at the latest time 
point included, 21 dpi20. Retino-retinal projecting RGCs, of which the soma are located in the 
eye contralateral to the injured optic nerve, were also speculated to die after axotomy188. 
Indeed, RGC numbers in retinas contralateral to the transected optic nerve showed a 
decreasing trend in correlation to the time post-lesion188. However, this trend did not reach 
significance within the time scale of the study, with the latest time point being 14 dpi. Of 
note, as retino-retinal projecting RGCs only account for less than 0.03 % of the RGC 
population in mice341, their loss would probably not result in any statistically detectable 
consequence188. Remains of degenerated RGCs undergo phagocytosis by microglia, the 
resident macrophages of the retina. In case these RGC soma have been filled with retrograde 
tracer before injury, phagocytic microglia that engulf dead RGC bodies after injury, will also 
become tracer-labeled themselves. The presence of such tracer-containing phagocytic 
microglia in the retina contralateral to the transected optic nerve, underscored the 
hypothesis of RGCs dying in the retina contralateral to the injured optic nerve188. However, 
our results did not show any sign of RGC degeneration in the contralateral retina after 
induction of the optimized mild ONC.  
Overall, the temporal course of RGC degeneration was characterized in two models of 
experimentally-induced glaucoma, the OHT model and the ONC model. These degeneration 
profiles have contributed to the designation of the experiments presented in the following 
chapters of this manuscript. These two models each focus on separate aspects of human 
glaucoma. The OHT model is of great interest to study how elevated IOP leads to RGC 
degeneration and to test the effectiveness of IOP lowering therapies. On the other hand, the 
ONC model is of particular benefit when investigating how initial axonal injury progresses 
towards soma degeneration. Furthermore, when performing a partial ONC, in contrast to 
complete ONC or ONT, some axons are not initially damaged by the procedure itself but are 
susceptible to harmful factors in the consequential neurotoxic environment, resulting in a 
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second wave of degeneration12. This phenomenon is of use in the search for neuroprotective 
methods that prevent the death of RGCs which escaped damage from the primary insult. 
Whithin this PhD project, the OHT model was employed to study the effects of OHT on 
central visual areas in the brain, described in Chapter 3. Additionally, the role of 
neurotrophins in glaucomatous RGC degeneration was investigated using both the OHT and 
ONC model (Chapter 5).  
 
5 CONCLUSION 
Animal models of glaucoma are crucial in the search for complete knowledge of glaucoma 
pathogenesis. The results presented within this chapter, underscore the importance of 
carefully choosing the mouse strain and model best suited to address specific research 
questions. Prominent differences were illustrated amongst visual system-related features of 
C57Bl/6, C57Bl/6-Tyrc, and CD-1 mouse strains. After optimization, temporal RGC 
degeneration patterns were characterized in two mouse models of experimental glaucoma: 
the LP-induced OHT model in CD-1 mice and the optimized mild ONC model in C57Bl/6 mice. 
These degeneration profiles formed an important basis for the rest of the PhD work. 
Although neither model fully resembles human glaucoma, both are suitable to improve the 
understanding of the pathophysiology involved in glaucomatous damage to the visual 
system.  
 
 
  
 
 
 
 
 
CHAPTER 3  
EFFECTS OF OCULAR HYPERTENSION ON 
THE SUPERIOR COLLICULUS AND VISUAL 
CORTEX OF MICE  
 
 
The data presented in this chapter have been published:  
Dekeyster, E.*, Aerts, J.*, Valiente-Soriano, F.J., De Groef, L., Vreysen, S., Salinas-Navarro, 
M., Vidal-Sanz, M., Arckens, L., Moons, L. (* joined first authorship) Ocular hypertension 
results in retinotopic alterations in the visual cortex of adult mice. Current Eye Research 23, 
1-15 (2015) 
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1 INTRODUCTION 
Glaucoma refers to a group of optic neuropathies involving structural damage to the optic 
nerve, retinal ganglion cell (RGC) death and visual field defects. It is a leading cause of 
irreversible blindness worldwide and an increasingly important public health concern due to 
the aging world population62. While age is a significant causative factor, so far the only 
modifiable risk factor and sole target for clinical intervention is elevated intraocular pressure 
(IOP) or ocular hypertension (OHT)361-363. Glaucoma is a neurodegenerative disease affecting 
the entire visual system rather than the eye alone. Indeed, degenerative changes in several 
visual brain centers have been seen both in patients and in animal models of glaucoma7,96-
101,364. For example, several case studies of glaucoma patients describe atrophy of the lateral 
geniculate nucleus (LGN), thinning of the cortex, and activity alterations in the primary visual 
cortex (V1)7,100,102,103. Furthermore, metabolic activity changes in the LGN and V1, and also 
shrinkage and loss of neurons, micro- and macroglial activation, and structural dendritic 
plasticity in the LGN have been linked to glaucoma based on primate OHT models8,96,98,99,107-
115. In the murine optic nerve crush (ONC) model, cell loss in the superficial layers of the 
superior colliculus (sSC) has been described365 and in the murine N-methyl-D-aspartate 
(NMDA) excitotoxicity model, besides neuron loss, also glial reactivity has been revealed 
both in the LGN and the sSC117,118. Experimental elevation of the IOP in rats evoked similar 
subcortical glial responses119 and resulted in dendritic changes of both LGN and sSC 
neurons120. Also in DBA/2 mice, astroglial reactivity in the sSC has been reported to be 
associated with OHT119. Furthermore, impaired visual evoked potentials (VEP) have been 
described in the cortex of rats suffering from severe RGC damage upon ONC121, as well as in 
aged DBA/2 mice122. However, such VEP changes were not detected in rats subjected to an 
OHT model, despite reduced retinal function verified by histology and electroretinography 
(ERG)366. To our knowledge, effects on V1 and higher order visual areas have not been 
described so far in any murine OHT glaucoma model.  
The goal of the present study was to advance the knowledge on the effect of OHT on the 
adult visual system. Thereto, using the ocular hypertension (OHT) mouse glaucoma model, 
RGC degeneration patterns were analyzed and linked to morphological changes in the sSC 
and functional changes in V1 and higher order visual areas, V2 lateral (V2L) and medial 
(V2M), at an early and late time point after OHT induction. This study was performed in close 
collaboration with Dr. F.J. Valiente-Soriano (Department of Ophthalmology, University of 
Murcia, Spain), who performed the OHT inducing surgery, IOP follow up, and the RGC 
counts, and Dr. J. Aerts (Laboratory of Neuroplasticity and Neuroproteomics, KU Leuven, 
Belgium), who analyzed and interpreted the data on the visual cortex. Custom-made 
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MATLAB scripts for analyses of collicular and cortical data, were designed by Drs. S. Vreysen 
(Laboratory of Neuroplasticity and Neuroproteomics, KU Leuven, Belgium). Other 
procedures were performed by our own research group (Neural Circuit Development and 
Regeneration, KU Leuven, Belgium).   
 
2 MATERIALS AND METHODS  
2.1 ANIMALS 
All experiments were performed on male CD-1 mice of ten to twelve weeks old, housed in 
standard laboratory conditions under a 12/12h light/dark cycle with food and water ad 
libitum. The experiments were approved by the KU Leuven Animal Ethics Committee and 
followed the guidelines of the ARVO statement for the use of animals in ophthalmic and 
vision research. 
2.2 THE OHT MODEL: LASER PHOTOCOAGULATION AND IOP MEASUREMENTS  
Ocular hypertension (OHT) was induced in the left eye through laser photocoagulation (LP) 
of the perilimbal and episcleral veins as described previously, creating an increased 
resistance of aqueous humor outflow13,291. Briefly, a 532 nm diode laser (Quantel Medical, 
France) was used to deliver approximately 70 laser spots (0.5 s exposure time and 0.3 W 
power intensity) to the perilimbal and episcleral veins of animals, anesthetized with xylazine 
hydrochloride (10 mg/kg, Rompún, Bayer, Germany) and ketamine hydrochloride (75 mg/kg, 
Ketalar, Parke-Davis, MI, USA). During recovery, tobramycin eye ointment (Tobrex, Alcon, TX, 
USA) was applied to the cornea of both eyes to prevent desiccation. The intraocular pressure 
(IOP) was measured under general anesthesia (10 mg/kg xylazine and 75 mg/kg ketamine) 
before and at 24 h, 48 h and 7 days after LP using a calibrated rebound tonometer (Tono-
Lab, Icare, Finland).  
2.3 TISSUE PROCESSING  
At one and four weeks post-LP and prior to sacrifice, mice underwent an overnight dark-
exposure followed by 45 min of bright light to obtain an optimal visually evoked immediate 
early gene (IEG) expression367-371. Animals were anesthetized with sodium pentobarbital 
(200 mg/kg, Nembutal, Ceva Sante Animale, France) prior to cervical dislocation. Upon 
dissection, eyes were fixed for 1 h in 4 % paraformaldehyde (PFA) in 0.01 M phosphate-
buffered saline (PBS). Subsequently, retinas were dissected, flat-mounted, and post-fixed for 
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1 h in 4 % PFA. Brains were dissected, immediately frozen in 2-methylbutane at -40 °C, and 
kept at -80 °C until sectioning. Twenty-five μm-thick coronal sections were prepared on a 
cryostat (Microm HM 500 OM, Walldorf, Germany), mounted on 0.1 % poly-L-lysine (Sigma-
Aldrich, MO, USA)-coated slides and stored at -20 °C until further processing. 
2.4 IMMUNOHISTOCHEMISTRY  
Whole-mount retinas were stained for Brn3a, a POU-domain transcription factor and a 
reliable marker for healthy RGCs20,91,188. Retinas were permeabilized in PBS containing 0.5 % 
Triton X-100 (Fisher Scientific, NY, USA) (PBST0.5), frozen at -80 °C for 15 min, rinsed in 
PBST0.5 and incubated overnight at RT with primary antibody (goat anti-Brn3a, Santa Cruz 
Biotechnology, TX, USA), diluted 1:500 in PBS containing 2 % Triton X-100 and 2 % donkey 
pre-immune serum (Invitrogen, CA, USA). The next day, retinas were rinsed in PBST0.5 and 
incubated for 2 h with secondary antibody (Alexa Fluor-568-conjugated donkey anti-goat 
IgG, Invitrogen, CA, USA), diluted 1:500 in PBS containing 2 % Triton X-100. Retinas were 
subsequently rinsed in PBST0.5 and PBS before being mounted on glass slides with anti-
fading mounting medium Mowiol (Sigma-Aldrich, MO, USA). 
RGC synapses and reactive astrocytes were visualized on serial 25 µm transverse brain 
sections throughout the sSC (every 100 µm) by IHC for vesicular glutamate transporter 2 
(VGluT2) and glial fibrillary acidic protein (GFAP), respectively. Sections were post-fixed in 
4 % PFA for 45 min, rinsed in 0.01 M Tris-buffered saline (TBS) and incubated for 1 h in TBS 
containing 0.5 % blocking reagents (Perking Elmer, MA, USA) (TNB) and 20 % normal goat 
serum (Invitrogen, CA, USA), followed by overnight incubation at RT with primary antibody 
rabbit anti-VGluT2 (1:250 in TNB, Invitrogen, CA, USA) or rabbit anti-GFAP (1:1000 in TNB, 
Dako, Denmark). The next day, sections were rinsed in TBS, incubated for 2 h with secondary 
antibody (Alexa Fluor-488-conjugated goat anti-rabbit IgG, 1:200 in TNB, Invitrogen, CA, 
USA) and rinsed in TBS. Finally, a 4’,6-diamidino-2-phenylindole (DAPI, 1 µg/ml in PBS, Dako, 
Denmark) nuclear staining was performed for 30 min, before mounting with Mowiol (Sigma-
Aldrich, MO, USA). 
2.5 ANALYSIS OF IMMUNOHISTOCHEMICAL PATTERNS 
Brn3a stained whole-mount retinas were imaged with the Axioscop 2 Plus epifluorescence 
microscope (Zeiss, Germany) equipped with a digital high-resolution ProgResTM C10 
camera. Brn3a+ RGCs were automatically counted using the Image-Pro Plus 5.1 analysis 
program for Windows, as previously described13,35,298. Next, images of the retinas were 
transformed into pseudocolor isodensity maps using SigmaPlot 9.0, to have a better view of 
the spatial differences in RGC density13,35,298. The pseudocolor scale ranges from 0 (dark 
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blue) to 5625 cells/mm² (red) in 45 different steps. Mice with less than 20 % RGC death in 
the LP eye as compared to the right control eye were excluded from the study. 
Brain sections immunostained for VGluT2 or GFAP were photographed with the Axio Imager 
Z.1 epifluorescence microscope (Zeiss, Germany) equipped with an AxioCam MRm camera 
and analyses were performed using the Axiovision 4.8 digital image processing software 
(Zeiss, Germany). The sSC area, including stratum zonale (SZ), stratum griseum superficiale 
(SGS), and stratum opticum (SO), was outlined and within this region the immunopositive 
area was detected372. Analyses were performed on 100 µm spaced 25 µm sections within 
the rostrocaudal region between Bregma -3.50 mm and -4.30 mm, with the operator blind to 
the procedure to avoid biased results. Results are shown as the percentage of the 
immunopositive area over the total sSC area, relative to values in naive mice.  
To visualize topographic changes in the VGluT2 signal within the sSC, pseudocolour top view 
images representing VGluT2 levels were created, using a custom-made MATLAB script 
(MATLAB R2011b, The MathWorks Inc., Natick, MA) developed by Drs. S. Vreysen 
(Laboratory of Neuroplasticity and Neuroproteomics, KU Leuven, Belgium). The sSC area 
between Bregma -3.50 mm and -4.30 mm was delineated in 100 µm spaced 25 µm brain 
sections. For each section the mean optical density relative to the white matter was 
calculated within 20 equally spaced segments positioned along the curvature of the sSC in 
each hemisphere. The acquired data were projected spatially along the dorso-ventral axis to 
the horizontal plane and linearly interpolated to acquire a smooth image. The relative color 
scale ranges from a low fluorescent signal (dark blue) to a high fluorescent signal (red). 
2.6 HISTOLOGY AND NEURONAL CELL COUNTS  
Cryostat sections of the sSC were Nissl stained (Cresyl violet 1 %, Fluka Chemika, Sigma-
Aldrich, MO, USA) according to standard procedures, in order to visualize general 
morphology and cell density at four weeks post-LP. Images of the stained coronal sections 
were obtained with the Axio Imager Z.1 light microscope (Zeiss, Germany) equipped with an 
AxioCam MRm camera using the software program Axiovision Rel. 4.6. Cells exhibiting 
stained cytoplasm, pale nucleus, and stained nucleolus were defined as healthy neurons373. 
At four weeks post-LP, healthy neurons were counted within 8 frames of 10,000 µm² located 
in the affected zone of the sSC contralateral to the OHT eye, as well as in corresponding 
frames in the ipsilateral sSC as an internal control. Affected zones of the sSC were outlined 
based on VGluT2 staining on adjacent sections. Nissl analyses were performed on sections 
within the rostrocaudal region between Bregma -3.50 mm and -4.30 mm, on two sections 
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for each mouse (N=4). Cell counts were performed with the operator blind to the procedure 
in order to avoid biased results. 
2.7 IN SITU HYBRIDIZATION 
In situ hybridization (ISH) was performed with a mouse-specific synthetic oligonucleotide 
probe (Eurogentec, Seraing, Belgium) with sequence 
5’-ccgttgctcagcagcatcatctcctccagtttggggtagttgtcc-3’ for zif268. This oligonucleotide probe has 
been used successfully for the analysis of zif268 mRNA expression in the mouse brain in 
previous publications374-376. As described earlier377,378, the probe was 3’-end labeled with 
33P-dATP, using terminal deoxynucleotidyl transferase (Invitrogen, CA, USA). Unincorporated 
nucleotides were separated from the labeled probe with miniQuick SpinTM Oligo Columns 
(Roche Diagnostics, Brussels, Belgium). Series of cryostat sections spanning the primary 
visual cortex (every 100 µm, between Bregma -2.80 mm and -4.16 mm) were fixed, 
dehydrated and delipidated. The radioactively labeled probe was added to a hybridization 
cocktail (50 % (vol/vol) formamide, 4x standard saline sodium citrate buffer, 1x Denhardt’s 
solution, 10 % (wt/vol) dextran sulphate, 100 µg/ml herring sperm DNA, 250 µg/ml tRNA, 60 
mM dithiothreitol, 1 % (wt/vol) N-lauroyl sarcosine, 20 mM NaHPO4, pH 7.4) and applied to a 
series of cryostat sections (106cpm per section) for an overnight incubation at 37 °C in a 
humid chamber. The following day, sections were rinsed in 1x standard saline sodium citrate 
buffer at a temperature of 42 °C, dehydrated, air-dried and exposed to an autoradiographic 
film (Biomax MR, Kodak, NY, USA). Six days later, films were developed in Kodak D19 
developing solution, followed by fixation in Rapid fixer (Ilford Hypam, Kodak, NY, USA).  
For each mouse, autoradiographic images from three sections were scanned at 1200 dpi 
(CanoScan LIDE 600F, Canon, NY, USA). Pseudocolor maps were generated with a custom-
made MATLAB script (MATLAB R2011b, The MathWorks Inc., Natick, MA) developed by Drs. 
S. Vreysen, and represent a false coloring of the grey values: a low grey value is represented 
in black/green, a high grey value in white/yellow, indicating a low signal response or a high 
signal response, respectively. This is done in accordance with a grey scale ranging from black 
(0) to white (255). This allows for qualitative evaluation of ISH data.  
2.8 LOCALIZATION OF VISUAL AREAL BOUNDARIES WITH CRESYL VIOLET  
To anatomically delineate the areal borders of the different visual subdivisions in the visual 
cortex, a comparison was made with Nissl-counterstained sections as described 
previously45,357,374,379. All topographic denominations were adopted from these papers. This 
method allows for the generation of animal specific coronal atlases of the visual cortex and 
thus provides a reliable guide for the interpretation of zif268 in situ hybridization results. In 
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all figures, large arrowheads indicate the total extent of the visual cortex while small 
arrowheads indicate interareal borders. We here focus on three regions from medial to 
lateral: medial extrastriate cortex (V2M), primary visual cortex (V1), and lateral extrastriate 
cortex (V2L)371,374. 
2.9 OPTICAL DENSITY PROFILES: QUANTIFICATION OF CORTICAL ZIF268 EXPRESSION 
For quantification of cortical zif268 expression, optical density values (mean gray value per 
pixel) from the autoradiograms of different experimental and control groups were quantified 
using a custom-made MATLAB script (MATLAB R2011b, The MathWorks Inc., Natick, MA, 
USA), as described before375,379. In order to demarcate the region of interest in the 
hemisphere contralateral to the lasered eye, the top edge of the cortex and the boundary 
where layer VI meets the white matter were determined. These borders were computed by 
a contour smoothing algorithm based on the Gaussian weighted least squares fit380 from 
manually drawn lines on the autoradiogram. The different areal and functional boundaries 
as derived from Nissl patterns were subsequently registered to the curvature of the top and 
bottom boundaries. Next, the delineated region of interest was equally divided into 24 
segments, each spanning the 6 cortical layers. To compensate for possible variation in brain 
size and morphology, the lattice was translated over the cortical curvature on each 
autoradiogram, fixing the border of a specific segment to an areal border. For each segment 
created this way, the relative optical density was calculated as the mean gray value of all 
pixels normalized to the mean gray value of a square measured in the thalamus (a defined 
region with no zif268 expression above background). This procedure was required to 
compare autoradiograms across experiments374,381. These optical density profiles were 
assessed along the anatomically defined visual subdivisions V2L, V1, and V2M.  
2.10  STATISTICS 
All data are presented as mean ± SEM. A normal distribution was verified using the 
Kolmogorov-Smirnov test and parallel equal variance between groups was tested. If the test 
requirements were fulfilled, a parametrical two-way ANOVA was used and Fisher’s Least 
Significant Difference post hoc tests were used for pairwise comparisons. When criteria for 
parametric statistics were not fulfilled, non-parametrical Kruskal-Wallis analysis with a 
Mann-Whitney U rank sum test for pairwise comparison of independent samples was 
applied. A probability level (α-level was set to 0.05) of <0.05 was accepted as statistically 
significant (*p<0.05, *p<0.01, ***p<0.001). All statistical analyses were performed using 
SigmaStat 3.1 (SYSTAT Software, CA, USA). 
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3 RESULTS  
3.1 LASER-INDUCED IOP ELEVATION AND RGC DEGENERATION  
Laser photocoagulation (LP) of the perilimbal and episcleral veins of the left eye resulted in a 
significant elevation of IOP at one and two days post-LP (p<0.001), which returned to 
baseline values after seven days (Figure 3.1 A). The IOP of the right control eye (15.5 ± 0.1 
mmHg, N=12) did not change over time and equaled the basal IOP of naive control mice 
(15.2 ± 1.0 mmHg, N=6). At one and four weeks following laser-treatment, surviving RGCs 
were visualized on retinal whole-mounts by IHC for the RGC marker Brn3a. The average 
number of RGCs in retinas of the right control eye of mice sacrificed at one (42,822 ± 1,051, 
N=7) and four weeks (44,497 ± 924, N=5) after LP were similar to those in naive retinas 
(46,127 ± 1,042, N=6). Laser-treated eyes showed 56.8 ± 6.7 % RGC survival at one week 
post-LP (p<0.001, N=7), and 41.4 ± 8.5 % (p<0.01, N=5) at four weeks post-LP when 
normalized to the experimentally matched right control eyes (Figure 3.1 B). Isodensity maps 
of the retinas showed a sectorial pattern of RGC death on top of diffuse RGC loss in all 
experimental eyes (Figure 3.1 C), which is in line with previous publications73. 
3.2 EARLY CHANGES IN SSC AND THE VISUAL CORTEX TRIGGERED BY OHT  
In mice, almost all RGCs project to the sSC14,15,35, making this brain center the most 
prominent direct retinal target and the area of choice to examine morphological changes in 
subcortical brain regions upon OHT induction in this study. 
Since degeneration processes are almost always preceded or accompanied by gliosis382,383, 
astroglial reactivity was examined. At one week post-LP, a significant enlargement of the 
GFAP+ area was observed within the sSC contralateral to the hypertensive eye (+327.8 ± 
19.1 %, N=7, p<0.001), as compared to naive mice (N=4) (Figure 3.2 A, B). Glial reactivity was 
also detectable in the ipsilateral sSC (+222.5 ± 13.3 %, p<0.001), although less pronounced 
(Figure 3.2 A, B).  
RGC synaptic terminals in the sSC were visualized using IHC for VGluT2, a presynaptic 
glutamatergic vesicle marker, and decreased VGluT2 IHC signal was used as a measure for 
loss of RGC synapses. In comparison to naive mice (N=6), a clear decrease in VGluT2 
immunopositive (VGluT2+) area was detected in the contralateral sSC of laser-treated mice 
at one week post-LP (-71.4 ± 7.9 %, N=7, p<0.001, Figure 3.2 C). A more subtle reduction was 
also noticeable in the ipsilateral sSC, although not significant. In a next step, we investigated 
whether the diminished VGluT2 immunoreactivity in the sSC could be linked to the sectorial 
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 RGC degeneration pattern observed in the retina. RGCs located in the dorsal, ventral, nasal, 
and temporal mouse retina, project respectively to the lateral, medial, caudal, and rostral 
sSC, thereby constructing the retinotopically organized map of the visual field in the 
midbrain384. In all mice, the loss of VGluT2+ RGC terminals in the contralateral sSC was 
undeniably retinotopically linked to zones of extensive RGC death in the eye. Two 
representative examples are shown in Figure 3.3. Both in mice with low (<30 %) and high 
(>60 %) amounts of RGC death, a zone of low RGC density in the dorsonasal part of the 
retina was associated with a decrease in VGluT2 immunoreactivity located caudolaterally in  
 
 
Figure 3.1:  Effects of LP on IOP and RGC degeneration in the glaucomatous eye. A. IOP measurements before 
and after LP of the perilimbal and episcleral vessels of the left eye (OS) reveal a transient IOP rise in this eye as 
compared to the right control eye (OD) at 24 h and 48 h post-LP, and a return to baseline levels at 7 days post-
LP (N=12). B. Analysis of the density of Brn3a
 
labeled RGCs in retinal whole-mounts, relative to the number in 
naive retinas, discloses a significantly reduced RGC survival in the photocoagulated OS both one and four weeks 
after LP, as compared to naive or control OD eyes (Nnaive=6, N1week=7, N4weeks=5). C. Illustrative isodensity maps 
of a Brn3a stained control and laser-treated retina with the latter showing a sectorial pattern of RGC death on 
top of diffuse RGC loss. The pseudocolor scale ranges from 0 RGCs/mm² (dark blue) till 5625 or higher 
RGCs/mm² (red). Scale bar: 1 mm. All data are mean ± SEM with significance based on Kruskal-Wallis analysis 
and Mann-Whithney U rank sum post hoc tests with *p<0.05, **p<0.01, ***p<0.001. Key: LP, laser 
photocoagulation; IOP, intraocular pressure; RGC, retinal ganglion cell; OS, oculus sinister; OD, oculus dexter; D, 
dorsal; V, ventral; N, nasal; T, temporal. 
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Figure 3.2: Astroglial reactivity and disregulation of RGC synapse function in the sSC at one and four weeks 
post-LP. A. Morphometric analyses of the GFAP density (GFAP
+
 area over total sSC area, relative to the density 
in naive brain) in the sSC ispilateral and contralateral to the LP eye, reveal an increase in astrocyte reactivity 
within the sSC at one week after LP, both ipsilateral and contralateral to the hypertensive eye, although less 
pronounced ipsilaterally. At four weeks post-LP, the ipsilateral glial response is no longer detectable, while the 
contralateral sSC still shows a significant upregulation in GFAP expression, albeit lower than at one week post-
LP (Nnaive=6, N1week=7, N4weeks=5). B. GFAP immunopositive astrocytes in naive control, one week post-LP, and 
four weeks post-LP. Scale bars: 1 mm. C. Morphometric analysis of the VGluT2 density (VGluT2
+
 area over total 
sSC area, relative to density in naive brain) in the sSC ispilateral and contralateral to the hypertensive eye, 
shows a clear and similar decrease in the RGC synapses in the contralateral sSC at one and four weeks post-LP 
(Nnaive=6, N1week=7, N4weeks=5). Data in A and C are mean ± SEM with significance based on Kruskal-Wallis 
analysis and Mann-Whithney U rank sum post hoc tests with *p<0.05, **p<0.01, ***p<0.001. The large asterisk 
in A indicates a significant difference with all other conditions. Key: sSC, superficial superior colliculus; LP, laser 
photocoagulation; GFAP, glial fibrillary acidic protein, VGluT2, vesicular glutamate transporter 2; RGC, retinal 
ganglion cell; contra, contralateral; ipsi, ipsilateral.  
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Figure 3.3: Retinotopic effects of OHT induction in the sSC at one week post-LP. A. Isodensity maps of Brn3a 
stained retinas show both a diffuse RGC loss and a sectorial pattern of RGC degeneration at one week after LP 
(middle and right) as compared to a naive control retina (left). Pseudocolor scale ranges from 0 RGCs/mm² 
(dark blue) till 5625 or higher RGCs/mm² (red). B. Representative pictures of VGluT2 immunostained sSC 
contralateral and ipsilateral to the retinas shown in A, reveal that the loss of RGC synapses in the contralateral 
sSC is retinotopically linked to the retinal RGC degeneration pattern. Dotted lines mark the border between sSC 
and the dSC. Scale bars: 1 mm.  C. Top view images of the sSC surface contralateral to retinas shown in A to 
illustrate retinotopic effects on VGluT2 levels at one week post-LP (middle and right) as compared to control 
(left). The pseudocolor scale represents VGluT2 immunofluorescence levels from low signal (dark blue) to high 
signal (red). Retinotopically linked positions in A, B, and C are marked with an asterisk, circle and square. Key: 
OHT, ocular hypertension; LP, laser photocoagulation; RGC, retinal ganglion cell; sSC, superficial superior 
colliculus; dSC, deep layers of the SC; VGluT2, vesicular glutamate transporter 2; contra, contralateral; ipsi, 
ipsilateral; D, dorsal; V, ventral; N, nasal; T, temporal. 
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the sSC (asterisks in Figure 3.3, middle and right column). RGC degeneration in the 
dorsotemporal retina, was linked to loss of RGC synapses in the rostrolateral region of the 
sSC (square in Figure 3.3, middle and right column). 
ISH for the activity reporter gene zif268, allowed the screening of striate and extrastriate 
cortical areas for neuronal activity changes triggered by OHT. At one week post-LP, the 
zif268 mRNA expression pattern revealed reduced neuronal activity in distinct areas across 
the mediolateral extent of the visual cortex, retinotopically linked to the RGC degeneration 
pattern in the retina (Figure 3.4 A, B). Of note, representative mice used to illustrate cortical 
effects in Figure 3.4, are the same animals as depicted in Figure 3.3 concerning the related 
sSC effects. In mice with rather mild RGC death (<30 %), RGC loss in the dorsonasal part of 
the retina resulted in a reduced neuronal activity in all layers of the medial monocular part 
of V1 (asterisks in Figure 3.4, middle column). In this animal, the central retinal RGC death 
induced a reduction in zif268 expression in the retinotopically corresponding anterior part of 
the medial monocular zone of V1 (circle in Figure 3.4, middle column). A similar retinotopic 
pattern was discerned in mice with severe RGC death (>60 %), where dorsonasal retinal 
damage corresponded to a reduced activity in the medial monocular zone of V1 (asterisks in 
Figure 3.4, right column). In contrast to the mild RGC death condition, mice with severe RGC 
death in the dorsotemporal retina displayed an additional reduced neuronal activity in V2L 
(square in Figure 3.4, right column), indicative of a certain threshold before RGC death 
clearly affects this extrastriate visual area. In both cases, area V2M was also characterized by 
a slightly reduced zif268 expression, mainly in the posterior part of the visual cortex and in 
the infragranular layers. Quantitative analysis of optical density values of the zif268 signal 
(Figure 3.4 C) of all conditions confirmed these qualitative observations, emphasizing that 
IOP elevation did reduce the functional integrity of the visual projection. 
Thus, besides a more diffuse astroglial response, our results show clear retinotopic effects in 
both sSC and distinct areas of the visual cortex studied at one week post-OHT induction. 
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Figure 3.4: Retinotopic effects of OHT in the visual cortex at one week post-LP. A. Isodensity maps of Brn3a 
stained retinas show both a diffuse RGC loss and a sectorial pattern of RGC degeneration at one week after LP 
(middle and right) as compared to a naive control retina (left). Pseudocolor scale ranges from 0 RGCs/mm² 
(dark blue) till 5625 or higher RGCs/mm² (red). Scale bar: 1 mm. B. Immediate early gene (zif268) expression in 
the visual cortex contralateral to the retinas shown in A, discloses zones of reduced neuronal activity in V2L, 
V1, and V2M that are retinotopically linked to areas of extensive RGC death. The corresponding pseudocolor 
representations of signal intensity differences are displayed next to each section (between Bregma levels -2.80 
mm and -4.16 mm) and represent a false coloring of the gray values: a low gray value is represented in 
black/green, a high gray value in white/yellow, indicating a low signal response or a high signal response 
respectively. Scale bar: 2 mm. C. Optical density profiles of the three sections in B (1, 2, 3) visualize the spatial 
extent of cortical regions of reduced zif268 expression, as seen qualitatively in panel B. Note how severe RGC 
loss leads to the largest fluctuation in low and high optical density values along the profiles. Retinotopically 
linked positions in A, B, and C are marked with an asterisk and circle. Key: OHT, ocular hypertension; LP, laser 
photocoagulation; RGC, retinal ganglion cell; sSC, superficial superior colliculus; VGluT2, vesicular glutamate 
transporter 2; contra, contralateral; ipsi, ipsilateral; V2M, medial extrastriate cortex; V1, primary visual cortex; 
V2L, lateral extrastriate cortex. 
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3.3 LONG-TERM EFFECTS OF OHT INDUCTION  
Previously, a more elaborate hypoactivity in V1 has been reported after one week of 
monocular enucleation (ME) in adult mice, followed by a complete cortical reactivation 
during the subsequent weeks374. To investigate whether a similar cortical reactivation might 
occur in the OHT model, we analyzed zif268 expression at a later time point after laser-
treatment. At four weeks post-LP the activity patterns in V2L, V1, and V2M in mice with 
significant RGC degeneration in the retina (Figure 3.5 A), were comparable to control mice 
(Figure 3.5 C). In the sSC, however, no significant recovery of VGluT2 immunoreactivity was 
seen (Figure 3.5 B). Thus, these data clearly indicate neuronal reactivation in all areas of the 
visual cortex, but no concomitant increase in VGluT2 immunoreactivity in the sSC at four 
weeks post-OHT induction.  
To survey whether the OHT model has additional long-term effects in the sSC, such as a 
prolonged astroglial response, we also performed IHC for GFAP at four weeks post-LP (Figure 
3.3 B). Remarkably, the ipsilateral GFAP immunoreactivity, which increased at one week 
post-LP (p<0.01), attenuated to control levels at four weeks (p=0.612), while the 
contralateral sSC (+227.0 ± 33.6 %, p<0.001) still showed a significant glial response, albeit 
lower than at one week post-LP (p<0.001, Figure 3.2 A). Thus, these results illustrate that 
gliosis in the sSC is still present at four weeks after LP. Of note, in comparison to the 
retinotopic decrease of VGluT2+ signal (Figure 3.3), glial reactivity was found to be a rather 
diffuse phenomenon (Figure 3.2 B) and may therefore more reflect the diffuse RGC loss at 
the level of the retina. 
As prolonged astroglial reactivity in the sSC contralateral to the OHT eye might point 
towards neuronal degeneration of the sSC neurons due to a lack of input, we further 
investigated the general morphology and density of these neurons. A Nissl staining 
performed at four weeks post-LP showed that sSC neurons appeared healthy in both 
hemispheres and subsequent quantification revealed a normal neuronal density in affected 
zones (2,081.9 ± 120.2 cells/mm²) of the sSC contralateral to the laser-treated eye, in 
comparison to matched internal control regions (1,939.4 ± 55.8 cells/mm²) in the ipsilateral 
sSC (N=4, p=0.633). Hence, sSC neurons did not degenerate upon OHT induction at the time 
points analyzed.  
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Figure 3.5: Long-term effects of OHT induction throughout the visual pathway. A. The isodensity map of a 
Brn3a stained retina at four weeks post-LP shows a massive and sectorial degeneration of RGCs. Pseudocolor 
scale ranges from 0 RGCs/mm² (dark blue) till 5625 or higher RGCs/mm² (red). B. In the sSC contralateral to the 
glaucomatous eye depicted in A, a drop in VGluT2 immunoreactive RGC synapses is still visible at four weeks 
post-LP. C. In V2L, V1, and V2M, the immediate early gene (zif268) expression pattern at four weeks post-LP is 
comparable to control conditions, indicative for neural reactivation and cortical plasticity. The corresponding 
pseudocolor representation of signal intensity differences is displayed next to the ISH sections (Bregma -3.40 
mm) and represent a false coloring of the gray values: a low gray value is represented in black/green, a high 
gray value in white/yellow, indicating a low signal response or a high signal response respectively. Note how 
the related optical density profiles are comparable between the naive control mouse and at 4 weeks post-LP. 
Scale bars A and B: 1 mm, C: 2 mm. Key: OHT, ocular hypertension; LP, laser photocoagulation; RGC, retinal 
ganglion cell; VGluT2, vesicular glutamate transporter 2; contra, contralateral; ipsi, ipsilateral; V2M, medial 
extrastriate cortex; V1, primary visual cortex; V2L, lateral extrastriate cortex; ISH, in situ hybridization.  
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4  DISCUSSION  
Over the past decade, glaucoma is increasingly being recognized as a disease of the entire 
visual system rather than an eye disease7,99-101,106,365,385. In this study we intended to 
contribute to a better understanding of the interplay between the eye and the brain in 
glaucoma pathology, by examining the impact of OHT on the sSC and the visual cortex in the 
mouse.  
4.1 RETINOTOPIC EFFECTS OF OHT INDUCTION: REDUCED RGC SYNAPSE DENSITY IN 
THE SSC  
Since elevated IOP remains the most important modifiable risk factor, several murine OHT 
models have been developed to study mechanisms underlying glaucoma pathology. All of 
these models have their own advantages and drawbacks, thoroughly reviewed by Vidal-Sanz 
et al.73, none of them covering all aspects of human glaucoma. Nevertheless, these models 
are applicable to improve our understanding on the relation between OHT and vision loss.  
Within the model used in this study, IOP values had normalized and about 50 % of the RGC 
had died at one week after successful OHT induction. Although these features only partially 
mimic the chronic progression of glaucoma in human patients, transient OHT has previously 
been described to induce similar features as observed in the more chronic inherited DBA/2 
mouse model of OHT, suggesting analogous pathological characteristics and underlying 
mechanisms73. Indeed, the temporary OHT in our model resulted in diffuse and sectorial RGC 
death, a typical glaucomatous retinal degeneration pattern described in human patients356 
and several animal models13,73,79,357.  
To further investigate whether RGC death is accompanied by morphological changes in 
subcortical brain regions upon OHT induction, we focused on the sSC, since this is the main 
direct retinal target, receiving input from almost all RGCs in mice14,15,35. Furthermore, the 2D 
retinotopic organization of the retinocollicular projections is straightforward and thoroughly 
described48,386, allowing retinotopic comparison of retinal degeneration patterns with 
morphological features in the sSC. Moreover, recently, alterations in saccadic eye 
movements have been reported in glaucoma patients387-389. Thus, given that the SC is an 
important player in the neuronal network underlying saccade generation388,390, studying this 
brain center in glaucoma research is very relevant.  
Our study demonstrated pronounced effects of OHT on the sSC in mice. A clear reduction in 
VGluT2 immunoreactivity was observed in the sSC located contralaterally to the 
hypertensive eye, while in the ipsilateral sSC, only a slight diminishing trend was visible. 
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Although reduced VGluT2 immunoreactivity does not necessarily imply structural 
degeneration of RGC axon terminals, but might also be a consequence of downregulated 
VGluT2 expression in se, we believe that within the OHT model, which is characterized by 
massive RGC death, diminished VGluT2 levels can be linked to RGC synapse loss. In addition, 
the spatial location of VGluT2 depletion unequivocally reflected the sectorial RGC 
degeneration seen in the retina, a finding which is in line with our interpretation and with 
published results obtained in other experimentally induced or genetic rodent glaucoma 
models107,119,156. Of note, the visualization of non-retinal-derived VGluT2+ synapses, e.g. 
those coming from cortical areas or local connections, cannot be entirely excluded; however, 
VGluT2+ axon terminals in the sSC are generally recognized as RGC synapses119,156,297,391.  
4.2 TRANSIENT RETINOTOPIC EFFECTS REFLECT FUNCTIONAL RECOVERY IN THE 
VISUAL CORTEX AFTER LP 
Our study revealed clear effects on activity levels in primary and extrastriate visual cortex in 
the murine OHT model. Interestingly, Georgiou et al.366 did not find any VEP alterations in 
the visual cortex of OHT rats. Their methodology of VEP recordings encompassed the use of 
sub-dermal electrodes, which may lack the sensitivity to detect small but significant changes 
in activity. In our study, ISH for zif268 revealed cortical hypoactivity in distinct subregions 
within area V1 and V2M, at one week post-LP, which appeared to be retinotopically linked to 
the sectorial RGC loss in the retina392-395. Hypoactivity in the monocular regions of V2L was, 
however, only observed in animals with severe RGC death. This suggests the existence of a 
certain threshold of RGC death before higher order visual areas are affected and may reflect 
the larger receptive fields of neurons in extrastriate areas. In comparison, previous studies 
also showed hypoactivity in all monocular driven zones of V2L, V1, and V2M after one week 
of ME in adult mice374. Seven weeks post-ME a complete reactivation of all these visual areas 
was the result of potentiation of inputs from the remaining eye in combination with 
multimodal plasticity events374. In the current study, four weeks post-LP the neuronal 
activity patterns across the entire mediolateral extent of the visual cortex were also 
comparable to control mice. Such a reactivation within four weeks was expected based on 
an earlier study by Keck et al.396, in which monocular retinal photocoagulator lesions 
resulted in a structural and functional reorganization in the monocular zone of V1 of adult 
mice between 2 and 3 weeks post-lesion. Also in our OHT model the recovery of normal 
activity levels in V1 and extrastriate areas might be the result of the unmasking of local 
connections and potentiation of the adjacent binocular zones, including the central 
binocular zone and the binocular zone at the medial border of V2M374,393,396,397. Taken 
together, these data indicate that the observed cortical reactivation in function of post-LP 
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survival time is most likely visually driven either via the spared eye or the remaining RGCs in 
the laser-treated eye. 
4.3 NO RECOVERY OF RGC SYNAPSE DENSITY IN THE SSC 
In contrast to the activity patterns of the visual cortex, VGluT2 immunoreactivity in the sSC 
did not return to normal levels, suggesting that local sprouting of surviving RGC 
glutamatergic terminals did not occur to compensate for degenerated RGC synapses in our 
experimental setup. Similarly, Tropea et al. did not detect any axonal sprouting in the sSC 
from one to three weeks after induction of retinal lesions in adult rats398. This is in line with 
the hypothesis that the critical period for reorganization of the retinofugal pathway is 
restricted to the first three postnatal weeks in mammals398,399. Indeed, several reports 
describe that, although neonatal ME or retinal lesions cause territorial expansion of the 
intact eye into the deafferented sSC zones399-403, in adult rodents, RGCs lack the ability to 
reinnervate sSC areas that have lost their retinal input398,399.  
Newly available synapse positions may however still be reoccupied. Following RGC synapse 
elimination, the postsynaptic sites might be conquered by non-retinal terminals from the 
immediate vicinity404 or from cortical origin405,406. Another phenomenon, confirming 
adaptive capacities of the adult visual system, is the expansion in receptive-field size of 
retinal target neurons upon IOP increase407, which might originate from dendritic field 
extension at the level of either surviving RGCs in the retina407,408, or the retinal target 
neurons themselves113,115. Glaucoma-induced alterations in RGC synaptic 
strength112,407,409,410 possibly lead to activation of previously silent synapses, resulting in a 
broader activation area, and thus, larger receptive fields410. In addition, decreased inhibition 
might account for unmasking of silent connections410,411, since reorganization of intrinsic 
inhibitory GABAergic synaptic terminals in the sSC has been described upon loss of retinal 
innervations in adult rats404.   
4.4 PROLONGED ASTROGLIAL REACTIVITY IN THE SSC 
To investigate whether the OHT model has other long-term features in the sSC, we studied 
gliosis at one and four weeks post-LP. Animals subjected to OHT showed vigorous astroglial 
reactivity in both sSCi early after laser-induction, confirming studies in several animal models 
as well as in human patients, reporting astrogliosis in the retinal projection areas, even at 
mild glaucoma stages99,111,119,412-414. Conversely, three weeks later, this effect was only visible 
in the sSC contralateral to the experimental eye, albeit less pronounced than early post-LP, 
suggesting that also the contralateral glial response will disappear over time. Transient 
subcortical astroglial activation has likewise been described in other glaucoma models, 
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shortly in the sSC ipsilateral and more prolonged, although also temporary, in the sSC 
contralateral to the experimental eye118,412.  
Studying glial reactivity in the brain in relation to glaucoma pathology is very relevant, since 
glial cells, in particular astrocytes, are becoming increasingly recognized as important players 
in the pathogenesis of various central nervous system disorders, such as epilepsy and 
Alzheimer’s disease413. Moreover, noninvasive imaging of gliosis in the human LGN has 
recently been proposed as a possible diagnostic tool for glaucoma414.  
4.5 OHT DOES NOT CAUSE NEURONAL DEGENERATION IN SSC  
Long-term glial reactivity detected in the sSC upon OHT induction, might be indicative for 
neuronal degeneration of the RGC target neurons, possibly caused by the sustained 
reduction or loss of retinal input. Surprisingly, quantitative analysis on Nissl stained sections 
from mice sacrificed four weeks post-OHT induction, revealed a normal cell density and cell 
morphology of sSC neurons in affected zones. At first sight, our observations might be in 
contrast with previous reports, describing cell shrinkage and a reduced number of neurons 
in retinal target areas upon experimentally induced glaucoma. However, neurodegeneration 
in visual brain centers shown in these studies typically appears only at late stages of disease 
progression108,116,118,152. Thus, our experimental setup might not have been long enough to 
detect delayed processes such as transsynaptic neurodegeneration8. Nevertheless, dendritic 
shrinkage and loss in sSC neurons has been described in OHT rats at four weeks after IOP 
elevation120. Unfortunately, Nissl staining did not allow detailed examination of dendritic 
characteristics in the current study.  
 
5 CONCLUSION  
Within the laser-induced OHT model, we could largely confirm previous findings described 
for subcortical RGC projection areas in other glaucoma models, such as changes in RGC 
synapse functioning and intensive but transient astroglial reactivity. However, our data 
uniquely extend to findings in the visual cortex, where OHT resulted in reduced neuronal 
activity in V1 and extrastriate areas, and is characterized by recovery of neuronal activity 
over time. To our knowledge, this is the first study describing effects on activity patterns in 
the visual cortex in a murine OHT model.  
 
 
  
 
 
 
 
 
CHAPTER 4  
CHARACTERIZATION OF VIRAL VECTORS  
FOR TRANSGENE EXPRESSION IN THE  
MOUSE SUPERIOR COLLICULUS  
 
 
Part of the data presented in this chapter have been submitted for publication:  
Dekeyster, E., Geeraerts, E., Mebis, C., Salinas-Navarro, M., De Groef, L., Moons, L. Tackling 
glaucoma from within the brain: an unfortunate interplay of BDNF and TrkB. Manuscript 
submitted to PLoS One.  
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1 INTRODUCTION 
Viral vector technology allows for the genetic modification of cells in vivo in a site- and time-
specific way. The method is widely employed in scientific research as well as in the clinical 
application of gene therapy415. Recombinant adenoviral, lentiviral (LV), and adeno-
associated viral (rAAV) vectors have been used frequently in the central nervous system 
(CNS)416,417. The present work focuses specifically on LV and rAAV vectors. LV vectors are 
derived from lentiviruses, a family of complex retroviruses, and generally have a packaging 
capacity of 8 kb415. Retroviruses are single-stranded RNA viruses that reversely transcribe 
their genetic material into DNA and integrate into the host genome. Retroviral virions 
average 100 nm in size418 and are composed of a phospholipid envelope surrounding a 
protein capsid in which the genome is housed415. rAAVs, conversely, have a much lower 
packaging capacity of 4.7 kb and are derived from parvoviruses, which are non-enveloped 
single-stranded DNA viruses, generally not integrating into the host genome and having 
virions with an average capsid size of 25 nm415. The capsid proteins, which vary between 
serotypes, facilitate binding of the virion to receptors on the surface of the host cell and thus 
determine the tropism415,416. For example, the rAAV vector derived from AAV serotype 2 
(rAAV2), being used extensively in biomedical research, mainly transduces neuronal cells via 
interactions with heparin sulfate proteoglycans on their cell membrane415,419. Cross-
packaging of rAAV2 DNA constructs in capsids of other rAAV serotypes results in differential 
transduction efficiency and tropism415,420. Furthermore, the specificity and efficiency of a 
viral vector to genetically modify the target cells is not only determined by the serotype, but 
also by the promoter that drives transgene expression415. 
Glaucoma, one of the main causes of blindness worldwide, is an important 
neurodegenerative disease outlined by death of retinal ganglion cells (RGCs) that project 
their axons from the eye to the brain62. Although the underlying causes are diverse and far 
from completely understood, it is nowadays generally accepted that early stages of 
glaucomatous pathogenesis are characterized by diminished active transport along these 
RGC axons. According to the neurotrophin deprivation hypothesis, disruption of retrograde 
delivery of trophic support from the brain to the eye, as a result of the reduced axonal 
transport, is one of the main triggers that induces apoptotic signaling in the RGCs5,69. Based 
on this hypothesis, we intend to induce long-distance neurotrophic protective effects on the 
RGCs in different glaucoma models (established in Chapter 2), by modulating their central 
target areas.  
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The main retinal target area in the mouse brain is the superior colliculus (SC)14. The 
mammalian SC is an important subcortical integrator of sensorimotor behaviors421 that can 
be structurally and functionally divided into two entities: the superficial visual region (sSC) 
and the deep multimodal motor region (dSC)58. The sSC contains three layers: the stratum 
zonale (SZ), the stratum griseum superficiale (SGS), and the stratum opticum (SO). The 
underlying dSC is comprised of four layers: the stratum griseum intermediale (SGI), the 
stratum album intermediale (SAI), the stratum griseum profundum (SGP), and the stratum 
album profundum (SAP) (Chapter 1, Figure 1.4)46,47.  
In light of the overarching research goal of this PhD project, namely counteracting 
glaucomatous RGC degeneration via brain-directed treatment, we envisioned to stimulate 
the pro-survival colliculoretinal signaling. Two different strategies were designed. At the one 
hand, local overexpression of neurotrophic factors in the SC was implemented to enhance 
retrograde delivery of these trophic molecules to the retina (Chapter 5). On the other hand, 
optogenetic stimulation of the SC was used to generally augment collicular activity (Chapter 
6).  
Both strategies required the use of viral vector technology. To optimize viral vector 
transduction in the mouse SC, the tropism and transduction efficiency of one LV and four 
rAAV serotypes (2/1, 2/7, 2/8, and 2/9) were evaluated. Subsequently, the effect of different 
promoters, the cytomegalovirus (CMV) promoter versus a shortened sequence of the 
Ca2+/calmodulin-dependent protein kinase II  promoter (CaMK), on the cell-specificity of 
viral vector-based reporter gene expression was studied. The most suitable vector, 
determined by serotype and promoter, for local modulation of the SC should ideally 
transduce many cells throughout the entire SC without retrograde transduction of the 
retina. Next, in order to enhance brain-derived neurotrophic factor (BDNF) levels in the SC, a 
BDNF-expressing vector was developed. Finally, viral vector-induced expression and 
membrane targeting of the stabilized step-function opsin (SSFO)18, for optogenetic 
stimulation in the SC, were examined.  
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2 MATERIALS AND METHODS  
2.1 ANIMALS 
The C57Bl/6J mice used in this study were eight to ten weeks of age at the start of the 
experiments and housed under standard laboratory conditions in a 12/12h light/dark cycle 
with food and water available ad libitum. All experiments were approved by the Animal 
Ethics Committee of KU Leuven and were carried out in strict accordance with European 
Communities Council Directive of 22 September 2010 (2010/63/EU).  
2.2 VIRAL VECTOR PRODUCTION  
2.2.1 Serotypes and promoters 
The viral vectors used to determine the best serotype and promoter for optimal 
transduction of the mouse SC, were produced by the Viral Vector Core of KU Leuven, 
supervised by Prof. V. Baekelandt (Laboratory of Neurobiology and Gene Therapy, KU 
Leuven, Belgium) and Prof. Z. Debyser (Laboratory of Molecular Virology, KU Leuven, 
Belgium). One human immunodeficiency virus type 1 (HIV-1)-derived LV vector and four 
rAAV vectors, containing the enhanced green fluorescent protein (eGFP) gene, were tested 
for transduction in the SC. These vectors were produced as described previously416,422. The 
rAAV vectors all contained the inverted terminal repeats (ITRs) of AAV2, but were cross 
packaged in the capsids of AAV1, AAV7, AAV8, or AAV9, resulting in four different vector 
serotypes rAAV2/1, rAAV2/7, rAAV2/8, and rAAV2/9. Expression of the eGFP reporter gene 
was controlled by the general cytomegalovirus (CMV) promoter or by the Ca2+/calmodulin-
dependent protein kinase II  promoter shortened sequence of 0.4 kb (CaMK), described to 
drive cell-specific expression in excitatory neurons in the mouse cortex423,424. All vectors 
used to study the transduction efficiency of the viral vector types and the expression 
patterns induced by different promoters are listed in Table 4.1.   
2.2.2 BDNF- and SSFO-expressing vectors  
Besides vectors inducing expression of the cytosolic reporter gene eGFP, in addition, vectors 
for expression and secretion of secretory proteins, such as BDNF, and for expression and 
membrane incorporation of membrane-embedded channels, such as SSFO, were evaluated 
for their applicability in the mouse SC. 
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Table 4.1: Viral vectors tested for transduction and expression efficiency in the mouse SC. Transduction is 
determined by the serotype, while expression is promoter driven. Key: SC, superior colliculus; LV, lentiviral 
vector; rAAV2/x, recombinant adeno-associated viral vector serotype 2/x; CaMK, Ca
2+
/calmodulin-dependent 
protein kinase II  shortened sequence 0.4 kb promoter; CMV, cytomegalovirus promoter; eGFP, enhanced 
green fluorescent protein; BDNF, brain-derived neurotrophic factor; SSFO, stabilized step-function opsin; TU, 
transducing units; GC, genome copies. 
Vector Titer  
Type Promoter Transgene 
LV CMV eGFP  1.52E09 TU/ml 
rAAV2/1 CMV eGFP 1.10E12 GC/ml 
rAAV2/7 CMV eGFP 1.90E12 GC/ml 
rAAV2/8 CMV eGFP 2.61E12 GC/ml 
rAAV2/9 CMV eGFP 3.20E12 GC/ml 
rAAV2/1 CaMK  eGFP 1.34E12 GC/ml 
rAAV2/7 CaMK eGFP 2.59E12 GC/ml 
 
2.2.2.1 Generation of the BDNF vector construct 
For the development of the BDNF overexpressing vector, RNA was isolated from mouse tail 
tissue using TRIzol reagent (Invitrogen, CA, USA) according to the manufacturer’s 
instructions. RNA was precipitated in ethanol, washed, and dissolved in nuclease-free water. 
cDNA synthesis was carried out following standard procedures as described previously425, 
and samples were stored at -20 °C until further use.  
Amplification of the BDNF cDNA was carried out by polymerase chain reaction (PCR) with 
Phusion high fidelity DNA polymerase (New England Biolabs, UK) according to the 
manufacturer’s instructions using the Mastercycler EP Gradient PCR Thermal Cycler 
(Eppendorf, Germany). Based on the coding sequence of the murine BDNF gene, as found on 
NCBI426, two forward primers, implementing the XbaI restriction site, and three reverse 
primers, containing the SpeI restriction site, were designed using the free online tool, 
Primer3 (http://simgene.com/Primer3). According to the first trial experiments, forward 
primer 5’-TCTAGAGATGACCATCCTTTTCCTTAC-3’ and reverse primer 
5’-ACTAGTCTATCTTCCCCTTTTAATGGTC-3’ were selected for cDNA production. 
Thermocycling conditions were programmed as follows: 2 min initial denaturation at 98 °C; 
35 cycles of denaturation (98 °C, 15 sec), annealing at primer-specific temperatures (55 °C, 
30 sec), and extension (72 °C, 40 sec); with a final extension step at 72 °C for 10 min. Product 
size was verified by electrophoresis on a 1 % agarose gel. The band predicted to contain 
mouse BDNF cDNA was purified using the QIAEX II Gel Extraction kit (QIAGEN, Germany). 
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Subsequently, mouse BDNF cDNA was cloned using the Zero Blunt TOPO PCR Cloning kit 
(Invitrogen, CA, USA) and the resulting BDNF cDNA-containing plasmid (Figure 4.1 A) was 
transformed into competent Escherichia coli cells (One shot, Invitrogen, CA, USA). Plasmids 
were isolated from positive clones using the PureLink Quick Plasmid Miniprep kit (Invitrogen, 
CA, USA) and stored at -20 °C until subsequent use.  
PCR was performed on the BDNF gene-containing plasmids (Figure 4.1 A), using forward 
primer 5’-AAAAAAGGATCCGCCACCATGACCATCCTTTTCCTTACTATGG-3’, containing the 
BamH1 restriction site, and reverse primer 
5’-GCCCTTACTAGTCTATCTTCCCCTTTTAATGGTCAGT-3’, containing the Kozak consensus 
sequence, generally thought to improve transgene translation. Thermocycling conditions 
were programmed as follows: 2 min initial denaturation at 98 °C; 30 cycles of denaturation 
at 98 °C (10 sec), annealing at 60 °C (30 sec), and extension at 72 °C (45 sec); with a final 
extension step at 72 °C for 10 min. Product size was verified by electrophoresis on a 0.8 % 
agarose gel. The band containing the PCR product was excised and purified using the 
GenElute Gel Extraction kit (Sigma-Aldrich, MO, USA) according the manufacturer’s protocol.  
To clone the purified BDNF PCR product in the plasmids for rAAV vector production (Figure 
4.1 B), both were BamH1 and Spe1 digested. The digestion product of the BDNF PCR product 
was purified using the GenElute PCR Clean-Up kit (Sigma-Aldrich, MO, USA). Digestion 
products of the rAAV vector plasmid were separated by electrophoresis on a 0.8 % agarose 
gel. The band corresponding to the rAAV vector plasmid without the eGFP gene was excised 
and extracted using the GenElute Gel Extraction kit (Sigma-Aldrich, MO, USA). Next, BDNF 
was ligated in the rAAV vector plasmid and the resulting BDNF-rAAV plasmids (Figure 4.1 C) 
were transformed into Max Efficiency Stbl2 competent cells (Invitrogen, CA, USA). Plasmids 
were isolated from positive clones using the GenElute Plasmid Miniprep kit (Sigma-Aldrich, 
MO, USA) and DNA concentrations were determined spectrophotometrically 
(NanoPhotometer, Implen, Germany). 
2.2.2.2 BDNF and SSFO carrying rAAV vectors  
The Viral Vector Core of KU Leuven produced the BDNF- and SSFO-expressing rAAV vectors, 
starting from the BDNF-rAAV plasmid (Figure 4.1 C) and the SSFO sequence, the latter kindly 
provided by Prof. P. Hegemann (Experimental Biophysics, Humboldt University, Germany). 
The actual vector production process has been described in detail by Van der Perren et al.416. 
The vectors used for validation of transgene expression of BDNF and SSFO, together with the 
control vectors, produced in parallel, are listed in Table 4.2. Just before injection, control 
vectors were diluted in sterilized 0.01 M phosphate-buffered saline (PBS) in order to equalize 
titers. 
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Table 4.2: Viral vectors developed to induce BDNF and SSFO expression in the mouse SC and their 
concomitant control vectors. Transduction is determined by the serotype, while expression is promoter driven. 
Key: SC, superior colliculus; rAAV2/x, recombinant adeno-associated viral vector serotype 2/x; CaMK, 
Ca
2+
/calmodulin-dependent protein kinase II  promoter shortened sequence of 0.4 kb; CMV, cytomegalovirus; 
eGFP, enhanced green fluorescent protein; BDNF, brain-derived neurotrophic factor; SSFO, stabilized step-
function opsin; GC, genome copies. 
Vector Titer 
(GC/ml) 
Control vector Titer 
(GC/ml) Type Promoter Transgene Type Promoter Transgene 
rAAV2/1 CMV BDNF  3.16E11 
rAAV2/1 CMV eGFP 1.32E12 
rAAV2/1 CMV SSFO-mCherry 9.82E11 
rAAV2/7 CaMK SSFO-mCherry 1.62E12 rAAV2/7 CaMK eGFP  2.59E12 
 
 
 
 
Figure 4.1: Maps of the plasmids used to generate the murine BDNF vector construct. A. BDNF cDNA was 
flanked by Xba1 and Spe1 restriction sites and cloned into the pCR4Blunt-TOPO plasmid. B. Plasmid for rAAV 
production with reporter gene eGFP in control of the CMV promoter. ITR regions are important for packaging in 
rAAV particles, while the WPRE sequence improves transgene expression. C. Plasmid generated for production 
of rAAV vectors inducing CMV promoter-controlled BDNF expression. Key: BDNF, brain-derived neurotrophic 
factor; ori, origin of replication; ITR, inverted terminal repeats; WPRE, woodchuck post-transcriptional 
regulatory element; CMV, cytomegalovirus; eGFP, enhanced green fluorescent protein; Amp-R, ampicilin 
resistence gene; Kan-R, geniticin resistance gene; SV-40 misc intron, miscellaneous intron from simian virus 40.  
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2.3 INTRACOLLICULAR VECTOR DELIVERY  
For intracollicular injection of the viral vectors, mice were anesthetized by intraperitoneal 
(i.p.) administration of ketamine (75 mg/kg body weight, Anesketin, Eurovet, Belgium) and 
medetomidin (1 mg/kg body weight, Domitor, Janssen Pharmaceutics, Belgium). In addition, 
lidocaine hydrochloride (5 %, Xylocaine, AstraZeneca, UK) was applied onto the scalp as a 
topical anaesthetic and tobramycin eye ointment (Tobrex, Alcon, TX, USA) was applied to the 
cornea of both eyes to prevent desiccation. During the procedure, body temperature was 
controlled by use of a heating pad (TCAT-2LV, Physitemp Instruments INC, NJ, USA). After 
opening the scalp, a craniotomy was drilled into the skull above the injection site. Using the 
Nanoject II (Drummond Scientific Company, PA, USA), 1 µl of the LV vector or 200 nl of the 
rAAV vectors (Table 4.1) was stereotactically injected through a glass capillary into the right 
SC at a rate of 100 nl/min to study expression patterns of the eGFP reporter gene (NLV=2, 
NrAAV2/x=4). For sham controls, 200 nl sterile PBS was injected (Nsham=3). For validation of the 
BDNF- and SSFO-expressing vectors (Table 4.2), 1 µl and 200 nl were injected, respectively 
(NBDNF=4, NSSFO=4). Coordinates for mouse right SC were anteroposterior -3.3 mm and 
mediolateral +0.4 mm relative to Bregma, and dorsoventral -1.3 mm from the dura.  
2.4 TISSUE PROCESSING  
Two weeks after viral vector injection for reporter gene- or BDNF-expressing vectors and 
four weeks after vector injection of the SSFO vector and its controls, animals were 
anesthetized through i.p. administration of sodium pentobarbital (200 mg/kg body weight, 
Nembutal, Ceva Sante Animale, France) and transcardially perfused with 0.9 % NaCl, 
followed by 4 % paraformaldehyde (PFA, Acros Organics, NJ, USA) in PBS for standard 
immunohistochemistry (IHC). Brains were dissected and post-fixed overnight in 4 % PFA. For 
γ-aminobutyric acid (GABA) IHC, mice were perfused with 1 % PFA and 0.3 % glutaraldehyde 
(GA, Sigma-Aldrich, MO, USA) in PBS. Brains were dissected and post-fixed overnight in 4 % 
PFA with 0.3 % GA. For BDNF IHC, perfusion was performed using 4 % PFA containing 0.4 % 
parabenzoquinone (pBQ, Sigma-Aldrich, MO, USA) in PBS and post-fixation took place for 2 h 
in the same solution. The SC brain region was sectioned into 50 µm coronal sections using 
the Micron H650 vibratome (Thermo Scientific, MA, USA) and stored in PBS with 0.004 % 
sodium azide at 4 °C until IHC. 
Following perfusion, eyes were enucleated and fixed for 1 h in 4 % paraformaldehyde (PFA) 
in PBS. Next, retinas were dissected, flat-mounted and post-fixed for 1 h in 4 % PFA. After 
thorough washing with PBS, retinas were stored in PBS at 4 °C for a maximum of 24 h until 
IHC. 
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2.5 HISTOLOGY 
Coronal brain sections of the SC region were mounted on gelatin-coated glass slides and 
dried overnight. The sections were Nissl stained in order to visualize general SC morphology. 
Dehydration of the sections through a series of increasing alcohol concentrations was 
followed by incubation in chloroform and subsequent rehydration. The next steps were, one 
min staining in 1 % Cresyl violet (Fluka Chemika, Sigma-Aldrich, MO, USA), destaining with 
acetic acid and a second dehydration series. Upon final incubation in xylene, sections were 
cover slipped with Depex (VWR, PA, USA). The Nissl stained SC sections were imaged using 
the Axio Imager Z.1 light microscope (Zeiss, Germany), driven by ZEN LE digital imaging 
software. Cells exhibiting stained cytoplasm, pale nucleus, and stained nucleolus were 
defined as healthy neurons373 and collicular boundaries were determined by comparison 
with the stereotaxic mouse brain atlas427.  
2.6 IMMUNOHISTOCHEMISTRY ON BRAIN SECTIONS 
IHC was performed under uniform conditions on free-floating coronal SC sections in order 
to: 1) amplify the fluorescent reporter signal of eGFP/mCherry; 2) to visualize glial fibrillary 
acidic protein (GFAP), a marker for astroglial cells428; 3) to label all neurons via the neuronal 
nuclei marker (NeuN)416; 4) to visualize collicular layers through staining of RGC synaptic 
terminals that label for vesicular glutamate transporter 2 (VGluT2)297; 5) to mark GABA-ergic 
inhibitory neurons429; and 6) to visualize BDNF expression.  
For general IHC, sections were rinsed in PBS containing 0.1 % Triton X-100 (Fisher Scientific, 
NY, USA) (PBST0.1) and incubated for 1 h in PBST0.1 containing 20 % goat pre-immune 
serum (Invitrogen, CA, USA), followed by incubation with primary antibodies, listed in Table 
4.3, diluted in PBST0.1 and 10 % goat pre-immune serum. After rinsing and incubation for 2 
h with secondary antibody (Alexa Fluor-488/568-conjugated goat anti-rabbit and/or goat 
anti-mouse IgG, Invitrogen, CA, USA), diluted 1:200 in PBST0.1, sections were rinsed, nuclei 
were 4’,6-diamidino-2-phenylindole stained (DAPI, 1 µg/ml in PBS, Dako, Denmark), and 
sections were mounted on gelatin-coated microscopy slides, and cover slipped with Mowiol 
(Sigma-Aldrich, MO, USA).  
For NeuN IHC, extra steps were added because amplification of the signal was necessary. 
Before incubation with goat pre-immune serum, endogenous peroxidases were blocked via 
incubation in methanol containing 0.3 % H2O2 for 20 min, followed by thorough rinsing. After 
overnight primary antibody incubation, washing, and 45 min incubation with biotin-
conjugated goat anti-rabbit antibody (1:300 in PBST0.3, DAKO, Denmark), the TSATM Cy3 
System (NEL744001KT, Perkin Elmer, MA, USA) was used for amplification and visualization.  
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For GABA IHC, sections were treated with sodium borohydride 2 % in PBS to reduce 
glutaraldehyde linkages and extensively rinsed in PBS before starting the general IHC 
protocol as described above.  
Table 4.3: List of primary antibodies used for fluorescent IHC on SC sections. Key: IHC, immunohistochemistry; 
SC, superior colliculus; eGFP, enhanced green fluorescent protein; RFP, red fluorescent protein; BDNF, brain-
derived neurotrophic factor; GFAP, glial fibrillary acidic protein; VGluT2, vesicular glutamate transporter 2; 
GABA, γ-aminobutyric acid. 
Primary antibody Labels 
Incubation time 
and dilution 
Reference 
Rabbit anti-eGFP eGFP reporter 24 h, 1:10,000 provided by Prof. V. Baekelandt
430
 
Rabbit anti-RFP mCherry reporter 24 h, 1:5,000 600-401-379, Tebu-Bio, France 
Rabbit anti-BDNF Pro- and mature BDNF 48 h, 1:500  
sc-546, Santa Cruz Biotechnology, TX, 
USA 
Mouse anti-GFAP Reactive astrocytes 24 h, 1:1,000 G3893, Sigma-Aldrich, MO, USA 
Mouse anti-NeuN Neuronal nuclei  24 h, 1:200 MAB377, Millipore, Germany 
Rabbit anti-VGluT2 Synaptic terminals  24 h, 1:250 42-7800, Invitrogen, CA, USA 
Mouse anti-GABA GABA-ergic neurons 24 h, 1:5,000 A0310, Sigma-Aldrich, MO, USA 
 
Immunofluorescent labeling was visualized using the FV1000-D laser confocal scanning 
microscope (Olympus Corporation, Japan), controlled by Fluoview 4.0 software, or the Axio 
Imager Z.1 epifluorescence microscope (Zeiss, Germany), driven by ZEN LE digital imaging 
software. 
2.7 IMMUNOHISTOCHEMISTRY ON WHOLE-MOUNT RETINAS 
In order to examine possible retrograde transduction of the retina after viral vector injection 
into the SC, Brn3a and eGFP IHC was performed on whole-mount retinas. Brn3a is a POU-
domain transcription factor and a reliable marker for RGCs20,91,188. Retinas were washed in 
PBS containing 0.5 % Triton X-100 (PBST0.5) and frozen at -80°C for 15 min to enhance 
permeability. After rinsing in PBST0.5, they were incubated overnight with goat anti-Brn3a 
(1:500, sc-31984, Santa Cruz Biotechnology, TX, USA) and rabbit anti-eGFP (1:10,000, 
provided by Prof. V. Baekelandt) diluted in PBS containing 2 % Triton X-100 and 2 % donkey 
pre-immune serum (Invitrogen, CA, USA). Subsequently, retinas were rinsed in PBST0.5 and 
incubated for 2 h with Alexa Fluor-594-conjugated donkey anti-goat IgG and Alexa Fluor-488-
conjugated donkey anti-rabbit (Invitrogen, CA, USA) diluted 1:500 in PBS containing 2 % 
Triton X-100. Retinas were then rinsed in PBST0.5 and PBS before being mounted on glass 
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slides with Mowiol (Sigma-Aldrich, MO, USA). The stained retinal whole-mounts were 
imaged with the FV1000-D laser confocal scanning microscope (Olympus Corporation, Japan) 
controlled by Fluoview 4.0 software. 
2.8 IN VITRO SECRETION OF VECTOR-BASED BDNF BY HEK CELLS 
To verify secretion of BDNF produced by cells transduced with the BDNF-expressing vector, 
human embryonic kidney 293T (HEK293T) cells (American Type Culture Collection, VA, USA) 
were cultured in Dulbecco modified Eagle medium (DMEM, Invitrogen, CA, USA) 
supplemented with 8 % fetal calf serum (Invitrogen, CA, USA) and gentamicyn (Sabex, 
Canada), plated at 100,000 cells per well in 24-well plates. HEK293T cells were transduced 
with either the BDNF or eGFP vector. After 48 h incubation with medium containing vector 
at 4.29E9 GC/ml, the cells were transferred to 6-well plates and medium was harvested 24 h 
and 72 h later.  To quantify BDNF levels in the medium, the mouse BDNF enzyme-linked 
immune-sorbent assay (ELISA) kit (KA0331, Abnova, Taiwan) was used following the 
manufacturer’s guidelines. Analyses were performed with Skanit 3.1 software (Thermo 
Scientific, MA, USA). ELISA data are presented as mean ± SEM. A normal distribution was 
verified using the Kolmogorov-Smirnov test and parallel equal variance between groups was 
tested. Subsequently, a parametrical two-way ANOVA was used and Bonferroni post hoc 
tests were applied for pairwise comparisons. The probability level (α-level was set to 0.05) of 
<0.05 was accepted as statistically significant. Statistical analyses were performed using 
GraphPad Prism S5 (GraphPad Software, CA, USA).  
To estimate transduction efficiency, eGFP vector-transduced cells were fixed for 15 min in 
4 % PFA and incubated for 30 min with 1 µg/ml DAPI in PBS (Dako, Denmark) for nuclear 
staining. The DAPI and eGFP signals were visualized with the FV1000-D laser confocal 
scanning microscope (Olympus Corporation, Japan). The percentage of eGFP-expressing cells 
was calculated over 400 randomly chosen DAPI+ cells per well (N=4 wells).  
2.9 EX VIVO VALIDATION OF VECTOR DERIVED BDNF ACTIVITY  
2.9.1 Retinal explants 
To validate the bio-activity of vector-derived BDNF, postnatal retinal explants were cultured 
in medium supplemented with conditioned medium derived from transduced HEK293T cells, 
and neurite outgrowth was studied. Retinal explants were isolated as previously 
described431,432. Briefly, 750 μm explants were punched from dissected retinas from 
postnatal mouse pups (P3) and cultured in poly-L-lysin and laminin-coated wells (NunclonTM 
delta surface, Thermo Scientific, Rochester, NY, USA) for 3 d. Explants were cultured in 
NeurobasalTM-A medium (Invitrogen, CA, USA), containing 0.4 % methylcellulose (Sigma-
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Aldrich, MO, USA), 1 % penicillin/streptomycin, 0.2 % fungizone, 0.5 % L-glutamine and 2 % 
B-27 supplement for retina (all from Invitrogen, CA, USA). The explant culture medium was 
supplemented with 1) conditioned medium from BDNF vector-transduced HEK293T cells, to 
a final concentration of 50 ng/ml BDNF, 2) conditioned medium from eGFP vector-
transduced HEK293T cells, or 3) with recombinant BDNF in a final concentration of 50ng/ml 
(Peprotech Laboratories, UK). Every day, half of the culture medium was replaced with fresh 
medium, containing the same concentration of compound or vehicle.  
2.9.2 Immunohistochemistry on retinal explants and neurite outgrowth analysis  
Explants were fixed in 4 % phosphate buffered PFA and neurite outgrowth was visualized by 
immunostaining for β-tubulin using the monoclonal mouse anti-β-tubulin III antibody (1:500, 
T8660 clone SDL.3D10, Sigma-Aldrich, MO, USA), as described431,432. β-tubulin III stained 
explants were imaged by the FV1000-D laser confocal scanning microscope controlled by 
Fluoview 4.0 software (Olympus Corporation, Japan) and analyzed using Axiovision software 
(Zeiss, Germany). Automated analysis of axonal outgrowth was performed by measuring the 
neurite outgrowth area, as previously described431,432.   
2.10  STATISTICS  
All data are presented as mean ± SEM. Outliers were determined via a Grubbs’ test and 
excluded from further analyses. Student’s t-test for pairwise comparison was used (* p<0.05, 
*** p<0.001). Statistical analyses were performed using GraphPad Prism S5 (GraphPad 
Software, CA, USA). 
 
3 RESULTS  
3.1 LV AND RAAV VECTORS IN THE SC: GLIAL REACTIVITY AND TRANSDUCTION 
EFFICIENCY   
Nissl staining on coronal sections of the viral vector-injected SCi, revealed no apparent tissue 
damage at two weeks post-injection (data not shown). In some cases, the injection site could 
be determined via recognition of the needle track, which remained limited to one section 
only. Thus, the SC maintained its normal morphology after viral vector delivery. 
VIRAL VECTOR TECHNOLOGY   ___________________________________________________   105 
 
 
Two weeks after viral vector injection in the SC, glial responses elicited by the various 
vectors, containing the eGFP gene under control of the CMV promoter (Table 4.1), were 
compared via IHC for GFAP (Nnaive=2, Nsham=3, NLV=2, NrAAV2/x=4). Astroglial reactivity, defined 
by upregulated GFAP labeling, remained locally around the injection site (± 300 µm) for each 
vector. Qualitatively, a trend was seen whereby the LV vector (Figure 4.2 C) injections 
induced a higher glial response compared to rAAV vectors (Figure 4.2 D-G). The difference 
between rAAV vector-injected SC and sham controls (Figure 4.2 B) was limited. Of note, the 
difference in the glial reactivity observed after LV versus rAAV or sham injections might be 
based on the variation in injection volume, with 1 µl injected for LV and 200 nl for all other 
conditions.  
In the same mice (NLV=2, NrAAV2/x=4), the eGFP expression pattern, clearly visualized by eGFP 
IHC, was investigated to estimate transduction efficiency of the tested viral vectors in the 
mouse SC (Table 4.1). The ability of a vector to spread throughout the whole SC is crucial for 
its applicability in our research. The LV vector showed very limited anteroposterior and 
lateromedial distribution (Figure 4.3 A), with the eGFP reporter signal only visible near the 
injection site, although 1 µl of vector was injected. In contrast, all rAAV vectors transduced a 
larger volume in the SC after 200 nl injection, with the eGFP reporter signal visible 
throughout the complete anteroposterior and lateromedial volume of the SC (Figure 4.3 B-
D). None or a very limited number of eGFP-positive cells were observed in the non-injected 
SC of the same animal, which therefore served as an internal control in future experiments. 
No obvious differences between rAAV serotypes were noticed, as all of them showed robust 
transduction efficiencies. However, eGFP expression upon rAAV2/1 injection tended to 
remain slightly more localized compared to the other vectors, both along the 
anteroposterior and lateromedial axis. Nevertheless, in the rAAV2/1-transduced area, many 
cells were positively labeled for eGFP. Variation in qualitatively evaluated transduction 
efficiency between serotypes rAAV2/7, rAAV2/8 and rAAV2/9 was no more than the 
interindividual variation between animals within one group, injected with one serotype. 
Upon rAAV transduction, eGFP labeled cells occurred in all collicular layers. Near the 
injection site, both the dSC and sSC were brightly eGFP-labeled, while further along the 
anterioposterior axis especially the sSC appeared to be transduced. 
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Figure 4.2: Astroglial responses induced by viral vector injection, visualized through GFAP IHC.  A. In a naive 
control SC, almost no GFAP signal is detectable. B. In the sham-injected SC (200 nl sterile PBS), enhanced glial 
reactivity around the injection site is seen compared to the naive condition. C. Injection of 1 µl LV vector 
induces more glial activation compared to the sham condition. D-G. Collicular injection with 200 nl rAAV2/x 
results in astroglial reactivity near the needle track at the injection site. The level of glial response is 
comparable to what is observed for sham animals. No clear difference is visible in astroglial response induced 
by rAAV2/1 (D), rAAV2/7 (E), rAAV2/8 (F), or rAAV2/9 (G) collicular delivery. Scale bars: 100 µm. Key: GFAP, glial 
fibrillary acidic protein; IHC, immunohistochemistry; SC, superior colliculus; PBS, phosphate-buffered saline; LV, 
lentiviral vector; rAAV2/x, recombinant adeno-associated viral vector serotype 2/x.  
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To investigate whether the viral vectors have a preference in transducing neurons and/or 
glial cells, double stainings for eGFP and GFAP, an astroglial marker, and for eGFP and NeuN, 
a neuronal marker, were performed (Figure 4.4). For both LV and rAAV vectors (NLV=2, 
NrAAV2/x=4), eGFP expression was observed in NeuN immunopositive cells. For the LV vector, 
also colocalisation of eGFP and GFAP signal was visible, yet this was not the case for any of 
the tested rAAV serotypes.  
 
Figure 4.4: Viral vector transduction of neurons and astrocytes in the mouse SC. The LV vector transduces 
both neurons and glial cells, visualized through NeuN and GFAP IHC respectively, while rAAV2/x vectors almost 
exclusively induce eGFP expression in neurons and not in glial cells. rAAV2/1 and rAAV2/7 are depicted as 
representative examples of all rAAV2/x serotypes tested in this study. Filled arrowheads point towards 
double-labeled cells, while unfilled arrowheads mark eGFP expressing cells that do not stain for GFAP (lower 
panels). Scale bars: 20 µm. Key: SC, superior colliculus; LV, lentiviral vector; rAAV2/x, recombinant adeno-
associated viral vector serotype 2/x; GFAP, glial fibrillary acidic protein; NeuN, neuronal nuclei; IHC, 
immunohistochemistry; eGFP, enhanced green fluorescent protein; CMV, cytomegalovirus promoter.  
Overall, the LV vector induced a higher glial response and showed very low efficiency for SC 
transduction as compared to all rAAV vector serotypes. Within the rAAV serotypes, rAAV2/1 
transduction remained slightly more localized around the injection site compared to 
rAAV2/7, rAAV2/8, and rAAV2/9, which exhibited very similar eGFP expression patterns 
throughout the entire SC. Furthermore, the LV vector transduced both neurons and glial 
cells, while rAAV vectors almost exclusively induced reporter gene expression in neurons in 
the mouse SC.  
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3.2 RETROGRADE TRANSDUCTION OF THE RETINA  
The larger scope of this thesis is to enhance the growth factor release or the neuronal 
activity within the SC, and to study the effect of these collicular modifications on RGC 
survival in glaucoma models. Therefore, it is essential to use viral vectors that do not 
retrogradely transduce retinal cells upon injection in the SC, as in that case, RGCs would be 
directly affected, instead of indirectly, via collicular modification. At two weeks after 
intracollicular viral vector delivery, whole-mount retinas were stained for Brn3a, a marker 
for RGCs, and eGFP, the reporter gene (NLV=2, NrAAV2/x=3). For the LV and rAAV2/1 vectors, 
no eGFP expression was detected in retinal cells. Despite a similar transduction efficiency 
observed in the SC, the other collicular-injected rAAV2/x vectors retrogradely transduced 
RGC cell bodies in the retina to differing degrees, with rAAV2/9 showing strong RGC 
transduction throughout the entire retina, rAAV2/7 labeling RGCs in restricted zones mainly 
located in the central retina, and rAAV2/8 only showing sparse RGC labeling (Figure 4.5). All 
eGFP-expressing cells in the retina were RGCs, as determined by colocalization of the eGFP 
signal with Brn3a IHC.  
3.3 DIFFERENT EXPRESSION PATTERNS WITH CMV AND CAMK PROMOTERS  
Based on the results described above, rAAV2/1 is the most promising serotype for further 
experiments, with low induction of glial reactivity, good transduction of the SC, and no 
retrograde RGC labeling. However, at the start of this PhD project, only rAAV2/7 optovectors 
were available (section 3.5). Therefore, besides rAAV2/1, also rAAV2/7 transduction 
characteristics were further investigated. In the next set of experiments (N=3 per condition), 
eGFP expression controlled by the general CMV promoter was compared to the expression 
driven by the CaMK promoter, which is known to drive cell-specific expression in excitatory 
neurons in the cortex423,424. Although these CaMK vectors were designed for use in the visual 
cortex and little is known about CaMK specificity in the SC, we believed they might be of 
potential interest for collicular use as well. Strikingly, both for the rAAV2/1 and the rAAV2/7 
serotype, CaMK-driven eGFP expression showed a remarkable layered expression pattern 
(Fout! Verwijzingsbron niet gevonden.). Neurons, and not glial cells as verified by NeuN and 
GFAP IHC (data not shown), were eGFP labeled throughout all collicular layers, however, one 
band of cells showed brighter labeling. VGluT2 IHC was performed to mark the collicular 
layers and this revealed that the CaMK promoter-driven bright expression band was 
specifically located in the lower SO, slightly extending into the underlying SGI. No retrograde 
labeling of RGCs was detected with the rAAV2/1-CaMK-eGFP vector, while for the rAAV2/7-
CaMK-eGFP vectors, a similar RGC staining pattern as illustrated earlier for the rAAV2/7-
CMV-eGFP vector was noticed (data not shown). 
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Figure 4.5: Retrograde transduction of RGCs upon collicular vector delivery. In contrast to LV and rAAV2/1 
viral vectors (data not shown), unilateral injection of rAAV2/7 (left), rAAV2/8 (middle), and rAAV2/9 (right) 
vectors into the mouse SC results in CMV promoter-driven eGFP (green) expression in RGCs, identified through 
Brn3a IHC (red) in the eye contralateral to the injected SC. Double-labeled cells show green cytoplasm and a 
red nucleus. Scale bars: 20 µm. Key: LV, lentiviral vector; rAAV2/x, recombinant adeno-associated viral vector 
serotype 2/x; CMV, cytomegaloviral promoter; eGFP, enhanced green fluorescent protein; RGC, retinal ganglion 
cell; SC, superior colliculus; IHC, immunohistochemistry.   
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Figure 4.6: Comparison between CMV and CaMK promoter-controlled eGFP expression patterns in the SC. 
CMV promoter-controlled eGFP expression (green) is distributed with similar intensities throughout the 
collicular layers, while CaMK promoter-controlled expression is brighter in the SO. However, eGFP-expressing 
neurons are also present in the other layers. VGluT2 IHC (grey) was performed to distinguish the different 
layers within the retinorecipient SC: SZ, SGS, and SO. Right panels show a magnification of the rectangle in the 
middle panels, with only the eGFP signal being displayed. Scale bars left and middle: 200 µm, right: 40 µm. Key: 
CMV, cytomegalovirus; CaMK, Ca
2+
/calmodulin-dependent protein kinase II  promoter shortened sequence of 
0.4 kb; rAAV2/x, recombinant adeno-associated viral vector serotype 2/x; eGFP, enhanced green fluorescent 
protein; VGluT2, vesicular glutamate transporter 2; IHC, immunohistochemistry; SZ, stratum zonale; SGS, 
stratum griseum superficiale; SO, stratum opticum; SGI, stratum griseum intermediale.  
to verify whether CaMK-based eGFP expression is specific for excitatory neurons in the SC as 
has been described for the cortex, GABA IHC was performed to label inhibitory neurons 
(Figure 4.7). With the CMV promoter, eGFP and GABA immunostaining only partially 
colocalized, indicating that both inhibitory and excitatory cells were transduced. This was the 
case for every serotype - rAAV2/1, rAAV2/7, rAAV2/8, and rAAV2/9 (N=3). rAAV2/1-CaMK-
eGFP and rAAV2/7-CaMK-eGFP vectors (N=3) almost exclusively induced eGFP expression in 
non-GABA-labeled neurons, both in the intense eGFP-expressing band, localized in the SO, 
and within the other layers where eGFP expression appeared more faintly. These data 
suggest that the CaMK promoter induces more specific reporter gene expression in 
excitatory neurons.  
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Figure 4.7: The CaMK promoter induces expression mainly in excitatory neurons. After transduction of 
neurons with rAAV2/1 or rAAV2/7 vectors, the CMV promoter induces eGFP expression both in inhibitory 
(GABA-ergic) and excitatory (non-GABA-ergic) neurons, as shown by double staining for eGFP (green) and GABA 
(red). CaMK promoter-induced eGFP expression only sporadically colocalizes with GABA IHC. Filled arrowheads 
point towards double-labeled cells, while unfilled arrowheads mark eGFP expressing cells that do not stain for 
GABA. Scale bars: 10 µm. Key: CMV, cytomegalovirus; CaMK, Ca
2+
/calmodulin-dependent protein kinase 
promoter shortened sequence of 0.4 kb; rAAV2/x, recombinant adeno-associated viral vector serotype 2/x; 
eGFP, enhanced green fluorescent protein; GABA, γ-aminobutyric acid; IHC, immunohistochemistry.  
Taken together, reporter gene expression patterns were clearly affected by the promoter. 
The CMV promoter induced equal expression in all collicular layers, while CaMK promoter-
driven expression was stronger in the SO, although also the other layers cells were faintly 
eGFP labeled. Furthermore, the CMV promoter did not distinguish between excitatory and 
inhibitory neurons, while the CaMK promoter was mainly active in non-GABA-ergic 
excitatory neurons.  
3.4 SECRETION AND BIOACTIVITY OF VIRAL VECTOR-DERIVED BDNF  
In the previous sections, rAAV2/1 and rAAV2/7 vector serotypes were shown to successfully 
transduce SC neurons and both CMV and CaMK promoters induced reporter gene 
expression. In contrast to the eGFP reporter, which is a cytosolic protein, BDNF is a protein 
that needs to be secreted and the SSFO channel has to be translocated to the membrane. 
Therefore, additional experiments were performed to test the applicability of BDNF and 
SSFO vectors.  
Unilateral delivery of the BDNF vector into the mouse SC resulted in extensive upregulation 
of BDNF expression, visualized through IHC (Figure 4.8 A) at two weeks post-injection, as  
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Figure 4.8: Validation of the BDNF vector. A. Unilateral rAAV2/1-CMV-BDNF vector-induced BDNF upregulation 
is visualized through IHC. Scale bar: 200 µm. B. Based on eGFP reporter signal, HEK293T cells are transduced 
with a success rate of 81.2 ± 2.5 %. Scale bar: 10 µm. C. In contrast to HEK293T cells transduced with the eGFP 
control vector, HEK293T cells transduced with BDNF vector secrete large amounts of BDNF in the culture 
medium, quantified by ELISA on medium harvested 24 h and 72 h post-transduction (N=4). Thus, vector-
derived BDNF is secreted by transduced cells. D. Retinal explants cultured in medium supplemented with 
recombinant BDNF (rBDNF, N=11) or vector-derived BDNF (vBDNF, N=6) show enhanced neurite outgrowth 
areas compared to control explants (eGFP, N=8) with N = number of explants, derived from three mice. Data in 
C and D are mean ± SEM with *** p<0.001 and * p<0.05 based on Student’s t-test compared to eGFP control. 
Key: BDNF, brain-derived neurotrophic factor; eGFP, enhanced green fluorescent protein; DAPI, 4’,6-diamidino-
2-phenylindole; SC, superior colliculus; rAAV2/1, recombinant adeno-associated viral vector serotype 2/1; CMV, 
cytomegaloviral promoter; IHC, immunohistochemistry; ELISA, enzyme-linked immune-sorbent assay; 
HEK293T, Human embryonic kidney cell line.  
compared to the non-injected hemisphere. Injection of the eGFP control vector, produced in 
parallel with the BDNF vector, yielded similar labeling patterns as the rAAV2/1-CMV-eGFP 
vectors shown in Figure 4.4. Next, the characteristics of vector-derived BDNF were 
investigated in more detail in vitro. To verify whether transgenically-expressed BDNF could 
be secreted by transduced cells, BDNF concentrations were measured in medium harvested 
from cultured HEK293T cells, transduced at a success rate of 81.2 ± 2.5 % (Figure 4.8 B) with 
either the BDNF- or eGFP-expressing viral vector. As expected, BDNF levels were much 
higher (***p<0.001, N=4) in medium harvested from BDNF vector-transduced cells, both at 
24 h (298.45 ± 19.51 ng/ml) and at 72 h (264.03 ± 55.24 ng/ml) post-transduction, as 
compared to medium harvested from cells transduced with the control vector at 24 h (0.01 ± 
0.00 ng/ml) and 72 h (0.01 ± 0.00 ng/ml) post-transduction (Figure 4.8 C). Thus, viral vector-
derived BDNF can be secreted by transduced cells in vitro.  
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Next, using the well-established retinal explant model, bio-activity of the vector-derived 
BDNF was verified. Explants incubated with medium supplemented with recombinant BDNF 
(rBDNF, N=11) or with conditioned medium from BDNF vector-transduced HEK293T cells 
(vBDNF, N=6) showed enhanced neurite outgrowth compared to control explants, which 
were cultured in medium supplemented with equal amounts of conditioned medium from 
eGFP vector-transduced HEK293T cells (eGFP, N=8) (Figure 4.8 D). Thus, viral vector-derived 
BDNF was shown to be bio-active.  
3.5 SSFO INCORPORATION IN THE MEMBRANE 
Besides the BDNF-vector, also the functionality of two optovectors, rAAV2/1-CMV-SSFO-
mCherry and rAAV2/7-CaMK-SSFO-mCherry, and their respective controls, rAAV2/1-CMV-
eGFP and rAAV2/7-CaMK-eGFP, was validated (Table 4.2). Animals were sacrificed four 
weeks post-viral vector delivery, to allow sufficient time for the opsin to be expressed and 
incorporated into the cell membrane. IHC, used to enhance the mCherry or eGFP reporter  
 
 
Figure 4.9: Validation of viral vector-mediated SSFO expression and its plasmamembrane incorporation. Four 
weeks after unilateral viral vector delivery to the SC, robust reporter gene expression is visible. Reporter signal 
was amplified by IHC for eGFP for control vectors (left panels) and mCherry for SSFO vectors (middle panels). 
Right panels are a magnification of the indicated area in the middle panels, showing clear membrane-directed 
localization of the SSFO channels. Scale bars left and middle: 200 µm, right: 10 µm. Key: CMV, cytomegalovirus 
promoter; CaMK, Ca
2+
/calmodulin-dependent protein kinase II  shortened sequence 0.4 kb promoter; 
rAAV2/x, recombinant; rAAV2/x, recombinant adeno-associated viral vector serotype 2/x; SSFO, stabilized step-
function opsin; eGFP, enhanced green fluorescent protein; DAPI, 4’,6-diamidino-2-phenylindole; IHC, 
immunohistochemistry.  
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signal, revealed a pronounced distribution of all four vectors throughout the SC, similar to 
the results for the rAAV2/1 and rAAV2/7 serotypes shown before in Figure 4.3. Larger 
magnification verified clear membrane localization of the SSFO channels for both 
optovectors (Figure 4.9). 
 
4 DISCUSSION  
The overall goal of the work described in this chapter was to optimize viral vector 
transduction in the mouse SC. Based on the fact that the applicability of different viral vector 
systems depends on the experimental setup, tissue, and species433,434, it is necessary to 
define the optimal vector system for each application424. Therefore, the induced glial 
response, the transduction efficiency, and the cell tropism were compared between one LV 
and different rAAV2/x serotypes - rAAV2/1, rAAV2/7, rAAV2/8, and rAAV2/9 - upon delivery 
to the mouse SC. Furthermore, CMV and CaMK promoter-driven reporter gene expression 
patterns were evaluated. Retinas were investigated to unmask any retrograde transduction 
of RGCs.  
4.1 DETERMINATION OF THE VECTOR OF CHOICE  
4.1.1 Glial response and intracollicular distribution  
The in vivo use of viral vectors may induce glial responses, which can be indicative of tissue 
damage and possibly reduce transgene expression435. In general, both LV and rAAV vectors 
are considered to be non-damaging, and thus, are not expected to elicit large glial 
responses435,436. Indeed, in all rAAV2/x-injected animals, collicular astroglial reactivity, 
observed through GFAP IHC, was similar to the sham controls. Enhanced GFAP expression 
was observed after LV injection compared to rAAV2/x and sham conditions. This could be a 
consequence of the larger injection volume for the LV vector (1 µl) versus the rAAV2/x 
vectors and the sham controls (200 nl). The astroglial response induced by rAAV2/x vectors 
remained very local and disappeared over time, just like in sham animals, confirming the 
applicability of these vectors in the mouse SC without major side effects related to glial 
reactivation.  
Next, the vectors were compared for efficiency in SC transduction. The vector of choice for 
our purposes should demonstrate vigorous anteroposterior and lateromedial distribution 
throughout the entire SC and a high number of transgene-expressing cells within the 
transduced volume. Transgene expression upon viral vector delivery has been described to 
reach maximum expression levels at two weeks post-transduction, persisting stably 
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thereafter416,434. Therefore, transduction efficiency was studied at two weeks post-injection. 
For transduction of the SC, the performance of the LV vector was particularly poor, showing 
a weak distribution within the SC, and even near the injection site, the number of 
transduced cells was low. All rAAV2/x vectors performed better compared to the LV vector, 
exhibiting obvious anteroposterior and lateromedial distribution, with large numbers of cells 
targeted within the transduced volume. Although quantitative analyses were not performed, 
qualitative evaluations clearly revealed that all of the rAAV2/x vectors were suitable for 
further research. Interestingly, despite robust collicular transduction by all rAAV2/x 
serotypes, the use of rAAV2/1 resulted in a slightly more localized eGFP expression 
compared to the other rAAV2/x vector, both along the anteroposterior and lateromedial 
axis.  
In line with this observation, a very recent study by Scheyltjens et al.424, using the same viral 
vectors as evaluated here, also described a more restricted transduction in the primary 
visual cortex (V1) of the mouse upon rAAV2/1 injection as compared to other rAAV2/x 
serotypes. However, in the V1 study, this difference was more pronounced compared to the 
slightly more localized expression induced by rAAV2/1 in our SC study, again stressing the 
necessity to retest the applicability of viral vector systems for each target tissue. Although 
differences in titers may lead to differences in transduction efficiency and even tropism437, 
no titer equalizing dilutions were performed in our experiments because all rAAV2/x titers 
were in the range of E12 GC/ml. As such, we cannot entirely exclude that the minor variation 
in titers might explain the more localized transduction by rAAV2/1, having the lowest titer as 
compared to the other rAAV2/x serotypes. On the other hand, by comparing rAAV2/1 
batches with low and high titers, Drs. I. Scheyltjens and colleagues demonstrated that the 
localized spreading of the rAAV2/1 serotype in mouse V1 was not determined by variation in 
titers (unpublished results). Therefore, also in the SC, the more localized spread of rAAV2/1 
might rather be explained by the specific capsid structure. Nevertheless, our findings clearly 
disclosed that all rAAV2/x serotypes, including rAAV2/1 that yielded more localized 
transgene expression, efficiently transduced the SC.  
4.1.2 Cell tropism 
The next step in characterizing the transduction behavior of the viral vectors in the mouse SC 
was studying their ability to transduce different cell types. The tropism of each vector for 
neuronal and glial cells was investigated through NeuN and GFAP IHC. The LV vector was 
demonstrated to transduce both neuronal and glial cells, an observation in agreement with 
literature438,439. For the rAAV2/x vectors, the data presented here indicate that transduced 
cells were almost exclusively neurons. These results are in line with previous reports 
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describing that rAAV2/7, rAAV2/8, and rAAV2/9 only transduce neurons, but not astrocytes 
or oligodendrocytes, in cortex, striatum, hippocampus, and thalamus in mice424,440. In 
primates, intrastriatal delivery of rAAV2/1 transduced neurons almost exclusively, while 
rAAV2/8 transduced a more even distribution across neurons and glia, both containing a 
CMV-eGFP construct441. On the contrary, in the mouse striatum, rAAV2/1 has been shown to 
limitedly target astrocytes, oligodendrocytes, and microglia, although neurons remained the 
predominantly transduced cell type442. In these experiments and similar to the current study, 
vector titers of a high order of magnitude (E11 GC/ml) and a constitutive CMV promoter 
were used; however, the vectors were delivered into the striatum442. Transduction tropism 
of certain viral vectors might therefore be dependent on tissue433,434. Furthermore, small 
differences might possibly exist between the used rAAV2/1 vectors. Here, a vector produced 
in-house at the Viral Vector Core of KU Leuven was employed, potentially slightly differing 
from the vector used in the referred study on rAAV2/1 tropism in the mouse striatum442. Our 
observations are underscored by findings of other investigations utilizing the vectors 
developed in the KU Leuven Viral Vector core, demonstrating that in rodents, rAAV2/1, 
rAAV2/7, and rAAV2/8 almost exclusively transduce neurons416,424,434.  
Of note, the observed eGFP expression is the result of both transduction, mainly determined 
by the serotype, and promoter activity. The reason for the neuronspecific labeling remains 
elusive, as CMV is considered an ubiquitous promoter that induces expression in both 
neurons and glia439,441,442, and rAAV2/1 does have the ability to transduce glial cells, since 
combining the rAAV2/1 serotype with the gfaABC1D promoter443 resulted in eGFP expression 
in SC astrocytes (Geeraerts 2015, preliminary results). Thus, the neuronal specificity 
observed in the current study, specifically focusing on the mouse SC, might be attributed to 
the combination of the rAAV2/1 serotype with the CMV promoter. 
4.1.3 Retrograde transduction of RGCs 
After viral vector delivery to the SC, retinal cells may also express the transgene because of 
retrograde transduction, which is transduction of cell bodies in regions distant from the 
injection site projecting axons towards the injection site434. Within the scope of this PhD 
project, transduction of the retina was a definite no-go as the ultimate goal was to study the 
indirect effect of viral vector technology-based modulation of the SC on RGC survival. If the 
RGCs themselves were to be transduced by the viral vector, the results would be distorted 
and the research questions posed would remain unanswered because of difficulties in 
interpreting the data. Therefore, the retrograde transduction capacity of the different viral 
vectors was examined. The retina contralateral to the injected SC of mice injected with 
rAAV2/7, rAAV2/8, and rAAV2/9 displayed eGFP expression in a portion of the RGCs, 
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identified via Brn3a IHC91,352, while this was never observed in LV- or rAAV2/1-transduced 
animals. It did not come as a surprise that for the LV vector no eGFP labeling was observed in 
the retina, as also within the SC, this vector showed a very limited transduction efficiency. 
rAAV2/1 tended to induce a slightly more localized transgene expression within the SC as 
well, but overall, the vector performed well. rAAV2/1 was found to be the only non-
retrogradely transducing rAAV2/x vector tested. The remaining vectors, rAAV2/7, rAAV2/8, 
and rAAV2/9, evincing very similar transduction patterns within the SC, induced different 
retrograde transduction levels. rAAV2/9 showed the strongest retrograde transduction 
capacity, followed by rAAV2/7 and rAAV2/8. Intracollicular rAAV2/9 injection exhibited the 
highest eGFP labeling in RGCs, uniform throughout the central and the peripheral retina, 
while for rAAV2/7 and rAAV2/8, this retrograde RGC labeling remained restricted to certain 
retinal areas, while other areas did not contain a single eGFP-expressing RGC. Of note, as the 
collicular transduction patterns were very similar in the different serotype groups, the 
observed differences in retrograde transduction capacity were not simply caused by 
variation in injection site. Since rAAV2/9 and rAAV2/1 were the vectors with the highest and 
lowest titer, respectively (Table 4.1), at first sight one might think that variations in 
retrograde transduction capacity are partially related to differences in titers. However, titer 
variability is certainly not the main contributing factor, as the results with rAAV2/7 and 
rAAV2/8 do not underlie this explanation. Indeed, rAAV2/7 contains a lower titer than 
rAAV2/8, yet more RGCs are retrogradely labeled with rAAV2/7. Alternatively, differences in 
capsid proteins between serotypes, which are responsible for variations in cell tropism440, 
might underlie the observed differences in retrograde transduction capacities, as they might 
determine whether or not a certain serotype is capable of binding to the membrane of RGCs’ 
axon terminals. In line with the results, rAAV2/9 has been shown to perform widespread 
transduction of brain regions that are known to project towards the injection site, clearly 
indicating that rAAV2/9 is capable of being retrogradely transported440. Further, and 
consistent with the data presented here, other research groups using the same rAAV2/x 
vectors, delivered by the KU Leuven Viral Vector Core, also reported a retrograde 
transduction capability of rAAV2/x vectors416,424,434. For example, upon injection of rAAV2/1, 
rAAV2/7, rAAV2/8, and rAAV2/9 into mouse V1, retrograde labeling of neurons in the dorsal 
lateral geniculate nucleus (dLGN) was observed424. Furthermore, vector delivery in the 
striatum of adult mice resulted in retrograde transduction of substantia nigra neurons for 
rAAV2/1, rAAV2/5, rAAV2/7, and to a lesser extent, rAAV2/8434. In adult rats, conversely, 
only minor retrograde transport was observed for rAAV2/1, rAAV2/7, rAAV2/8, and rAAV/9, 
while rAAV2/5, not included in the present work, appeared to be very capable of 
retrogradely transducing substantia nigra neurons after delivery to the striatum416. The 
difference in rAAV2/1 results described in the mouse V1424 and the mouse striatum study32 
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versus the current mouse SC study might be explained by the different brain regions in 
which the vectors were delivered. 
Although viral vector transport was an undesirable property when considering the goals of 
this work, in itself, it is a very interesting and useful feature. First, it increases distribution of 
the transgene so less vector injections are needed to transduce larger brain areas440. Second, 
it allows viral vectors to be treated as tracers that can map neuronal circuitries. Third, parts 
of neuronal circuits can be manipulated together, even if they are in distant locations. 
Fourth, by injecting the viral vector in an afferent region, the only neurons transduced in the 
projecting area will be the ones projecting to the injection site. As such, a specific population 
of neurons can be targeted in the projecting area. Taken together, the transport of viral 
vectors is still poorly understood but has many interesting uses and applications. However, 
to address the research questions within this PhD project, a vector was needed exhibiting 
robust transduction efficiency in the mouse SC without spreading to other brain regions or 
the retina. Therefore, vector rAAV2/1 was certainly the vector of choice.  
4.1.4 CMV versus CaMK promoter  
In the search for an optimal vector system for SC targeting, we first focused on the casing of 
the viral vector, determining which and how many cells are transduced, as discussed above. 
However, to achieve a suitable expression of the transgene, also the promoter is of vital 
importance. The CMV promoter is often employed because it induces high expression levels 
in a variety of mammalian cells444. In comparison, a shortened sequence of the CaMK 
promoter, which is described to be a neuron specific promoter439,445, was tested. Both for 
the rAAV2/1 and the rAAV2/7 serotypes, CaMK promoter-regulated eGFP expression 
showed a high number of transduced cells distributed throughout the anteroposterior and 
lateromedial volume of the SC, comparable to what was seen in the CMV data. However, a 
distinct band with a higher intensity of eGFP signal was noticed. This band appeared to 
coincide mainly with the SO slightly crossing the boundary to SGI, as confirmed by VGluT2 
IHC297. The higher fluorescence intensity was indicative of an elevated expression level for 
eGFP in these cells, presumably related to a higher activity of the CaMK promoter. This 
effect was strictly promoter dependent and not determined by the amount of vector copies 
entering the cells, as CaMK and CMV controlled expression was evaluated for the same 
serotypes. Although the SO is made up largely of fibers arising from the retina and the visual 
cortex, it also contains neurons446. For example, wide-field and narrow-field vertical neurons, 
which are excitatory projection neurons447-449, have been observed not only in the SGS but 
also in the SO446. Immediately below the SO lies the SGI, containing the neurons that project 
to eye movement centers in the brainstem and also cells providing feedback projection 
120   _______________________________________________________________   CHAPTER 4 
 
towards the SGS and SO446. While the SZ and SGS are especially abundant in GABA-ergic 
inhibitory neurons58,421, the density of GABA-ergic cells is generally lower in the SO versus 
the SGS and although GABA-ergic cells do exist in the deep SC layers, they are relatively 
fewer in number as compared to the sSC421. Therefore, based on the position of the bright 
CaMK-eGFP-expressing neurons and the fact that there is almost no GABA-colocalization, we 
can assume the CaMK-eGFP labeled cells are excitatory neurons. As such, our results are 
completely in line with earlier data, describing the CaMK promoter to be active in excitatory 
neurons in the mouse cortex423,424. However, before any firm conclusions can be drawn, 
further investigation is warranted to distinguish between the different subtypes of excitatory 
neurons located in the SO and SGI, as well as to explain the difference in eGFP intensity 
between labeled cells within the different layers. The latter is probably related to cell type 
specific differences in native Ca2+/calmodulin-dependent protein kinase II  (CaMKII) 
expression levels, and thus, CaMK promoter activity.  
Although the expression pattern of the reporter gene in the SC was largely altered by the 
change of the CMV promoter into the CaMK promoter, the retrograde RGC labeling was 
unaffected by the promoter switch. For the rAAV2/1 serotype, no retrograde RGC labeling 
was seen, neither with the CMV or CaMK promoter, while in combination with the rAAV2/7 
serotype, both CMV and CaMK promoters induced eGFP expression in RGCs. This was not 
unexpected, as intravitreal (ivt) delivery of rAAV2/x vectors containing eGFP under control of 
the CMV versus the CaMK promoter induced comparable reporter gene expression in RGCs, 
suggesting both promoters to be active in at least certain subtypes of RGCs (De Groef 2015, 
unpublished results). Remarkably, this observation was made both for the rAAV2/1 and 
rAAV2/7 serotype. Accordingly, although no retrograde RGC transduction was obtained by 
rAAV2/1 after intracollicular delivery, when ivt delivered, this serotype is capable of 
transducing RGCs. Thus, rAAV2/1 is clearly not retrogradely transported towards the retina 
upon injection into the SC. Whether a defined subset of RGCs was determined by CaMK 
promoter-driven expression could not be concluded based on the available data and was 
beyond the scope of this project. However, this might be expected based on experiments in 
primates, which have shown that CaMKII expression is present or absent in 
morphologically distinct subtypes of RGCs450. 
Thus, depending on what neurons one wants to target, the CMV or CaMK promoter is the 
best choice. The CMV promoter should be applied to induce high transgene expression in 
collicular neurons in general, while the CaMK promoter appears to be more specific for 
excitatory neurons. However, as the properties of the CaMK promoter in the SC are to date 
not fully understood, the more general CMV promoter was defined as the best suited for our 
viral vector-related experiments.  
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4.2 VALIDATION OF THE BDNF- AND SSFO-EXPRESSING VECTORS  
According to the neurotrophin deprivation hypothesis, RGC death in glaucoma is triggered 
by diminished retrograde transport, resulting in deprivation of brain-derived neurotrophic 
support to the retina10,69. Although local administration of BDNF to the eye reduced loss of 
RGCs in various glaucoma models10,21,22,163,181,188,194,451, this neuroprotective effect was 
mostly transient and insufficient to support sustained RGC survival. As target-derived 
neurotrophins might induce signaling pathways that differ from local neurotrophin 
signaling9,126,134,135 initiated at the cell soma, it may be beneficial to consider delivery of 
neuroprotectants via natural extraretinal sources in the brain. This hypothesis is investigated 
in detail in Chapter 5 by use of viral vector technology to overexpress BDNF in the SC. The 
BDNF-expressing vector was developed and validated here, together with the control eGFP 
vector. Unilateral delivery of rAAV2/1-CMV-BDNF or rAAV2/1-CMV-eGFP vectors into the 
mouse SC resulted in extensive unilateral transgene expression by two weeks post vector 
delivery as shown in the IHC results. Intracollicular vector-derived BDNF should interact with 
its receptor located at the RGC axon terminals to be able to retrogradely influence the 
retina. Therefore, it is important that the transduced collicular neurons not only overexpress 
BDNF, but also secrete the protein into the extracellular space. To ensure a natural 
destination for transgenically-expressed BDNF, primers for cDNA production were developed 
to include the complete sequence, including any possible signal sequence426. Still, it is 
important to validate the capability of transduced cells to secrete the transgenically-
expressed BDNF in order to verify that nothing is hampering this complex production-
secretion process. BDNF measurements in the medium of HEK293T cells transduced with 
rAAV2/1-CMV-BDNF or rAAV2/1-CMV-eGFP vectors demonstrated that BDNF vector-
transduced cells secreted vast amounts of BDNF in their medium, this not being the case 
using eGFP vector-tranduced cells. These results demonstrated that vector-derived BDNF 
was successfully secreted by transduced cells in vitro. In addition, this secreted BDNF was 
demonstrated to be bio-active, since it stimulated neurite outgrowth in an ex vivo retinal 
explant culture. Whether in vivo BDNF overexpression in SC neurons also results in its 
release into the collicular extracellular space, in theory, could have been investigated 
through implementation of microdialysis in combination with mass spectrometry452,453. 
Unfortunately, microdialysis tools are not well-suitable for application in the mouse SC, due 
to its small dimensions together with its superficial location in the brain. However, based on 
both the in vivo and in vitro positive results demonstrated here, we decided to apply the 
BDNF vector in vivo in the mouse SC in further research (Chapter 5).   
Another strategy to counteract glaucomatous RGC death from within the brain is to enhance 
SC activity, as described in detail in Chapter 6. Enhanced neuronal activity has indeed been 
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shown sufficient to increase neuronal, and also RGC, survival25,454-456. Optogenetics is a very 
novel and specific technique to modulate neuronal activity, based on the introduction of 
microbial genes encoding opsins, ion-conducting channels of which the activity can be 
controlled by illumination with a specific wavelength17,244. An optogenetic approach will be 
applied to investigate whether modulation of neuronal activity in the SC can protect against 
experimentally-induced RGC loss. As expression and correct targeting of microbial proteins 
in mammalian cell systems have been reported to be problematic in some situations457, it 
was important to verify the efficiency of the available optovectors in the mouse SC. Within 
this context, vector-induced expression and membrane targeting of SSFO18, the opsin of 
choice in this project, was examined. SSFO expression and membrane targeting was shown 
to be successfully induced by intracollicular delivery of rAAV2/1-CMV-SSFO-mCherry and 
rAAV2/7-CaMK-SSFO-mCherry vectors. Both optovectors were thus declared to be applicable 
in the context of our SC-related research questions.   
 
5 CONCLUSION 
Viral vector technology was optimized for use in the mouse SC. rAAV2/1 was established as 
the serotype of choice for local targeting of the SC without retrograde transport towards the 
retina. Furthermore, the CMV promoter was shown to be the most suitable for induction of 
transgene expression in collicular neurons in general. A vector for overexpression and 
secretion of BDNF was developed and validated. Moreover, optovectors were shown to elicit 
robust SSFO expression and correct membrane targeting in the mouse SC. The vectors 
developed and evaluated here will be used in Chapters 5 and 6 to address glaucoma-related 
research. 
  
 
 
 
 
 
CHAPTER 5  
A ROLE FOR BRAIN-DERIVED 
NEUROTROPHIC FACTOR IN GLAUCOMA 
 
 
The data presented in this chapter have been submitted for publication:  
Dekeyster, E., Geeraerts, E., Mebis, C., Salinas-Navarro, M., De Groef, L., Moons, L. Tackling 
glaucoma from within the brain: an unfortunate interplay of BDNF and TrkB. Manuscript 
submitted to PLoS One.  
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1 INTRODUCTION 
In a significant fraction of glaucoma patients, intraocular pressure (IOP) control cannot 
prevent the progression of retinal ganglion cell (RGC) degeneration62, encouraging 
researchers to search for alternative treatment strategies that aim for neuroprotection of 
the RGCs. The neurotrophin deprivation hypothesis proposes that diminished retrograde 
transport, resulting in deprivation of neurotrophic support to the RGCs, is one of the triggers 
that induces glaucomatous retinal cell death10,69. Based on this theory, experimental 
strategies have sought to supply exogenous neurotrophins to curb neurodegeneration in 
experimental glaucoma models10. Among the neurotrophins linked to glaucoma, such as 
nerve growth factor (NGF)193 and neurotrophin-4 (NT-4)458, brain-derived neurotrophic 
factor (BDNF) stands out for its vital role in maintaining RGCs and its potent protective effect 
in different glaucoma models10,21,22,122,163,181,188,194,451.  
BDNF is synthesized locally in the retina by RGCs144 and glia143,148, but it is also produced in 
the RGC projection areas in the brain from where it is taken up by RGC terminals and 
retrogradely transported via their axons to the cell bodies69. BDNF is expressed as pro-BDNF 
and subsequently cleaved to form mature BDNF (mBDNF)126. The neurotrophic effects of 
BDNF are primarily mediated through binding of mBDNF to its high-affinity receptor, 
tropomyosin receptor kinase B (TrkB)163. TrkB exists in different splice variants, of which 
TrkB-full length (TrkB-FL) and TrkB-truncated from 1 (TrkB-T1), lacking the C-terminal 
intracellular kinase domain, are the most abundant in the central nervous system (CNS)459. 
Binding of BDNF to TrkB-FL induces dimerization and transphosphorylation, leading to 
activation of cellular signaling pathways involved in cell viability126. Until now, the exact role 
of TrkB-T1 has been less clear459. TrkB-T1 was first defined as a dominant-negative receptor 
that heterodimerizes with TrkB-FL to indirectly inhibit BDNF survival signaling. However, 
more recently, TrkB-T1 has been linked to the regulation of extracellular BDNF 
concentrations and glial signaling459.  
Although local administration of BDNF to the eye reduces loss of RGCs in various glaucoma 
models10,21,22,122,163,181,188,194,451, the neuroprotective effect is mostly transient and 
insufficient to support sustained RGC survival. Besides retinal administration, it might be 
beneficial to consider treatment at the level of extraretinal sources in the brain, as target-
derived neurotrophins are likely to induce signaling pathways that differ from local 
neurotrophin signaling9,126,134,135. Indeed, this hypothesis was partially confirmed through a 
very novel treatment paradigm, combining intravitreal (ivt) injection with chronic delivery of 
BDNF into the visual brain centers, resulting in prolonged and enhanced RGC survival in cats 
subjected to optic nerve trauma194,204.  
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A better understanding of the pathological processes underlying glaucoma is crucial to 
develop new neuroprotective approaches for this incurable disease. The overall objective of 
this study was to advance the knowledge of the role of neurotrophin signaling between the 
eye and the brain in glaucoma pathology. Therefore, two different mouse models of 
experimental glaucoma were used, being the optic nerve crush (ONC) model and a laser 
induced ocular hypertension (OHT) model, each highlighting specific aspects of glaucoma 
pathology. The temporal patterns of BDNF and TrkB-FL/TrkB-T1 levels in the retina and 
superior colliculus (SC), the primary target for RGC axons in rodents14, were visualized in 
both models of experimentally induced glaucoma. Furthermore, the previously reported 
neuroprotective effect of ivt recombinant BDNF administration was re-examined in the ONC 
model. In addition, the effect of BDNF upregulation in the SC during RGC survival/death in 
both the ONC and the OHT model was investigated.  
 
2 MATERIALS AND METHODS  
2.1 ANIMALS AND ANESTHETICS 
All experiments were performed on adult C57Bl/6J and CD-1 mice of ten to twelve weeks old 
at the start of the experiment, housed under a 12/12h light/dark cycle with ad libitum access 
to food and water. The experiments were approved by the KU Leuven Animal Ethics 
Committee and followed the guidelines of the ARVO statement for the use of animals in 
ophthalmic and vision research. Surgical procedures to induce experimental glaucoma or for 
BDNF administration were performed under general anaesthesia, brought on by 
intraperitoneal (i.p.) administration of a mixture of ketamine (75 mg/kg body weight, 
Anesketin, Eurovet, Belgium) and medetomidin (1 mg/kg body weight, Domitor, Janssen 
Pharmaceutics, Belgium). Additionally, for glaucoma induction and ivt injections, a droplet of 
local analgesic, oxybuprocaïne hydrochloride (0.4 %, Unicaïne, Théa, Belgium) was applied to 
the eye. For intracollicular injections, the head region was topically anesthetised by applying 
lidocaine hydrochloride (5 %, Xylocaine, AstraZeneca, UK) to the scalp. To encourage waking 
after any surgical procedure, atipamezole (1 mg/kg body weight, Antisedan, Pfizer, Belgium) 
was administered i.p. in an effort to counteract the anaesthesia. During recovery, 
tobramycin eye ointment (Tobrex, Alcon, TX, USA) was applied to the cornea of both eyes to 
prevent desiccation and mice were placed on a heat pad to maintain body temperature.  
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2.2 EXPERIMENTAL GLAUCOMA INDUCTION 
In both models, experimental glaucoma was induced in the left eye (oculus sinister, OS) 
while the right eye (oculus dexter, OD) served as an internal control.  
Optic nerve crush (ONC) was performed in C57Bl/6J mice as described previously294. Briefly, 
a small incision was made in the conjunctiva in the temporal corner of the eye. By gently 
retracting the conjunctiva, the globe was rotated nasally. Subsequently, a curved forcep was 
used to create a space between the temporal lateral rectus muscle and the inferior oblique 
muscle to expose the optic nerve. The optic nerve was then crushed 1 mm behind the globe 
for 5 s using self-closing cross-action forceps (11262-30, Fine Science Tools, Germany) in 
order to provide constant and consistent pressure. Before and after the ONC procedure, 
funduscopy was performed to ensure a normal blood flow in the retinal vessels. 
Ocular hypertension (OHT) was induced in CD-1 mice through laser photocoagulation (LP) of 
the perilimbal and episcleral veins as described previously13,291,292. Briefly, after dilating the 
pupil by a droplet of tropicamide (1 %, Mydriacyl, Alcon, TX, USA) a 532 nm diode laser 
(Vitra, Quantel Medical, France) was employed to deliver approximately 70 laser spots (0.5 s 
exposure time and 0.3 W power intensity) to the perilimbal and episcleral veins. Before and 
immediately after LP, funduscopy was performed to account for ischemic effects. The 
intraocular pressure (IOP) was measured in awake animals before and every 24 h up to 7 d 
after LP using a calibrated rebound tonometer (Tono-Lab, Icare, Finland). 
2.3 BDNF ADMINISTRATION    
In an attempt to protect the RGCs from dying, mice that were subjected to the ONC model 
received local recombinant mBDNF administration via ivt injection of 2 µl BDNF (Peprotech 
Laboratories, UK) diluted at 1 mg/ml in 0.01 M phosphate-buffered saline (PBS) containing 
1 % bovine serum albumin (BSA, PanReac Applichem, Germany) (BSA-PBS), at a rate of 
500 nl/s using the Micro4 Microsyringe controller (World Precision Instruments, FL, USA). 
Control groups received an ivt injection of 2 µl vehicle (BSA-PBS). Treatment paradigms were 
one single dose immediately after crush with sacrifice at 7 d and 14 d, or repeated ivt 
injection at 0, 3, and 5 d with sacrifice at 7 days post-injury (dpi) and 0, 5, and 10 d with 
sacrifice at 14 d post-ONC.  
To induce a prolonged delivery of BDNF in the superior colliculus (SC), the main retinal target 
area in mice, viral vector-based overexpression technology was applied. During the 
procedure of intracollicular viral vector delivery, the body temperature of the mice was 
controlled by use of a heating pad connected to a rectal probe (TCAT-2LV, Physitemp 
Instruments INC, NJ, USA). After making a midline incision in the scalp, a small hole was 
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drilled into the skull above the right SC. Using the Nanoject II (Drummond Scientific 
Company, PA, USA), 1 µl adeno-associated viral vector serotype 2/1 containing the mouse 
BDNF gene under control of a general CMV promoter (rAAV2/1-CMV-BDNF) was 
stereotactically injected into the right SC at 3.16E11 GC/ml at a rate of 100 nl/min. Control 
groups received 1 µl injection of rAAV2/1-CMV-eGFP vector at 3.25E11 GC/ml. Production 
and validation of the vectors was described in Chapter 4. From here on, rAAV2/1-CMV-BDNF 
and rAAV2/1-CMV-eGFP vectors will be referred to as the BDNF vector and the eGFP vector, 
respectively. Coordinates for mouse SC were anteroposterior -3.3 mm and mediolateral +0.4 
mm relative to Bregma, and dorsoventral -1.3 mm from the dura.  
2.4 DETECTION OF BDNF AND TRKB LEVELS  
Using both models of experimental glaucoma, BDNF and TrkB levels in the glaucomatous 
retina and the contralateral SC were determined at 6 h, 12 h, 24 h, 3 d, 5 d and 7 d after 
glaucoma induction. Furthermore, retinal and collicular BDNF and TrkB levels were also 
determined in two groups of mice, receiving either BDNF or eGFP viral vector delivery to the 
SC, at 18 d post vector delivery. In four additional groups of animals, BDNF concentrations 
were determined in the retina upon BDNF or eGFP transduction in the SC in combination 
with ONC- or OHT-induced glaucoma. Within these groups, glaucoma induction was 
performed 14 d post vector injection and animals were sacrificed 4 d post glaucoma 
induction.  
2.4.1 Sample processing and protein concentration  
Animals were anesthetized with sodium pentobarbital (200 mg/kg body weight, Nembutal, 
Ceva Sante Animale, France) prior to cervical dislocation. Retinas and SCi were dissected on 
ice and immediately snap-frozen and stored at -80°C until homogenization and 
determination of protein concentration. Samples were homogenized on ice in RIPA buffer 
(25 mM Tris-HCl, 150 mM NaCl, 1 % NP-40, 1 % sodium deoxycholate, 0.1 % sodium dodecyl 
sulfate, pH 7.6) containing a protease and phosphatase inhibitor cocktail (Thermo scientific, 
MA, USA). After incubation for 30 min at RT, samples were centrifuged (13000 rpm) at 4°C. 
The supernatant was collected and protein concentrations were determined using the Qubit 
Protein Assay (Molecular probes, Invitrogen, CA, USA) according to the manufacturer’s 
protocol. Samples were stored at -80°C until use for western blotting or ELISA. 
2.4.2 Western blotting  
Levels of mBDNF and both TrkB-FL and TrkB-T1 were detected in the retina and SC samples 
using western blotting. Equal amounts of the samples (retina: BDNF 120 µg, TrkB 50 µg; SC: 
BDNF 60 µg, TrkB 20 µg) were loaded onto 4-12 % Bis-Tris gels (BioRad Laboratories, CA, 
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USA) and transferred to polyvinylidene difluoride (PVDF) membranes (BioRad Laboratories, 
CA, USA). The membrane was incubated for 2 h in 5 % ECL Blocking Agent (GE Healthcare, 
UK) in 0.01 M Tris-buffered saline (TBS). Overnight incubation with primary antibodies, 
rabbit anti-BDNF (1:500, sc-546, Santa Cruz Biotechnology, TX, USA) or rabbit anti-TrkB 
(1:1500, 07-225, Millipore, MA, USA), was followed by 45 min incubation with horseradish 
peroxidase (HRP)-conjugated secondary antibodies (Dako, Denmark). Antibodies were 
diluted in blocking buffer. Specific protein bands were visualized using the luminally-based 
enhanced chemiluminescent kit (SuperSignal West Dura, Thermo Scientific, MA, USA). In 
order to normalize detected amounts of BDNF and TrkB to the total amount of protein 
loaded, LavaPurple- (Gelcompany, CA, USA) based total protein stain was performed prior to 
primary antibody incubation. Moreover, to correct for intergel variability, data were 
expressed relative to the reference sample, i.e. a pool of independent naive SC samples. 
Exceptionally, in the case no reference sample was included, data were expressed relative to 
the control samples loaded on the same gel. Two technical replicas were performed for each 
experiment. Specific protein bands and LavaPurple staining were imaged using the 
ChemiDoc MP Imaging System (BioRad Laboratories, CA, USA). Optical density analyses were 
performed using Image Lab 4.1 software (BioRad Laboratories, CA, USA).  
2.4.3 ELISA  
Total BDNF levels, including both pro- and mature forms, were quantified based on standard 
sandwich enzyme-linked immune-sorbent assay (ELISA) technology by means of the Mouse 
BDNF ELISA kit (KA0331, Abnova, Taiwan), which contains all necessary products. Briefly, a 
monoclonal rat antibody specific for mouse BDNF was precoated onto 96-well plates. 
Standards and test samples were loaded in duplicate into the wells and incubated for 90 min 
at 37°C. Subsequently, a biotinylated polyclonal goat antibody specific for mouse BDNF was 
added for 60 min at 37°C. Avidin-Biotin-Peroxidase Complex was then added and 30 min 
later, unbound conjugates were washed away. The HRP substrate tetramethylbenzidine 
(TMB) was used to visualize the peroxidase enzymatic reaction. TMB was catalyzed by HRP 
to produce a blue color product that changed into yellow after adding acidic stop solution. 
The color density, detected by the Multiskan FC spectrophotometer (Termo Scientific, MA, 
USA) at 450 nm, was proportional to the amount of BDNF in the sample. Data analyses were 
performed with Skanit 3.1 software (Thermo Scientific, MA, USA).  
2.5 IMMUNOHISTOCHEMISTRY AND ANALYSES  
Animals were anesthetized with sodium pentobarbital (200mg/kg body weight, Nembutal, 
Ceva Sante Animale, France) prior to cervical dislocation or perfusion.  
BDNF-SIGNALING IN GLAUCOMA   ________________________________________________   129 
 
 
 
Upon enucleation, eyes were fixed for 1 h in 4 % paraformaldehyde (PFA, Acros Organics, NJ, 
USA) in PBS. Subsequently, retinas were dissected, flat-mounted, and post-fixed for 1 h in 
4 % PFA. Whole-mount retinas were stained for Brn3a, a POU-domain transcription factor 
and a reliable marker of healthy RGCs20,91,188. Retinas were permeabilized in PBS containing 
0.5 % Triton X-100 (Fisher Scientific, NY, USA) (PBST0.5), frozen at -80°C for 15 min, rinsed in 
PBST0.5, and incubated overnight at RT with primary antibody (goat anti-Brn3a, sc-31984, 
Santa Cruz Biotechnology, TX, USA), diluted 1:500 in PBS containing 2 % Triton X-100 and 2 % 
rabbit pre-immune serum (Invitrogen, CA, USA). The next day, the retinas were rinsed in 
PBST0.5 and incubated for 2 h with secondary antibody (Alexa Fluor-488-conjugated rabbit 
anti-goat IgG, Invitrogen, CA, USA), diluted 1:500 in PBS containing 2 % Triton X-100. Retinas 
were then rinsed in PBST0.5 and PBS before being mounted on glass slides with anti-fading 
mounting medium, Mowiol (Sigma-Aldrich, MO, USA). Images of the stained retinal 
whole-mounts were obtained with a FV1000-M multiphoton microscope (Olympus 
Corporation, Japan), controlled via Fluoview 4.0 software. Brn3a-labeled RGCs were counted 
using an in-house script developed for freely available ImageJ software (Geeraerts et al., 
manuscript in preparation).  
In order to verify the efficacy of vector delivery in each experiment, three randomly selected 
animals of each viral vector injected group were transcardially perfused with 0.9 % NaCl, 
followed by 4 % phosphate-buffered PFA for eGFP IHC and 4 % phosphate-buffered PFA with 
0.4% parabenzoquinone (pBQ, Sigma-Aldrich, MO, USA) for BDNF IHC. Retinas were 
dissected and Brn3a stained as described in the previous alinea. Brains were dissected and 
post-fixed overnight in 4 % PFA or for 2 h in 4 % PFA and 0.4 % pBQ, all in PBS. The SC brain 
region was sectioned in 50 µm coronal sections using the Micron H650 vibratome (Thermo 
Scientific, MA, USA) and stored in PBS with 0.004 % sodium azide at 4°C until IHC. IHC was 
performed under uniform conditions on free-floating sections. Sections were rinsed in PBS 
containing 0.1 % Triton X-100 (PBST0.1) and incubated for 1 h in PBST0.1 containing 10 % 
goat pre-immune serum (Invitrogen, CA, USA), followed by 24 h incubation with rabbit anti-
eGFP (1:10,000, provided by Prof. V. Baekelandt, Laboratory of Neurobiology and Gene 
therapy, KU Leuven, Belgium) or 48 h incubation with rabbit anti-BDNF (1:500, sc-546, Santa 
Cruz Biotechnology, TX, USA), recognizing both pro- and mBDNF, diluted in PBST0.1 and 10 % 
goat pre-immune serum. After rinsing and incubation for 2 h with secondary antibody (Alexa 
Fluor-488-conjugated goat anti-rabbit IgG, Invitrogen, CA, USA) 1:200 in PBST0.1, sections 
were rinsed, mounted, and cover slipped with Mowiol (Sigma-Aldrich, MO, USA). eGFP and 
BDNF immunolabeling was visualized utilizing the FV1000-D laser confocal scanning 
microscope (Olympus Corporation, Japan), controlled by Fluoview 4.0 software. 
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2.6 STATISTICS 
All data are presented as mean ± SEM. Outliers were determined via Grubbs’ test for outliers 
and excluded from further analyses. A normal distribution was verified using the 
Kolmogorov-Smirnov test and parallel equal variance between groups was tested. If the test 
requirements were fulfilled, one-way ANOVA, followed by Bonferroni post hoc tests, was 
used to compare three or more conditions and to test for time-related changes in the 
expression patterns. Two-way ANOVA was used to examine the influence of two different 
categorical factors on one continuous variable. Additionally, for pairwise comparison, 
Student’s t-test was used. For all tests, a probability level (α-level was set to 0.05) of <0.05 
was accepted as statistically significant (* p<0.05, * p<0.01, *** p<0.001). All statistical 
analyses were performed using GraphPad Prism S5 (GraphPad Software, CA, USA). 
 
3 RESULTS  
3.1 EXPRESSION OF BDNF AND TRKB IN EXPERIMENTAL GLAUCOMA  
The effect of experimental glaucoma on BDNF and TrkB levels in the glaucomatous retina 
and the SC contralateral to the experimental eye was examined via ELISA for total BDNF 
levels and western blotting for mBDNF, TrkB-FL, and TrkB-T1. For western blot experiments, 
to correct for intergel variability, data should ideally be expressed relative to the reference 
sample, i.e. a pool of independent naive SC samples loaded on every gel. Unfortunately, it 
was not possible to include a reference pool in all experiments, as it depended on the 
number of samples and the capacity per gel. Therefore, two representations of data in which 
a pool was included were first compared: 1) all values were normalized via the reference 
pool to correct for intergel normalization and subsequently they were put relative to the 
mean of all naive controls together, versus 2) all values were analyzed relative to the mean 
of naive control conditions per gel. Since the observed trends of the protein levels were 
always similar using both analysis methods, from now on, all results will be presented 
relative to naive control condition per gel to ensure consistency. As a representative 
example, a comparison between both strategies for determining relative TrkB levels in the 
retina after ONC is illustrated in Figure 5.1. 
In the first model of experimentally-induced glaucoma, the ONC model, total BDNF levels in 
the retina, as determined by ELISA, changed significantly over time (p=0.045). BDNF levels 
increased marginally from 6 h post-ONC onwards, reaching significance at 3 dpi (+79 ± 15 %, 
N=3) to 5 dpi (+62 ± 16 %, N=4), attenuating afterwards (Figure 5.2 A). The retinal TrkB-FL  
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Figure 5.1: Comparison between data representation normalized through reference pool (A) versus relative 
to naives per gel (B). Depicted example is the retinal TrkB level after ONC (6 h, 12 h, 24 h, 3 d, 5 d: N=4; Naive, 
3 d, 5 d, 7 d: N=3). All data are mean ± SEM with significant differences compared to naive, * p<0.05 based on 
Student’s t-test. Key: TrkB, tropomyosin receptor kinase B; TrkB-FL, TrkB full-length form; TrkB-T1, TrkB 
truncated form 1; ONC, optic nerve crush.  
level increased slightly in the ONC model (Figure 5.2 B, p=0.032), with the highest level and 
only significant difference to the naive control situated at 5 dpi (+95 ± 23 %, N=4). TrkB-T1, 
also showed an increase upon ONC (p=0.043), reaching peak levels between 24 h (+223 ± 
66 %, N=3) and 5 d (+235 ± 151 %, N=4) post-ONC, however only the 24 h value differed 
significantly from the naive condition due to the quite large variation within groups. The 
TrkB-T1 increase was higher than the TrkB-FL increase. In the SC, total BDNF levels changed 
with time post ONC (Figure 5.2 C, p=0.0051). The BDNF levels were significantly enhanced as 
soon as 6 h post-ONC (+70 ± 12 %, N=4) and slowly decreased to baseline levels thereafter, 
remaining significantly different from naive until 3 dpi (+55 ± 18 %, N=4). Collicular TrkB-FL 
and TrkB-T1 levels  followed a very similar pattern after ONC induction (Figure 5.2 D, 
pFL=0.048, pT1= 0.046), increasing from 6 hpi onwards (TrkB-FL +158 ± 34 %, TrkB-T1 +123 ± 
17 %, N=4) with the turning point situated around 3 d post-ONC (TrkB-FL +192 ± 74 %, TrkB-
T1 +159 ± 91 %, N=4). 
For the OHT model, patterns of BDNF and TrkB levels in the retina and SC were different 
from the ONC model (Figure 5.3). In the retina of hypertensive eyes as compared to naive 
eyes, no changes in the total BDNF level, neither in the TrkB-FL and TrkB-T1 levels, could be 
detected (Figure 5.3 A, B, p>0.05). In the SC, total BDNF levels were not noticeably altered by 
OHT induction either (Figure 5.3 C, p>0.05). However, OHT induction did induce a slight but 
significant decrease in collicular TrkB-FL levels (Figure 5.3 D, p=0.016), with the lowest point 
situated at 5 dpi (-36 ± 6 %, N=8). TrkB-T1 levels followed a similar decreasing pattern in the 
OHT model, however, this decrease did not reach significance (p>0.05).  
In the ELISA results described above, total BDNF levels were measured, not allowing to 
distinguish between pro- and mBDNF. Therefore, in addition, western blot was performed, in  
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Figure 5.2: Retinal and collicular BDNF and TrkB levels in the ONC model. A. In the retina, total BDNF levels, 
analyzed via ELISA, rise upon ONC, reaching a peak at 3 to 5 d, attenuating afterwards (12 h, 24 h, 5 d: N=4; 
naive, 6 h, 3 d, 7 d: N=3). B. The retinal TrkB-FL level only slightly increases in the ONC model, while TrkB-T1 
rises more, reaching peak levels between 24 h and 5 d post-ONC (5 d: N=4; naive, 6 h, 12 h, 24 h, 3 d, 7 d: N=3). 
C. In the SC, total BDNF levels are enhanced as soon as 6 h post-ONC and slowly decrease to baseline levels 
thereafter (Naive, 6 h, 12 h, 24 h, 3 d, 5 d: N=4; 7 d: N=3). D. Collicular TrkB-FL and TrkB-T1 levels follow a very 
similar increase-decrease pattern after ONC induction, with the turning point situated around 3 d post-ONC 
(Naive, 6 h, 12 h, 24 h, 3 d, 5 d: N=4; 7 d: N=3). All data are mean ± SEM with significant differences compared 
to naive, * p<0.05 and ** p<0.01 based on Student’s t-test. Graphs are representative examples of 2 technical 
replicas. Key: BDNF, brain-derived neurotrophic factor; TrkB, tropomyosin receptor kinase B; TrkB-FL, TrkB full-
length form; TrkB-T1, TrkB truncated form 1; ONC, optic nerve crush.  
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Figure 5.3: Retinal and collicular BDNF and TrkB levels in the OHT model. A. In the retina, total BDNF levels do 
not change by OHT induction (Naive, 12 h, 24 h: N=7; 6 h, 3 d, 5 d, 7 d: N=6). B. The retinal levels of TrkB-FL and 
TrkB-T1 do not show significant alterations in the OHT model (12 h, 24 h: N=9; naive, 3 d: N=8; 6 h, 7 h: N=7; 5 
d: N=6). C. In the SC, total BDNF levels are not influenced by OHT induction (Naive: N=8; 12 h, 24 h: N=7; 6 h, 3 
d, 5 d: N=6). D. Collicular TrkB-FL and TrkB-T1 levels follow a very similar slightly decreasing pattern after OHT 
induction (12 h, 5 d, 7 d: N=8; naive, 3 d, 6 d: N=7; 24 h: N=5). All data are mean ± SEM with significant 
differences compared to naive, * p<0.05 and ** p<0.01 based on Student’s t-test. Key: BDNF, brain-derived 
neurotrophic factor; TrkB, tropomyosin receptor kinase B; TrkB-FL, TrkB full-length form; TrkB-T1, TrkB 
truncated form 1; ONC, optic nerve crush.  
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which the two forms of BDNF become separated based on size. Unfortunately, after 
optimization of western blot for detection of pro- and mBDNF with one batch of sc-546 
antibody (I2112), no reproducible results were yielded with new batches of antibodies  
(L1014, I0414), as they seemed to be less sensitive and less specific compared to the first 
batch. High variability within conditions and between technical replicas neither allowed for 
consistent results. Therefore, the western blot data on endogenous pro- and mBDNF 
expression upon ONC and OHT are not shown.  
3.2 INTRAVITREAL BDNF ADMINISTRATION IS TRANSIENTLY NEUROPROTECTIVE IN 
THE ONC MODEL 
A single ivt administration of recombinant mBDNF at the time of crush resulted in 10 % 
neuroprotection at 7 dpi after ONC (Figure 5.4 A). Brn3a+ RGC density was 2,125 ± 52.7 
RGCs/mm² and 1,658 ± 65.4 RGCs/mm² in BDNF- and vehicle-treated crushed eyes, 
respectively (N=5), as compared to 3,758 ± 73.1 RGCs/mm² and 3,662 ± 69.1 RGCs/mm² for 
the right control eyes. However, the protective effect was transient, as at 14 dpi, there was 
no longer a difference in Brn3a+ RGC counts between BDNF- (700 ± 65.8 RGCs/mm²) and 
vehicle-treated (710 ± 93.2 RGCs/mm²) ONC eyes (N=4). In the control retinas, RGCs were 
counted at 3,630 ± 23.0 RGCs/mm² and 3,783 ± 51.3 RGCs/mm², respectively.  
Strikingly, triple BDNF administration at 0, 3, and 5 dpi was not found to enhance the 
neuroprotective effect at 7 dpi (Figure 5.4 B). Using this repetitive treatment paradigm, 
again, only a 10 % reduction in RGC death was detected in BDNF-treated crushed eyes (1,785 
± 38.7 RGCs/mm², N=7) as compared to vehicle-injected eyes (1,393 ± 41.9 RGCs/mm², N=8),  
 
 
 
Figure 5.4: Ivt BDNF administration results in temporary RGC protection in the ONC model. A. One single ivt 
injection at the moment of ONC application leads to a temporarily enhanced survival effect of 10 % more 
survival at 7 dpi (N=4), later being attenuated at 14 dpi (N=5). B. Repeated ivt BDNF administration at 0, 3 and 5 
dpi could not ameliorate the survival effect obtained with one single injection at 7 dpi (N=8), however, triple 
BDNF treatment at 0, 5, and 10 dpi did result in 4.5 % enhanced survival at 14 dpi. All data are mean ± SEM 
with ** p<0.01 and *** p<0.001 based on one-way ANOVA with Bonferroni post hoc test. Key: ivt, intravitreal; 
RGC, retinal ganglion cell; OD, oculus dexter; OS, oculus sinister; BDNF, brain-derived neurotrophic factor; dpi, 
days post-injury.  
BDNF-SIGNALING IN GLAUCOMA   ________________________________________________   135 
 
 
 
with RGC densities in respective control retinas measured at 4,017 ± 41.9 RGCs/mm² and 
4,009 ± 93.8 RGCs/mm². However, ivt BDNF injections at 0, 5, and 10 dpi did slightly prolong 
the neuroprotective effect, with 4.5 % enhanced survival in the crushed eyes of the BDNF 
(N=8) versus vehicle (N=4) groups. RGC densities in left crushed eyes and right control eyes 
were 532 ± 20.2 RGCs/mm² and 3,208 ± 89.4 RGCs/mm² in BDNF-treated groups, versus 389 
± 28.4 RGCs/mm² and 3,223 ± 65.9 RGCs/mm² in the vehicle group. 
3.3 INTRACOLLICULAR BDNF DELIVERY IS NOT NEUROPROTECTIVE TO RGCS IN THE 
ONC AND OHT MODEL 
Two weeks after intracollicular vector delivery to induce BDNF or eGFP expression, mice 
received unilateral ONC or OHT induction and were sacrificed 7 d later.  Through IHC, BDNF 
and eGFP expression was validated in three randomly chosen animals of each group and, for 
all, a robust transgene expression was observed throughout the SC (data not shown, similar 
to results of vector validation described in Chapter 4). Within the ONC model, RGC counts  
 
 
Figure 5.5: Glaucomatous RGC death is not counteracted by BDNF upregulation in the SC. A. At 7 d post-ONC, 
no difference is detected in RGC survival between groups with eGFP (N=10) or BDNF (N=8) transgene 
expression in the SC. B. At 7 d post-OHT induction, eGFP (N=6) and BDNF (N=6) collicular transgene expressing 
mice show a similar degree of RGC degeneration. C. IOP elevation in both eGFP and BDNF transgene expressing 
groups follow a similar pattern. All data are mean ± SEM with significant differences compared to OD,  
*** p<0.001 based on Student’s t-test in A and B, based on two-way ANOVA with Bonferroni post hoc test in C. 
Key: RGC, retinal ganglion cel; SC, superior colliculus; OD, oculus dexter; OS, oculus sinister; BDNF, brain-derived 
neurotrophic factor; eGFP, enhanced green fluorescent protein; LP, laser photocoagulation.  
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were not found to be different between treatment groups (Figure 5.5 A), with RGC densities 
of 1,326 ± 54.7 RGCs/mm² and 3,237 ± 85.1 RGCs/mm² measured in respectively crushed 
and control eyes of the BDNF vector-transduced group (N=8) and 1,170 ± 89.3 RGCs/mm² 
and 3,113 ± 39.2 RGCs/mm² in crushed and control eyes of the eGFP group (N=10). Also, for 
the OHT model in which IOP patterns were very similar between groups (Figure 5.5 C), no 
differences were detected in RGC survival rates between BDNF and eGFP transgene 
expressing groups (Figure 5.5 B). Measured RGC densities were 2,386 ± 214.7 RGCs/mm² in 
the hypertensive eye and 3,804 ± 112.8 RGCs/mm² in the control eye of the BDNF group 
(N=6), while these were respectively 2,473 ± 192.2 RGCs/mm² and 3,824 ± 158.2 RGCs/mm² 
in the eyes of the eGFP group (N=6).  
3.4 EXAMINATION OF THE CHARACTERISTICS OF VECTOR-DERIVED BDNF  
As covered in detail in Chapter 4, unilateral delivery of BDNF vector into the mouse SC 
resulted in extensive upregulation of BDNF, visualized through IHC, while subsequent in vitro 
experiments showed that transgenically-expressed BDNF can be secreted by transduced 
cells.  
In addition to the IHC data, the total BDNF levels, including both pro- and mature forms, 
were quantified using ELISA at 18 d post vector delivery (Figure 5.6 A). The total BDNF level 
in BDNF vector-transduced SC (5,780 ± 453 pg BDNF/mg protein, N=7) was highly 
augmented compared to both non-transduced SCi in the same animals (716 ± 162 pg 
BDNF/mg protein, N=7) and eGFP vector-transduced SCi (407 ± 91 pg BDNF/mg protein, 
N=5). Since pro- and mature forms of BDNF partially induce divergent signaling cascades, it 
was important to verify whether transgenically-expressed pro-BDNF was transformed into 
 
Figure 5.6: Viral vector-derived BDNF in the SC is not transported towards the retina. A. Total BDNF levels 
in BDNF vector-transduced SC (N=7) are sharply enhanced compared to non-transduced SC (N=7) in the same 
animals and both SCi of eGFP vector-transduced mice (N=5), quantified via ELISA. B. Western blot analyses 
show an upregulation of mBDNF levels in BDNF vector-transduced SC (N=5) compared to both internal controls 
and eGFP vector- transduced animals (N=5). Data are shown relative to the eGFP internal control. C. Unilateral 
vector-based BDNF upregulation in the SC (A, B) does not lead to changes in total BDNF levels in the retina 
ipsilateral or contralateral to the transduced SC compared to naive control retinas, measured via ELISA (N=5). 
D. Western blot analysis for detection of mBDNF does not show any difference between retina ipsilateral and 
contralateral towards unilateral BDNF or eGFP vector-transduced SC (N=5). Data are shown relative to the eGFP 
ipsilateral internal control. E. Total retinal BDNF levels in crushed or uncrushed eyes, contralateral towards the 
transduced SC, are not influenced by the type of vector used for transduction (N=3). F. Similar results as shown 
in E. were obtained using OHT induction instead of ONC (N=5). All data are mean ± SEM with *** p<0.001 
based on two-way ANOVA with Bonferroni post hoc test.  Key: BDNF, brain-derived neurotrophic factor; 
mBDNF, mature form of BDNF; ELISA, enzyme-linked immune-sorbent assay; eGFP, enhanced green fluorescent 
protein; ONC, optic nerve crush; OHT, ocular hypertension; dpi, days post-injury.  
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 mBDNF. This was validated through western blotting, in which a clear upregulation of the 14 
kDa mBDNF band was identified in transduced SC samples derived from BDNF vector 
injected mice, as compared to both the internal control (+567 ± 168.4 %, N=5) and eGFP 
vector-transduced SC of the external control animals (+462 ± 116.4 %, N=5) (Figure 5.6 B). 
Thus, mBDNF is clearly upregulated in the mouse SC upon vector delivery.  
To be able to support RGC survival, the BDNF released and activated within the SC has to 
reach the retina via retrograde transport through the RGC axons. Unfortunately, both ELISA 
and western blot analyses of retinal samples (N=5), dissected at 18 d post-collicular 
injection, revealed no change in total and mBDNF levels in the retina upon vector-based 
BDNF overexpression in the SC (Figure 5.6 C, D). Possibly, RGCs do not retrogradely transport 
the extra BDNF unless additional trophic support is needed, e.g. to counteract injury. 
Therefore, retinal BDNF measurements were repeated in animals, in which viral vector 
injection was combined with experimentally induced glaucoma. Thereto, mice were 
subjected to ONC (N=3) and OHT (N=5) at 14 d post vector injection, and samples were 
processed 4 d post glaucoma induction. Based on the fact that ELISA is more sensitive than 
western blotting, ELISA was the method of choice here. Unfortunately, retinal BDNF levels 
remained unaltered in both conditions (Figure 5.6 E, F). Overall, we were not able to 
establish any effect of BDNF upregulation in the SC on BDNF levels in the retina in neither 
non-injured nor injured eyes.  
The responsiveness of both SC and retina to BDNF was studied by analyses of TrkB-FL and 
TrkB-T1 levels upon vector injection. Importantly, at 18 d post vector delivery, vector-based 
enhancement of BDNF levels in the SC led to a reduction of TrkB-FL levels in the BDNF 
vector-transduced SC (-47 ± 7.3 % compared to internal control, N=4, Figure 5.7 A), while 
TrkB-T1 levels did not change (N=4, Figure 5.7 B). Viral vector-derived BDNF did not affect 
retinal TrkB-FL (NBDNF=4, NeGFP=5, Figure 5.7 D) and TrkB-T1 levels (N=5, Figure 5.7 E). Thus, 
our data indicate that in response to vector-based BDNF upregulation in the SC, TrkB-FL 
levels are downregulated in the transduced SC, thereby possibly reducing responsiveness to 
BDNF. 
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Figure 5.7: Collicular and retinal TrkB levels upon unilateral viral vector delivery to the SC. A. Western blot 
analysis shows reduced TrkB-FL levels in BDNF vector-transduced SC compared to both internal controls and 
eGFP vector-transduced animals (N=4). B. Collicular TrkB-T1 levels are not influenced by unilateral SC vector 
transduction (N=4). C. Western blot for TrkB-FL and TrkB-T1 in the SC 18 d after viral vector delivery showing 
representative bands for the graphs in A and B, with 1) internal control SC of eGFP vector injected mice, 2) SC 
transduced with eGFP vector, 3) internal control SC of BDNF vector-transduced mice, 4) BDNF vector-injected 
SC. D, E. No differences in full-length (D) or truncated (E) forms of TrkB are detected in retinas ipsilateral or 
contralateral towards unilateral SC transduction with eGFP (NFL=4, NT1=5) or BDNF (N=5) vector. F. TrkB-FL and 
TrkB-T1 western blot detection in the retina 18 d after viral vector delivery, representative bands for the graphs 
in D and E, with 1) internal control retina ipsilateral to eGFP vector-injected SC, 2) retina contralateral to the SC 
transduced with eGFP vector, 3) internal control retina ipsilateral to BDNF vector-transduced SC, 4) retina 
contralateral to BDNF vector-injected SC. All data are mean ± SEM with significance * p<0.05 based on two-way 
ANOVA with Bonferroni post hoc test. Key: SC, superior colliculus; BDNF, brain-derived neurotrophic factor; 
TrkB, tropomyosin receptor kinase B; TrkB-FL, TrkB full-length form; TrkB-T1, TrkB truncated form 1, eGFP, 
enhanced green fluorescent protein.  
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4 DISCUSSION  
In glaucoma pathology, RGCs die via apoptotic mechanisms. According to the neurotrophin 
deprivation hypothesis, diminished delivery of neurotrophins derived from RGC target areas 
in the brain is one of the main triggers inducing apoptotic pathways in RGCs10,69. The 
objective of the current experiments was to study the contribution of BDNF, the most 
commonly studied neurotrophin, to disease progression in glaucoma by use of the ONC and 
OHT mouse glaucoma models.  
4.1 ENDOGENOUS EXPRESSION OF BDNF AND TRKB IN EXPERIMENTAL GLAUCOMA  
4.1.1 Experimental glaucoma affects BDNF and TrkB levels in the retina 
The current study, investigating BDNF and TrkB-FL/TrkB-T1 levels in the retina and SC in two 
mouse models of experimentally-induced glaucoma, demonstrated that retinal BDNF protein 
levels were elevated after ONC. This upregulation was significant at 3 and 5 dpi. Also, retinal 
levels of both the TrkB-FL and TrkB-T1 isoforms increased upon ONC, with TrkB-T1 showing 
the most pronounced increase. Crushing of the optic nerve induces immediate axonal 
damage that results in blocking the retrograde delivery of neurotrophins from the brain. 
Rapid upregulation of endogenous BDNF expression in the retina may act as a natural 
protection factor for RGCs when they encounter injury and neurotrophin deprivation10,179. In 
line with the results presented here, ONC applied to rats has been reported to upregulate 
BDNF mRNA in the ganglion cell layer (GCL), first observed at 24 h with a peak at 48 h (38 % 
elevation above control levels) and attenuating to basal levels two weeks after ONC (Table 
5.1)179. Furthermore, temporary upregulation of downstream actors within neurotrophin-
induced pathways, such as Nrn1, have been previously described in the ONC model, 
hypothetically to overcome neurotrophin transport deficits178. Ivt application of exogenous 
BDNF has been reported to elicit a decrease in retinal TrkB-FL mRNA and protein levels210, 
suggesting that regulation of TrkB receptor availability is sensitive to feedback mechanisms 
related to BDNF concentration180. In our study, the enhanced retinal BDNF levels induced by 
ONC were accompanied by a rise in TrkB levels. This might seem contrary to the study of 
Cheng et al.168 describing reduced TrkB mRNA levels in RGCs from 3 dpi onwards after optic 
nerve transection (ONT) in rats (Table 5.1). They documented no changes in TrkB mRNA in 
amacrine cells. However, it is important to note that the results of the present work reflect 
findings from the whole retina, and that responses unique to RGCs may be diluted by 
contributions from other retinal cells, for example Müller glia, which also express TrkB460. 
The current results showed that the TrkB upregulating effect was the highest for the TrkB-T1 
isoform. Since this isoform has previously been related to intracellular signaling in glia, the 
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observed effect might be due to TrkB upregulation in Müller glia and astrocytes rather than 
in RGCs459. When extracellular BDNF is abundant, non-neuronal cells might sequester BDNF 
through TrkB-T1 and store BDNF in transport vesicles, ready to quickly release BDNF into the 
extracellular space again by exocytosis if required459. On the other hand, not only glial cells, 
but also neurons express TrkB-T1, and the neuroprotective effect of BDNF has been 
suggested to become suppressed in cells that overexpress TrkB-T1. Indeed, upregulation of 
TrkB-T1 in neurons has been shown to stimulate heterodimerization with TrkB-FL, leading to 
decreased autophosphorylation and inhibition of BDNF-mediated cell survival signaling459. 
Thus, although both BDNF and TrkB concentrations increased in the retina after ONC, this 
does not necessarily prevent RGCs from dying. The extra BDNF might be internalized by glia 
or the expected neuroprotective role of this extra BDNF could potentially be attenuated 
because of the shift towards TrkB-T1 in the TrkB ratio in RGCs. In future experiments, 
measuring precise levels of phosphorylated versus non-phosphorylated TrkB-FL163, can 
additionally provide interesting details on the activation or inhibition of intracellular, 
presumably pro-survival, signaling pathways. Furthermore, a combination of ISH and IHC on 
retinal sections can provide more information on the source and cellular distribution of 
BDNF and TrkB isoforms.  
In contrast to ONC, BDNF or TrkB levels in the retina were not affected by OHT at the time 
points outlined in this study. Although OHT has been described to negatively influence RGC 
axonal transport, leading to neurotrophin deprivation10, the effect is less direct compared to 
ONC. This difference between the models is one possible explanation for the variation in the 
results of BDNF and TrkB profiles. Furthermore, various studies using a number of rodent 
OHT models show assorted effects of elevated IOP on retinal BDNF levels (Table 
5.1)163,166,175,176,180. In a study by Gupta and colleagues163, OHT, induced by microbead 
injection in the anterior chamber of mice, resulted in a decrease in BDNF protein 
concentration in the mouse optic nerve head (ONH) at 8 weeks after OHT onset. However, 
their results do not have to be contradictory to those presented here. First of all, in their 
study, western blot analysis was used without specifying the difference between pro- and 
mBDNF. It is possible that total BDNF levels remain stable, as demonstrated by our ELISA 
data, yet there still may be changes in the pro-/mBDNF ratio. Moreover, the decrease in 
ONH BDNF levels was detected at 8 weeks post-OHT induction, a time point far exceeding 
the current experimental paradigm. However, research on the hypertonic saline model in 
rats did show a decrease in retinal BDNF expression one week post-OHT induction166, though 
this effect, visualized via IHC, was only localized in the ONH and the superior retina, with the 
inferior retina remaining unaffected at 7 dpi. In the vein cauterization model, retinal BDNF 
mRNA levels have been described to remain relatively unchanged until day 28, at which they  
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 Glaucoma 
model 
Technique Results on BDNF and TrkB levels Reference 
O
p
ti
c 
n
e
rv
e
 in
ju
ry
 
mouse ONC  ELISA  total BDNF in retina with peak at 
3-5dpi 
current study  
western blot  TrkB FL, significant at 5dpi, and 
TrkB-T1 with peak at 24h-5dpi 
 
rat ONC  ISH  
northern blot 
 BDNF mRNA in GCL with peak at 
48hpi, attenuated by 2 weeks  
post-ONC 
Gao et al. 1997
179
 
rat ONT ISH  TrkB mRNA in RGCs, but not in 
amacrine cells, from 3dpi onwards  
Cheng et al. 2002
168
 
O
cu
la
r 
h
yp
e
rt
e
n
si
o
n
 
mouse LP  ELISA  unchanged total BDNF in retina  current study  
western blot  unchanged retinal TrkB-FL and 
TrkB-T1  
 
mouse 
microbead 
occlusion 
western blot  BDNF in ONH at 8 weeks 
post-OHT induction 
 pTrkB, and unchanged total TrkB 
upon 8 weeks of OHT 
Gupta et al. 2014
163
 
 IHC 
 
 BDNF in ONH and superior retina 
at 7dpi, and in superior or whole 
retina at 14 dpi 
Johnson et al. 
2000
166
 
rat hypertonic 
saline 
 glia label for BDNF in ONH at 14dpi 
 heavy label of BDNF in isolated 
RGC soma at more than 14dpi 
 
  
RT-PCR 
  At 5 weeks post-OHT induction: 
 unchanged retinal BDNF mRNA  
 TrkB-FL mRNA, and unchanged 
TrkB-T1 mRNA in retina 
Guo et al. 2009
180
 
 western blot   pro-BDNF, unchanged mBDNF  
 unchanged TrkB-FL, and pTrkB 
 
 IHC  unchanged TrkB-FL in GCL and NFL   
rat vein 
cauterization 
RT-PCR  retinal BDNF mRNA by 28 dpi 
  unchanged TrkB mRNA 28 d post-
cauterization 
Rudzinki et al. 
2004
175
 
western blot   BDNF in retina by 28 dpi  
 RT-PCR   BDNF mRNA in retina at 7 dpi, 
lower but still  at 4 and 8 weeks 
post-OHT 
Kim et al. 2007
176
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Table 5.1:  Overview of the discussed studies on retinal BDNF and TrkB expression in murine optic nerve 
injury and OHT models. Key: BDNF, brain-derived neurotrophic factor; mBDNF, mature form of BDNF; TrkB, 
tropomyosin receptor kinase B; TrkB-FL, TrkB full-length form; TrkB-T1, TrkB truncated form 1; pTrkB, 
phosphorylated TrkB; ONC, optic nerve crush; LP, laser photocoagulation; ONH, optic nerve head; GCL, ganglion 
cell layer; NLF, nerve fiber layer; ELISA, enzyme-linked immune-sorbent assay; ISH, in situ hybridization; IHC, 
immunohistochemistry; RT-PCR; reverse transcription polymerase chain reaction; hpi, hours post-injury; dpi, 
days post-injury.   
 
 
Table 5.2:  Overview of the discussed data on collicular BDNF and TrkB expression in murine models of 
glaucoma. Key: BDNF, brain-derived neurotrophic factor; mBDNF, mature form of BDNF; TrkB, tropomyosin 
receptor kinase B; TrkB-FL, TrkB full-length form; TrkB-T1, TrkB truncated form 1; ONC, optic nerve crush; LP, 
laser photocoagulation; sSC, the superficial layers of the superior colliculus; NMDA, N-methyl-D-aspartate; 
ELISA, enzyme-linked immune-sorbent assay; ISH, in situ hybridization; IHC, immunohistochemistry; RT-PCR; 
reverse transcription polymerase chain reaction; hpi, hours post-injury; dpi, days post-injury. 
 Glaucoma 
model 
Technique Results on BDNF and TrkB levels Reference 
IO
P
-i
n
d
e
p
e
n
d
e
n
t 
mouse ONC  ELISA  total BDNF at 6h-3dpi, peak at 6h, 
slowly attenuating afterwards 
current study  
western blot  TrkB FL and TrkB-T1 at 6h-3dpi, 
slowly normalizing thereafter 
 
mouse NMDA IHC  BDNF in collicular neurons and 
astrocytes at 30 and 90 dpi 
Tanaka et al. 2009
118
 
O
cu
la
r 
h
yp
e
rt
e
n
si
o
n
 
mouse LP  ELISA  unchanged total BDNF  current study  
western blot  TrkB-FL and TrkB-T1 slightly, with 
the lowest point at 5dpi 
 
DBA/2 mice RT-PCR 
ISH  
IHC 
 
 
ISH 
     
IHC 
 BDNF mRNA and mBDNF protein 
in sSC, colocalized with sectorial 
deficits in anterograde transport 
towards RGC axontermini, from 3 
months of age on 
 strongest signal of BDNF mRNA in 
neurons 
 mBDNF especially within 
hypertrophic astrocytes 
Crish et al. 2013
119
 
rat microbead 
occlusion 
IHC  mBDNF within hypertrophic 
astrocytes, colocalized with zones 
of reduced anterograde transport 
towards RGC axontermini, upon 5 
weeks of OHT 
Crish et al. 2013
119
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nearly doubled175. In the same study, TrkB mRNA levels remained constant throughout the 
experimental period. While using a similar cauterization model, Kim et al.176 found that OHT 
resulted in elevated retinal BDNF mRNA levels that peaked four times over control levels at 
one week, and subsequently declined to approximately twice the control levels at four and 
eight weeks post-OHT induction. In the rat hypertonic saline-induced OHT model, retinal 
BDNF mRNA and mBDNF protein levels were reported to remain unchanged, however pro-
BDNF levels did decrease 5 weeks post-OHT induction. In the same report, the mRNA level of 
TrkB-FL decreased while TrkB-T1 mRNA levels remained unaltered. On the contrary, and 
surprisingly, there were no alterations in TrkB-FL protein detected180. Consequently, 
literature that describes the effect of OHT on BDNF and TrkB mRNA and protein levels in the 
retina and ONH is confusing and far from complete. Discrepancies between the existing 
reports are probably the resultant of differences in how OHT is induced as well as of the 
techniques applied for sample processing and subsequent mRNA and protein detection.  
4.1.2 … and in the superior colliculus  
In the SC, total BDNF was significantly enhanced as soon as 6 h post-ONC, slowly decreasing 
to baseline levels afterwards. Collicular TrkB-FL and TrkB-T1 levels followed a parallel 
increase-decrease pattern after ONC. The increasing phase began as soon as 6 h post-ONC. 
To date, the link between ONC and BDNF/TrkB expression in the retinal target areas has not 
yet been elucidated. However, in the acute N-methyl-D-aspartate (NMDA) excitotoxicity 
murine glaucoma model, BDNF upregulation in the dLGN and the SC at 30 and 90 d post-ivt 
NMDA injection has been associated with RGC degeneration (Table 5.2)118,152. The difference 
in timing may be attributed to the use of a different model of RGC injury. In the NMDA 
model, RGC degeneration is initiated at the RGC soma in the retina, while in the ONC model, 
the initial injury takes place at the axonal level in the optic nerve. ONC directly obstructs the 
retinal output, producing a quick drop in RGC-derived input into the visual brain centers. 
Therefore, the observed responses in the SC soon after ONC were not entirely unpredicted. 
Upregulation of BDNF and TrkB in retinal target areas might in fact be an attempt to prevent 
postsynaptic degeneration.  
In the OHT model, no significant effect on the BDNF concentration in the SC was measured. 
Nevertheless, the results presented in this work illustrated reduction in TrkB-FL and TrkB-T1, 
albeit only slightly. Quite possibly, this reduction stems from diminished anterograde TrkB 
delivery from the cell soma in the retina towards the axon terminals in the SC. Alternatively, 
the functional and structural degeneration of the RGC axon terminals might well lead to 
reduced TrkB levels in the SC. As described in Chapter 3, as soon as 1 week post-OHT 
induction, RGC synaptic terminals in the SC are affected292. In comparison, in DBA/2 mice 
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pre-degenerative transport deficits were found to be accompanied by a decrement in BDNF 
mRNA expression in the retinorecipient SC, while conversely, mBDNF protein IHC signal 
increased (Table 5.2)119. This mBDNF protein appeared to be primarily internalized in 
astrocytes, an observation that was confirmed in the microbead-based OHT model at 5 
weeks post-OHT induction. The authors theorized that astrocytes take up the extracellular 
BDNF that is released from collicular neurons, storing it for later re-release. The fact that no 
differences were measured in the total amount of BDNF in the SC within our study might be 
related to the time points analyzed. As such, reviewing later time points post-OHT induction 
might shed more light on changes in BDNF levels in this context. However, there is also the 
additional possibility that a redistribution of BDNF occurs, changing its location and the 
pro-/mBDNF ratio at the time points included in this study without modifying the total 
concentrations. 
Indeed, BDNF-TrkB signaling is regulated by spatial and temporal changes in protein 
localization, gene expression, the mBDNF/pro-BDNF ratio, the TrkB-FL/TrkB-T1 ratio, and 
downstream signaling molecules459. Defining a specific role for BDNF signaling within 
glaucoma pathology remains difficult as various studies using a number of animal glaucoma 
models have culminated in a variety of unique results180, the present work included. 
4.2 INTRAVITREAL DELIVERY OF BDNF DELAYS GLAUCOMATOUS RGC 
DEGENERATION WHILE COLLICULAR BDNF UPREGULATION DOES NOT  
Based on the neurotrophin deprivation hypothesis, neurotrophins gained wide acceptance 
as suitable candidates for neuroprotective drug usage. Indeed, RGCs have been described to 
survive longer upon experimentally-induced glaucoma by ivt administration of various 
neurotrophic factors21,22,185, amongst which BDNF has been consistently shown as one of the 
most powerful21,194,461, though only delivering a transient neuroprotection5,21. The current 
study confirms the temporary neuroprotective effect of ivt delivery of recombinant mBDNF 
in the ONC model. One single administration at the time of injury resulted in 10 % more RGC 
survival at 7 dpi. This effect had the same order of magnitude as the neuroprotective effect 
described at 3 dpi for one single ivt dose of BDNF administered to mice subjected to ONT188. 
This is in line with what was expected in relation to timing, because ONC is less acute than 
ONT185. One explanation for the neuroprotective effect of ivt delivered BDNF on injured 
RGCs observed at 7 dpi may be that these neurons express TrkB204,462 and thus the pathways 
involved in the upregulation of survival and the suppression of apoptotic mechanisms might 
be activated via enhanced BDNF-TrkB signaling. Yet, ivt BDNF might also affect RGC survival 
indirectly via stimulation of Müller cells, also expressing TrkB, to secrete other RGC 
supporting compounds167. Retinal TrkB levels were not downregulated upon ONC as 
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discussed above, and so ivt administered BDNF could provide additional survival by 
promoting signaling through TrkB on RGCs or glia. However, the TrkB-FL/TrkB-T1 ratio 
shifted slightly towards the T1 isoform of which the exact role is not fully understood. 
TrkB-T1 was initially defined as a dominant-negative receptor that dimerizes with TrkB-FL, 
counteracting TrkB-FL signaling459. Nevertheless, more recently, the truncated receptor also 
seems to fulfill other, possibly even survival promoting, functions459. Therefore, it is hard to 
draw strong conclusions on how ivt BDNF delivery promotes RGC survival and why this effect 
is transient (discussed in further detail below).  
Unfortunately, at 14 dpi our experiments did not establish any differences between single 
BDNF and vehicle treated groups. On the contrary, in a study by Galindo-Romero et al.188, a 
30 % gain of survival by one single ivt BDNF administration has been described at 14 dpi in 
ONT mice. This discrepancy is rather striking based on the fact that they also used Brn3a as a 
marker for surviving RGCs and the dose of BDNF was identical to the one used in our study. 
Moreover, one single ivt BDNF administration at the moment of ONC application in rats has 
been described to result in complete protection against RGC loss by 7 dpi, and the protection 
remained significant by 12 dpi with a 35 % enhancement in survival185. Furthermore, in the 
rat ONT model, similar protective effects have been accounted for up to 14 dpi induced by a 
single ivt BDNF administration186. Strikingly, in the present work, repeated BDNF 
administration could not ameliorate the 10 % protection effect seen at 7 dpi, however the 
neuroprotective effect could slightly be prolonged, retaining 4.5 % protection at 14 dpi. 
Regrettably, despite its ability to prevent RGC degeneration in the short-term, the long-term 
effectiveness of ivt BDNF administration was limited when provided as a single injection, or 
even as multiple injections. Presumably, this is partly due to limited supply and presence of 
the protein when administered ivt, but also to downregulation of the relevant receptors and 
desensitization of the signal transduction pathways194,204. The decrease in RGC 
responsiveness to BDNF most likely stems from a downregulation in TrkB receptor 
availability, brought about by decreased TrkB expression, internalization of the BDNF-bound 
receptors with reduced replacement in the cell membrane, or competitive interactions with 
truncated TrkB receptors204. Indeed, combining ivt BDNF injections with transduction of 
RGCs with the TrkB gene notably enhanced the duration of ivt BDNF-induced 
neuroprotection after optic nerve axotomy168,204.  
Accordingly, local administration of BDNF in the eye has a pro-survival effect on RGCs, but 
this effect is temporary: it delays, but does not completely prevent RGC death. Therefore, its 
role as a potential glaucoma therapeutic remains equivocal. With the cellular response to 
neurotrophin-receptor interaction being suggested to be different depending on the 
neuronal compartment from where the signal is initiated (in the cell body, in the axon 
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terminals, or on the dendrites)9,126, it seems plausible to hypothesize that delaying or 
preventing RGC death could be better achieved by interfering with their target areas. 
Indeed, Weber et al.194,204 have demonstrated that combined application of BDNF to the eye 
and the central visual pathway enhanced RGC survival and function relative to treatment of 
the eye alone in an ONC model in cats. Furthermore, this combined treatment approach 
provided a more sustained level of neuroprotection than has been achieved in localized 
treatment paradigms focusing on the eye. Based on this finding, our intention was to deliver 
BDNF to the RGCs from a natural extraretinal source, the SC, in order to induce RGC 
neuroprotection in the murine ONC or OHT model. Unfortunately, although viral vector-
mediated BDNF upregulation in the mouse SC was validated via IHC (Chapter 4) and ELISA, 
the attempts to protect RGCs from dying in the ONC and OHT glaucoma models via BDNF 
vector delivery to the SC were unsuccessful. Nonetheless, vector-derived BDNF was shown 
to be secreted by transduced cells in vitro and to be bio-active in an ex vivo retinal explant 
culture (Chapter 4). Besides, vector-derived BDNF was transformed into the 14 kDa mature 
form of BDNF in vivo, as verified by western blotting. Furthermore, viral vector based BDNF 
upregulation in the SC elicited effects on the availability of its receptor (discussed below), 
demonstrating that transgenically-expressed BDNF was secreted into the extracellular space 
by transduced collicular neurons in vivo as well. Based on unpublished results showing that 
treatment of the visual cortex alone was insufficient to provide RGC neuroprotection, Weber 
et al.6,21 postulated that the enhanced survival achieved in the dual treatment paradigm was 
the result of the contribution from both the eye and visual brain center treatment. They 
hypothesized that direct treatment of the eye is necessary to sustain RGCs during the 
immediate post-injury period in order to counter the initial insult and short-term 
degenerative effects, whereas treatment of the brain center provides more long-term 
stability. Thus, in future experiments, it would be interesting to combine both the 
approaches of ivt BDNF delivery and viral vector-based SC treatment to investigate this 
hypothesis. However, some additional issues need to be taken into account. Indeed, more 
detailed investigation of collicular responses to viral vector-mediated BDNF overexpression 
revealed that upregulation of BDNF in the SC did not result in any enhancement of BDNF 
levels in the retina. Thus, transgenically-expressed BDNF did not seem to be retrogradely 
transported by RGC axons. This was the case in both healthy conditions and after ONC- or 
OHT-induced injury. This unfortunate finding was attributed to the demonstrated 
downregulation of collicular TrkB-FL levels as a response to BDNF upregulation and 
secretion. Potentially, this downregulatory effect may be explained by a reduction in the 
delivery of TrkB from the retina to the RGC axon terminals of the target area. Assuming this 
downregulation of TrkB-FL is due to reduced availability of TrkB-FL on the RGC axon 
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terminals, the viral vector-derived BDNF will not be taken up at the RGC synapses and thus 
will not be transported towards the retina. In keeping with the observation that collicular 
TrkB-T1 levels did not change upon vector delivery, there remains another possibility to 
explain the lack of retrograde transport of vector-derived BDNF. It is plausible that the viral 
vector-derived BDNF is sequestered by glia in an effort to maintain extracellular BDNF levels 
within normal ranges. However, we were not able to distinguish glial morphology in the 
BDNF signal obtained via IHC of viral vector-injected SC sections. Double staining for BDNF or 
TrkB and markers for glia, neurons, and axonterminals, will be performed to further 
elucidate the changes evoked by BDNF-vector delivery into the SC. In our opinion, reduced 
TrkB-FL availability at the RGC axon terminals seems the most reasonable explanation for 
the absence of retrograde transport of the vector-derived BDNF. This is in agreement with 
previous findings in the retina, whereby downregulation of TrkB has been described upon ivt 
injection of recombinant BDNF168,194,210. Of note, downregulation of the receptor might 
especially be evoked by exposure to high BDNF concentrations and thus, slow releasing 
devices that release low amounts of BDNF over a long period might possibly avoid this 
problem. In future experiments, the problem of reduced responsiveness might be overcome 
via restoration of trophic responsiveness by endeavoring to increase the number of TrkB-FL 
receptors present on the RGC terminals surface by overexpression or by enhancing their 
recruitment to the plasma membrane. Overexpression could be achieved by viral vector 
transduction of RGCs as previously described168,463. Surface recruitment could be elicited by 
elevating the intracellular cyclic adenosine monophosphate (cAMP) levels in the RGCs 
through pharmacologic treatment464.  
Thus, Weber et al.194,204 stated that sustained RGC protection can only be achieved by 
delivery of neurotrophic support both at the level of the cell soma in the retina and at the 
axon terminals in the brain. In addition, we revealed the existence of a reduced 
responsiveness upon viral vector-derived BDNF upregulation. Therefore, future experiments 
should combine viral vector-mediated BDNF overexpression in the SC with ivt BDNF delivery 
at the moment of injury and viral vector-mediated TrkB overexpression in RGCs or 
pharmacological manipulation of cAMP levels enhancing TrkB membrane translocation. 
Furthermore, based on our studies, we came to the contention that OHT should be the 
model of choice for subsequent experiments, because of a lower direct effect on RGC axonal 
transport compared to the physical transport obstruction effected by ONC.  
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5 CONCLUSION  
Endogenous BDNF and TrkB expression patterns in the retina and SC were shown to be 
differentially affected in mouse ONC and OHT models. Using the ONC model, the 
neuroprotective capacity of ivt BDNF administration was confirmed. Unfortunately, viral 
vector induced overexpression of BDNF in the SC did not result in enhanced RGC survival in 
none of the two experimentally-induced glaucoma models. These negative results seem 
mainly attributed to reduced neurotrophin responsiveness as a response to vector-mediated 
BDNF overexpression and secretion. Therefore, in future experiments collicular BDNF 
overexpression should be combined with experimental enhancement of receptor availability. 
   
  
 
 
 
 
 
CHAPTER 6  
OPTOGENETIC STIMULATION IN THE MOUSE 
SUPERIOR COLLICULUS  
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1 INTRODUCTION 
Recent advancements in neuromodulatory techniques, like electrical or chemical 
manipulation of the nervous system, open perspectives for treatment of neurological 
disorders465. Indeed, electrical stimulation is presently used by neurosurgeons to treat 
chronic pain, movement disorders, and psychiatric illness465. In animal models, both 
electrical and chemical neuromodulation is mainly employed as a research tool to shed light 
onto the complexity of neuronal networks. However, though efficient and widely used, 
neuromodulation has always been plagued with difficulties related to a lack of spatial and 
temporal resolution, often resulting in unwanted side effects26. Optogenetics is a 
revolutionary technique, described for the first time in 2005227,466,467 and awarded ‘Method 
of the Year’ in 2010 by Nature Methods26,213, which overcomes the drawbacks of classical 
neuromodulation. In 2013, the Brain Prize was awarded to the sextet of researchers that 
pioneered optogenetic manipulation (Ernst Bamberg, Ed Boyden, Karl Deisseroth, Peter 
Hegemann, Gero Miesenböck, and Georg Nagel), demonstrating the impact of it on the 
neuroscientific world468. By combining optical and genetic methodologies, it is now possible 
to stimulate or inhibit specific cell populations on a millisecond time scale26,214. The basic 
principle underlying optogenetics is the introduction of genes encoding light-sensitive ion 
channels, or opsins, into excitable cells, rendering these cells responsive to light of an opsin 
specific wavelength17,244. Channelrhodopsin 2 (ChR2), a blue light-responding photoreceptor 
from the unicellular green algae Chlamydomonas reinhardtii, was the first opsin used for 
light induced neurostimulation in the mammalian brain227. In the following years, the 
optogenetic toolbox has been steadily expanded as variants of opsins with different spectral 
peak activation and kinetic properties have been discovered and generated17, turning 
optogenetics into an important field in neuroscience research.  
Optogenetics holds promise through translation into clinical applications, replacing current 
therapies that focus on less specific electrical stimulation465. However, first, thorough 
optimization and validation is required in animal models. As such, the present work intends 
to use optogenetic modulation of visual brain centers in order to halt or, at the least, retard 
neurodegeneration in glaucoma, which is one of the main causes of blindness worldwide and 
characterized by retinal ganglion cell (RGC) death2,62. Although glaucoma was considered a 
retinal disease limited to the eye for many years, the involvement of visual areas in the brain 
is now widely recognized7,8. As was described in detail in Chapter 5, diminished retrograde 
signaling between the brain and the eye plays an important role in proper RGC function16, as 
well as in glaucoma disease progression10,69. Therefore, it seems plausible to hypothesize 
that the preservation of RGCs could be achieved by maintaining physiological electrical 
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activity patterns in RGC target areas. With this, electrical activity has been shown sufficient 
to increase neuronal, and also RGC, survival, presumably because such activity stimulates 
certain molecular signaling pathways that are known to enhance viability23-25. In this context, 
it was our intention to investigate whether optogenetic modulation of neuronal activity in 
the superior colliculus (SC), the principal retinal target structure in mice, can protect against 
RGC loss in experimental mouse glaucoma models.  
To contribute to this lofty research goal, a setup for chronic optogenetic SC stimulation in 
awake and freely moving mice was optimized. This was achieved through close collaboration 
with the Optobrain Consortium, a consortium of eight partners established in 2010, working 
together to introduce the optogenetic research field in Belgium. Besides utilizing the fast 
spiking ChR2 double mutant, ChR2-L132C/T159C469, for primary validation of the techniques, 
also the stabilized step-function opsin (SSFO), ChR2-C128S/D156A18, was employed. The 
latter is a more novel opsin, which can be turned on and off with very low power and very 
short-lasting light pulses of varying wavelengths. In contrast to fast spiking opsins that 
directly trigger action potential firing in illuminated neurons, SSFO activation increases 
responsiveness to endogenous stimuli for 20-30 min according to the literature17,18,214. Thus, 
the behavior of an SSFO-stimulated cell remains fairly natural, reducing the risk for adverse 
effects during prolonged and repeated stimulation regimes. 
To introduce a chronic optogenetic setup into the outlined research, SSFO activation in SC 
neurons was first validated ex vivo. Next, optogenetic stimulation was successfully induced 
in the SC of anesthetized animals in vivo. Subsequently, the setup was expanded to repeated 
optogenetic stimulation in awake, freely moving animals. As readout for optogenetically-
enhanced network activity immediate early gene (IEG) expression was used. Furthermore, 
behavioral effects were noted and further characterized, and possible neurotoxic side effects 
of optogenetic modulation were examined. 
 
2 MATERIALS AND METHODS  
2.1 ANIMALS 
All experiments were performed in CD-1 and C57Bl/6J mice at eight weeks of age at the start 
of the experiments, housed under standard laboratory conditions in a 12/12h light/dark 
cycle with food and water ad libitum. All animal experiments were approved by the Animal 
Ethics Committee of KU Leuven and were carried out in strict accordance with European 
Communities Council Directive of 22 September 2010 (2010/63/EU). 
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2.2 DELIVERY OF OPSIN CARRYING VIRAL VECTORS TO THE SC  
To induce targeted expression of opsins, specific viral vectors, produced by the Viral Vector 
Core of KU Leuven and listed in Table 6.1, were stereotactically delivered to the right SC. 
Two optochannels were used: the fast spiking ChR2-L132C/T159C channel469 and the slow 
modulating ChR2-C128S/D156A or SSFO18. Both opsin sequences were obtained from Prof. 
P. Hegemann (Experimental Biophysics, Humboldt University, Germany). For production and 
validation of the SSFO-expressing vectors, see Chapter 4. As described there, recombinant 
adeno-associated viral vector (rAAV) serotype 2/1, in combination with the CMV promoter, 
was the vector of choice for general SC stimulation. Notably however, the initial optogenetic 
experiments were performed with other vectors depending on availability at the time. 
Mice were anesthetized by intraperitoneal (i.p.) administration of a mixture of ketamine (75 
mg/kg body weight, Anesketin, Eurovet, Belgium) and medetomidin (1 mg/kg body weight, 
Domitor, Janssen Pharmaceutics, Belgium). In addition, lidocaine hydrochloride (5%, 
Xylocaine, AstraZeneca, UK) was applied on the head skin as a topical anesthetic. During this 
procedure, the body temperature was controlled by use of a heating pad connected to a 
rectal probe (TCAT-2LV, Physitemp Instruments INC, NJ, USA). After making a midline 
incision of the scalp, the periosteum was removed locally, the skull was disinfected with 
70 % ethanol, and a small craniotomy was drilled above the right SC. Using the Nanoject II 
(Drummond Scientific Company, PA, USA), 200 nl rAAV was injected at a rate of 100 nl/min. 
Coordinates for mouse SC were anteroposterior -3.3 mm and mediolateral +0.4 mm relative 
to Bregma, and dorsoventral -1.3 mm from the dura.  
Table 6.1: Optovectors for optogenetic stimulation in the mouse SC. Transduction is determined by the 
serotype, while expression is promoter driven. All opsins were fused to the red fluorescent reporter, mCherry. 
For control experiments, vectors of the same serotype containing a reporter gene, eGFP, under control of the 
same promoter, were used with normalized titers. Key: SC, superior colliculus; CaMK, Ca
2+
/calmodulin-
dependent protein kinase II  promoter shortened sequence of 0.4 kb; CMV, cytomegalovirus promoter; eGFP, 
enhanced green fluorescent protein; GC, genome copies. 
Vector Titer (GC/ml) Abbreviation Control 
Serotype Promoter Opsin 
rAAV2/7 CaMK ChR2-L132C/T159C 1.42E12  2/7-CaMK-LC/TC 
2/7-CaMK-eGFP 
rAAV2/7 CaMK ChR2-C128S/D156A 1.62E12 2/7-CaMK-SSFO 
rAAV2/1 CMV ChR2-C128S/D156A 9.82E11 2/1-CMV-SSFO 2/1-CMV-eGFP 
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2.3 EX VIVO PATCH CLAMP  
Ex vivo experiments were performed using SC slices of 2/7-CaMK-SSFO-transduced C57Bl/6J 
mice at four weeks after vector injection, in collaboration with Prof. D. Balschun and Dr. V. 
Sabanov (Laboratory for Biological Psychology, KU Leuven, Belgium). Animals were 
decapitated and the brain was quickly removed from the skull, placed in ice-cold artificial 
cerebrospinal fluid (ACSF) containing 124 mM NaCl, 4.9 mM KCl, 1.2 mM NaH2PO4, 25.6 mM 
NaHCO3, 2 mM MgSO4, 2 mM CaCl2, and 10 mM glucose, and saturated with 95% O2 and 5% 
CO2; pH 7.4. Coronal 400 µm thick SC slices were cut with the Micron H650 vibratome 
(Thermo Scientific, MA, USA) and stored at room temperature in a holding bath containing 
ACSF solution. After a recovery period of at least 1 h, an individual slice was transferred to 
the recording chamber where it was continuously superfused with oxygenated ACSF at a 
rate of 2.5 ml/min. Cells were visualized with the Axioskop2 FC Plus upright confocal 
microscope (Zeiss, Germany) using infrared differential interference contrast (DIC) optics. 
Whole-cell recordings from SSFO-expressing SC neurons were performed using a patch 
clamp amplifier (MultyClamp 700B, Molecular devices, CA, USA). Patch microelectrodes 
were filled with a solution containing 135 mM K-gluconate, 5 mM MgCl2, 10 mM K-Hepes, 
20 mM glucose; pH 7.25. Pipette resistance was 3-6 MΩ. Recorded signals were low-pass 
filtered at 2 kHz and acquired at 10 kHz. For optical manipulation, two KSL70 units were used 
(LED 470 nm and 590 nm) lighting the slice through the objective of the microscope.  
2.4 ACUTE OPTOGENETIC STIMULATION IN ANESTHETIZED ANIMALS  
The first in vivo optogenetic experiments were performed in collaboration with Drs. S. 
Vreysen (Laboratory of Neuroplasticity and Neuroproteomics, KU Leuven, Belgium). 
Optogenetic stimulation in anesthetized animals was performed in CD-1 mice, 4 weeks after 
stereotactic viral vector or saline injection. In these experiments,  IEG upregulation was used 
as readout for enhanced neuronal activity, and therefore, prior to stimulation, mice were 
dark adapted for 24 h to allow IEG expression to be downregulated to basal levels in the SC. 
For light delivery to the SC, mice were anesthetized with i.p. administration of 
chloroprothixene (1.25 mg/kg bodyweight, Sigma-Aldrich, MO, USA) and urethane (1.2 g/kg 
bodyweight, Sigma-Aldrich, MO, USA). Body temperature was monitored and kept at 36.5 °C 
during the procedure (TCAT-2LV, Physitemp Instruments INC, NJ, USA). The eyes were closed 
with surgical tape and covered with tin foil to prevent retinal damage from laser light and to 
avoid stimulation of the innate light-sensitive retinal cells. After reopening the scalp, a blunt 
end optical fiber (200 µm diameter, Doric lenses, Canada), coupled to a blue diode laser 
(wavelength 473 nm, DPSSL drive, Sloc Lasers, China) was positioned stereotactically above  
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the transduced SC through the craniotomy from the vector injection. Four groups were 
included (N=2) based on the vector and light stimulation paradigm: 2/7-CaMK-LC/TC with 
light stimulation, 2/7-CaMK-SSFO with light stimulation, 2/7-CaMK-SSFO without light 
stimulation, and saline-injected with light stimulation. For the condition without light 
stimulation, the optical fiber was inserted but no light was delivered through it. For 
stimulation of the LC/TC opsin, a stimulation paradigm of 10 Hz light pulses was applied for 
15 min with an intensity of 70 mW/mm² (Figure 6.1 A). For SSFO stimulation and for the 
saline control condition, two 2 s pulses were applied with 15 min in-between (Figure 6.1 B). 
Stimulation paradigms were based on those previously outlined in the literature by Yizhar et 
al.18. Animals were sacrificed 90 min after the onset of the stimulation.  
 
 
 
Figure 6.1: Acute stimulation paradigms applied for optogenetic activation of LC/TC and SSFO opsins.  A. 
LC/TC opsin channels were stimulated during 15 min with 10 Hz light pulses of 70 mW/mm²  for 2 s alternated 
with 3 s without stimulation. 90 min after the first pulse, mice were sacrificed. B. For SSFO stimulation, light 
was switched on twice for 2 s at 70 mW/mm² with 15 min of no light in-between. The same stimulation 
paradigm was applied to non-opsin-expressing saline-injected mice. Sacrifice occurred 90 min after the onset of 
the first stimulus. Key: LC/TC, ChR2-L132C/T159C double mutant; SSFO, stabilized step-function opsin.  
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2.5 OPTOGENETIC STIMULATION IN AWAKE, FREELY MOVING ANIMALS  
2.5.1 Headpiece implantation 
Optogenetic stimulation in awake, freely moving animals was performed in C57Bl/6J mice. 
The experimental setup was developed in collaboration with Drs. I. Scheyltjens (Laboratory 
of Neuroplasticity and Neuroproteomics, KU Leuven, Belgium). Three weeks after vector 
delivery, a headpiece (MFC_200/245-0.37_1.9mm_RMR_A60, Doric Lenses, Canada) 
consisting of a short 1.9 mm fiber piece for implantation in the brain and a magnetic 
receptacle allowing coupling to the long optic fiber for stimulation, was stereotactically 
positioned and permanently attached to the skull of the mice. In preparation for this 
procedure, animals were gas anesthetized by isoflurane (1.4 % mixture with O2, Isoba, MSD 
Animal Health, NJ, USA). Additionally, analgesic and inflammatory meloxicam (2 mg/kg 
bodyweight, Metacam, Boehringer Ingelheim, Germany) was administered subcutaneously. 
The scalp was reopened to visualize the craniotomy from the vector injection. Subsequently, 
the skull was disinfected with 70 % isopropanol and after positioning of the headpiece with 
cyanoacrylate-based superglue (Loctite 406, Henkel KGaA, Germany), dental cement (Unifast 
Trad, GC Europe, Belgium) was used to further firm the device’s placement.  
2.5.2 Acute stimulation in awake animals  
Acute stimulation in awake animals was optimized using the opsin vector 2/7-CaMK-SSFO 
and the control vector 2/7-CaMK-eGFP with normalized titer (Table 6.1). One week after 
implantation, the headpiece was coupled to a long optical fiber connected to a blue diode 
laser (wavelength 473 nm, DPSSL drive, Sloc Lasers, China). A schematic representation of 
the setup for optogenetic stimulation in freely moving animals is depicted in Figure 6.2 A. In 
the first experiment, stimulation was performed in dark after 24 h dark adaptation to allow 
IEG readout, using the same stimulation paradigm used in the anesthetized animals (Figure 
6.1 B). Three conditions were compared: SSFO expression with and without light stimulation, 
and eGFP expression with light stimulation, with two animals per condition. A second 
experiment using the same conditions (N=2) was performed in daylight to allow observation 
of the animals’ behavior. Two extra SSFO-expressing mice were stimulated in daylight using 
an alternative stimulation paradigm of one 2 s light pulse of 473 nm blue light with an 
intensity of 70 mW/mm². All optogenetic experiments performed in awake, freely moving 
animals are listed in Table 6.2.   
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Figure 6.2: Optogenetic stimulation in awake, freely moving animals. A. Technical setup for optogenetic 
stimulation in awake, freely moving animals (illustrated by Drs. I. Scheyltjens). On account of the rotary joint, 
mice can freely move without breaking the optic fiber. Walls of the stimulation cage can be changed from 
transparent to dark, meeting the experimental demands. B. Stimulation paradigm for triple repeated 
optogenetic SSFO stimulation. Three stimulation sessions occurred every other day, with 24 h dark adaptation 
preceding the third session. Within each session, light was switched on twice for 2 s at 70 mW/mm² with 15 
min light off in-between. Sacrifice of animals occurred 90 min after the onset of the third session. Key: SSFO, 
stabilized step-function opsin. 
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Table 6.2: Optogenetic experiments in awake, freely moving animals. Every SSFO stimulation session existed of 
one or two 2 s blue light (473 nm) flashes administered at the viral vector-transduced SC, with 15 min in-between 
if 2 pulses were applied. For IEG readout, animals were sacrificed 90 min after the onset of the final stimulation. 
N=2 for each condition. Key: SC, superior colliculus; 2/x, recombinant adeno-associated viral vector serotype 2/x; 
CaMK, Ca
2+
/calmodulin-dependent protein kinase II  promoter shortened sequence of 0.4 kb; CMV, 
cytomegalovirus promoter; eGFP, enhanced green fluorescent protein; IEG, immediate early gene. 
 
 Stimulation paradigm Light pulse Viral vectors Readout 
A
cu
te
 
Dark adaptation 
Stimulation in dark 
Two 2 s pulses 
2/7-CaMK-SSFO*  
2/7-CaMK-eGFP  
IEG expression 
Stimulation in daylight Two 2 s pulses 
2/7-CaMK-SSFO*  
2/7-CaMK-eGFP  
Behavior 
Stimulation in daylight One 2 s pulse  2/7-CaMK-SSFO  Behavior 
R
e
p
e
at
e
d
 
In light: day 1 and 3 
Dark adaptation 
In dark: day 5 
Two 2 s pulses 
2/7-CaMK-SSFO  
2/7-CaMK-eGFP  
Day 1 and 3: behavior 
Day 5: IEG expression 
 + activated caspase-3 
In light: day 1 and 3 
Dark adaptation 
In dark: day 5 
Two 2 s pulses 
2/1-CMV-SSFO  
2/1-CMV-eGFP  
Day 1 and 3: behavior 
Day 5: IEG expression 
 + activated caspase-3 
In light: day 1 and 2 
Dark adapatation 
Two 2 s pulses 2/7-CaMK-SSFO  
Day 1 and 2: behavior 
Day 3: IEG expression 
In light: day 1-14  One 2 s pulse 2/1- CMV-SSFO  Day 1-14: behavior 
* an extra negative control condition was included, in which SSFO-expressing animals were sham illuminated, 
meaning all was the same except that the blue laser was not switched on.  
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2.5.3 Chronic stimulation in awake animals  
Repetitive stimulation was performed using the opsin vectors, 2/7-CaMK-SSFO and 
2/1-CMV-SSFO, and the respective control vectors, 2/7-CaMK-eGFP and 2/1-CMV-eGFP, both 
with normalized titers (Table 6.1). A schematic representation of the standard repeated 
stimulation paradigm, performed in two animals for each vector condition, is depicted in 
Figure 6.2 B. In the setup for repeated stimulation, three times every other day, mice were 
connected and disconnected to and from the optic fiber for each stimulation session. Upon 
connection, animals were allowed to adapt for at least 30 min before onset of stimulation. 
Each individual stimulation session was identical to the acute stimulation of SSFO. During 
stimulation sessions in daylight, the animals’ behavior was observed. Prior to the last of the 
three sessions, mice were dark adapted in the stimulation cage for 24 h to allow the use of 
IEG detection as readout for optogenetically-induced neuronal activity. Mice were sacrificed 
90 min after the onset of the last stimulation.  
Additionally, two extra animals were 2/7-CaMK-SSFO-transduced, light-stimulated on two 
consecutive days in daylight, following the standard two times 2 s stimulation paradigm, 
dark adapted, and sacrificed without extra light stimulation. Lastly, one long-term 
experiment with daily stimulation of one 2 s blue light pulse for 14 d in daylight was 
performed in two mice transduced with 2/7-CMV-SSFO vector. Table 6.2 provides an 
overview of these experiments.  
2.6 HISTOLOGY AND IMMUNOHISTOCHEMISTRY  
Animals were anesthetized with sodium pentobarbital (200 mg/kg body weight, Nembutal, 
Ceva Sante Animale, France) and transcardially perfused with 0.9 % NaCl, followed by 4 % 
paraformaldehyde (PFA) in phosphate-buffered saline (PBS). Brains were dissected and post-
fixed overnight in 4 % PFA. The SC brain region was sectioned in 50 µm coronal sections 
using the Micron H650 vibratome (Thermo Scientific, MA, USA) and stored in PBS with 
0.004 % sodium azide at 4 °C until histological or immunohistochemical (IHC) staining.  
2.6.1 Histology 
SC sections were mounted on gelatin-coated microscopy slides and Nissl stained in order to 
visualize general morphology. After dehydratation through a series of increasing alcohol 
concentrations, the sections were incubated in chlorophorm and subsequently rehydratated. 
One min staining in 1 % Cresyl violet (Fluka Chemika, Sigma-Aldrich, MO, USA) was followed 
by destaining with acetic acid and a second dehydratation series. Upon final incubation in 
xylene, sections were cover slipped with Depex (VWR, PA, USA). The stained coronal SC 
sections were inspected using the Axio Imager Z.1 light microscope (Zeiss, Germany), driven 
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by ZEN LE digital imaging software. Cells exhibiting stained cytoplasm, pale nucleus, and 
stained nucleolus were defined as healthy neurons373. 
2.6.2 DAB based immunohistochemistry   
Visualization of the IEG cFos in the acute experiments performed in anesthetized mice was 
obtained via diaminobenzidine (DAB) staining on free-floating brain sections under uniform 
conditions. Sections were incubated for 20 min in 0.3 % H2O2 in 0.01 M Tris-buffered saline 
(TBS), followed by washing with TBS. After incubation for 1 h with 10 % normal goat serum 
(Invitrogen, CA, USA) in PBS containing 0.1 % Triton-X-100 (Fisher Scientific, NY, USA) 
(PBST0.1), primary antibody rabbit anti-cFos (1:10,000 in PBST0.3, produced and 
characterized by Dr. E. Van der Gucht470) was applied overnight. Upon washing and 45 min 
incubation with horse radish peroxidase (HRP)-conjugated goat anti-rabbit antibody (1:300 
in PBST0.3, DAKO, Denmark), the TSATM Biotin system (NEL700A001KT, Perkin Elmer, MA, 
USA) was used for amplification, and subsequently, DAB solution (0.125 mg/ml in Tris buffer) 
containing 0.03 % H2O2 was applied to allow chromogen precipitation. DAB staining patterns 
were inspected and pictured using the Axio Imager Z.1 light microscope (Zeiss, Germany), 
driven by ZEN LE digital imaging software. 
2.6.3 Fluorescent immunohistochemistry   
For better visualization of the reporters, eGFP and mCherry, free-floating vibratome sections 
were rinsed in PBST0.1 and incubated for 1 h in PBST0.1 containing 10 % normal goat serum, 
followed by overnight incubation with primary antibody rabbit anti-eGFP (1:10,000, provided 
by Prof. V. Baekelandt, Laboratory of Neurobiology and Gene therapy, KU Leuven, Belgium) 
or rabbit anti-red fluorescent protein (RFP, 1:5,000, 600-401-379, Tebu-Bio, France) in 
PBST0.1. Subsequently, the brain sections were rinsed, incubated for 2 h with secondary 
antibody goat anti-rabbit IgG, Alexa Fluor-488- and -568-conjugated for eGFP and mCherry 
respectively (1:200 in PBST0.1, Invitrogen, CA, USA), rinsed again, counterstained for 30 min 
with 4’,6-diamidino-2-phenylindole (DAPI, 1 µg/ml in PBS, Dako, Denmark), mounted and 
cover slipped with Mowiol (Sigma-Aldrich, MO, USA). 
For cFos and cleaved caspase-3 fluorescent IHC, markers for neuronal activity and apoptosis 
respectively, vibratome sections were mounted and dried overnight before staining. The 
next day, sections were rehydrated and rinsed in PBST0.3, followed by 20 min incubation in 
antigen retrieval citrate buffer (10 mM citrate, 0.05 % Tween-20, pH 6) heated at 95 °C.  The 
subsequent steps were rinsing, 20 min incubation in 0.3 % H2O2 in TBS, rinsing, 1 h blocking 
with PBST0.5 and 20 % normal goat serum, and overnight primary antibody incubation with 
rabbit anti-cFos, (1:7,500) or rabbit anti-caspase-3 (1:100, 3015-100, Gentaur, Belgium) in 
PBST1. Upon washing and 45 min incubation with biotin-conjugated goat anti-rabbit 
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antibody (1:300 in PBST0.3, DAKO, Denmark), TSATM FITC or Cy3 System (NEL701001KT or 
NEL704A001KT , Perkin Elmer, MA, USA) was used for amplification and visualization. Finally, 
nuclei were DAPI stained (1 µg/ml in PBS, Dako, Denmark) and sections were cover slipped 
with Mowiol (Sigma-Aldrich, MO, USA). 
Immunofluorescence was visualized with the FV1000-D laser confocal scanning microscope 
(Olympus Corporation, Japan), controlled by Fluoview 4.0 software; or the Axio Imager Z.1 
epifluorescence microscope (Zeiss, Germany) controlled by ZEN LE digital imaging. 
 
3  RESULTS  
3.1 EX VIVO OPTOGENETIC STIMULATION WITH THE SSFO CHANNEL 
Using ex vivo whole-well patch clamp recording, the ability to modulate the membrane 
potential of SSFO-expressing SC neurons was demonstrated in multiple cells per animal 
(N=2), one representative example being depicted in Figure 6.3. A lasting depolarization 
effect was measured upon blue light activation of the channels, while subsequent inhibition 
with amber light eliminated this effect, even causing hyperpolarization of the cell 
membrane.  
 
 
 
 
Figure 6.3: Ex vivo whole-cell patch clamp recording of an SSFO-expressing SC neuron. Upon stimulation with 
470 nm blue light, depolarization of the neuronal membrane potential is detected. Subsequent 590 nm amber 
light illumination causes hyperpolarization. Key: SSFO, stabilized step-function opsin; SC, superior colliculus.  
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3.2 IN VIVO OPTOGENETIC STIMULATION IN ANESTHETIZED ANIMALS  
Upon blue light stimulation in anesthetized animals (N=2 per group), a notable rise in the 
expression of activity marker cFos was observed in LC/TC- and SSFO-expressing SC as 
compared to their internal controls (Figure 6.4 A, B). Furthermore, in comparison to both 
control groups, 2/7-CaMK-SSFO-transduced SC without illumination (Figure 6.4 C) and saline-
injected SC with illumination (Figure 6.4 D), the combination optochannel expression with  
 
 
Figure 6.4: cFos expression upon unilateral optogenetic stimulation in anesthetized animals. Experimental 
and internal control SCi are depicted at left and right, respectively, in each image. A. Unilateral LC/TC 
expression in combination with light stimulation results in a clear upregulation of the activity reporter, cFos. B. 
Enhanced cFos detection was obtained in the SSFO-expressing SC upon illumination. C. SSFO expression 
without subsequent illumination does not influence cFos expression levels. D. Saline-injected controls do not 
show any change in cFos expression upon intracollicular blue light stimulation. Scale bars overview: 200 µm, 
zoom: 40 µm. Key: LC/TC, ChR2-L132C/T159C double mutant; SSFO, stabilized step-function opsin; SC, superior 
colliculus.  
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light stimulation resulted in significantly upregulated cFos levels. All vector-injected animals 
used for in vivo optogenetic stimulation in anesthetized conditions showed satisfactory 
vector expression, as was shown via fluorescent reporter signals spread throughout the 
injected SC (data not shown, similar to the results presented in Chapter 4). None of the 
animals showed any change in general morphology of the SC, as investigated via Nissl 
staining.  
3.3 ACUTE SSFO STIMULATION IN AWAKE, FREELY MOVING ANIMALS 
Acute stimulation in awake, freely moving animals (N=2 per group, Table 6.2) resulted in 
changes in cFos expression in line with the results obtained in anesthetized animals. Indeed, 
unilateral SSFO expression, induced by 2/7-CaMK-SSFO vector transduction, combined with 
blue light stimulation resulted in an explicit and unilateral cFos upregulation when compared 
to both internal and external controls (Figure 6.5). Furthermore, SSFO-expressing non-
illuminated and eGFP-expressing illuminated control brains did not show any visible change 
in cFos levels. Upon light stimulation, all SSFO-expressing cells were found to be cFos-
positive (Figure 6.5, right column, filled arrowheads), indicating simultaneous stimulation of 
all transduced cells under the applied stimulation paradigm. However, some non-SSFO-
expressing cells in the targeted region were also cFos-labeled, suggesting that modulation of 
the transduced cells elicits network stimulation (Figure 6.5, right column, unfilled 
arrowheads). Nissl staining showed normal general SC morphology and the SC neurons 
appeared healthy in each condition tested. 
Next to IEG expression as readout for enhanced SC activity, behavioral responses were also 
noticed upon acute unilateral optogenetic stimulation (N=2 per condition, Table 6.2). These 
responses were only visible in SSFO-expressing animals in combination with illumination, 
while control mice, SSFO-expressing without illumination and eGFP-expressing with blue 
light stimulation, did not change their normal behavior upon the blue light flashes. With the 
initial 2 s light pulse, in a first response phase, stimulated mice showed escape behavior 
characterized by undirected fast running. Sometimes running appeared to be oriented 
ipsilaterally to the stimulated SC, with the animals running in mainly clockwise circles upon 
stimulation in the right SC. This escape response lasted for about 30 s and subsequently 
evolved to contralaterally-oriented pursuit-like behavior, in which the animals stayed on one 
spot and circled counterclockwise as if they were following a moving object. Right before the 
second 2 s illumination pulse, at 15 min after the first pulse, the mice were still showing the 
counterclockwise pursuit-like behavior, however its intensity had diminished. With the 
second 2 s illumination pulse, no escape response was observed, and the animals 
immediately displayed the pursuit-like behavior with higher intensity again. If no second 
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light pulse was applied (N=2), the pursuit-like behavior lasted for about 30 min after the first 
2 s illumination pulse. 
 
 
Figure 6.5: Acute optogenetic stimulation in awake, freely moving animals. Expression of reporter genes, 
mCherry and eGFP, shows efficient transduction of the targeted SC in each condition (left panels). Unilateral 
SSFO expression in combination with intracollicular blue light stimulation results in a clear upregulation of IEG 
and activity reporter cFos (middle panels). All SSFO-transduced and illuminated cells express cFos (upper right 
panel, filled arrowheads), while some non-transduced cells are also cFos-labeled (unfilled arrowheads). No 
changes in cFos levels are detected in SSFO-expressing SC without illumination, nor does blue light illumination 
of eGFP-expressing SC have any effect on neuronal activity, as reported by cFos levels. In control groups, 
coincidental partial colocalization of cFos with reporter expression is observed. Scale bars left, middle: 200 µm, 
right: 10 µm. Key: 2/x, recombinant adeno-associated viral vector serotype 2/x; CaMK, Ca
2+
/calmodulin-
dependent protein kinase promoter shortened sequence of 0.4 kb; eGFP, enhanced green fluorescent protein; 
SSFO, stabilized step-function opsin; SC, superior colliculus; IEG, immediate early gene.  
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3.4 REPEATED SSFO STIMULATION IN AWAKE, FREELY MOVING ANIMALS 
The triple repeated stimulation paradigm depicted in Figure 6.2 was applied to four groups 
of mice (N=2 per group, Table 6.2), specifically determined by the vector they were injected 
with: 2/7-CaMK-SSFO, 2/7-CaMK-eGFP, 2/1-CMV-SSFO, and 2/1-CMV-eGFP. Both SSFO-
expressing groups showed a clear cFos upregulation during the last stimulation session 
(Figure 6.6), comparable to cFos patterns seen after a single light stimulation pulse in the 
acute setup, illustrated above. None of the eGFP-expressing negative control groups showed 
any effect of the procedure in se on cFos levels. Also, no effect on general morphology was 
noticed, as judged by Nissl staining. Furthermore, activated caspase-3 IHC did not label cells 
in the SC of any animal, while positive control sections, harvested from cerebellum of eight 
days old mouse pups471, were successfully stained for apoptotic caspase-3.  
Two extra animals were 2/7-CaMK-SSFO-transduced, light-stimulated twice in daylight, dark 
adapted and sacrificed without a third session of light stimulation (Table 6.2). These animals 
showed cFos levels in a range comparable to non-SSFO-expressing single or triple stimulated 
groups (data not shown). This seems to be indicative of the cFos upregulation being only 
temporary after intracollicular SSFO blue light activation. 
As the first two stimulation sessions of the chronic stimulation paradigm occurred in daylight 
(Figure 6.2, Table 6.2), behavior could be monitored. In each of these sessions, behavioral 
responses were the same as described for the acute stimulation, starting with an escape 
response followed by intense pursuit-like behavior that weakened over time for the first 
pulse, and a reinstatement of strong pursuit-like behavior upon the second light pulse. This 
behavior was similarly observed in 2/7-CaMK-SSFO- and 2/1-CMV-SSFO-transduced animals, 
but not in 2/7-CaMK-eGFP and 2/1-CMV-eGFP controls. 
Additionally, in the long-term experiment with daily stimulation of one 2 s pulse for 14 d in 
2/1-CMV-SSFO-transduced animals (N=2, Table 6.2), mice did not show desensitization and 
displayed the same behavioral response each day, i.e. subsequent escape and pursuit 
behavior.  
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Figure 6.6: Repeated optogenetic stimulation in awake, freely moving animals. Efficient unilateral SC 
transduction is demonstrated by expression of reporter genes, mCherry and eGFP (left panels). Unilateral 
2/7-CaMK-SSFO or 2/1-CMV-SSFO transduction, in combination with three repetitions of intracollicular light 
stimulation (every other day), results in a clear upregulation of the IEG activity reporter, cFos, 90 min following 
the onset of the latest stimulation session (middle panels), while no effect on cFos expression was seen in 
2/7-CaMK-eGFP- and 2/1-CMV-eGFP-transduced SCi. All SSFO-transduced and illuminated cells express cFos, 
while a number of non-transduced cells are also cFos-labeled (right panels). cFos labeling coincidently partially 
colocalizes with reporter expression in control groups. Scale bars left, middle: 200 µm, right: 10 µm. Key: 2/x, 
recombinant adeno-associated viral vector serotype 2/x; eGFP, enhanced green fluorescent protein; SSFO, 
stabilized step-function opsin; CaMK, Ca
2+
/calmodulin-dependent protein kinase promoter shortened sequence 
of 0.4 kb; CMV, cytomegalovirus promoter; SC, superior colliculus; IEG, immediate early gene.  
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4 DISCUSSION  
Together with the other members of the Optobrain Consortium, our research group was one 
of the first to introduce optogenetics in Belgium. On the longer term, we intend to use 
optogenetic modulation of the midbrain as a tool to protect RGCs from dying in murine 
glaucoma models. Since communication between the brain and the eye is highly involved in 
glaucoma pathology15,16, preserving physiological activity in visual brain centers might lead 
to preserving RGC functionality in the retina. For this purpose, a chronic stimulation setup is 
needed in which animals can be repeatedly stimulated without causing negative side effects 
from stress or overstimulation and desensitization of the cells. Therefore, we chose to use 
the SSFO channel rather than fast spiking channelrhodopsins because the modulating effect 
of SSFO is more suited for chronic setups due to the robust stability of the activated state of 
this opsin18. In addition, step-function opsins do not directly evoke action potential firing, 
but rather induce long and reversible subthreshold depolarization232,469. As such, 
optogenetic stimulation sensitizes targeted neurons for native synaptic input. Therefore, the 
elucidated firing patterns remain more natural compared to stimulation with opsins 
containing rapid kinetic properties.  
4.1 OPTOGENETIC STIMULATION ENHANCES NEURONAL ACTIVITY  
Before proceeding towards chronic optogenetic stimulation, several acute experiments were 
performed. Firstly, the response of SSFO-expressing SC neurons to optostimulation had to be 
validated. Upon in vivo optogene delivery by viral vector technology, ex vivo whole-cell patch 
clamp measurements showed subthreshold depolarization and subsequent 
hyperpolarization of transduced neurons’ membrane potential as a response to blue and 
amber light illumination, respectively. These results were in agreement with the 
literature18,232, and thus, SSFO guided light responses in SC neurons were successfully 
validated. However, it should be noted that, in our experimental setup, SC neurons did not 
survive for a long period, in contrast to cortical neurons present in the same slice. As a 
consequence of the limited survival time of the neurons of interest, responses to repeated 
light stimuli or long-term depolarization effects upon one light pulse could not be tested. 
Therefore, to use ex vivo patch clamp recording in the adult SC in future experiments, 
further optimization of the protocol is warranted. Nevertheless, vector-based delivery of 
SSFO to SC neurons was proven to render these cells light-sensitive, demonstrating 
effectiveness of the used construct and allowing us to proceed towards in vivo stimulation.  
Since IEG expression is generally accepted to be a powerful tool for identification of 
neuronal activity in the brain470,472,473, and has been applied as a readout for optogenetic 
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stimulation before18,474, cFos IHC was used in our experiments as the primary readout for 
optogenetically-induced SC activation. After transduction with the 2/7-CaMK-LC/TC and 
2/7-CaMK-SSFO vectors, optogenetic stimulation in anesthetized animals resulted in 
elevated cFos levels in the opsin-expressing and enlightened hemisphere, confirming our 
predefined views. The LC/TC channel was known to have rapid kinetic properties, eliciting 
action potentials upon illumination, based both on the literature469 and on preliminary 
findings of other members of the Optobrain Consortium (Sabanov 2012, unpublished 
results). Therefore, this channel was chosen to serve as a positive control in the first in vivo 
experiments. Comparable results were obtained using LC/TC and SSFO opsins, and thus both 
channels evidently enhanced neuronal activity in the SC upon illumination with blue light in 
anesthetized animals. With this in mind, acute light stimulation in non-anesthetized animals 
was shown to result in similar cFos upregulation in the 2/7-CaMK-SSFO-transduced SC, 
providing evidence for the effectiveness of the developed setup for stimulation in awake, 
freely moving animals. Furthermore, cFos expression was detected in all SSFO-expressing 
cells, suggesting simultaneous optogenetic stimulation of all transduced cells. However, 
since the time scale of cFos expression exceeded the time scale of optogenetic stimulation, 
the observation that cFos labeling was detected in all SSFO-expressing cells might also be the 
result of subsequent, rather than simultaneous, activity of the labeled neurons, specifically 
within the 90 min window between optic stimulation and sacrifice of the animals. Elevation 
of cFos expression is a transient, albeit rather slow, event associated with novel stimulation. 
IEG protein levels tend to gradually increase immediately following stimulus and reach a 
peak between 1 and 3 h post-stimulus475. cFos upregulation upon optostimulation was 
reported to be restricted to opsin-expressing cells in hippocampal slice cultures474. However, 
our investigation indicates cFos expression to be present in a proportion of non-transduced 
cells, suggesting network activation as a result of manipulating key components of the 
network. Notably, this observation was made on cFos stained sections, looking at cFos IHC 
labeling and mCherry signal directly without IHC enhancement of the fluorescent reporter 
signal, because cFos and RFP IHC could not be combined in a double staining due to the 
rabbit origin of both antibodies. As such, we cannot exclude that all cFos-labeled cells also 
expressed SSFO. On the other hand, cFos labeling in non-SSFO-expressing cells might also be 
the product of basal activity rather than optogenetic network activation, as in negative 
control conditions a minor amount of cells were cFos-labeled as well. However, in our 
opinion, synaptic transmission of enhanced activity leading to network activation upon 
optogenetic stimulation is the most plausible explanation for non-transduced cells 
expressing rather high levels of cFos, as observed in the current results. Future experiments 
based on electrophysiology or Ca2+ imaging performed ex vivo or in vivo might help to dispel 
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any doubts and provide more details about the exact responses of both transduced and non-
transduced cells upon light stimulation.  
In the last of three repeated stimulation sessions, enhanced IEG expression was detected in 
the 2/7-CaMK-SSFO transduced SC, resembling the pattern induced by a single stimulation 
session. This observation suggests that the neurons react in a similar way in each stimulation 
session, meaning there is no long-term adaptation, desensitization, and degeneration 
occurring in the illuminated SC. However, as mentioned previously, caution is required when 
interpreting IEG expression levels, as the IEG expression time scale greatly surpasses action 
potential firing time scales. Yet, two stimulation sessions followed by dark adaptation and 
sacrifice without an extra illumination session did not lead to detection of enhanced IEG 
levels. This extra control condition indicates that the detected cFos levels upon the third 
stimulation session in the chronic setup are related to the last stimulation, rather than being 
the artifact of overstimulation in the previous sessions. Furthermore, unique behavioral 
effects, discussed in detail in the following section, were also seen in each of the subsequent 
stimulation sessions, suggesting that cells remain responsive to stimuli. Still, care must be 
taken when overexpressing membrane proteins, since this manipulation might lead to 
toxicity and loss of membrane integrity476. Both cFos upregulation and behavioral responses 
may continue to be detectable, even when part of the neuronal population in the SC 
network has lost its function. Although membrane integrity, cell health, and electrical 
properties were described to remain normal in neurons expressing wild type ChR2 and 
exposed to light stimulation227, the effect of repeated stimulation with SSFO channels, 
causing effects on the cells over a longer time period, has not been described in the 
literature before. Therefore, we performed activated caspase-3 IHC to study potential 
apoptotic effects upon repeated stimulation. Activated caspase-3 staining did not show a 
greater propensity towards apoptosis upon repeated optic stimulation in the triple 
stimulation experiments. Although activated caspase-3 IHC only marks cells in a specific 
phase of the apoptotic cascade, therefore conceivably not exposing all apoptotic cells, also 
morphological examination of the SC confirmed the absence of any clear degenerative effect 
in any of the experimental setups.  
All optogenetic experiments discussed so far were performed using 2/7-CaMK vector 
constructs, originally designed for use in the visual cortex, which were available at the time. 
However, since the properties of the CaMK promoter in the SC are not fully understood, it 
seemed preferable to utilize a more general CMV promoter. Furthermore, the rAAV2/7 
serotype was exchanged for rAAV2/1, since rAAV2/1 typically induced good transduction of 
the SC without retrograde transduction of the retina, as described in detail in Chapter 4. This 
feature is important because in future experiments, it is our intention to study the effects of 
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local manipulation of the SC onto retinal cells, without directly manipulating the retina. As 
soon as the viral vectors were produced, the triple stimulation paradigm, with cFos and 
activated caspase-3 as readout, was repeated using the new 2/1-CMV-SSFO and 
2/1-CMV-eGFP vectors. The obtained results qualitatively matched the findings with the 
2/7-CaMK-SSFO and 2/7-CaMK-eGFP vectors: cFos was upregulated in the entire SSFO-
transduced SC upon the last of three every other day stimulation session, and no signs of 
tissue or cell degeneration were detected through activated caspase-3 IHC. Furthermore, 
when daily stimulated in daylight for 14 d, 2/1-CMV-SSFO-transduced mice displayed 
behavioral responses (discussed below) every day, without any sign of desensitization. In 
conclusion, the 2/1-CMV-SSFO construct can be applied to enhance broad-spectrum 
neuronal activity in the SC in a chronic setup.  
4.2 BEHAVIORAL EFFECTS UPON UNILATERAL OPTOGENETIC SC STIMULATION  
Besides the determination of IEG expression, indicative of enhanced neuronal activity, 
behavioral responses were also noticed during unilateral optogenetic SC stimulation in freely 
moving animals. Upon the first of two light flashes, SSFO-expressing animals showed an 
overt escape response, followed by pursuit-like behavior. Both responses were previously 
described being guided by SC activity477. The second light flash, 15 min after the first, did not 
evoke the escape response, however, pursuit-like behavior seemed to be reinitiated. The 
dual response was identical in subsequent stimulation sessions with 24 to 48 h in-between. 
One single light pulse brought about a consecutive sequence of escape and pursuit-like 
behaviors, with the frequency of the pursuit-like circling decreasing gradually over time, 
remaining noticeable up to 30 min post-stimulus. Control mice, being SSFO-transduced 
without illumination or eGFP-transduced with illumination, did not show any behavioral 
response, excluding direct or side effects of the procedure. Thus, the observed behavior 
could certainly be attributed to unilateral optogenetic stimulation of the right SC. No 
differences were observed between the 2/7-CaMK-SSFO versus 2/1-CMV-SSFO and 
2/7-CaMK-eGFP versus 2/1-CMV-eGFP conditions. Escape and pursuit-like behavior have 
been shown to be driven by separate collicular pathways477. The escape response is 
governed by the ipsilateral descending pathway, making the animal run from a visual 
stimulus. In our setup, the stimulated animals were running mainly undirected, or in some 
cases, more specifically, in a clockwise direction. Because of the mapping of the visual field 
in the SC, ipsilaterally directed movements, being equal to clockwise running in our setup, 
correspond to movements away from a stimulus, like a predator, for instance477. The 
pursuit-like response, on the other hand, resembles the behavior that a mouse exhibits 
when following a moving stimulus, for example a prey, and is controlled by the contralateral 
descending pathway in the SC 477. This behavior is similar to what is seen in an optomotor 
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task285, a behavioral task aimed at testing SC functioning, which uses moving stimuli on a 
screen to yield head-movements of the mouse. In our setup, during the pursuit-like 
response, the animal is spinning counterclockwise (left-turn) upon stimulation of the right 
SC, as if it is following a prey moving from right to left through the visual field. Similarly, 
optogenetic manipulation of SC activity predictably affected the direction of the orienting 
movements towards odor stimuli. Unilateral stimulation of SC neurons biased movements 
contraversely, while inhibition resulted in an ipsiversive bias267.  
Under natural conditions, the decision between one of the two responses to a new visual 
stimulus is believed to be guided by three main factors477. First, the position of the new 
stimulus in the visual field is crucial, since SC neurons driving one pathway or the other are 
unequally distributed in the retinotopically organized SC, which is in line with the fact that 
mouse predators mainly approach from above, while preys are especially located in the 
lower part of the visual field. Second, the way of movement of the stimulus is also very 
important. Rapidly approaching stimuli, also called looming stimuli, trigger defensive 
responses, such as the escape response, while fluttering moving stimuli, like insects, evoke 
pursuit behavior. Third, since the first two explanations cannot explain every situation, other 
factors must affect behavior. One possibility is that contextual information becomes 
integrated. This is plausible, since the SC not only receives extensive input from sensory 
systems, but also from forebrain structures with functions in context interpretation477. In our 
setup, optogenetic stimulation of the SC triggered specific behavioral responses, 
demonstrating that our manipulation activated neuronal networks that naturally become 
activated by specific visual stimuli.  
Whether local electrical stimulation of the superficial layers of the SC (sSC), including the 
stratum zonale (SZ), the stratum griseum superficiale (SGS), and the stratum opticum 
(SO)35,36, evokes escape or pursuit-like behavior has been described to depend on the 
location of stimulation477. Indeed, Dean et al.477 reported that rostromedial and caudolateral 
regions are respectively linked to escape and pursuit-like behavior. Based on comparison of 
the collicular maps drawn by Dean et al.477  with our injection and optic fiber implantation 
coordinates, the assumption can be made that in our setup, the optic fiber was implanted in 
the sSC region presumably linked to the escape response. As such, it may be presumed that 
the light beam directly illuminated most of the rostromedial located SSFO-expressing 
neurons in the sSC linked to escape behavior. However, as SSFO channels are extremely 
light-sensitive, not only direct illumination, but also scattered light could be strong enough 
to activate the channels. Intensities as low as 8 µW/mm² have been described to generate 
photocurrents in SSFO-expressing neurons18, as compared to a minimum of 8-12 mW/mm² 
of light needed to elicit activation of the traditional ChR2227. Therefore, in our setup, 
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transduced cells located further away from a light source of 70 mW/mm² might also become 
activated, and these cells are possibly responsible for the pursuit-like behavior.  
Furthermore, besides the link between the topographic map in the sSC and behavioral 
responses, also projecting neurons in the intermediate and deep layers are believed to 
specifically contribute to one pathway or the other. Most cells projecting into the crossed 
pathway, guiding pursuit-like behaviors, are located between the fiber bundles of the 
stratum album intermediale (SAI), while cells projecting in the uncrossed pathway, guiding 
escape-like behavior, are mainly concentrated in the upper laying stratum griseum 
intermediale (SGI), as well as in the deep layers477-479. Since vector transduction was not 
limited to the sSC and SSFO channels are very light-sensitive, our blue light stimulation with 
fiber implantation in the sSC might also have directly activated the output pathways via 
optogenetic stimulation of intermediate and deep neurons, with escape-linked neurons 
being the closest to the light source. Thus, the behavioral responses observed in the current 
study are believed to be a product of direct, as well as indirect, activation of crossed and 
uncrossed SC descending pathways.  
At this point, one may ask why then did the first of the two subsequent light flashes induce 
an escape response while the second did not? As it is understood that the kinetic properties 
of the SSFO channel are much slower than of wild type ChR2, the lifetime of the open state 
far exceeds the illumination time18. This means that 15 min after the first stimulus, a portion 
of the activated channels might still be in the open state, while others may have evolved to a 
desensitized state18,474. All of these channels will not respond to a second light pulse. 
Intuitively, cells that are located further away from the light source were stimulated with 
lower light intensity. Therefore, it can be assumed that in these neurons further away, only a 
fraction of the SSFO channels was activated, leaving a larger pool of channels available for 
the second stimulation pulse. This might also explain the re-enhancement of the pursuit-like 
behavior without the preceding escape response upon the second light pulse. Besides 
activation of more channels in the same cells, also activation of cells that were not activated 
initially could have taken place, as it has been reported that repeated stimulation enhances 
the number of responding cells to a certain degree474. Notably, a light pulse given at 24 h or 
48 h after the first stimulation session, again induced both response phases, being in line 
with the transition of all channels to the available state474. Future experiments using smaller 
injection volumes and/or lower light power might further elucidate both behavioral features 
of optogenetic SC stimulation observed in our experiments. 
After one single illumination pulse of 2 s, the pursuit-like behavior lasted for about 30 min. 
Similar pursuit-like behaviors have been observed by Prof. T. Isa and colleagues (National 
Institute for Physiological Sciences, Japan) after unilateral stimulation of the SC with wild 
174   _______________________________________________________________   CHAPTER 6 
 
type ChR2 in mice. However, this behavior stopped as soon as the laser stopped flashing 
blue light pulses (Isa 2014, personal communication). Thus, the prolonged response in our 
setup demonstrated the more chronic features of the SSFO channel as compared to the wild 
type ChR2 opsin. Accordingly, in a social behavioral test where mice received a single 2 s 
pulse of blue light, followed by removal of the fibre optic 1 min before introduction into the 
behavioral chamber, SSFO activation in prefrontal cortical excitatory neurons led to 
profound impairment in social function18. In these experiments, SSFO stimulation was shown 
to result in prolonged behavioral effects, remaining detectable even after light off. However, 
this effect was attenuated over time, just as was the case in our own studies.  
 
5 CONCLUSION 
In conclusion, a setup for chronic optogenetic stimulation in awake, freely moving animals 
was successfully developed and validated, now ready to use in future experiments, as 
described in more detail in the next chapter (Chapter 7). 
 
  
 
 
 
 
 
CHAPTER 7 
GENERAL CONCLUSIONS AND FUTURE 
PERSPECTIVES  
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1 SOCIAL RELEVANCE OF GLAUCOMA RESEARCH   
Glaucoma patients experience slow, progressive loss of vision, significantly affecting the 
quality of their life. Worldwide, 3-4 % of people over 40 years of age suffer from this 
disease480 and thus, precautionary measures and therapeutic treatments of glaucoma are 
important challenges for public health481. As pathological elevation of the intraocular 
pressure (IOP) is a major risk factor for development and progression of glaucoma2, the main 
purpose of current therapies, including topical application of hypotensives and ocular 
surgeries, is to lower the IOP4,481. Unfortunately, a number of patients continue to lose vision 
despite successful pressure control3,4, indicating the necessity of introducing new 
treatments, aiming at sustained protection of the retinal ganglion cells (RGCs), that are dying 
in glaucoma481. The development of such neuroprotective therapies largely depends on the 
knowledge of the pathophysiological mechanisms underlying glaucomatous 
neurodegeneration. The previous chapters summarized, our investigations intended to 
contribute to such increased insights and to bring up novel strategies towards RGC 
protection.  
 
2 MOUSE MODELS TO STUDY GLAUCOMA  
In order to unravel the mechanism of glaucomatous RGC degeneration and to test new 
treatment strategies, animal models of glaucoma are indispensable. Therefore, the first part 
of this PhD was dedicated to the introduction, optimization, and characterization of two 
experimental mouse models of glaucoma: the IOP-related ocular hypertension (OHT) model 
and the IOP-independent optic nerve crush (ONC) model, each highlighting different aspects 
of the disease.  
As a first important observation, differences were noticed in basic characteristics of the 
visual system of three mouse strains that are all commonly used in glaucoma research, 
namely C57Bl/6, C57Bl/6-Tyrc, and CD-1 mice13,74,77-79,81,83,156,188,283. Of particular importance 
in relation to glaucoma, C57Bl/6-Tyrc and CD-1 mice exhibited higher and lower eye 
pressures compared to C57Bl/6 mice, respectively. In addition, RGC density was higher in 
CD-1 mice versus both C57Bl/6 strains. These observations are all in line with the literature, 
generally reporting lower IOP values77,95,274,278,283,291-293 and higher RGC numbers12,20,54 for 
CD-1 mice compared to C57Bl/6 mice. The elevated IOP in tyrosinase-deficient C57Bl/6 mice 
has been documented previously as well276. Dissimilarities in IOP between mouse strains are 
attributed largely to variation in resistance of the aqueous humor outflow pathway through 
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the trabecular meshwork273. Furthermore, a Tyrc null mutation in C57Bl/6 mice has been 
linked to incorrect anterior chamber angle development, also affecting the aqueous humor 
outflow299. Concerning the variation in RGC numbers observed between different types of 
mice, several genetic factors have been determined as important underlying 
determinants300.  
In addition, tyrosinase deficiency in both albino strains was associated with reduced 
ipsilateral retinal projections towards the dLGN and SC, along with diminished eye-specific 
territorial segregation within these areas. Our results confirm earlier reports describing less 
decussation of RGC axons at the optic chiasm associated with albinism in several animal 
species53,279,280,302-315 including humans301,316-318. Although the underlying mechanism of this 
albino-related phenotype is not completely understood, a delay in the neurogenesis of RGCs 
located in the ventrotemporal crescent (VTC) in the retina of albino mice has been suggested 
to underly the disrupted regulation of ipsilateral and contralateral fate of VTC originating 
RGCs307. Furthermore, for the first time, a remarkable patch of densely organized RGC axon 
terminals originating from the ipsilateral retina, was observed in the stratum zonale (SZ) of 
the SC in C57Bl/6 and C57Bl/6-Tyrc, but not in CD-1 mice. These results underscore the need 
for careful examination of the basic characteristics related to the research question before 
selecting a mouse strain.  
Besides differences in the aforementioned basic characteristics of the visual system, the 
three strains under study also showed differential RGC vulnerability to OHT, induced by 
laser photocoagulation (LP) of the perilimbal and episcleral vessels13, with CD-1 mice 
showing the most degeneration. In contrast, no significant discrepancies between the strains 
were detected to the extent of RGC death induced by traditional ONC293. Since strain-specific 
differences in sclera biomechanics are proposed to promote or prevent the transmission of 
IOP-related mechanical pressure from the sclera to the RGC axons, these differences 
might - at least in part - account for strain-specific variation in the severity of OHT-induced 
RGC death35,277. In contrast to OHT, which rather indirectly induces RGC-death, ONC acts 
directly on the RGC axons334. Therefore, non-RGC intrinsic differences between strains, such 
as the sclera biomechanics mentioned above35,277, are less probable to contribute to ONC-
induced RGC degeneration334. This might explain why the genetic background-dependent 
difference in RGC vulnerability was more pronounced in the OHT model than in the ONC 
model. In the OHT model, the interindividual variability was demonstrated to be much 
smaller within the CD-1 strain compared to the C57Bl/6 mice. Therefore, within this PhD 
project, CD-1 mice were the strain of choice for all future experiments using this 
hypertension model. The OHT model in CD-1 mice was thus used to examine morphological 
and functional effects of OHT on the central visual pathway, to study neurotrophin 
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expression patterns induced by OHT, and to test a novel approach to protect RGCs from 
OHT-induced dying. However, because of the interest of the research group in studying 
glaucoma in transgenic mouse lines with a C57Bl/6 genetic background, together with the 
fact that CD-1 mice are visually impaired285,286 and are therefore not suitable for research 
including visually guided behavioral tasks, it might still be interesting in the future to use the 
OHT model in C57Bl/6 mice. Furthermore, C57Bl/6 and C57Bl/6-Tyrc mice showed slower 
progression in RGC degeneration upon OHT induction, which might be considered an 
advantage with respect to mimicking the chronic slow neurodegeneration observed in 
glaucoma patients. Although not further used within this PhD project, the laser parameters 
for optimal OHT induction in C57Bl/6 mice are optimized by now, and thus the model can be 
performed in these mice in future projects. Since the ONC model was equally effective in the 
C57Bl/6, C57Bl/6-Tyrc, and CD-1 mice, further research using the ONC model was always 
performed in C57Bl/6 animals. 
As the traditional ONC model, used to compare the susceptibility of different mouse strains 
to ONC, was quite invasive and induced rather fast RGC degeneration, alternative methods 
to crush the optic nerve were tested. Successful optimization resulted in a less invasive and 
less acute model of axonal injury leading to RGC soma loss. Within this thesis, this novel mild 
ONC model, performed with a self-closing cross-action forceps to assure balanced pressure 
control, was implemented to study the effect of optic nerve injury on neurotrophin levels 
and the possibility of counteracting ONC-induced RGC degeneration via neurotrophin 
application via different strategies.  
Of note, besides the cross-action ONC that was selected as the model of choice for our 
purposes, also the clamp ONC, in which the optic nerve was crushed with aneurysm clamps, 
yielded promising results. The degenerative effect at 7 days post-crush was less severe 
compared to the cross-action ONC. However, this clamp ONC model was not fully optimized 
within this thesis, mainly because the commercially available aneurysm clamps were not 
optimal in size for use on the small mouse optic nerve. Thus, it seems interesting to order 
custom-made clamps that better fit the anatomical dimensions of the mouse optic nerve 
and give it a second try. This might lead to a new model of slow but progressive and 
well-controlled degeneration in the future. 
Temporal RGC degeneration patterns were characterized for the two models of choice at 
present: the LP-induced OHT model in CD-1 mice and the optimized mild ONC model in 
C57Bl/6 mice. LP-induced OHT produced progressive RGC degeneration between 5 and 14 
days post-injury (dpi) without further progressing afterwards. Conversely to what was 
expected, the optimized mild ONC model appeared less acute, showing decreasing RGC 
densities with increasing post-survival intervals until 21 dpi, the latest time point included in 
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the study. Differences in the way RGCs are visualized, e.g. using Nissl staining334,336, IHC for a 
diversity of RGC markers91,344-347, reporter lines348-350, or retrograde tracing35, along with 
different imaging and quantification methods, make it hard to compare these results directly 
to previous reports. Importantly, not only the temporal degeneration profile differed 
between the OHT and ONC model. In addition, OHT resulted in a pie-shaped sectorial 
pattern of RGC death on top of diffusely distributed RGC loss throughout the entire retinal 
surface, while RGC degeneration induced by ONC occurred diffusely throughout the whole 
retina, without any evidence of more severely affected sectors, all as described before73,293. 
The outlined degeneration profiles have contributed to the design of all following 
experiments within this work, and also for other projects performed within the research 
group. In the future, similarly, degeneration profiles will be characterized for the OHT model 
in C57Bl/6 mice, for reasons discussed above, and in an ONC model using small-size 
aneurysm clamps. 
In conclusion, since animal models of glaucoma are crucial in the search for in depth 
knowledge of glaucoma pathogenesis, our results form an important basis for the glaucoma 
research field.  
 
3 GLAUCOMA AS A DISEASE OF THE ENTIRE VISUAL SYSTEM  
Glaucoma has long been considered merely an eye disease, however it is increasingly 
becoming recognized that the entire visual system is affected. Indeed, anatomical and 
functional examinations in human patients and animal models revealed degenerative effects 
in several visual brain centers7,96-101, characterizing glaucoma as a disease beyond the eye. In 
order to gain improved insights into the effect of OHT on the adult visual system, RGC 
degeneration patterns observed in the mouse OHT model were linked to morphological 
changes in the superficial layers of the superior colliculus (sSC), the main RGC projection 
region in mice, and functional changes in the visual cortex. Early after OHT induction, focal 
reduction in RGC synapse density was observed in the sSC contralateral towards the LP eye, 
and could be retinotopically linked to the sectorial RGC degeneration patterns in the retina. 
Furthermore, OHT resulted in focal hypoactivity in the primary visual cortex (V1) that 
extended to the extrastriate areas V2 lateral (V2L) and medial (V2M). This hypoactivity 
completely recovered over time, which was attributed to cortical plasticity374,393,396,397. The 
reactivation was most likely visually driven, either through the control eye or the remaining 
RGCs in the glaucomatous eye. In comparison, previous studies also showed hypoactivity 
followed by recovery in V1, V2L, and V2M after monocular enucleation (ME) in adult mice374. 
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In contrast to the reactivation of the visual cortex, there was no recovery of RGC synapse 
density in the sSC, which is in agreement with the theory that the critical period for 
reorganization of the retinofugal pathway is restricted to the first three postnatal weeks in 
mammals398,399. Nevertheless, sSC neurons appeared healthy upon histological inspection. 
Whereas the effect of OHT on RGC synapse density in the sSC and on neuronal activity in the 
visual cortex was only observed in the hemisphere contralateral to the LP eye, astroglial 
reactivity was seen in both sSCi. Although the observed glial response was transient in both 
sSCi, it was more pronounced and more prolonged in the contralateral compared to the 
ipsilateral hemisphere. These results largely confirmed previous reports on subcortical 
effects in other glaucoma models107,118,119,152,156. Moreover, our study provided new 
discoveries on the effect of OHT on visual cortex functioning. These findings highlight the 
importance of looking beyond the eye and including the whole visual system in glaucoma 
research. 
 
4 A ROLE FOR NEUROTROPHINS IN GLAUCOMA PATHOGENESIS  
Neurotrophins play an important role in RGC development, but also in the maintenance of 
mature RGCs69,153. Ganglion cells transport these factors along their axons in both directions, 
from the eye to the brain and vice versa69,128,141. The neurotrophin deprivation hypothesis, 
which has been very influential in the design of this PhD project, focuses on the retrograde 
transport, in which neurotrophins are produced in the RGC projection areas and bind to their 
receptors on RGC terminals; subsequently, receptor-neurotrophin complexes are 
retrogradely transported via RGC axons to the cell bodies69. During one of the early stages of 
glaucoma pathogenesis, RGC axonal transport is blocked67,68, thereby reducing delivery of 
neurotrophic support to the RGC soma, which in turn is presumed to activate apoptotic 
pathways64,65,69. Among the neurotrophins linked to glaucoma, such as nerve growth factor 
(NGF)193 and neurotrophin-4 (NT-4)458, brain-derived neurotrophic factor (BDNF) is best 
known for its potent neuroprotective effect10,21,22,163,181,188,194,451. Therefore, this project 
focused on BDNF and its main receptor, tropomyosin-related kinase B (TrkB), in defining the 
role of neurotrophic signaling between the eye and the brain in glaucoma pathology. BDNF, 
TrkB-full length (TrkB-FL), and TrkB-truncated form 1 (TrkB-T1) levels in the retina and SC 
were shown to be differentially modulated in the ONC and OHT models.  
ONC led to a rise in BDNF protein concentrations in the retina, accompanied by a rise in 
TrkB-FL and, even more pronounced, in TrkB-T1 levels. Rapid upregulation of retinal BDNF 
may act as an endogenous protection factor for RGCs in response to the abrupt block of 
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retrograde delivery of BDNF as a consequence of crushing the optic nerve. Unfortunately, as 
demonstrated by the RGC degeneration patterns discussed above, ONC still results in 
progressive RGC death and thus this pronounced BDNF upregulation alone proves not 
enough to protect RGCs from dying. Possibly, the observed shift in the TrkB isoform ratio 
towards TrkB-T1 might partially be responsible for this, since TrkB-T1 is thought to 
counteract the pro-survival signaling initiated by binding of BDNF to TrkB-FL459. Furthermore, 
TrkB-T1 has been connected to the regulation of extracellular BDNF concentrations by glial 
cells459. In the SC, BDNF levels immediately increased after ONC, and thereafter slowly 
attenuated towards baseline levels, while both TrkB-FL and TrkB-T1 levels followed an 
increase-decrease pattern. Upregulation of BDNF and TrkB in the main retinal target area 
may be an attempt to prevent postsynaptic degeneration in relation to the abrupt drop in 
RGC-derived input induced by ONC.  
In contrast to ONC, retinal BDNF and TrkB levels were not affected in the OHT model within 
the experimental timeline; neither did OHT have any effect on collicular BDNF 
concentrations. However, TrkB-FL and TrkB-T1 levels slightly diminished in the contralateral 
SC of mice subjected to unilateral LP. This decline might be associated with diminished 
anterograde TrkB delivery from the RGC soma towards the axon terminals in the SC. 
Alternatively, retinotopic degeneration of the RGC axon terminals in the sSC after OHT 
induction, as mentioned in the previous paragraph, might well lead to reduced TrkB levels in 
the SC. 
Of note, upon ONC and OHT, the BDNF levels described in this manuscript were determined 
using ELISA, a method that did not allow to distinguish between pro- and mature forms of 
BDNF. However, their separate identification could be very important, as the two forms have 
unique signaling capacities. The neurotrophic effects of BDNF are assumed to be primarily 
mediated through binding of mature BDNF to the full length form of TrkB163, while on the 
contrary, pro-BDNF binding to the p75NTR receptor is believed to activate apoptotic 
pathways128. Therefore, it would be worthwhile to repeat the experiments using western 
blotting, in which pro- and mature forms of BDNF can be separated based on size. While we 
had the intention to perform these experiments, further optimization of western blotting for 
this neurotrophin proved to be required. Furthermore, TrkB-FL/TrkB-T1 levels characterized 
here yielded interesting results, yet, in the future, the determination of precise levels of 
phosphorylated versus non-phosphorylated TrkB-FL163, would provide more details on the 
activation of intracellular, presumably pro-survival, pathways. Moreover, addition of p75NTR 
detection would also lift the veil concerning the signaling pathways that are involved. 
Combining protein detection methods with mRNA measurements, through in situ 
hybridization or real-time PCR, may permit discrimination between the changes in 
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expression levels compared to translocation and activation of the proteins involved. In 
addition, including later time points might also be fruitful in an effort to understand the 
long-term chronic effects, which may have been missed in the current study because of the 
experimental timing. 
Overall, the work completed within this PhD project produced valuable information on the 
effect of ONC and OHT on total BDNF and TrkB-FL/TrkB-T1 levels in the retina and SC. With 
this in mind, though, in order to further characterize the role of neurotrophin signaling in 
glaucoma pathology, a continued in depth investigation is warranted.  
 
5 A NOVEL APPROACH TOWARDS RGC PROTECTION  
Based on the neurotrophin deprivation hypothesis10, and because retrograde signaling from 
the SC has recently been shown essential for proper RGC functioning16, it was theorized that 
delaying or preventing glaucomatous RGC death could be achieved through experimental 
manipulation of their projection regions. This novel approach towards RGC protection was 
addressed via two methods: 1) by increasing target-derived trophic support via upregulation 
of BDNF in the SC; 2) by enhancing neuronal activity through optogenetic stimulation of the 
collicular network, both of which were assumed to result in improved RGC survival after 
experimental induction of glaucoma.  
The concept of improved target-derived trophic support was based on two recent reports 
from Weber et al.194,204 demonstrating that combining intravitreal (ivt) injection with chronic 
delivery of BDNF into the visual target areas of the brain resulted in prolonged and enhanced 
RGC survival in cats subjected to ONC194,204. In keeping with this, experiments were designed 
to provide a proof-of-concept for the neurotrophin deprivation hypothesis in our mouse 
models of experimentally-induced glaucoma. Although the previously reported temporary 
neuroprotective effect of ivt-delivered recombinant BDNF5 was confirmed in the optimized 
mouse ONC model, regrettably, viral vector-induced overexpression of BDNF in the SC did 
not elicit enhanced RGC survival in either of the two models. This unfortunate result was 
mainly attributed to decreased neurotrophin responsiveness due to downregulation of TrkB-
FL levels as a response to vector-mediated BDNF overexpression. Furthermore, based on 
unpublished results, showing that treatment of the brain alone was inadequate to obtain 
neuroprotection in ONC cats, Weber et al.6,21 suggested that both the ivt and brain 
treatments significantly contributed to the enhanced survival achieved in their dual 
treatment paradigm. Hence, in future experiments, it would be appealing to test a triple 
treatment paradigm of ivt recombinant BDNF delivery, viral vector-based SC treatment, and 
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experimental enhancement of receptor availability to maintain the responsiveness. 
Furthermore, in the RGC target regions in the brain, both neurons and glial cells are thought 
to play a role in BDNF production and activation118,119,152. Viral vector-mediated 
overexpression of BDNF in our experiments was restricted to collicular neurons, mainly 
because of viral vector tropism. It might be meaningful to consider adaptation of the vector 
system in order to provide BDNF delivery from within glial cells to potentially provide a more 
natural way of signaling. Besides, within this thesis, we chose to use a viral vector system 
with no retrograde transduction of retinal cells upon intracollicular delivery, to allow 
straightforward interpretation of the results. However, the simultaneous transduction of 
retinal and collicular cells with the BDNF-expressing vector, might increase the chance to 
achieve long-term neuroprotection. In addition, further improvement of the glaucoma 
models, within the context of making them more slow and chronic as discussed above, may 
also be of relevance to provide a larger time window for possible neuroprotective agents to 
do their job. Indeed, in their report, Weber et al.204 stressed the importance of using a mild 
form of ONC, in which part of the RGCs retain functional connections to their target areas 
early after crush, being in direct contrast to complete crush or transection, both abruptly 
disconnecting all RGC somas from their target areas.  
Besides viral vector-based BDNF upregulation, a second strategy aiming for neuroprotection 
via RGC target treatment was assessed. As increased neuronal activity has been associated 
with elevated production of neurotrophic factors23-25, optogenetic enhancement of 
neuronal activity in the SC was proposed to be of use as a more general strategy to 
chronically boost production of endogenous neurotrophic factors23. For this purpose, a 
chronic stimulation setup was needed, and therefore, the stabilized step-function opsin 
(SSFO) was the light-controllable channel of choice, based on its slow kinetic properties18. 
For the first time, the applicability of SSFO in stimulating the mouse SC was tested. 
Optogenetic stimulation of SSFO-expressing SC neurons was first validated ex vivo through 
patch clamp measurements in collicular slices from mice in which SSFO expression had been 
induced through viral vector technology. Next, enhanced neuronal activity was successfully 
generated in vivo in the SC of anesthetized animals via optogenetic stimulation, verified 
through immediate early gene (IEG) upregulation. Subsequently, the setup was expanded to 
optogenetic stimulation in awake, freely moving animals. Using this setup, optogenetic 
stimulation was shown feasible in repeated stimulation paradigms without causing 
detrimental side effects, as no signs of tissue or cell degeneration were detected upon 
consecutive stimulation sessions. The new setup also allowed for examination of behavioral 
responses induced by single or repeated unilateral optogenetic SC activation. Two sequential 
responses were exhibited: a short overt escape response followed by prolonged pursuit-like 
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behavior. As both of these reflex behaviors have previously been described to be guided by 
SC activity477, this observation underscores the effectiveness of activation of the SC through 
the developed experimental setup for optogenetic stimulation. Moreover, our experiments 
demonstrated the more chronic features of the SSFO channel as compared to the wild type 
channelrhodopsin-2 (ChR2) opsin. Indeed, the pursuit-like response lasted for about 30 min 
after short illumination of the SSFO-expressing SC. Conversely, similar experiments 
performed by Prof. T. Isa (National Institute for Physiological Sciences, Japan) demonstrated 
that this pursuit-like behavior could be elicited by the use of wild type ChR2, although it 
stopped as soon as the collicular illumination ceased (Isa 2014, unpublished results).  
In the near future, the developed optogenetic setup will be implemented in glaucoma-
related research, as was premised in the general scope of this project. Communication 
between the SC and the retina has been proven to be essential for normal RGCs 
functionality16. Upon pharmacologic blockade of axonal transport, reversible changes in 
pattern electroretinogram (PERG) recordings have been reported, demonstrating changes in 
RGC functioning. In future experiments within our research group, optogenetic SC 
stimulation will be combined with PERG recordings to visualize the effect of target 
stimulation at the level of the retina. Furthermore, as mentioned before, we hypothesize 
that an increased activity in the visual brain centres might confer long-term neuroprotection 
in glaucoma, which will be evaluated by studying the impact of repeated photostimulation in 
the main retinal target region on RGC survival in mice subjected to OHT or other more 
chronic glaucoma models. Finally, to identify the underlying mechanisms and signaling 
pathways involved in long distance retrograde neuroprotection to damaged RGCs, state-of-
the-art proteomics is envisioned to identify the molecules and signaling pathways involved. 
Even though the neuroprotective effect of optogenetic stimulation in the SC might not be 
achieved, proteomics studies on optogenetically-stimulated tissue would be of great interest 
to all groups implementing the optogenetic toolbox into their research. These results will 
therefore contribute to the optogenetic research field, in general. 
 
6 FUTURE PERSPECTIVES FOR THE OPTOGENETIC TOOLSET  
Together with the other members of the Optobrain Consortium, our research group was one 
of the first to introduce optogenetics in Belgium. Depending on the research questions being 
asked, some modifications to the setup, developed and validated within this PhD project, 
might be needed. In this thesis, SSFO expression was induced through viral vector 
technology, with the expression being regulated by the cytomegalovirus (CMV) promoter. 
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Subsequent light stimulation resulted in an enhanced neuronal activity throughout the SC, 
but it should be taken into account that CMV is a general promoter. Nonspecific activation of 
all neurons presumably drives neuronal responses outside normal physiological activity 
patterns, which may cause unnatural plasticity in the circuit482. Indeed, one of the most 
favorable features of optogenetic technology is precisely its specificity. Photostimulation of 
specific cell populations is possible by using optovectors with selective promoters, such as 
the GAD67 promoter to target γ-aminobutyric acid (GABA)-ergic neurons, or the recently 
developed gfaABC1D promoter, a modified glial fibrillary acidic protein (GFAP) promoter, to 
drive opsin expression in astrocytes483. Besides promoters, Cre-dependent ‘FlexSwitch’ viral 
vectors can be used in combination with cell-specific Cre-expressing mouse lines. 
Furthermore, by coupling Cre to the anterograde and transsynaptic tracer wheat germ 
agglutinin (WGA), opsin expression can be achieved in monosynaptically connected cells 
within a region transduced with a ‘FlexSwitch’ vector254,457. These alternative vector systems 
are currently being tested by different members of the Optobrain Consortium, including our 
own research group, and will probably be implemented in the near future.  
Besides the slow-activating SSFO channel validated here, inhibiting or fast-spiking channels 
can also be examined using the protocols for overexpression and stimulation in awake 
animals optimized as described here, though with some adaptations for illumination 
wavelengths and frequencies. In the experiments described in this manuscript, standard 
illumination settings were used to validate the technique. In the next phase of optogenetic 
experiments, further fine-tuning of the stimulation parameters will be aimed for. 
Electrophysiological measurements, in combination with optogenetic stimulation in vivo, 
provide an opportunity for improvement of the stimulation parameters, both for SSFO and 
for other opsins. Lower light intensities will probably be strong enough to stimulate the very 
light-sensitive SSFO. Using ex vivo single-cell electrophysiological measurements, responses 
at the cellular level of both transduced and non-transduced cells can be further dissected to 
confirm or deny network stimulation. Furthermore, by the use of smaller injection volumes 
and lower light intensities, direct optogenetic stimulation could be limited to the sSC and 
may allow verification of whether this stimulus spreads towards the deeper layers of the SC.  
Similarly, in order to further understand the mechanisms underlying the observed behavioral 
responses, localized stimulation should be employed. By combining stimulation and 
inhibition e.g. by means of blue and amber light illumination of the SSFO expressing region, 
it might be possible to activate and stop the behavioral response well-timed. Additionally, 
combining optogenetic stimulation with an optomotor task could add to the current 
knowledge of complex SC functioning.  
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In conclusion, the optogenetic setup for in vivo stimulation in awake, freely moving animals 
that was developed and validated within this PhD project might now be implemented in 
divergent research lines. 
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SUMMARY  
Glaucoma refers to a group of optic neuropathies, all characterized by progressive 
degeneration of retinal ganglion cells (RGCs) - the cells that send visual information from the 
eye to the brain - resulting in a gradual loss of vision. Ocular hypertension (OHT) is 
considered one of the major risk factors for development and progression of glaucoma, and 
thus lowering eye pressure through topical application of hypotensive eye drops or surgery, 
is the cornerstone of glaucoma therapy today. Unfortunately, a number of patients do not 
benefit from such treatments, and although it generally slows down disease progression, 
controlling eye pressure does not really halt RGC degeneration. This stresses the need for 
development of new therapies aimed at long-term retinal neuroprotection and 
preservation of vision. Within this context, this PhD project intends to contribute to the 
knowledge on the pathological mechanisms underlying glaucomatous RGC death and to 
highlight possible novel strategies towards RGC protection.  
The first part of this thesis was dedicated to the optimization and characterization of two 
mouse models of glaucoma: the OHT model and the normotensive optic nerve crush (ONC) 
model, each focusing on different aspects of the disease.  
Next, a closer look was taken at the link between glaucoma and the brain. Although long 
considered purely an eye disease, glaucoma is increasingly becoming recognized as a disease 
of the entire visual system. Using the OHT model, the effect of elevated eye pressure on the 
central visual brain areas was evaluated. Reduced RGC synapse density, retinotopically 
correlated to degeneration of RGC soma, and intensive but transient astroglial reactivity 
were observed in the main subcortical RGC projection area, which for mice is the superior 
colliculus (SC). Furthermore, diminished neuronal activity in the primary visual cortex 
extending to specific extrastriate areas was seen early after OHT induction. Recovery of 
cortical activity over time demonstrated the capacity of the adult visual cortex to 
functionally reorganize in an attempt to adapt to glaucomatous RGC degeneration. Our 
results uncovered for the first time effects on visual cortex activity patterns in a murine OHT 
model and, yet again, highlight the importance of including the brain in glaucoma research.  
For their survival, RGCs depend on neurotrophic factors, e.g. neurotrophins, produced locally 
in the eye as well as in the projection areas in the brain, from where they are retrogradely 
transported along the RGC axons towards the cell bodies in the retina. According to the 
neurotrophin deprivation hypothesis, diminished retrograde delivery of neurotrophic 
support during an early stage of glaucoma pathogenesis is one of the main triggers that 
induce apoptotic signaling in RGCs. Therefore, interfering with neurotrophic signaling seems 
an attractive tool to achieve neuroprotection. In this PhD project, the well-known 
neurotrophin brain-derived neurotrophic factor (BDNF) was chosen as the lead molecule to 
study the role of neurotrophic factors in glaucoma. The levels of BDNF and its high-affinity 
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receptor, tropomyosin receptor kinase B (TrkB), were examined in the retina and SC of mice 
subjected to OHT or ONC. Both models differentially influenced BDNF and TrkB levels. 
Defining a specific role for BDNF signaling within glaucoma pathology remains difficult as 
various studies using a variety of animal models of glaucoma have yielded unique results, 
including those presented within this manuscript. 
In line with the hypothesis of deprived neurotrophic support being an important contributor 
to glaucomatous RGC death, exogenous neurotrophin administration to the eye has been 
shown to reduce loss of RGCs; however, the neuroprotective effect was mostly transient and 
insufficient for sustained RGC survival. Therefore, we hypothesized that treatment at the 
level of extraretinal neurotrophin sources in the brain might be beneficial, as target-derived 
neurotrophins are likely to induce signaling pathways that diverge from local neurotrophin 
signaling. Brain-directed treatment was approached in two ways: 1) viral vector-mediated 
upregulation of BDNF in the SC was used to boost retrograde delivery of BDNF to the retina; 
2) a more broad strategy to optogenetically increase neuronal activity in the SC was 
implemented to enhance production of a whole spectrum of endogenous neurotrophic 
factors. In light of these hypotheses, viral vector technology was optimized for use in the 
mouse SC.  
Although the previously reported temporary neuroprotective effect of intravitreally-
delivered recombinant BDNF was confirmed, viral vector-induced overexpression of BDNF in 
the SC did not lead to protection of the RGCs in our glaucoma models. This unfortunate 
result most likely resulted from decreased neurotrophin responsiveness upon vector 
mediated BDNF overexpression. Regarding the second strategy employing SC manipulation 
to aim for RGC protection, optogenetic methods were introduced and validated. The basic 
principle underlying optogenetics is the introduction of genes, e.g. through viral vector 
technology, encoding light-sensitive ion channels or opsins into cells, rendering them 
responsive to light of a specific wavelength. For the first time, the application of an opsin 
with specifically slow kinetic properties, the stabilized step-function opsin (SSFO), was 
validated for use in the mouse SC. A setup for chronic optogenetic stimulation in awake, 
freely moving animals, was developed, and shown to effectively stimulate collicular activity. 
Two consecutive behavioral responses were observed upon unilateral SC stimulation, a short 
escape response, followed by prolonged pursuit-like behavior.  
In conclusion, a large component of this thesis was dedicated to method optimization, such 
as the two mouse models of glaucoma, viral vector technology, and a setup for in vivo 
optogenetic stimulation. These methods will importantly contribute to future research 
within the research group. Furthermore, new findings on the role of higher order visual brain 
centers in glaucoma pathogenesis were discovered. Although we were not able to deliver a 
proof-of-concept for the neurotrophin deprivation hypothesis, important insights concerning 
the complexity of neurotrophic factor treatments were highlighted. 
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SAMENVATTING 
De term glaucoom verwijst naar een groep optische neuropathieën, die gekenmerkt worden 
door progressieve degeneratie van de retinale ganglioncellen (RGC’s) - de cellen die visuele 
informatie van de ogen naar de hersenen sturen. Oculaire hypertensie (OHT) wordt 
beschouwd als een van de belangrijkste risicofactoren voor het ontwikkelen en het 
evolueren van glaucoom. Daarom vormen oogdrukverlagende therapieën, via 
drukverlagende oogdruppels of chirurgische ingrepen, vandaag de standaardbehandeling 
voor glaucoom. Een deel van de patiënten baat echter niet bij deze behandelingen en, 
hoewel oogdrukcontrole over het algemeen het ziekteproces vertraagt, stopt het de RGC-
degeneratie niet. Dit benadrukt de nood aan nieuwe therapieën, die ook op lange termijn 
neuroprotectie en behoud van het gezichtsvermogen kunnen bieden. In deze context tracht 
dit doctoraatsproject de kennis over de onderliggende pathologische mechanismen van 
glaucomateuze RGC-dood te vergroten en mogelijk nieuwe strategieën voor RGC-
bescherming op te stellen.  
Het eerste deel van deze thesis is gewijd aan de optimalisatie en karakterisatie van twee 
muis glaucoommodellen: het OHT model en het normotensieve optic nerve crush (ONC) 
model, die elk focussen op verschillende aspecten van het ziektebeeld.  
Vervolgens werd de link tussen glaucoom en de hersenen onderzocht. Hoewel lang 
beschouwd als louter een ziekte van het oog, wordt glaucoom recentelijk meer en meer 
erkend als een aandoening van het hele visuele systeem. Gebruikmakend van het OHT 
model, werd het effect van een verhoogde oogdruk op de visuele hersengebieden 
onderzocht. In de superior colliculus (SC), het belangrijkste subcorticale RGC-projectiegebied 
bij de muis, werden gereduceerde RGC-synapsdensiteit, retinotopisch gecorreleerd met de 
RGC-soma-degeneratie, en een sterke maar tijdelijke astrogliale reactiviteit waargenomen. 
Verder werd vroeg na OHT-inductie een verminderde neurale activiteit gedetecteerd in de 
primaire visuele cortex, een effect dat zelfs reikte tot in bepaalde hogere visuele 
cortexgebieden. Na verloop van tijd was de corticale activiteit hersteld, wat wijst op de 
capaciteit van de adulte visuele cortex om functionele reorganisatie te ondergaan in een 
poging om zich aan te passen aan glaucoomgerelateerde RGC-dood. Onze resultaten 
onthulden voor de eerste keer effecten op activiteitspatronen in de visuele cortex in een 
murien OHT model en benadrukken eens te meer het belang van het opnemen van de 
hersenen in glaucoomonderzoek.  
RGC’s zijn voor hun overleving afhankelijk van neurotrofe factoren, bv. neurotrofines, die 
zowel lokaal in het oog als in de projectiegebieden in de hersenen geproduceerd worden. 
Vanuit de hersenen worden ze retrograad getransporteerd langs de RGC axonen naar de 
cellichamen in de retina. Volgens de neurotrofine deprivatie hypothese is de verminderde 
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retrograde toevoer van neurotrofe ondersteuning tijdens vroege stadia van glaucoom 
pathogenese één van de belangrijkste prikkels die apoptose induceren in RGC’s. Daarom lijkt 
interfereren met neurotrofe signaalwegen een aantrekkelijke manier om neuroprotectie na 
te streven. In dit doctoraatsproject werd de goed gekende brain-derived neurotrophic factor 
(BDNF) gekozen als referentiemolecule om de rol van neurotrofe factoren in glaucoom te 
bestuderen. BDNF en zijn receptor, tropomyosine receptor kinase B (TrkB), werden 
onderzocht in de retina en SC van muizen onderworpen aan het OHT of ONC model. In elk 
van de modellen werden specifieke veranderingen in de BDNF- en TrkB-expressieniveaus 
waargenomen. Door een gebrek aan overeenkomst tussen verschillende studies die 
gebruikmaken van diverse diermodellen, blijft het echter moeilijk om een exacte rol toe te 
kennen aan BDNF-signalering in glaucoompathologie. Zo resulteerden ook de hier 
uitgevoerde experimenten in een set van unieke bevindingen.  
In overeenstemming met de hypothese dat een tekort aan neurotrofe ondersteuning een 
belangrijke rol speelt in glaucoomgerelateerde RGC-dood, werd aangetoond dat lokale 
toediening van exogene neurotrofines ter hoogte van het oog RGC-degeneratie tegengaat. 
Dit neuroprotectieve effect was echter slechts tijdelijk en onvoldoende om een langdurige 
RGC-overleving te verzekeren. Daarom stelden wij de hypothese voorop dat het behandelen 
ter hoogte van de extraretinale neurotrofinebronnen in de hersenen een sterker en meer 
langdurig protectief effect zou kunnen hebben, aangezien neurotrofines afkomstig van de 
doelwitstructuren andere signaalwegen activeren dan lokaal inwerkende neurotrofines.  
De hersengerichte behandeling werd op twee manieren aangepakt: 1) virale vector-
geïnduceerde opregulatie van BDNF in de SC werd gebruikt om de retrograde aanlevering 
van BDNF naar de retina te bevorderen; 2) een bredere benadering bestond eruit de neurale 
activiteit in de SC optogenetisch te verhogen, om zo de productie van een breed spectrum 
aan endogene neurotrofe factoren te stimuleren. In het kader van deze hypotheses, werd 
virale vectortechnologie geoptimaliseerd voor toepassing in de muis SC.  
Hoewel het eerder beschreven tijdelijk neuroprotectief effect van intravitreaal toegediend 
BDNF bevestigd werd, resulteerde virale vector-geïnduceerde overexpressie van BDNF in de 
SC niet in RGC-bescherming in onze glaucoommodellen. Dit spijtige resultaat werd 
toegeschreven aan een verlaagde neurotrofine-responsiviteit als reactie op de BDNF-
overexpressie. Voor de tweede aanpak, waarbij we de neurale activiteit in de SC trachtten te 
verhogen met het oog op RGC-protectie, werden optogenetische technieken op punt gesteld 
en gevalideerd. Het basisprincipe van optogenetica is het introduceren van genen die 
coderen voor lichtgevoelige ionenkanalen, opsines, in cellen, bv. via virale 
vectortechnologie, waardoor deze cellen gevoelig worden voor licht van een bepaalde 
golflengte. Voor het eerst werd het gebruik van een opsine met heel trage kinetische 
eigenschappen, het stabilized step-function opsin (SSFO), gevalideerd in de muis SC. Een 
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setup voor chronische optogenetische stimulatie in wakkere, vrij bewegende dieren werd 
ontwikkeld en gevalideerd voor het doeltreffend stimuleren van de colliculaire activiteit. 
Twee opeenvolgende gedragsreacties werden geobserveerd na unilaterale SC stimulatie: 
een korte vluchtrespons, gevolgd door een meer langdurige volgrespons.  
Tot besluit, een groot deel van deze thesis is gewijd aan de optimalisatie van technieken, 
zoals twee muis glaucoommodellen, virale vectortechnologie en een setup voor in vivo 
optogenetische stimulatie. Deze methodes zullen geïmplementeerd worden in toekomstig 
onderzoek binnen de onderzoeksgroep. Bovendien werden nieuwe inzichten verkregen over 
de rol van hogere orde visuele hersengebieden in glaucoompathogenese. Hoewel we er niet 
in slaagden een bewijs te leveren voor de neurotrofine deprivatie hypothese, werden 
belangrijke inzichten verkregen over de complexiteit van neurotrofe factor behandelingen. 
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